| Title | Collaboration Type | HHS Participating Agencies | NIH Participating Institutes, Centers, and Offices | Description |
|---|---|---|---|---|
| 12th Annual Conference on the Science of Dissemination and Implementation | Meeting/ Workshop | AHRQ | NHLBI, NCCIH, NCI, NIAAA, NIAID, NIDA, NIDDK, NIMH, NINR | A forum for discussing the science of dissemination and implementation, the 10th annual conference aimed to grow the research base by bridging the gap between evidence, practice, and policy in health and medicine. http://www.academyhealth.org/events/site/10th-annual-conference-science-dissemination-and-implementation-health |
| 2024-2028 NIH-Wide Strategic Plan on Research on the Health of Women | Other | AHRQ, CDC, FDA, HRSA, OASH | OD/DPCPSI/ORWH, CC, CSR, NCATS, NCCIH, FIC, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/AoU, OD/DPCPSI/OAR, OD/DPCPSI/OBSSR, OD/DPCPSI/ODS, OD/DPCPSI/ODSS, OD/DPCPSI/OEPR, OD/DPCPSI/ONR, OD/DPCPSI/SGMRO | The Office of Research on Women’s Health (ORWH) is responsible for an NIH-wide strategic plan on research on the health of women that promotes allocation of NIH resources for conducting and supporting research efforts on the health of women across NIH Institutes and Centers. ORWH is currently undergoing the process of updating the NIH-Wide Strategic Plan for Research on the Health of Women. Recent, significant public health events (e.g., the COVID pandemic) have had an outsized effect on the health of women. Several topics relevant to the health of women were reviewed by the NIH and the NIH Advisory Committee on Research on Women’s Health (ACRWH) in 2021, through the congressionally directed and ORWH-led Women’s Health Conference. This convening included a review of NIH activities to identify research opportunities to address maternal mortality and morbidity, survival rates of cervical cancer, and chronic and debilitating diseases in women. The recommendations that the ACRWH made consequent to this conference as well as recent scientific advances; new technologies; current health priorities; and feedback from a Request for Information will all be considered in the development of the next NIH-Wide Strategic Plan for Research on the Health of Women to help guide future NIH research efforts to improve the health of all women throughout the entire life course. NIH published a Notice (NOT-OD-22-186) to solicit input from the basic, clinical, and translational scientists; advocacy and patient communities; and the public on topics under consideration for the next strategic plan. ORWH established NIH, HHS, and VA engagement in the development of the 2024-2028 NIH-Wide Strategic Plan on Research on the Health of Women that will be released in 2024. |
| 3D Bioprinted skin models for drug screening | Research Initiative | FDA | NCATS | 3D Bioprinted skin models for drug screening |
| 4th National Conference on Advancing Early Psychosis Care in the United States: Harnessing Resiliency in a Changing World | Meeting/ Workshop | SAMHSA | NIMH | The National Institute of Mental Health (NIMH), in collaboration with the Substance Abuse and Mental Health Services Administration (SAMHSA) through its National Training and Technical Assistance Center sponsored a meeting entitled, "Advancing Early Psychosis Care in the United States: Harnessing Resiliency in a Changing World," on March 10-11, 2022. With the rapid expansion of evidence-based early psychosis care in the United States, largely the result of the successful NIMH-funded Recovery After an Initial Schizophrenia Episode (RAISE) initiative, additional clinician training on early psychosis is needed. Thousands of clinicians and other professionals working in the early psychosis care field attended the virtual event. NIMH staff served on the planning committee and as presenters. https://www.psychiatry.org/psychiatrists/meetings/advancing-early-psychosis-care |
| A Glycopeptide from Interstitial Cystitis Patients as a Novel Anticancer Lead | Research Initiative | FDA | NCI | A Glycopeptide from Interstitial Cystitis Patients as a Novel Anticancer Lead |
| A nested case-control study of circulating per- and polyfluoroalkyl substances (PFAS) and prostate cancer | Research Initiative | CDC | NCI | National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating to measure serum levels of per- and polyfluoroalkyl substances (PFAS) for a nested case-control study of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. |
| A nested case-control study of circulating per- and polyfluoroalkyl substances (PFAS) and renal cell carcinoma | Research Initiative | CDC | NCI | National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating to measure serum levels of per- and polyfluoroalkyl substances (PFAS) for a nested case-control study of renal cell carcinoma (RCC) in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. |
| A nested case-control study of circulating per- and polyfluoroalkyl substances (PFAS) and uterine and ovarian cancers | Research Initiative | CDC | NCI | National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating to measure serum levels of per- and polyfluoroalkyl substances (PFAS) for nested case-control studies of endometrial (uterine) and ovarian cancers in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. |
| A nested case-control study of serum PFAS and testicular cancer in Air Force servicemen | Research Initiative | CDC | NCI | National Cancer Institute (NCI) is collaborating with Uniformed Services University of the Health Sciences (USUHS) and Centers for Disease Control and Prevention (CDC) on a nested case-control study measuring serum PFAS concentrations among Air Force servicemen with samples in the Department of Defense Serum Repository. |
| A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of escalating multiple oral doses of AG-348 in subjects with stable sickle cell disease | Research Initiative | FDA | NHLBI | A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of escalating multiple oral doses of AG-348 in subjects with stable sickle cell disease |
| A Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews | Research Initiative | CDC | NCI | National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating on a cross-sectional study of 83 airline pilots and 50 university faculty to assess the relation of stable chromosome translocations with cosmic radiation exposure. |
| A Study to Evaluate the Effects of fixed dose Flavonoid Isoquercetin on thrombo-inflammatory biomarkers in subjects with stable Sickle Cell Disease | Research Initiative | FDA | NHLBI | A Study to Evaluate the Effects of fixed dose Flavonoid Isoquercetin on thrombo-inflammatory biomarkers in subjects with stable Sickle Cell Disease |
| A Working Group to Consider the Question of Federal Public Health and Medical Resource Allocation | Committee, Work group, Advisory group, or Task Force | OS | CC | The National Institutes of Health (NIH) Clinical Center is participating in a working group to consider the question of federal public health and medical resource allocation. The group developed a framework for allocation of federal resources during scarcity after engaging with stakeholders in ethics, disaster preparedness, and emergency management. |
| A5349/TBTC S31 - Rifapentine - Containing Treatment Shortening Regimens for Pulmonary Tuberculosis: A Randomized, Open-Label, Controlled Phase 3 Clinical Trial | Research Initiative | CDC | NIAID | The purpose of this research initiative is to provide scientific discovery to improve patient care and safety by reducing the duration of treatment for drug-susceptible pulmonary tuberculosis to 4 months by using new regimens, including high-dose rifapentine. |
| A5418: Study of Tecovirimat For Human Monkeypox Virus (STOMP) | Other | CDC, FDA | NIAID | To see if tecovirimat is safe, and whether it helps treat monkeypox infection. https://www.stomptpoxx.org/main |
| Abuse Liability Evaluation for Research, Treatment, and Training (ALERTT) | Research Initiative | FDA | NIDA | Abuse Liability Evaluation for Research, Treatment, and Training (ALERTT) is part of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the US Food and Drug Administration (FDA). The mission of the (ACTTION) is to identify, prioritize, sponsor, coordinate, and promote innovative activities with a special interest in optimizing clinical trials that will expedite the discovery and development of improved analgesic, anesthetic, and addiction treatments for the benefit of public health. http://www.acttion.org/news/3_1_12.html |
| Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Therapeutics Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, ASPR | NIAID | Develop master protocols to support the ACTIV Research; Prioritize putative therapeutics candidates for entry into trials |
| Accelerating COVID-19 Therapeutic Interventions and Vaccines-1: Immune Modulators (ACTIV-1) | Research Initiative | FDA, ASPR | NCATS | The ACTIV public-private partnership has evaluated hundreds of available therapeutic agents with potential application for COVID-19, prioritized the most promising candidates, designed and harmonized adaptive master protocols for ACTIV clinical trials, and selected numerous NIH-supported networks to launch these clinical trials to test prioritized therapeutic candidates. The ACTIV-1 master protocol tested three promising immune modulator compounds, a class of drugs that help minimize the deleterious effects of an overactive immune response to SARS-CoV-2 infection. This Phase 3 trial enrolled hospitalized adults with moderate to severe COVID-19 disease. The goal of the trial was to evaluate the safety and efficacy of each immune modulator when given as an add-on therapy to standard of care (SOC) at local clinics, which may have included remdesivir (provided as part of the study to all participants), an antiviral approved for treatment of COVID-19. The different treatments were assessed with respect to illness severity, recovery speed, mortality, and hospital resource utilization. The trial is completed, and results on the two immune modulators that showed efficacy are available on medRxiv. https://www.nih.gov/research-training/medical-research-initiatives/activ/covid-19-therapeutics-prioritized-testing-clinical-trials#activ1MedRxiv |
| Accelerating COVID-19 Therapeutic Interventions and Vaccines-6: Outpatient Repurposed Drugs (ACTIV-6) | Research Initiative | CDC, FDA, ASPR | NCATS, NIAID, NHLBI | The ACTIV public-private partnership has evaluated hundreds of available therapeutic agents with potential application for COVID-19, prioritized the most promising candidates, designed and harmonized adaptive master protocols for ACTIV clinical trials, and selected numerous NIH-supported networks to launch these clinical trials to test prioritized therapeutic candidates. ACTIV-6 is designed to test the effectiveness of repurposed drugs (drugs that are FDA-approved for non-COVID-19 indications and have known safety profiles) in reducing the duration and severity of symptoms associated with mild-to-moderate COVID-19. The large, randomized, placebo-controlled Phase 3 trial is enrolling outpatient participants who are at least 30 years old, have tested positive for SARS-CoV-2 infection and show two or more mild-to-moderate symptoms of COVID-19 for no more than seven days. Results for ivermectin, fluvoxamine and fluticasone are available on medRxiv. Results for ivermectin and fluvoxamine have been published in JAMA. Testing of montelukast is ongoing. https://www.nih.gov/research-training/medical-research-initiatives/activ/covid-19-therapeutics-prioritized-testing-clinical-trials#activ6Ivermectin |
| Accelerating Medicines Partnership (AMP) | Other | FDA | OD/OSP, NIA, NIDDK, NIAMS, NINDS, NIMH | Public-private partnership between the National Institutes of Health (NIH), the Food and Drug Administration (FDA), multiple biopharmaceutical companies and multiple non-profit organizations, and managed by the Foundation for NIH (FNIH), to transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets for therapeutics. https://www.nih.gov/research-training/accelerating-medicines-partnership-amp |
| Accelerating Medicines Partnership® Schizophrenia (AMP SCZ) | Research Initiative | FDA | NIMH | The Foundation for the National Institutes of Health (FNIH), together with National Institute of Mental Health (NIMH) and public and private partners, is leading the Accelerating Medicines Partnership - Schizophrenia (AMP; SCZ) as the first neuropsychiatric project within the AMP program. The public-private partnership will tackle the critical need for more effective treatments for people with schizophrenia. https://fnih.org/our-programs/AMP/schizophrenia |
| AccessGUDID | Resource Development | FDA, GDM | NLM | The Global Unique Device Identification Database (GUDID) contains key device identification information submitted to the Food and Drug Administration (FDA) about medical devices that have Unique Device Identifiers (UDI). The National Library of Medicine (NLM), in collaboration with the FDA, has created the AccessGUDID portal to make device identification information in the GUDID available for everyone, including patients, caregivers, healthcare providers, hospitals, and industry. https://accessgudid.nlm.nih.gov |
| ACL Advisory Council on Grandparents Raising Grandchildren | Committee, Work group, Advisory group, or Task Force | ACL, ACF, SAMHSA, CDC, HRSA, ASPE, ONC | NIA | The mission of the Advisory Council to Support Grandparents Raising Grandchildren (SGRG) is to identify, promote, coordinate and disseminate information, resources, and best practices to help grandparents and older relative caregivers of children meet the health, educational, nutritional, and other needs of the children in their care, while maintaining their own physical, mental, and emotional well-being. As part of this vision, all recommendations will consider the needs of members of Native American tribes and families affected by the opioid crisis. https://acl.gov/programs/support-caregivers/supporting-grandparents-raising-grandchildren-0 |
| Adaptive Optics Imaging of Outer Retinal Diseases | Research Initiative | FDA | NEI | Adaptive Optics Imaging of Outer Retinal Diseases |
| Adaptive Optics Retinal Imaging | Research Initiative | FDA | NEI | Adaptive Optics Retinal Imaging |
| Adjuvant Working Group | Committee, Work group, Advisory group, or Task Force | BARDA, FDA, ASPR | NIAID, NCI | Staff from all National Institute of Allergy and Infectious Diseases (NIAID) Divisions, program staff from the Biomedical Advanced Research and Development Authority (BARDA), and regulatory staff from the Food and Drug Administration (FDA) exchange information about ongoing programs related to novel adjuvants for infectious disease vaccines, identify high priority research areas (and gap areas), and discuss ideas to accelerate progress in adjuvant research through better access to information and resources. |
| Adolescent Brain Cognitive Development (ABCD) Study | Research Initiative | CDC | NIDA, NCI, NIAAA, NICHD, NIMH, NIMHD, NINDS, OD/DPCPSI/OBSSR | The Adolescent Brain Cognitive Development (ABCD) project, a landmark longitudinal study of brain development and child health, will increase our understanding of how diverse experiences during adolescence interact with changing biology to influence brain, cognitive, and social/emotional development of youth. In partnership with area public and private schools, researchers at twenty-one research sites across the country will recruit 10,000 children at age 9-10 from diverse races and ethnicities, education and income levels, and living environments and follow them through their teens and into early adulthood. Throughout this period, researchers will assess each child’s physical and mental health, substance use, sleep patterns, genetics, childhood experiences, and cultural/environmental influences, as well as track brain and cognitive development with non-invasive magnetic resonance imaging scans at regular intervals. To enrich the value of the study, ABCD will release anonymized data annually to the research community in an open science model to allow scientists from all over the world to conduct analyses and pool resources to rapidly expand the types of scientific questions that can be answered. The actionable information coming out of this study will enable education, substance use prevention, and other health promotion policies to ensure the wellbeing and success of the Nation’s children. http://abcdstudy.org/ |
| Adolescent HIV Prevention and Treatment Implementation Science Alliance (AHISA) | Committee, Work group, Advisory group, or Task Force | CDC, OS | NICHD, FIC, NIAID, NIMH, OD/DPCPSI/OAR | The Adolescent HIV Prevention and Treatment Implementation Science Alliance (AHISA) aims to enhance the effective use of evidence and help overcome implementation challenges related to prevention, screening and treatment of HIV among adolescents (ages 15 to 24) in sub-Saharan Africa by catalyzing collaboration and communication among implementation scientists, program implementers and policymakers. The Center for Global Health Studies at Fogarty is launching the initiative in collaboration with the Office of the Global AIDS Coordinator and other NIH Institutes and Centers. https://www.fic.nih.gov/About/center-global-health-studies/Pages/adolescent-hiv-prevention-treatment-implementation-science-alliance.aspx |
| Adolescent Human Immunodeficiency Virus (HIV) Prevention and Treatment Implementation Science Alliance (AHISA) | Committee, Work group, Advisory group, or Task Force | CDC | FIC, NIAID, NICHD, NIMH, OD/DPCPSI/OAR | The Adolescent Human Immunodeficiency Virus(HIV) Prevention and Treatment Implementation Science Alliance (AHISA) aims to enhance the effective use of evidence and help overcome implementation challenges related to prevention, screening, and treatment of HIV among adolescents (ages 15 to 24) in sub-Saharan Africa by catalyzing collaboration and communication among implementation scientists, program implementers, and policymakers. The goals of the Alliance are to: 1) provide a platform for cross-fertilization and exchange of ideas and information among implementation scientists and other stakeholders focusing on different aspects of HIV in adolescents; 2) enable the research to be better informed by programmatic challenges and questions; 3) inform policymakers of promising evidence and encourage use of the data in decision making; and 4) extend the reach and impact of implementation science related to adolescent HIV prevention and treatment. https://www.fic.nih.gov/About/center-global-health-studies/Pages/adolescent-hiv-prevention-treatment-implementation-science-alliance.aspx |
| Advanced Anticonvulsant System Interagency Product Team | Committee, Work group, Advisory group, or Task Force | FDA, OS | NINDS | The Advanced Anticonvulsant System Interagency Product Team is a Department of Defense-led effort to facilitate activities, both research and regulatory, related to the FDA approval of midazolam for use in treating nerve agent exposure. |
| Advanced Viral Detection Technology IG (AVDTIG) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID | This working group seeks to develop guidelines for best practices for Next Generation Sequencing to identify viral contaminants in biological products. |
| Advancing American Kidney Health Initiative | Research Initiative | CDC, CMS, FDA, ASPE, ASPR, HRSA, IHS, OCR | NIDDK, NIEHS | This initiative aims to improve the lives of Americans suffering from kidney disease, expand options for American patients, and reduce healthcare costs. The initiative provides specific solutions to deliver on three goals: fewer patients developing kidney failure, fewer Americans receiving dialysis in dialysis centers, and more kidneys available for transplant. NIDDK promotes an integrated health system model of team-based clinical care based on the pragmatic experience of the IHS; Kidney Disease Program. NIDDK has developed new clinical tools and educational programs that improve the care of people with kidney disease in primary care settings. NIDDK works in collaboration with government, nonprofit, and health care organizations to raise awareness about screening for individuals at risk for kidney disease; educate individuals about how to manage their disease; provide information, training, and tools that help health care providers; and support important health systems changes. https://aspe.hhs.gov/advancing-american-kidney-health |
| Advancing Protection and Care for Children in Adversity: A U.S. Government Strategy for International Assistance (APCCA) | Committee, Work group, Advisory group, or Task Force | CDC | FIC, NICHD, NIMH | Interagency working group focused on Advancing Protection and Care for Children in Adversity, with a focus on developing a coordinated US government strategy for international assistance. The National Institutes of Health (NIH) funds research and evidence-based interventions, which often inform the development and refinement of other USG programs aimed at benefiting at-risk children around the globe. Several institutes and centers within the NIH fund research to build knowledge in areas related to APCCA priorities and objectives. https://www.childreninadversity.gov/docs/default-source/default-document-library/apcca-strategy-final-web.pdf?sfvrsn=4 |
| Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | CC, NHLBI | The Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) is a 31-member federal advisory committee that provides advice to the Secretary of Health and Human Services through the Assistant Secretary for Health on a range of policy issues related to blood, blood products, and tissues. https://www.hhs.gov/ohaidp/initiatives/blood-tissue-safety/advisory-committee/index.html |
| Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA | NICHD, NHGRI, NHLBI, NIDDK, NLM | The Advisory Committee on Heritable Disorders in Newborns and Children was established under the Public Health Service Act, Title XI, § 1109 (42 USC 300b-10), as amended by the Newborn Screening Saves Lives Reauthorization Act of 2014 (PL 113-240). The mission of the Advisory Committee on Heritable Disorders in Newborns and Children is to reduce morbidity and mortality in newborns and children who have or are at risk for heritable disorders. The Committee recommends that every newborn screening program include a Uniform Screening Panel that screens for 36 core disorders and 26 secondary disorders. The Committee advises the Secretary, US Department of Health and Human Services on the most appropriate application of universal newborn screening tests, technologies, policies, guidelines, and standards. Specifically, the committee provides to the Secretary, the following: Advice and recommendations concerning grants and projects authorized, awarded, or funded related to screening heritable disorders in newborns and children; technical information to develop Heritable Disorders Program policies and priorities that will enhance the ability of the state and local health agencies to provide screening; counseling and health care services for newborns and children who have or are at risk for heritable disorders, and recommendations; and advice and information to enhance, expand, or improve the ability of the Secretary to reduce mortality and morbidity from heritable disorders in newborns and children. The committee was chartered on May 7, 2015. http://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/ |
| Advisory Committee on Immunization Practices (ACIP WG) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID | Group is focused on influenza immunization issues such as vaccine response and effectiveness |
| Advisory Committee on Maternal/Pediatric RSV Vaccines (ACIP WG) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OASH, HRSA, IHS, CMS | NIAID | Group is focused on recommendation of RSV maternal immunization from Pfizer |
| Advisory Committee on Organ Transplantation (ACOT) | Committee, Work group, Advisory group, or Task Force | HRSA, OS | NIAID | The Advisory Committee on Organ Transplantation (ACOT) was established to assist the Department of Health and Human Services (HHS) Secretary in enhancing organ donation, ensuring that the system of organ transplantation is grounded in the best available medical science, and assuring the public that the system is as effective and equitable as possible, thereby increasing public confidence in the integrity and effectiveness of the transplantation system. https://www.hrsa.gov/advisory-committees/organ-transplantation |
| Advisory Committee on RSV Vaccines in Older Adults (ACIP WG) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OASH, CMS | NIAID | Group is focused on recommendation for RSV vaccines in older adults |
| Advisory Council on Blood Stem Cell Transplantation (ACBSCT) of the U.S. Department of Health and Human Services (HHS) | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, HRSA | NHLBI | The Advisory Council advises the Secretary, Department of Health and Human Services and Administrator, Health Resources and Services Administration (HRSA) on matters related to the activities of the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory Program. The principal purpose of these programs is to make blood stem cells from adult donors and cord blood units available for patients who need a transplant to treat life-threatening conditions such as leukemia, and who lack a suitably matched relative who can be the donor. https://bloodcell.transplant.hrsa.gov/about/advisory_council/index.html |
| Agency Priority Goals Maternal Health | Committee, Work group, Advisory group, or Task Force | HRSA, NIH, ASPE, CDC, CMS, FDA, OASH, ACF, OGA, AHRQ, ACL | NICHD, OD/DPCPSI/ORWH, OD/IMOD, OD/DPCPSI/OEPR | HHS-wide group to set an impact statement and priority goals regarding maternal morbidity and mortality. |
| Alaska Native Tumor Registry | Resource Development | CDC, IHS | NCI | In collaboration with the Centers for Disease Control and Prevention (CDC), Indian Health Service (IHS), and National Cancer Institute (NCI), and with technical assistance from the Surveillance, Epidemiology, and End Results Program (SEER), the Alaska Native Tumor Registry collects cancer information on all American Indian and Alaska Native people residing in Alaska at the time of diagnosis. http://seer.cancer.gov/registries/alaska.html |
| Alcohol Metabolism, Functional Consequences and Apoptosis Signaling Mechanism | Research Initiative | FDA | NIAAA | Alcohol Metabolism, Functional Consequences and Apoptosis Signaling Mechanism |
| All of Us IAA with CDC Office of Public Health Genomics | Other | CDC | OD/AoU | Interagency Agreement between CDC and NIH to support translational work n/a |
| Alzheimers.gov Collaborations with Federal Agencies | Public Education Campaign | ACL, ASPA, ASPE, CDC | NIA, NINDS | In the course of developing the new English and Spanish Alzheimers.gov websites, NIA consulted with the NAPA Federal Subgroup on website content, usability, and outreach, including working with NINDS, ACL, and CDC to review website content. https://www.alzheimers.gov |
| American Academy of Pediatrics (AAP) Committee on Drugs | Committee, Work group, Advisory group, or Task Force | FDA | NICHD | The AAP Committee on Drugs reviews all aspects of pediatric pharmacology, including drug indications, contraindications, absorption rates, routes of administration, dosing, use precautions, and mode of action as they apply to children. The Committee also advises the Board of Directors in matters related to drug labeling, safety, and efficacy for both prescription and over-the-counter drugs; monitors federal legislation related to the drug approval process; and promotes the need for expanded pediatric drug trials. https://www.aap.org/en-us/about-the-aap/Committees-Councils-Sections/pages/Committee-on-Drugs.aspx |
| American Academy of Pediatrics (AAP) Committee on Nutrition | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NICHD | The Committee on Nutrition (CON) studies the nutritional needs of infants, children, and adolescents and develops guidelines for the pediatrician based on sound, objective, clinical science as well as practical experience in fostering optimal health status. CON also maintains active liaisons with the Food and Drug Administration, United States Department of Agriculture (USDA), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and the Canadian Paediatric Society, pursues advocacy opportunities which promote healthy dietary habits; and provides technical assistance as needed relative to the federal regulatory process. https://crs.od.nih.gov/CRSAdmin/AddCollaborations.aspx |
| American Academy of Pediatrics (AAP) Committee on Pediatric AIDS (AAP-COPA) | Committee, Work group, Advisory group, or Task Force | CDC | NICHD | The Committee on Pediatric AIDS (COPA) provides guidelines and recommendations for the care and treatment of infants, children, and adolescents with HIV and their families through the development of AAP Policy Statements. https://www.aap.org/en-us/about-the-aap/Committees-Councils-Sections/Pages/Committee-On-Pediatric-AIDS.aspx |
| American Academy of Pediatrics (AAP) Council on Genetics (AAP-COG) | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NICHD | The AAP Council on Genetics (COG) studies and makes recommendations to the AAP Board of Directors on recent advances in genetics and provides support to chapters on state legislative issues as they relate to genetics. https://www.aap.org/en-us/about-the-aap/Councils/Genetics/Pages/COG.aspx |
| American Academy of Pediatrics (AAP) Section on Obesity (AAP-SOO) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NICHD | The Section on Obesity's mission is to improve the health and well-being of children and families by reducing the prevalence of childhood obesity and promoting healthy active living. https://services.aap.org/en/community/aap-sections/obesity/ |
| American Academy of Pediatrics Council on Injury, Violence and Poison Prevention (AAP-COIVPP) | Committee, Work group, Advisory group, or Task Force | ACF, HRSA, IHS | NICHD | The AAP Council on Injury, Violence, and Poison Prevention addresses all facets of injury prevention policy, programs, advocacy, and education of general pediatricians, pediatric subspecialists, and families as a unified group. https://www.aap.org/en-us/about-the-aap/Councils/Council-on-Injury-Violence-Poison-Prevention/Pages/COIVPP.aspx? |
| American Community Survey (ACS) Interagency Committee Meeting | Meeting/ Workshop | ACF, AHRQ, ASPE, CDC, CMS, HRSA | NICHD | Coordinated by the U.S. Census Bureau |
| American Congress of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NICHD | The National Institutes of Health (NIH) advises the American Congress of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice about research advances that can inform gynecologic clinical practice. |
| Americas Children Forum on Health and Family Statistics | Resource Development | SAMHSA | NIDA | As a member of this collaboration, the National Institute on Drug Abuse (NIDA) contributes data from the, “Monitoring the Future Survey on Illicit Drugs, Alcohol and Tobacco Trends”. http://www.childstats.gov/index.asp |
| AMP Bespoke Gene Therapy Program/Bespoke Gene Therapy Consortium (BGTC) | Research Initiative | FDA | NHLBI, NCATS, NIMH, NINDS | The Bespoke Gene Therapy Consortium (BGTC) is a developing public-private partnership dedicated to making gene therapy a reality for people with rare genetic diseases affecting populations too small to be viable from the current commercial perspective. https://fnih.org/what-we-do/programs/bespoke-gene-therapy-consortium#:~:text=The%20Bespoke%20Gene%20Therapy%20Consortium,from%20the%20current%20commercial%20perspective. |
| Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) | Research Initiative | FDA | NINDS, NCATS, NCI, NIAAA, NIDA | The mission of the Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership funded by the US Food and Drug Administration (FDA) is to identify, prioritize, sponsor, coordinate, and promote innovative activities — with a special interest in optimizing clinical trials — that will expedite the discovery and development of improved analgesic treatments for the benefit of the public health. http://www.acttion.org/ |
| Analytical Methods and Reference Materials Program (AMRM) | Resource Development | FDA | OD/DPCPSI/ODS, NCCIH, NCI, NIDDK | The National Institutes of Health's, Office of Dietary Supplement Analytical Methods and Reference Materials Program (AMRM) collaborates with NIH ICOs and other federal agencies to support the development and dissemination of research resources that scientists and analysts need to ensure that chemical characterizations of dietary supplements, natural products, and nutrient biomarkers are accurate, precise, reliable, and reproducible. https://ods.od.nih.gov/Research/AMRMProgramWebsite.aspx |
| Ancillary Swab Study to PREVENT-19 trial: Swab your Nose Inside to Find inFection (SNIFF) | Research Initiative | ASPR, CDC, FDA | NIAID | In this ancillary swab study, up to 3,000 adolescent participants 12-17 years of age who participated in the Pre-fusion Protein Subunit Vaccine Efficacy Novavax Trial COVID-19 (PREVENT-19) Pediatric Expansion study and who provided informed consent/assent for the ancillary swab study were sampled twice weekly starting at the day 21 visit, or as soon as possible thereafter, of the initial injection period until the second dose of the blinded cross-over (approximately 28 weeks) with nasal swabs for detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection by reverse transcription polymerase chain reaction (RT-PCR) and incident infections tallied. Data sources from the Observational Study (e.g., study product assignment, daily symptomatology) will be used in the ancillary study to estimate the vaccine efficacy against SARS-CoV-2 infection, including asymptomatic infection or mildly symptomatic infection not meeting the Coronavirus Disease 2019 (COVID-19) primary endpoint definition for the Phase 3 study. |
| Annual Conference on the Science of Dissemination and Implementation | Meeting/ Workshop | AHRQ, CDC | NCI, FIC, NHGRI, NHLBI, NIAAA, NIDA, NIDDK, NIMH, NIMHD, NINR, NIEHS, OD | Annual Conference on the Science of Dissemination and Implementation is a forum for discussing the science of dissemination and implementation and aims to grow the research base by bridging the gap between evidence, practice, and policy in health and medicine. Researchers, evaluators, and implementers who are interested in identifying opportunities, challenges, and strategies for disseminating the findings and implementation of research to key stakeholders are encouraged to attend. Discuss, debate, and explore in-depth approaches to advance dissemination and implementation science. https://www.academyhealth.org/events/site/12th-annual-conference-science-dissemination-and-implementation-health |
| Antibody Interest Group (ABIG) | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NHLBI, NIAID, NIDCR, NIDDK | The NIH Antibody Interest Group (ABIG) promotes information exchange and interaction among NIH scientists who work on various aspects of antibody engineering and therapy. The success of antibody therapy requires a thorough understanding of biological systems in relation to molecular and cell biology, immunology, biochemistry, and microbiology, as well as diseases such as cancer, autoimmunity, and infectious diseases. Interest in antibody therapy crosses traditional biomedical disciplinary boundaries. ABIG provides an open forum for multidisciplinary discussion among colleagues who otherwise may have limited interaction. The principal ABIG activities are monthly meetings on current topics as well as an annual symposium on the NIH campus. The monthly ABIG meetings are open to everyone interested. These meetings are devoted to research seminars on numerous aspects of antibody engineering and therapy presented by both NIH scientists and outside speakers. https://oir.nih.gov/sigs/antibody-interest-group |
| Antimicrobial Drugs Advisory Committee | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | The Committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of infectious diseases and disorders and makes appropriate recommendations to the Food and Drug Administration (FDA) Commissioner. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/default.htm |
| Antiretroviral Pregnancy Registry | Resource Development | CDC | NICHD | This is a registry of use of antiretroviral drugs in pregnancy that is sponsored by various pharmaceutical companies and has a committee of external experts and government staff from the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA). The registry provides a resource for clinicians and researchers to improve the healthcare quality and patient safety for HIV infected mothers and their infants. http://www.apregistry.com/ |
| Antiviral Program for Pandemics | Research Initiative | ASPR | NIAID, NCATS, OD/DPCPSI/ORIP | The Antiviral Program for Pandemics (APP) aims to develop safe and effective antivirals to combat SARS-CoV-2, the virus that causes COVID-19, as well as to build sustainable platforms for targeted drug discovery and development of a robust pipeline of antivirals against viruses with pandemic potential. https://www.niaid.nih.gov/research/antivirals |
| Arthritis Advisory Committee | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | This Committee provides expertise in the evaluation of evidence submitted by pharmaceutical companies to the Food and Drug Administration (FDA) for drug approval. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/default.htm |
| Assay optimization and screening for measuring the kinetics of antibacterial resistance emergence | Research Initiative | FDA | NCATS | Assay optimization and screening for measuring the kinetics of antibacterial resistance emergence |
| Assay subgroup for SARS-CoV-2 | Committee, Work group, Advisory group, or Task Force | CDC, FDA, BARDA, FDA | NIAID | The objective is to share assay development activities within the government Labs |
| Assessing the Burden of Diabetes by Type in Children, Adolescents, and Young Adults Network (DiCAYA) | Resource Development | CDC | NIDDK | The primary goal of the DiCAYA network is to modernize diabetes surveillance efforts to capitalize on large-volume, electronic health record data streams and on recent advances in statistics and clinical informatics to provide accurate, timely, cost-effective, granular, and representative indicators of diabetes prevalence and incidence among children, adolescents and younger adults. The network aims to monitor overall trends as well as trends within subgroups (e.g., age, sex, diabetes type, socioeconomic status, urbanicity, geographic area). NIDDK is a DiCAYA research sponsor. https://www.dicaya.org |
| Assessment of Inhalation Exposures to Indoor and Occupational Aerosols | Research Initiative | CDC | NIEHS | The primary goal of this collaboration is to study inhalation exposures to indoor and occupational aerosols, with a current focus on characterizing the health hazards associated with exposure to common fungal contaminants. NIOSH uses a specially developed exposure system to conduct subchronic toxicology studies following repeated exposure to molds identified by the NTP as a public health concern. Subprojects under this IAA are examining the association of exposure to mycotoxins and health by analyzing indoor air samples, developing biomarkers of exposure and response, and using genomic sequencing methodologies to assess fungal diversity associated with the built environment. |
| Assessment of task-based exposures that may affect reproductive health in nail salon employees | Research Initiative | CDC | NIEHS | The goal of this study is to better understand a nail technician's exposure profile to select reproductive toxicants by evaluating the contributions of different tasks. |
| Autoimmune Diseases Coordinating Committee | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA | NIAID, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NINDS, NINR | The purpose of the Autoimmune Diseases Coordinating Committee (ADCC) is to provide a forum for the coordination of research efforts in autoimmunity and autoimmune diseases among various stakeholders including the National Institutes of Health (NIH), other federal agencies such as the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC), and private organizations with an interest in autoimmune diseases. The ADCC meets twice yearly to discuss a broad range of basic, preclinical, and clinical endeavors. https://www.niaid.nih.gov/about/autoimmune-diseases-committee |
| Bacteriophage Interest Group (BIG) | Other | FDA | NIAID | Scientific interest group discussing science and issues around bacteriophage as treatment. Includes members from FDA, BARDA, and DMID |
| BARDA-DRIVe (DRIVE) | Research Initiative | ASPR | NIAID | BARDA DRIVe funds early stage companies for life saving innovation. Collaboration is on agnostic pathogen detection. `https://drive.hhs.gov/ |
| Behavioral Health Coordinating Council (BHCC) Children and Youth Behavioral Health Subcommittee | Committee, Work group, Advisory group, or Task Force | ACF, CMS, ACL, AHRQ, FDA, IHS, ASPE, CDC, OASH | NICHD, NIMH, NIDA | Our initial high-level priorities/areas of focus for children and youth: Ensure children, youth, and caregivers have access to appropriate behavioral health prevention resources, screening, referral, and treatments in their communities, schools, and early education settings; Address behavioral health needs resulting from the COVID-19 pandemic; Advance health equity by addressing the health needs of underserved communities; Support the behavioral health workforce that serves children and youth. https://alert.psychnews.org/2021/05/hhs-to-establish-behavioral-health.html |
| Behavioral Health Coordinating Council (BHCC) Performance Measures, Data, and Evaluation Subcommittee (MDE) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ASA, ASPE, CDC, CMS, FDA, IHS, NIH, ONC, SAMHSA | NIDA, NIMH | The goal of the Behavioral Health Coordinating Council (BHCC) Performance Measures, Data, and Evaluation Subcommittee (MDE) working group is to ensure that HHS leadership has the data and analyses needed to ensure that behavioral health is incorporated into HHS efforts. The working group will identify data gaps and propose ways to address them. |
| Bench to Bedside: Integrating Sex and Gender to Improve Human Health | Resource Development | FDA | OD/DPCPSI/ORWH | Bench to Bedside: Integrating Sex and Gender to Improve Human Health was developed in partnership with the Food and Drug Administration (FDA) Office of Women’s Health (OWH). This online course gives users a thorough and up-to-date understanding of sex and gender influences on health and disease so users can apply this knowledge when conducting research and interpreting evidence for clinical practice. Course material showcases examples from basic science through clinical trials and translation into practice to ensure participants understand the importance of considering the influence of sex and gender throughout the research spectrum and beyond. Through its six modules, the course focuses on key health conditions on which sex and gender have an impact. The six modules that compose the course are Immunology, Cardiovascular disease, Pulmonary disease, Neurology, Endocrinology, and Mental Health. https://orwh.od.nih.gov/career-development-education/e-learning/bench-bedside |
| Best Pharmaceuticals for Children Act (BPCA) Data Monitoring Committee | Committee, Work group, Advisory group, or Task Force | FDA | NICHD, NCI, NHLBI | This group provides safety oversight for all studies conducted under BPCA. https://www.nichd.nih.gov/research/supported/bpca |
| Best Pharmaceuticals for Children Act (BPCA) Research Oversight Committee | Committee, Work group, Advisory group, or Task Force | FDA | NICHD, NHLBI, NCI | This group provides programmatic support to project lead for the BPCA clinical program which includes the oversight prioritization and concept developments for the Pediatric Trials Network. https://www.nichd.nih.gov/research/supported/bpca |
| Best Pharmaceuticals for Children Act (BPCA) Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NICHD, NHLBI, NCI | This group provides safety oversight for all studies conducted under BPCA. https://www.nichd.nih.gov/research/supported/bpca |
| Biodefense Coordination Team (BCT) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP | Coordinates implementation of the U.S. National Biodefense Strategy and Presidential Memorandum on the Support for Biodefense towards an integrated, comprehensive approach to manage biodefense activities in support of the broader biodefense enterprise. |
| Biodosimetry Trans-NIH Working Group and Special Journal Issue | Committee, Work group, Advisory group, or Task Force | ASPR, FDA | NIAID | This collaboration highlights regulatory and scientific approaches in research and advancement of biodosimetry tests in both NIAID and BARDA portfolios |
| Biomarkers of Exposure and Effect in Agriculture (BEEA) | Research Initiative | CDC | NCI | National Cancer Institute (NCI) and the Centers for Disease Control and Prevention (CDC) are collaborating to characterize exposure to permethrin and other pesticides by measuring urinary metabolites among participants in the Biomarkers of Exposure and Effect in Agriculture (BEEA) study. |
| Biomarkers of Exposure and Effect in Agriculture (Water Contaminants) | Research Initiative | CDC | NCI | National Cancer Institute (NCI) and the Centers for Disease Control and Prevention (CDC) and the US Geological Survey (USGS) are collaborating on a study characterize exposure to water contaminants by measuring urinary nitrate excretion, and drinking water concentrations of nitrate, pesticides, and other chemicals, as well as hormone activity among a subset of participants in the Biomarkers of Exposure and Effect in Agriculture (BEEA) study. |
| Biomedical Studies and Cellular Imaging via Atomic Force Microscopy | Research Initiative | FDA | OD/OIR, NIBIB | Biomedical Studies and Cellular Imaging via Atomic Force Microscopy |
| Blood Products Advisory Committee | Committee, Work group, Advisory group, or Task Force | CDC, FDA | CC, NHLBI | The Food and Drug Administration (FDA) Blood Products Advisory Committee (BPAC) reviews and evaluates available data concerning the safety, effectiveness, and appropriate use of blood, products derived from blood and serum or biotechnology which are intended for use in the diagnosis, prevention, or treatment of human diseases, and, as required, any other product for which the Food and Drug Administration has regulatory responsibility. The committee also advises the Commissioner of Food and Drugs of its findings. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/BloodProductsAdvisoryCommittee/ |
| Blood, Organ, and Tissue Senior Executive Council (BOTSEC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, OS | NIAID, CC, NIAID7, NHLBI | The Blood, Organ, and Tissue Senior Executive Council (BOTSEC) is an advisory forum for senior leadership from the Department of Health and Human Services (HHS) organizational components, as well as liaison representatives from Department of Defense and Veterans’ Health Administration, that are involved in blood, organ, and tissue safety and availability. The HHS Assistant Secretary for Health serves as the Council Chair, and the Office of the Assistant Secretary for Health (OASH) Senior Advisor for Blood and Tissue Policy serves as the BOTSEC Executive Director. https://www.hhs.gov/oidp/topics/blood-tissue-safety/blood-organ-and-tissue-senior-executive-council/charter/index.html |
| Board of Scientific Counselors (BSC) of the CDC National Center for Injury Prevention and Control | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, CDC, HRSA, IHS, SAMHSA | NICHD, NIA, NIDA, NIMH | The BSC advises the Secretary, Department of Health and Human Services; the Director, Centers for Disease Control and Prevention (CDC); and the Director, National Center for Injury Prevention and Control (NCIPC) regarding surveillance, basic epidemiologic research, intervention research, and implementation, dissemination, and evaluation of promising and evidence-based strategies for the prevention of injury and violence. The Board makes recommendations regarding policies, strategies, objectives, projects, and priorities, and reviews progress toward injury and violence prevention. https://www.cdc.gov/injury/bsc/index.html |
| Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) | Committee, Work group, Advisory group, or Task Force | FDA | NICHD | The Committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drug products for use in the practice of osteoporosis and metabolic bone disease, obstetrics, gynecology, urology and related specialties, and makes appropriate recommendations to the Commissioner of Food and Drugs. https://www.fda.gov/advisory-committees/human-drug-advisory-committees/bone-reproductive-and-urologic-drugs-advisory-committee-formerly-reproductive-health-drugs-advisory |
| Botanical Safety Consortium | Research Initiative | FDA | NIEHS, NCCIH | Public-private partnership aimed at developing an in vitro toolkit for evaluating botanical safety https://botanicalsafetyconsortium.org/ |
| Botulism Guidelines Working Group | Committee, Work group, Advisory group, or Task Force | CDC | CC | The National Institutes of Health (NIH) Clinical Center is participating in a working group with the Centers for Disease Control and Prevention (CDC) to develop clinical guidelines for treatment of botulism and use of botulism antitoxin. |
| Brain Attack Coalition (BAC) | Committee, Work group, Advisory group, or Task Force | CDC | NINDS | The Brain Attack Coalition (BAC) is a group of public and private entities representing medical, scientific, advocacy, and government professionals from across the stroke continuum. The BAC is dedicated to setting direction, advancing knowledge, and communicating best practices to improve our ability to prevent and combat stroke. http://www.brainattackcoalition.org |
| Brain Research through Advancing Innovative Neurotechnologies Initiative (BRAIN Initiative) | Committee, Work group, Advisory group, or Task Force | FDA | NINDS, NCCIH, NEI, NIA, NIAAA, NIBIB, NICHD, NIDA, NIDCD, NIMH, OD/DPCPSI/OBSSR | The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is revolutionizing our understanding of the brain by developing and applying innovative technologies to study brain circuits and, ultimately, to develop new ways to treat brain disorders. Circuits of brain cells enable us to think, perceive our world, and act upon it, and disruption of these circuits underlies neurological, psychiatric, and substance misuse disorders. The BRAIN Initiative also facilitates collaborative neuroscience research partnerships, resource meetings, and working groups. http://braininitiative.nih.gov/ |
| BRIDG Standard Development | Research Initiative | FDA | NCI | Developing a conceptual data model that harmonize EMR data and protocol driven data http://bridgmodel.nci.nih.gov |
| Bridge to Artificial Intelligence (Bridge2AI) | Research Initiative | FDA | OD/DPCPSI/OSC, NLM, NEI, NHGRI, NCCIH, NIBIB, NICHD, NCATS, NIMH, NIMHD, NIAID, NCI, NIAMS, NINDS, NIDA, NIA, NIGMS, FIC, OD/DPCPSI/OBSSR, OD/AoU, OD/DPCPSI/ODSS | The Bridge to Artificial Intelligence (Bridge2AI) program seeks to propel biomedical research forward by setting the stage for widespread adoption of artificial intelligence (AI) and machine learning (ML) that tackles complex biomedical challenges beyond human intuition. Bridge2AI works with representatives from the Defense Advanced Research Projects Agency (DARPA), U.S. Department of Energy (DOE), National Science Foundation (NSF), National Institute of Standards and Technology (NIST), and U.S. Food and Drug Administration (FDA) in order to bring expertise from across the federal government to help develop this groundbreaking new program that aims to harness the power of AI/ML for human health. Bridge2AI is also collaborating with DOE Office of Science program in Advanced Scientific Computing Research to jointly address important issues and challenges in developing AI and machine learning methods for privacy-sensitive datasets. https://commonfund.nih.gov/bridge2ai |
| Build UP Trust Challenge Prize | Resource Development | CDC, HRSA, OASH | NHLBI, NIMHD, NCI, NIA, NIAID, NIEHS, NINDS, NCATS, NIAMS, NIBIB, NIDA, NICHD | The major objective of the Build UP Trust Challenge is to increase research participation, adoption of existing and new tools and strategies to detect, treat, and monitor diseases and disorders by improving engagement with underserved populations. |
| Canadian - U.S. Dietary Reference Intakes Working Group | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, OASH | OD/DPCPSI/ONR, NIDDK, OD/DPCPSI/ODS | The US and Canadian governments have each established Federal DRI Committees that work collaboratively to identify DRI needs and to coordinate government sponsorship of DRI reviews and related activities. The DRIs — which reflect nutrient reference values essential to national nutrition policies and to professionals working in the field of nutrition and health — have been developed under the auspices of the Institute of Medicine with funding from the US and Canadian governments. https://health.gov/our-work/food-nutrition/dietary-reference-intakes-dris/nutrient-assessment-dri-review |
| Cancer Diagnostic Devices Interagency Task Force (CD2) - MOU among NCI, FDA, HRSA | Committee, Work group, Advisory group, or Task Force | FDA, HRSA | NCI | Interagency Task Force: On Friday, September 17, 2021, leadership from the National Cancer Institute (NCI), Food and Drug Administration (FDA), and Health Resources and Services Administration (HRSA) signed a Memorandum of Understanding (MOU) to support solutions for early cancer detection and diagnosis to improve patient outcomes, quality of life, and reduce health disparities among medically underserved, geographically isolated, and otherwise vulnerable populations. MOU formalizes the establishment of a new interagency task force, the Cancer Diagnostic Devices Interagency Task Force (CD2), which includes representatives from the NCI, FDA, and HRSA. https://proteomics.cancer.gov/news_and_announcements/memorandum-understanding-signed-nci-fda-and-hrsa-bring-cancer-diagnostic |
| Cancer Moonshot Award | Research Initiative | OS | NIDCD, NCI | Cancer Moonshot Award to discover a panel of TCRs with various HLA restrictions for cancer and otolaryngic infectious disorders https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative |
| CCDI Molecular Target Platform | Resource Development | FDA | NCI | The CCDI Molecular Targets Platform allows users to browse and identify associations between molecular targets, diseases, and drugs. The RACE Act requires evaluation of new molecularly targeted drugs and biologics intended for the treatment of adult cancers and directed at a molecular target substantially relevant to the growth or progression of a pediatric cancer. This act also eliminates the orphan exemption for pediatric studies of cancer drugs directed at relevant molecular targets. In accordance with the RACE Act, the FDA, in collaboration with NCI and the pediatric cancer research community, developed a Relevant Molecular Target List (RMTL) to provide guidance to industry in planning for new drug and biologic submissions. NCI converted this RMTL list into a computer-readable format with gene-level granularity and all targets mapped and hyperlinked to additional resources and identifiers; integrated this list into Molecular Targets Platform. moleculartargets.ccdi.cancer.gov |
| CCR Vaccine Branch FACS Core | Research Initiative | FDA | NCI | CCR Vaccine Branch FACS Core |
| CCR, LGI, Flow Cytometry Core | Research Initiative | FDA | NCI | CCR, LGI, Flow Cytometry Core |
| CDC Acute Flaccid Myelitis Task Force | Committee, Work group, Advisory group, or Task Force | CDC | NINDS, NIAID | The AFM Task Force was established to aid in the ongoing investigation to define the cause of, and improve treatment and outcomes for, patients with AFM. The Task Force functions as a work group of the CDC Board of Scientific Counselors, Deputy Director for Infectious Diseases. https://www.cdc.gov/ddid/bsc/afm-task-force.html |
| CDC Integration with GrantSolutions | Resource Development | ACF, CDC | OD/OER | Collaboration with GrantSolutions to allow the Centers for Disease Control and Prevention (CDC) Research programs to seamlessly use electronic Research Administration (eRA) research grant support services, including the eRA Commons grantee portal and the eRA Peer Review suite while having grants management staff process awards within GrantSolutions. |
| CDC Office of Public Health Genomics | Public Education Campaign | CDC | NHLBI | This collaboration seeks to define and implement a translational trajectory for scientific discoveries in genomics and related fields to population health benefits in health areas relevant to National Heart, Lung, and Blood Institute (NHLBI) including, heart, lung, blood, and sleep disorders. |
| CDC Pathogen Genomic Centers of Excellence (PGCoE) | Research Initiative | CDC | NIAID | The PGCoE network is intended to foster and improve innovation and technical capacity in pathogen genomics, molecular epidemiology, and bioinformatics to better prevent, control. and respond to microbial threats of public health importance. https://www.cdc.gov/media/releases/2022/p0920-PGCoE-network.html |
| CDC-NIH Lyme Disease Serum Sample Repository | Resource Development | CDC, OS | NIAID | Initiated in 2008, this resource was made available to the scientific community on a broad basis in late 2011. Lyme disease and related serum samples are available upon request for testing and comparison of new and current diagnostic tests with a common serum sample set for standardization. Samples are distributed by the Centers for Disease Control and Prevention (CDC). CDC and National Institutes of Health (NIH) both provided support to acquire the samples and continue to work together to ensure the scientific community has access to samples needed for Lyme disease diagnostic test development. |
| CDC/NIH Quarterly Check-ins | Other | CDC | OD/DPCPSI/OAR, NIMH, NIAID | Regularly scheduled calls between CDC and NIH to share high level information, administrative updates, and upcoming initiatives related to HIV research. |
| Cell-Surface Interactions in Pathogenesis | Research Initiative | FDA | NIDCR | Cell-Surface Interactions in Pathogenesis |
| Center for Medicare and Medicaid Services (CMS) and National Institutes of Health (NIH) Opioids Work Group (OWG) | Committee, Work group, Advisory group, or Task Force | CMS | NIDA, NCCIH, NINDS, NIMH | With focused participation from both the Centers for Medicare and Medicaid Services (CMS) and experts across the National Institutes of Health (NIH), the Opioids Work Group (OWG) is designed to accelerate collaboration between these two HHS Operating Divisions related to addressing the U.S. opioid crisis. |
| Central Brain Tumor Registry of the United States (CBTRUS) | Research Initiative | CDC | NCI | CBTRUS is a resource for gathering and disseminating epidemiologic data on primary benign and malignant brain and other CNS tumors- Dr. Barnholtz-Sloan and her research team work with the CBTRUS team on a variety of research topics related to the epidemiology of brain tumors. |
| Cervical screening guidelines | Resource Development | CDC, HRSA, FDA | NCI | The National Cancer Institute (NCI) is generating risk estimates that inform cervical screening and management guidelines. NCI is working with CDC, HRSA, and FDA to collect study populations, conduct risk estimation, and disseminate guidelines. |
| CFAR Diversity, Equity, Inclusion Pipeline Initiative (CDEIPI) | Research Initiative | OASH | NIAID, NIMH, NCI, NHLBI, NIDDK, NINR, NIDCR, NIMHD, NICHD, NIA, FIC, OD/DPCPSI/OAR | The overarching goal of the NIH-supported CFAR Diversity, Equity, and Inclusion Pipeline Initiative (CDEIPI) is to support a diverse pool of trainees who are engaged in HIV science at the high school, undergraduate, graduate (masters, doctoral or medical) and post-doctoral levels, including trainees from underrepresented racial and ethnic groups. CDEIPI seeks to develop pathways for these "CFAR Scholars" to successful careers in science and medicine. OASH provided key information and advice in the development of this initiative. https://dccfar.gwu.edu/cfar-diversity-equity-and-inclusion-pipeline-initiative-cdeipi-0 |
| Characterize Emerging HIV Strains from Blood Donors and Patients | Resource Development | FDA | NIAID | This initiative will characterize emerging HIV strains from blood donors and patients to determine viral tropism based on co-receptor usage strains. It will update the global viral panels to analyze multiple, diverse isolates from different parts of the world. This activity is part of the National Institute of Allergy and Infectious Diseases (NIAID) ongoing efforts to develop a well-characterized repository for diagnostics, and drug and vaccine studies. https://eqapol.dhvi.duke.edu/ |
| Chemical Hazards Emergency Medical Management (CHEMM) Working Group | Committee, Work group, Advisory group, or Task Force | ASPR, CDC | NINDS, NLM, NICHD | The goal of CHEMM is to provide a comprehensive, user-friendly resource to help enable first responders and other healthcare providers to plan for, respond to, recover from, and mitigate the effects of mass-casualty incidents involving chemicals. https://chemm.hhs.gov/ |
| Chronic Kidney Disease Surveillance System | Health Survey | CDC | NIDDK | The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) assists the Centers for Disease Control and Prevention (CDC) in its surveillance program of chronic kidney disease, including taking part in an Advisory Group to provide feedback on the program. http://nccd.cdc.gov/ckd/ |
| Circulating Estrogens, Androgens, and Progestogens and Risk of Breast Cancer in the PLCO Cohort | Research Initiative | CDC | NCI | In a stratified cohort study of breast cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), restricted to postmenopausal women not on menopausal hormone therapy, researchers are using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay recently developed by the Centers for Disease Control and Prevention (CDC) to assess pre-diagnostic circulating levels of the endogenous steroid hormones believed to be involved in breast cancer etiology. Although it is known that endogenous hormones play a critical role in the etiology of breast cancer, the interrelationships among estrogens, androgens, and progesterone in determining risk are not well understood. |
| CLARITY - Mammary Gland efforts | Research Initiative | ATSDR | NIEHS | Collaboration between Fenton lab at NIEHS and Soto lab at Tufts University to study BPA effects on mammary gland |
| Clinical and Translational Research Course for PhD Students | Training Initiative | FDA | CC, NCATS, NCI, NHLBI, NIAID, NIDA, NIDCR, NIDDK, NIGMS, NIMH, NINDS | The Clinical and Translational Research Course for PhD Students is a two-week intensive introductory course for graduate students in the basic biomedical sciences who have at least one year of graduate study. The purpose of the course is to demonstrate and highlight the roles of PhD scientists in clinical and translational research, to provide an overview and examples of how basic science and clinical observations lead to translational research, and to increase awareness and access to PhD role models, research resources, and potential career opportunities at the National Institutes of Health (NIH). http://www.cc.nih.gov/training/phdcourse |
| Clinical and Translational Serology Task Force (CTTF) | Resource Development | CDC, FDA, ASPR | NCI, NIAID | The National Cancer Institute established a taskforce to catalyze translation of research findings into public health changes. The task force brings together government, academia and industry to provide relevant tools and information related to serology testing to help decisionmakers manage the current and future status of the SARS-CoV-2 pandemic. The task force includes scientists from several disciplines, clinicians, regulatory and public policy experts, and patient advocates. https://frederick.cancer.gov/initiatives/seronet/collaborators |
| Clinical Genome Resource and Genetic Testing Reference Material Program Collaborative Project (ClinGen and GeT-RM Collaborative Project) | Resource Development | CDC | NHGRI | ClinGen has partnered with the Centers for Disease Control and Prevention's Genetic Testing Reference Materials Program (or GeT-RM)to develop a publicly available list of expert curated, clinically important genomic variants that provides a foundation for designing comprehensive validation studies and for creating in silico reference materials for clinical genomic test development and validation. In August 2021, ClinGen and GeT-RM published their results in the Journal of Molecular Diagnostics. To assemble the expert curated variant list, members from 36 of ClinGen’s Expert Panels were asked to nominate clinically important variants, including SNPs, CNVs, difficult-to-sequence regions, and complex rearrangements. 546 genomic variants in 84 genes were nominated, including 29 genes on the American College of Medical Genetics and Genomics Secondary Findings v3.0 List. The nominated variants relate to a wide range of diseases, including heritable cancers, inborn errors of metabolism, cardiomyopathy, diabetes, and immune disorders. ClinGen and GeT-RM will continue to solicit feedback from the community and update the list on a regular basis. https://www.cdc.gov/labquality/get-rm/index.html |
| Clinical Immunization Safety Assessment Network (CISA) | Committee, Work group, Advisory group, or Task Force | CDC | NIAID, NHLBI | Subcommittee to evaluate myocarditis after COVID vaccination https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html |
| Clinical Investigator Interagency Working Group for the Development of Antiviral Influenza Therapeutics | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID | This working group discusses a range of issues relevant to the development of antiviral drugs for the treatment of influenza. |
| Clinical Pharmacology Quality Assurance Program (CPQA) | Other | CDC | NIAID | The Clinical Pharmacology Quality Assurance program provides proficiency test materials for the DAIDS clinical pharmacology labs, both domestic and internationally. The Proficiency testing panels include replicate samples of antiretroviral drugs of unknown concentration, which are determined by the labs using liquid-chromatography mass spectrometry (LC-MS/MS) methodology. Labs must determine concentrations with high accuracy and precision to 'Pass" the panel. In a partnership with the Center for Disease Control, two of their labs have been included to participate in the CPQA proficiency Testing Program. They ae the International Laboratory Branch Bioanalytical Laboratory and the Analytical and Clinical Evaluations Laboratory of the domestic CDC HIV Prevention Program. The CPQA also did validations of their drug quantification assay protocols and have conducted site visits to evaluate their operations. The CPQA contract operates through TRP in DAIDS. http://cpqaprogram.org/ |
| Clinical Research Using Medicare Data from the Virtual Research Data Center (VRDC) | Research Initiative | CMS | NLM | The National Library of Medicine (NLM) works with the Centers for Medicare and Medicaid Services (CMS) and other National Institutes of Health (NIH) institutes and centers (ICs) to demonstrate the value of the CMS Virtual Research Data Center (VRDC) as a source of data for research purposes. NLM's Clinical Data Discovery branch uses the VRDC to answer useful epidemiologic and clinical questions, specifically about drug benefits and possible harms. https://www.resdac.org/cms-data/request/cms-virtual-research-data-center |
| Clinical Trials of Biodefense Vaccines (Dengue) | Research Initiative | CDC | NIAID | Clinical Trials of Biodefense Vaccines (Dengue) |
| Clinical Utilization Plan for Anthrax Medical Countermeasure Use in a Mass Casualty Event (CUPAC) Medical Countermeasures Workgroup | Committee, Work group, Advisory group, or Task Force | CDC | CC | The National Institutes of Health (NIH) Clinical Center is participating as a member of the Medical Countermeasures Work Group to provide clinical algorithms that will assist clinicians to evaluate, triage, diagnose and treat large numbers of patients presenting with symptoms of anthrax. It will also provide a clinical prioritization schema for the use of medical countermeasures specific to anthrax and outline unique critical care issues that may require special consideration. |
| Clinical Vocabulary and Standards Development for Meaningful Use of Electronic Medical Records | Resource Development | CDC, CMS, FDA, ONC | NLM | The National Library of Medicine (NLM) collaborates with the Office of the Secretary OS and the Department of Health and Human Services (HHS) Office of the National Coordinator for Health Information Technology (ONC) and other parts of HHS on developing, maintaining, and disseminating clinical terminologies and codes related to health information technology, electronic health records, and messaging. http://www.nlm.nih.gov/healthit.html |
| CMS MCBS, Dietary Supplements, Measures of Malnutrition and Frailty | Health Survey | CMS | OD/DPCPSI/ODS | The National Institutes of Health's, Office of Dietary Supplement has been working with the Centers of Medicare and Medicaid Service to collect data on dietary supplement use, malnutrition and measures of frailty in the Medicare Current Beneficiary Study (MCBS). MCBS is a nationally representative survey that collects health and Medicare claims data from participants multiple times per year for up to 4 years. This information will be very helpful in assessing risk of malnutrition and frailty. Since the participants data are linked to their Medicare claims data, information can be validated against claims data, with the possibility for outcomes also to be assessed. https://www.cms.gov/Research-Statistics-Data-and-Systems/Research/MCBS |
| CMS-NIH Leadership Council | Committee, Work group, Advisory group, or Task Force | CMS | OD/OSP, NCCIH, NCI, NHGRI, NHLBI, NIA, NIDA, NIDDK, NIMHD, OD/IMOD, OD/OER | Facilitates leadership-level development of mutual priorities between both Department of Health and Human Services (HHS) operating divisions. |
| CMS/NIH/NHLBI Sickle Cell Disease Working Group | Meeting/ Workshop | CMS | NHLBI | Working group that meets to explore what is required to implement CMS coverage for curative therapies in SCD. |
| Collaborative Acute Toxicity Modeling Suite (CATMoS) | Committee, Work group, Advisory group, or Task Force | ATSDR, CDC | NIEHS, NCATS | With the increasing number of chemicals to assess for acute oral systemic toxicity potential (LD50) and the lack of in vitro approaches, the NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) and the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM), Acute Toxicity Workgroup organized an international collaborative project to develop in silico models as alternatives to predict LD50 and bridge data gaps. Participants from 35 groups submitted a total of 139 predictive models built using a dataset of 11,992 chemicals split into training (75%) and evaluation sets (25%). Crowdsourced models were developed for five endpoints: LD50 value, EPA hazard categories, GHS hazard categories, very toxic (LD50 < 50 mg/kg), and non-toxic (LD50 > 2000 mg/kg). Predictions within the applicability domains of the submitted models were evaluated, then combined into consensus predictions based on a weight-of-evidence approach. The resulting consensus model, forming the Collaborative Acute Toxicity Modeling Suite (CATMoS), leverages the strengths and overcomes the limitations of individual modeling approaches. The consensus predictions are fully reproduceable and performed at least as well as independent replicate in vivo acute oral toxicity assays. The CATMoS consensus model is available via the free and open-source tool OPERA (Open Structure-activity/property Relationship App). https://ntp.niehs.nih.gov/go/tox-models |
| Collaborative on Healthy Parenting in Primary Care | Public Education Campaign | CDC, HRSA, SAMHSA | NICHD | The Collaborative on Healthy Parenting in Primary Care recognizes the accumulated evidence of the effectiveness of family-focused prevention programs that promote the physical and behavioral health and emotional well-being of children from before their birth through adolescence. Members of the Collaborative have united around an initiative to support the integration of effective programs that promote healthy parenting into primary care settings in order to achieve optimal health for children. |
| Combating Antibiotic Resistant Bacteria (CARB) | Resource Development | CDC, FDA | NLM, NHGRI, NIAID | The National Action Plan for Combating Antibiotic-resistant Bacteria is a multi-agency initiative to deal with the threat of increasing antibiotic resistance. NLM's National Center for Biotechnology Information contributes to Sub-Objective 2.1.4: Develop and maintain a national sequence database of resistant bacteria. https://obamawhitehouse.archives.gov/sites/default/files/docs/national_action_plan_for_combating_antibotic-resistant_bacteria.pdf |
| Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) Joint Oversight Committee (CARBx-JOC) | Committee, Work group, Advisory group, or Task Force | BARDA, CDC | NIAID | CARB-X is a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria. CarbX is led by Boston University with funding from BARDA, NIAID, and other global funding agencies (Wellcome Trust, Germany's BMBF, UK GAMRIF and the Gates Foundation). The Joint Oversight Committee oversees operational, financial and strategic activities. NIAID and BARDA staff also monitor progress for projects in the CarbX portfolio, as well as act as reviewers for new proposals to the program. |
| Combined Exposures and Mixtures Research Program | Research Initiative | ATSDR, CDC, FDA, OASH | NIEHS | Combined Exposures and Mixtures Research Program |
| Commissioned Corps of the U.S. Public Health Service (USPHS) Oral Health Coordinating Committee (OHCC) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, CDC, CMS, FDA, OASH, IHS, SAMHSA | NIDCR | The OHCC includes representatives from HHS and other federal agencies, directs and coordinates a broad range of oral health policy, research, and programs within the USPHS, across federal agencies, and between the public and private sectors. The OHCC contributed to the HHS Oral Health Strategic Framework, 2014-2017 and the update is currently under publication review. https://dcp.psc.gov/OSG/dentist/ohcc.aspx |
| Community Guide Cardiovascular Coordination Team | Committee, Work group, Advisory group, or Task Force | CDC | NHLBI | The purpose of the workgroup is to assess the feasibility of and conducting an evidence-based review to assess the effectiveness of interventions using community health workers for cardiovascular disease prevention and other relevant topics. The completed reviews will be included in, “The Community Guide sponsored by the Community Preventive Services Task Force”. https://www.thecommunityguide.org/ |
| Community Preventive Services Task Force (CPSTF) | Committee, Work group, Advisory group, or Task Force | CDC, CMS, AHRQ, OASH, HRSA, IHS, SAMHSA | OD/DPCPSI/ODP, OD/DPCPSI | The Community Preventive Services Task Force (CPSTF) is an independent, non-federal panel of prevention experts that uses information from rigorously conducted systematic evidence reviews to make public health recommendations for preventive services that are delivered in community settings. These recommendations are intended to inform public health decision-making about policy, practice, and research priorities for community preventive services. Recommendations from the CPSTF are published in The Guide to Community Preventive Services. The Office of Disease Prevention (ODP) represents NIH as an official liaison member and works with the CDC and CPSTF members to ensure that recommendations represent the views, concerns, and needs of the NIH and our constituents. ODP staff also serve on, or recommend NIH scientists to serve on systematic evidence review teams, and help translate CPSTF recommendations and insufficient evidence findings into actions. http://www.thecommunityguide.org |
| Computational Toxicology for NIH Medications Discovery | Research Initiative | FDA | NIDA | Through an inter-agency agreement, the Food and Drug Administration (FDA) provides structure-activity, relationship-based toxicity predictions for compounds that are under evaluation in the National Institute on Drug Abuse (NIDA) Addiction Treatment Discovery Program. On a limited basis, other National Institutes of Health (NIH) ICs may utilize this resource by working through NIDA. |
| Computer-aided Diagnosis for Radiology Images | Research Initiative | FDA | CC, OD/OIR | This collaboration focuses on the improvement of computer-aided diagnosis for radiology images. Specific applications include computer-aided polyp detection for computed tomography (CT )colonography, improvements in the conduct and analysis of observer performance experiments using radiology images, and the use and development of advanced machine learning and receiver operating characteristics methods with application to computer-aided diagnosis. |
| Congenital Heart Public Health Consortium | Resource Development | AHRQ, CDC | NHLBI | The Congenital Heart Public Health Consortium (CHPHC) is a group of organizations uniting resources and efforts in public health activities. The mission of the CHPHC is to prevent congenital heart defects and improve outcomes for affected children and adults. The consortium achieves its mission by providing leadership and a unified voice for public health priorities, expanding opportunities for surveillance and public health research, and informing public policy priorities that benefit public health and affected persons. The CHPHC represents various federal, state, and community organizations, including those representing patient/family, clinical, and research interests. It is pooling expertise and experience and using a public health model to address Congenital Heart Disease (CHD) issues across the lifespan. https://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/chphc/Pages/default.aspx |
| Consumer Product Chemical Exposures in Pregnancy and Their Cumulative Impact on Disorders of Fetal Growth | Research Initiative | CDC | NIEHS | The purpose of this collaboration is to characterize exposure to organophosphate (OP) flame retardants and pesticides among pregnant women by measuring OP flame retardants and dialkyl phosphate metabolites (DAPs) in urine samples from 3 visits in pregnancy. We will examine associations between these markers and fetal growth as well as inflammation biomarkers. |
| Contract to fund Congressional mandated National Academies of Sciences, Engineering, and Medicine (NASEM) study on Organ Donation and Transplantation | Committee, Work group, Advisory group, or Task Force | HRSA | NIAID, NHLBI, NIDDK | Contract for a NASEM study to examine and recommend improvements to research, policies, and activities related to organ donation and transplantation. The report shall include: ( 1) identification of current challenges involved in modeling proposed organ allocation policy changes and recommendations to improve modeling; (2) recommendations about how costs should be factored into the modeling of organ allocation policy changes; (3) a review of scoring systems (e.g., CPRA, EPTS, KDPI, LAS, MELD, etc.) or other factors that determine organ allocation and patient prioritization and recommendations to assure fair and equitable practices are established, including reducing inequities affecting socioeconomically disadvantaged patient populations; ( 4) recommendations to update the OPTN's policies and processes to ensure that organ allocation decisions take into account the viewpoints of expert OPTN committees; and (5) such other issues as may be identified. |
| Coordinating Committee on Research on Women's Health (CCRWH) Sex, Gender, and Intersectionality (SG&I) Innovations Working Group (CCRWH SG&I Innovations WG) | Research Initiative | FDA, AHRQ, Other | OD/DPCPSI/ORWH, OD, NIA, NHLBI, OD/AoU, NIGMS, NICHD, NCI, NINDS, NIBIB, NCCIH, NIDA | To stimulate and accelerate innovation for women's health research and sex-, gender-, and intersectional-specific interventions thereby creating scientific, societal, economic opportunities (i.e. entrepreneurial opportunities) that promote gender equity |
| COPD National Action Plan | Meeting/ Workshop | AHRQ, CDC, CMS, HRSA, IHS | NHLBI, NCI, NIA, NIEHS, NINR | The Chronic Obstructive Pulmonary Disease (COPD) National Action Plan is the first-ever blueprint for a multi-faceted, unified fight against the disease. Developed at the request of Congress with input from the broad COPD community, it provides a comprehensive framework for action by those affected by the disease and those who care about reducing its burden. https://www.nhlbi.nih.gov/health-topics/education-and-awareness/COPD-national-action-plan |
| Countering Biothreats IPC on Promoting and Protecting the Bioeconomy | Committee, Work group, Advisory group, or Task Force | FDA, OS | OD/OSP | Discusses and coordinates policy options related to promoting and protecting the bioeconomy. |
| Countering Biothreats sub-IPC on Promoting and Protecting the Bioeconomy | Committee, Work group, Advisory group, or Task Force | FDA, OS | OD/OSP | Discusses and coordinates policy options related to promoting and protecting the bioeconomy; Sub-Committee of the Countering Biothreats PCC on Promoting and Protecting the Bioeconomy. |
| Countermeasures Against Chemical Threats program (CounterACT) | Research Initiative | ASPR | NIEHS, NIAID, NIAMS, NICHD, NEI, NINDS, NIDA | The overarching goal of the CounterACT program is to integrate cutting-edge research with the latest technological advances in science and medicine for a more rapid and effective response during these chemical emergencies. https://www.ninds.nih.gov/Current-Research/Trans-Agency-Activities/CounterACT |
| Country Work in Cancer Research and Cancer Control Planning Strengthening – Kenya | Research Initiative | CDC | NCI, FIC, NIAID | Kenya has an estimated population of over 42 million. Cancer ranks third as a cause of death after infectious and cardiovascular diseases. It estimated that over 18,000 Kenyans die of cancer annually. The most common types of cancer in Kenya are cancers of the cervix, breast, esophagus, and prostate. The Ministry of Health released a National Cancer Control Strategy (2010-2015) and a National Cervical Cancer Prevention Program Strategic Plan (2012-2015). NCI looks to build upon those efforts in coordination with the many US government and non-governmental partners (NGOs) working in the country. US government agencies, including the National Cancer Institute (NCI), the National Institute of Allergy and Infectious Disease (NIAID), the Fogarty International Center (FIC), the Centers for Disease Control (CDC), and the US Agency for International Development (USAID) have a significant presence in Kenya. Between FY 2010 and FY 2012, there were 121 NIH or CDC awards totaling $160.1M, and USAID invested $700 million in Kenya in FY 2011. At least six NCI-designated cancer centers have activities in Kenya ranging from capacity building for cancer screening and treatment to studies of cancers associated with chronic infection, including HPV. Notably, Moi University has hosted the Academic Model Providing Access to Healthcare (AMPATH) partnership, along with Indiana University (IU), since 2001. The AMPATH-Moi-IU partnership has created the largest clinical research data enterprises in the developing world and includes 18 HIV clinics in western Kenya with 2,000 new patients enrolling per month as of 2012. |
| COVID antibody testing | Research Initiative | ASPR | NIAID | Testing of candidate therapeutic antibodies for neutralization against SARS-CoV-2 variants |
| Covid Serology Research and Results Tracker (SeroHub) | Resource Development | CDC | NCI, NIAID | The Covid-19 Serology Research Tracking System and Dashboard serves as a research resource to the NCI/NIAID/CDC and to the broader research community to monitor seroprevalence. https://covid19serohub.nih.gov |
| COVID-19 and Influenza Scenario Modeling Hubs (SMH) | Research Initiative | CDC | FIC, NIGMS | Collaboration between NIH, CDC and academia for disease projections. From weather to infectious diseases, it has been shown that synergizing results from multiple models gives more reliable projections than any one model alone. The COVID-19 Scenario Modeling Hub is a collaborative effort between multiple government agencies and academic institutions to harmonize COVID-19 projections in the United States and facilitate planning and decision making at a 3-12 month time scale. Since December 2020, the COVID19 scenario modeling hub has released 12 rounds of projections on issues as varied as the impact of the vaccination program, non-pharmaceutical interventions, waning immunity, and new variants on the trajectory of cases, hospitalizations and deaths across the US. The most recent set of projections addresses the impact of Omicron. In each round of projections, a set of 4 scenarios are identified to allow alignment of model projections for collective insights. Scenarios are designed in consultation with academic modeling teams, NIH and the CDC. Between 6 and 10 models have contributed to each round. All projections are made publicly available via the COVID-19 scenario modeling hub github and website. After each round, a report summarizing key results is shared with decision-makers and public health stakeholders. There has been substantial media coverage on this effort and results have been used by CDC/ACIP to guide COVID19 vaccine recommendations. The hub expanded in 2022 to generate influenza projections. This study builds on long-standing efforts led by the Fogarty International Center's in-house research division to develop computational approaches to mitigate pandemic risk and foster collaborative network in disease modeling. This effort extends a prior collaboration titled the Multinational Influenza Seasonal Mortality Study (MISMS) to assess the epidemiology, ecology, and evolutionary dynamics of influenza and other rapidly transmissible respiratory viruses. Multinational and bilateral collaborations developed through MISMS collect, analyze, and disseminate research findings through scientific publications, training workshops, and communication tools for investigators and decision-makers. These research findings inform numerous national governments, multilateral organizations, and research stakeholders on interventions for both pandemic and seasonal influenza. To date, data have been acquired from more than 40 countries (representing ~3.2 billion people), resulting in over 220 publications. https://covid19scenariomodelinghub.org/ |
| COVID-19 Health and Safety Briefs | Training Initiative | CDC | NIEHS | A number of technical documents/briefs were created to provide guidance: Selection and Use of Portable Air Cleaners to Protect Workers from Exposure to SARS CoV-2; Key Information for Workplace and Training Provider; Respiratory Hazard Assessment Brief. https://tools.niehs.nih.gov/wetp/covid19worker/ |
| COVID-19 OpenData Portal | Research Initiative | ASPR | NCATS, NIAID, NLM | The NCATS OpenData COVID-19 portal is a resource designed to rapidly and openly share SARS-CoV-2 screening data and assay information with the global health community. NCATS scientists have worked to develop a number of SARS-CoV-2-related assays (18 high-throughput screens to date) to measure over 10,000 compounds, including the NCATS Pharmaceutical Collection of nearly 3,000 approved drugs, for their activity against the virus. These data include all positive and negative results from a diverse panel of repurposing screens, and can be viewed, sorted, searched and exported directly from the portal website. Screening datasets were uploaded to the website as soon as they were validated and available. This resource aims to reimagine the early translation process by sharing screening data immediately and without restrictions. We hope to enable a variety of drug repurposing activities and allow researchers to formulate and test hypotheses, prioritize research opportunities and speed the search for effective therapies against the virus and the disease it causes. In collaboration with ACTIV TRACE, the OpenData Portal has evolved to share a wider array of data, including the most comprehensive public database of in vitro therapeutic activity data available against known variants. To date, this living resource has compiled more than 17,000 activity data points from tested variants, curated from nearly 440 different publications/datasets. https://ncats.nih.gov/expertise/covid19-open-data-portal |
| COVID-19 Therapeutics Interagency Working Group | Committee, Work group, Advisory group, or Task Force | FDA, CDC | NIAID | To share updates on the wide range of COVID therapeutics efforts that are progressing across the agencies |
| Critical Path for Rare Neurodegenerative Diseases (CP-RND) | Research Initiative | FDA | NINDS | Critical Path for Rare Neurodegenerative Diseases is a public-private partnership aimed at advancing the understanding of neurodegenerative diseases and supporting the development and regulatory review of treatments for amyotrophic lateral sclerosis (ALS) and other rare neurodegenerative diseases. https://c-path.org/programs/cp-rnd/ |
| CTAC Ad hoc Strategic Planning Working Group (CTAC SPWG) | Committee, Work group, Advisory group, or Task Force | FDA, CMS | NCI | The Clinical Trials and Translational Research Advisory Committee (CTAC) SPWG was charged to re-assess NCI’s strategic vision for its clinical trials system for 2030 and beyond. The Working Group will review and address the capabilities of the clinical trials infrastructure necessary for achieving this vision as well as consider recommendations for relevant future CTAC activities. https://deainfo.nci.nih.gov/advisory/ctac/ctac.htm |
| CTAC ad hoc Working Group on Streamlining Clinical Trials (CTAC SCTWG) | Committee, Work group, Advisory group, or Task Force | FDA | NCI | The Clinical Trials and Translational Research Advisory Committee (CTAC) Streamlining Clinical Trials Working Group will address the implementation of the CTAC Strategic Planning Working Groups recommendations around streamlining NCI clinical trials. The Working Group will advise NCI on ways to limit data collection in clinical trials as well as optimize the utilization of Electronic Health Records (EHRs) to support clinical trials.*The working group released its interim report in FY2023. https://deainfo.nci.nih.gov/advisory/ctac/ctac.htm |
| CURE ID | Research Initiative | FDA | NCATS | CURE ID is an internet-based repository that lets the clinical community report novel uses of existing drugs for difficult-to-treat infectious diseases through a website, a smartphone or other mobile device. The platform enables the crowdsourcing of medical information from health care providers to facilitate the development of new treatments for neglected diseases. CURE ID is a collaboration between the FDA and the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH). FDA and NIH are also collaborating with the World Health Organization and the Infectious Disease Society of America to assess the global utility of the CURE ID. With an $8.3 million grant from HHS ASPE;s Patient-Centered Outcomes Research Trust Fund, CURE ID is also being expanded to include case reports extracted automatically from electronic health records using the EDGE Tool. This will significantly increase the quantity of data included in CURE ID. The EDGE tool is currently being used for COVID-19 data and is now being expanded to capture data on sepsis and meningitis treatments. https://cure.ncats.io/home |
| CURE ID App for Infectious Disease Case Reporting | Research Initiative | FDA | NCI | CURE ID App for Infectious Disease Case Reporting |
| Cytokine Interest Group | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NEI, NHGRI, NIA, NIAID, NIAMS, NICHD, NIDCR, NIDCD | The Cytokine Interest Group brings together the National Institutes of Health (NIH) and Food and Drug Administration (FDA) scientists from many different areas working with cytokines as mediators of immune processes. It provides a platform for establishing networks for the exchange of ideas and reagents. Its activities comprise multiple minisymposia throughout the year and an award for the best paper in cytokine research for postdoctoral fellows working at the NIH or FDA. https://oir.nih.gov/sigs/cytokine-interest-group |
| DailyMed | Resource Development | FDA | NLM | DailyMed provides high-quality information about marketed drugs, including FDA labels (package inserts). The website provides health information providers and the public with a standard, comprehensive, up-to-date, look-up and download resource of medication content and labeling as found in medication package inserts. National Library of Medicine (NLM) provides this DailyMed as a public service, free of advertising. http://www.dailymed.nlm.nih.gov |
| Data Access for Grantees | Resource Development | CMS | NIA | National Institute on Aging (NIA) has an Inter-Agency Agreement (IAA) to assist grantees with accessing Centers for Medicare Medicaid Services (CMS) data. It is anticipated that this initiative will create a more user-friendly and more cost-efficient means for grantees to access CMS data, especially the need to access Part D data. Specifically, this agreement gives CMS's Privacy Board justification to release Part D data to NIA grantees with Data Use Agreements. Researchers pay for data use. This includes activities for remote access data enclave. |
| Department of Defense Resuscitation and Transfusion Steering Committee | Committee, Work group, Advisory group, or Task Force | CDC | CC, NHLBI | This committee oversees the Department of Defense (DoD) research in resuscitation and transfusion. |
| Department of Health and Human Services (DHHS) Guidelines for Treatment of HIV Related Opportunistic Infections Among Adults and Adolescents | Committee, Work group, Advisory group, or Task Force | CDC | CC, OD/DPCPSI/OAR | The National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, and the Centers for Disease Control and Prevention (CDC) have developed guidelines for treatment of opportunistic infections (OIs) among adults and adolescents infected with human immunodeficiency virus (HIV). These guidelines are intended for clinicians and other health-care providers who care for HIV-infected adults and adolescents, including pregnant women; they complement companion guidelines for treatment of OIs among HIV-infected children and previously published guidelines for prevention of OIs in these populations. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5315a1.htm |
| Department of Health and Human Services (DHHS) Health Care Personnel Influenza Vaccination Interagency Working Group | Committee, Work group, Advisory group, or Task Force | OS | CC | This committee is charged with developing strategies to increase the number of healthcare professionals who are vaccinated with the influenza vaccine. http://www.hhs.gov/ash/initiatives/hai/hcpflu.html |
| Department of Health and Human Services (DHHS) Healthcare Infection Control Practices Advisory Committee (HICPAC) | Committee, Work group, Advisory group, or Task Force | OS | CC | This committee serves as the major policy advisory committee in the nation for healthcare epidemiology. |
| Department of Health and Human Services (DHHS) Medical Claims Review Panel | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | CC | The Medical Claims Review Panel (MCRP) assists the Department of Health and Human Services (DHHS) in meeting its responsibility to provide quality health care in its facilities and by its practitioners. The MCRP reviews paid claims against DHHS facilities and providers to determine if the care provided met the standard of care and makes quality improvement recommendations to health care facilities and individual providers. The Panel meets monthly and includes two National Institutes Health (NIH) representatives; the current Chair of the Panel is an NIH physician. |
| Department of Health and Human Services (DHHS) Steering Committee for the Prevention of Healthcare-Associated Infections | Committee, Work group, Advisory group, or Task Force | OS | CC | This steering committee is charged with developing a national action plan for addressing the important problem of healthcare-associated infections. https://health.gov/hcq/prevent-hai-action-plan.asp |
| Department of Health and Human Services (HHS) Biovigilance Committee | Committee, Work group, Advisory group, or Task Force | CDC | CC, NHLBI | This committee develops systems for reporting adverse events resulting from blood transfusion or donation. |
| Department of Health and Human Services AAPI Memorandum Workgroup | Meeting/ Workshop | AHRQ, FDA, OASH, CDC, ASFR, ASPE, CMS | NIMHD | This AAPI Workgroup provides input and supports the implementation of the Memorandum on Condemning and Combating Racism, Xenophobia, and Intolerance Against Asian Americans and Pacific Islanders in the United States. It also promotes best practices for advancing cultural competency, language access, and sensitivity and federal policies to ensure that official actions, documents, and statements do not contribute to racism, xenophobia, and intolerance. |
| Development of New Approach Methodologies to Reduce Animal Use in Toxicity Testing -SBIR/STTR Town Hall Meeting | Meeting/ Workshop | FDA | NIEHS | This webinar-based town hall meeting was presented to facilitate improved communication between New Approach Methodologies (NAMs) method developers, including small business (SBIR/STTR) applicants, developing assays to reduce animal use in toxicity testing, and end-users and regulatory agency staff, providing an opportunity for the assay developers to hear from Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM), agency and industry stakeholders on the desired characteristics and requirements for NAM to meet testing requirements. https://www.niehs.nih.gov/research/supported/translational/sbir/townhall/index.cfm |
| Development Of New Approaches To Vaccines Against Neurotropic Flaviviruses | Research Initiative | FDA | OD/OIR, NIAID | Development Of New Approaches To Vaccines Against Neurotropic Flaviviruses |
| Development testing of nucleic acid-based vaccine for HIV other indications | Research Initiative | FDA | NCI | Development testing of nucleic acid-based vaccine for HIV other indications |
| Diabetes Mellitus Interagency Coordinating Committee (DMICC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OASH | NIDDK | The DMICC, chaired by NIDDK, facilitates cooperation, communication, and collaboration on diabetes among the participating government entities. DMICC meetings, held several times a year, help members identify emerging issues and opportunities and develop ways in which different government components can work together and build upon each other's expertise and resources. This approach helps ensure that federal diabetes activities are coordinated and not duplicated, as well as stimulates collaborations where appropriate. https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/diabetes-mellitus-interagency-coordinating-committee-dmicc |
| Diabetes Prevention Program Outcomes Study (DPP/DPPOS) | Research Initiative | CDC | NIDDK, NCI, NHLBI, NIA | The Diabetes Prevention Program (DPP) showed that lifestyle change or the drug metformin delay the development of type 2 diabetes. The Diabetes Prevention Program Outcomes Study is studying the long-term effect of diet and exercise and the diabetes medication, metformin, on the delay of type 2 diabetes in participants of the DPP. https://dppos.bsc.gwu.edu/web/dppos/about |
| Diabetic Eye Disease Information Dissemination | Public Education Campaign | CDC | NEI | The Centers for Disease Control and Prevention (CDC's) National Diabetes Education Program is part of the National Eye Health Education Program Partnership. The National Eye Institute (NEI) continues to collaborate with CDC and other stakeholders to share information about diabetic eye disease with various communities. |
| Diagnosis, Treatment, and Medical Service Utilization in Medicare and Medicaid Population | Research Initiative | CMS | CC | Centers for Medicare and Medicaid Services (CMS) and the National Institutes of Health (NIH) Clinical Center (CC) Rehabilitation Medicine (RMD) agreed to collaborate in data-sharing for research, the results of which may be helpful to improve medical-service quality, utilization, and effectiveness for Medicare and Medicaid beneficiaries. CMS will provide electronic data to the NIH Clinical Center, which will perform analyses that are agreed to by both parties. |
| Diagnostics and Disease Management Tools for Use in Underserved Populations: An NHLBI Research & Implementation Workshop | Meeting/ Workshop | AHRQ, CMS, CDC, FDA, OASH, HRSA, IHS | NHLBI, NCATS, NIMHD, NIBIB | On April 14-15, 2021, the NHLBI convened a virtual workshop aimed at using technology to improve heart, lung, blood, and sleep health in historically underserved, low-resource, and remote communities. The goal was to identify more accessible and feasible technological solutions for disease diagnosis and management in these groups, highlight the ones that could have the greatest impact, and determine the ones best suited for further research. During the two-day event, approximately 1,800 participants came together to discuss sustainable and affordable technology solutions, effective community-based strategies, and innovative models for disease management and diagnosis in underserved populations. Participants included academic researchers, implementation scientists, technology and medical device experts, and community and federal health leaders. https://www.nhlbi.nih.gov/events/2021/diagnostics-and-disease-management-tools-use-underserved-populations-nhlbi-research |
| Diet Induced Hypomethylation in Preneoplastic Liver | Research Initiative | FDA | NCI | The Food and Drug Administration (FDA)'s the National Center for Toxicological Research, and the National Cancer Institute (NCI)'s Division of Cancer Prevention, Nutritional Sciences Research Group are collaborating on an Interagency Agreement in which NCI will provide funds to examine the role of epigenetic mechanisms as factors that determine susceptibility to the development of hepatocellular carcinoma and to examine epigenetic alterations which may be used as markers of susceptibility to disease development, and whether correction of those epigenetic abnormalities during hepatocarcinogenesis may be a crucial decisive factor in cancer prevention strategies. |
| Dietary Supplement Label Database (DSLD) | Resource Development | FDA, CDC | OD/DPCPSI/ODS, NLM, OD/DPCPSI/ODSS, NCCIH, NCI | The National Institutes of Health's, Office of Dietary Supplement Dietary Supplement Label Database (DSLD) is a non-regulatory catalog of all information printed on labels of dietary supplement products sold in the United States. Label records in the DSLD are sourced from products reported in national population-based surveys, and through voluntary submissions by dietary supplement manufacturers and marketers. Information in the DSLD can be used by healthcare providers to determine the contents of the products their patients are taking, consumers can learn more about the ingredients listed on the Supplement Facts label by linking to nutrient fact sheets, and research scientists may use the DSLD in studies to derive nutrient intakes from supplements. https://ods.od.nih.gov/Research/Dietary_Supplement_Label_Database.aspx |
| Dietary Supplement Relevant - Special Interest Databases (purines, nitrates/nitrates) | Resource Development | FDA | OD/DPCPSI/ODS | The National Institutes of Health's, Office of Dietary Supplement collaborates with the US Department of Agriculture's (USDA) Methods and Application of Food Composition Laboratory on the development of several special interest food composition databases, such as the USDA, FDA and ODS-NIH Database for the Iodine Content of Common Foods, the USDA Special Interest Databases on Flavonoids and more recently funding for the development of a database on nitrates/nitrites, thiocyanates, glucosinolates, and purines (including Methylxanthines). These databases allow researchers to estimate these components in their diet studies and provide information for clinicians/dietitians when providing dietary guidance. https://ods.od.nih.gov/Research/Iodine.aspx |
| Dietary Supplement Research Coordination Committee (DSRCC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | OD/DPCPSI/ODS, CC, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NINR, NLM, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH, OD/DPCPSI/ONR | The National Institutes of Health's, Office of Dietary Supplement Dietary Supplement Research Coordinating Committee (DSRCC) was established in 2022 by the Office of Dietary Supplements (ODS) to increase collaboration among NIH Institutes, Centers, and Offices and federal agency partners whose programs include work that focuses on dietary supplements and the intersection of dietary supplement, natural product, and nutrition research. The DSRCC provides research coordination through the exchange of programmatic and scientific information, collaborative planning, and the implementation of relevant activities and initiatives. https://ods.od.nih.gov/About/NIHDSRCC.aspx |
| Digestive Diseases Interagency Coordinating Committee (DDICC) | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA | NIDDK, NCI, NIBIB | The Digestive Diseases Interagency Coordinating Committee, chaired by NIDDK, is charged with facilitating cooperation and collaboration in research efforts in digestive diseases among NIH Institutes and other relevant Federal health agencies to provide a structure for coordinated efforts to combat digestive diseases. The Committee also prepares reports on the status of digestive disease research funding as well as needs for future research in specific areas of digestive diseases. The Committee meets to encourage exchange of information among member organizations and develop common initiatives. https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/digestive-diseases-interagency-coordinating-committee |
| Digital Quantitation of Plasma Cells in Marrow Biopsies | Research Initiative | FDA | CC | This project is a collaboration between the National Institutes of Health (NIH )Clinical Center and the Food and Drug Administration (FDA)that consists of developing software and establishing validations for the automated determination of marrow cellularity and enumeration of plasma cells identified by immunohistochemistry (IHC) using a CD138 antibody. This initial effort should serve as proof of principle for a broader plan to utilize IHC-based automated quantitation of different types of cells in bone marrow core biopsies for diagnosis, prognosis, and therapy monitoring of marrow disorders. |
| Drug Development Interest Group | Committee, Work group, Advisory group, or Task Force | ASPR | NIAID, FIC, NCI, NHLBI | Share information about state of the art and challenges in drug development for infectious diseases |
| Drug Induced Liver Injury Network (DILIN) | Resource Development | FDA | NIDDK, NCI | Both a prospective and retrospective database containing cases of drug-induced liver disease, the Drug-Induced Liver Injury Network (DILIN) is funded by a cooperative agreement and includes eight clinical centers and a central data coordinating center. Established by NIDDK, one of the goals of the DILIN is to establish a database of well-characterized cases of drug-induced liver injury along with serum, DNA, and tissue samples that will facilitate research on the mechanisms of hepatic injury due to drugs. Cases of liver injury due to herbal medications are also included. The DILIN will develop standardized definitions of drug-induced liver disease and standardization of scoring systems for causality. Employees of the Food and Drug Administration (FDA) serve as ad hoc members on the committee overseeing the network activities. http://www.dilin.org/ |
| EAGeR Trial - The Effects of Aspirin in Gestation and Reproduction Trial | Research Initiative | FDA | NICHD | EAGeR Trial - The Effects of Aspirin in Gestation and Reproduction Trial |
| Early Hearing Detection and Intervention | Meeting/ Workshop | CDC, HRSA | NIDCD | This is Federal collaboration program involving the National Institute on Deafness and Other Communication Disorders (NIDCD), the Centers for Disease Control and Prevention (CDC), and the Health Resources and Services Administration (HRSA). NIDCD collaborates on early identification and diagnosis of hearing loss and intervention services for newborns and infants. HRSA funds awards to states and healthcare providers to screen newborns and young children for hearing loss. CDC funds states to develop data systems to track hearing loss. NIDCD also funds research grants to scientists throughout the US to study early hearing detection and intervention services. Regular (roughly quarterly) meetings with federal partners, currently organized and facilitated by HRSA. http://www.cdc.gov/ncbddd/hearingloss/index.html |
| Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) Multisite with Coordinating Center | Research Initiative | HRSA | NHLBI, NICHD, NIDDK, OD/DPCPSI/OBSSR | To test the effectiveness of an implementation-ready intervention designed to promote cardiovascular health (CVH) and address CVH disparities in both mothers and children (0-5 yr.) who are of low socio-economic status (SES), or live in low-income underserved rural or urban communities, or in diverse geographic regions with high burden of cardiovascular disease (CVD) risk factors (obesity, hypertension, diabetes). |
| Ebola Clinical Research Response in Democratic Republic of the Congo | Research Initiative | CDC, ASPR | NIAID | Multi-lateral collaborative partnerships including, but not limited to National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and host countries Ministries of Health. Research focus includes Ebola and other emerging and re-emerging infectious diseases. These programs are capable of rapidly mounting a clinical research response. |
| Ebola Clinical Research Response in West Africa (Guinea, Liberia) | Research Initiative | CDC, FDA | NIAID | Multi-lateral collaborative partnerships including, but not limited to National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and host countries MoH. Research focus includes Ebola and other emerging and re-emerging infectious diseases. These programs are capable of rapidly mounting a clinical research response. |
| Ebola Vaccines Advisory Committee on Immunization Practices (ACIP) Working Group | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | Develop recommendations on Ebola Vaccines for Advisory Committee on Immunization Practices (ACIP) |
| ECHO Institute and Project ECHO for Cancer Research and Control | Other | CDC | NCI | The mission of Project ECHO (Extension for Community Healthcare Outcomes) at the University of New Mexico Health Sciences Center (UNMHSC) is to demonopolize knowledge and amplify the capacity to provide best practice care for underserved people all over the world. In pursuit of this mission, Project ECHO faculty, staff and partners have dedicated themselves to de-monopolizing knowledge in order to expand access to best-practice medical care across the United States and globally. The ECHO model utilizes a technology-enabled case-based knowledge exchange approach. The NCI/CGH through partnership with the ECHO Institute utilizes the ECHO model to convene global cancer research and control networks to exchange knowledge to advance the uptake of evidence-based interventions to advance cancer control and build research partnerships. Project Extension for Community Healthcare Outcomes (ECHO) is a collaborative medical education model that aims to build workforce and knowledge capacity, through use of online videoconferencing to allow for knowledge exchange across interdisciplinary teams on relevant medical, healthcare, and health systems related topics. The National Cancer Institute (NCI) Center for Global Health (CGH) Project Echo Cancer Control Planning Program will link participants active in cancer control planning in low- and middle-income country settings with researchers, regional colleagues, and relevant technical experts, through monthly ECHO sessions that will provide virtual didactic instruction, case study learning, and knowledge exchange on relevant evidence-based cancer control planning principles. These sessions will relay evidence-based, general cancer control principals and related to cervical cancer screening. The CGH Project ECHO program's primary goals are to increase participant knowledge of the aforementioned topics, improve the application of knowledge, including evidence-based practices and policies, and to increase collaboration among participants and experts who are active in cancer control planning in the participating countries. https://hsc.unm.edu/echo/ |
| Effective Data Management Subgroup of the Open Science Infrastructure Working Group of the Subcommittee on Open Science of the National Science and Technology Council Subcommittee on Open Science (NSTC OSTP SOS-EDM) | Committee, Work group, Advisory group, or Task Force | ACL, ASPR, CDC | NLM, OD/OSP | The SOS Effective Data Management Subgroup (formerly the Data Management Repository Standards Subgroup) was established to coordinate implementation of and ongoing support for federal agency policies on public access to research data. NLM co-chairs this group with NSF and ACL. |
| EHE Operations Leadership Team (OLT) | Committee, Work group, Advisory group, or Task Force | OASH, CDC, HRSA, IHS, SAMHSA, CMS | NIAID, NIMH, OD/DPCPSI/OAR | This is a multi-agency steering committee of HHS' EHE initiative. The charge of the OLT is to monitor the progress of the EHE initiative, exchange information, contribute critical thinking to the strategies and partnerships for the program |
| Emergency Preparedness, Medical Countermeasures (ASPR) | Resource Development | ASPR, CDC | NCI | The National Cancer Institute (NCI) provides expertise in radiation biology and radiation oncology to help guide the research and development of medical countermeasures for radiation injury and for biomarkers for assessing injury, dose, and who needs treatment. NCI also provides expertise in disaster preparedness and response to ASPR for radiological and nuclear incidents. https://aspr.hhs.gov/AboutASPR/ProgramOffices/Pages/ProgramOffice.aspx |
| Emerging Contaminants and Issues of Concern Research Program | Research Initiative | CDC | OD/OIR, NIEHS | Emerging Contaminants and Issues of Concern Research Program |
| Emerging Tobacco Products Communication Initiative Subject Matter Expert Work Group | Committee, Work group, Advisory group, or Task Force | CDC | NIMHD | The Subject Matter Experts workgroup provides input to CDC’s communication initiative on preventing and reducing use of emerging tobacco products through a multimedia campaign targeting educators. This workgroup is organized by the CDC Office on Smoking and Health. |
| End-stage Renal Disease Collaboration | Committee, Work group, Advisory group, or Task Force | CMS, FDA | NIDDK, NIBIB | Participating agencies, including NIDDK, and patient and physician groups are collaborating to help the medical product development community to understand the challenges and milestones needed to achieve the goal of a successful alternative to dialysis. Research, regulatory, and reimbursement needs for such a product are discussed in phone calls and structured meetings. |
| Ending the HIV Epidemic in the US administrative supplement announcement for NIH Centers for AIDS Research and NIMH AIDS Research Centers | Research Initiative | CDC, HRSA, Other | NIAID, NIMH, OD/DPCPSI/OAR | The NIH CFAR and NIMH ARC EHE administrative supplements support implementation research by addressing the four key pillars of the EHE initiative (Diagnose, Treat, Prevent, and Respond). Specifically, the NIH will support CFAR/ARC investigators to conduct research in collaboration with local partners funded by the participating HHS agencies to support local EHE plans. CDC and HRSA provided key support in the development of the research topics. https://www.niaid.nih.gov/research/cfar-arc-ending-hiv-epidemic-supplement-awards |
| Endocrinologic and Metabolic Drugs Advisory Committee | Committee, Work group, Advisory group, or Task Force | FDA | NIAID, NICHD | This Committee provides expertise in the evaluation of evidence submitted by pharmaceutical companies to the Food and Drug Administration (FDA) for drug approval. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/default.htm |
| Enhanced Federal Collaborations in Implementation Science and Research of HIV Prevention and Treatment | Other | CDC, HRSA | NIAID, NIMH | This paper describes federal collaborations that have supported this increased focus on implementation from the perspective of NIH, CDC, and HRSA, resulting in improved communication and coordination of efforts in the shaping and alignment of priorities in research and service delivery, increased implementation research conducted in real-world community and clinical settings. https://journals.lww.com/jaids/Fulltext/2022/06001/Enhanced_Federal_Collaborations_in_Implementation.3.aspx |
| Enhancing Scientific Collaboration between US and Colombia | Committee, Work group, Advisory group, or Task Force | OGA | NIA, NIAID, FIC | The Office of the Americas of the HHS has formed a group consisting of representatives from NIAID, FIC, and NIA to foster communication with the goal of enhancing scientific collaboration between US and Colombia. |
| Environmental Phthalate Exposures In Pregnancy in Relation to Fetal and Placental Development | Research Initiative | CDC | NIEHS | The purpose of this collaboration is to characterize exposure to phthalates and phthalate alternatives in pregnant women by measuring phthalate and phthalate alternative metabolites in urine samples from 8 visits in pregnancy. We will examine associations between these markers and fetal growth as well as ultrasound measures of placental development. |
| Epidemiology, immunology, and evolution of SARS-CoV-2 and other coronaviruses before and during the COVID-19 pandemic | Research Initiative | FDA | NIAID | Epidemiology, immunology, and evolution of SARS-CoV-2 and other coronaviruses before and during the COVID-19 pandemic |
| eRA Federal Shared Services (eRA) | Resource Development | AHRQ, FDA, SAMHSA, ASFR | OD/OER | Grants Quality Service Management Office (Grants QSMO) Marketplace solution provider. Collaboration with other HHS agencies and federal agencies to provide electronic Research Administration (eRA) grants management services and support across the full grants life cycle. |
| Establishment of representative examination and dose repository for patients undergoing interventional fluoroscopic procedures | Research Initiative | FDA | NCI | NCI and FDA investigators are collaborating to establish representative examination and organ doses for fluoroscopically-guided interventional procedures by collecting anonymized patient data from multiple US clinical institutions. |
| Evaluating Genetic and Genomic Medicine Implementation and Outcomes in the Regional Genetics Networks (EGGMIO RGN) | Research Initiative | HRSA | NHGRI | The purpose of this Evaluating Genetic and Genomic Medicine Implementation and Outcomes in the Regional Genetics Network (EGGMIO-RGN) project is to evaluate the implementation and outcomes of selected RGN program activities aimed to improve access to services for individuals with, or at risk for, genetic or genomic conditions and their families, especially those among underserved populations. This evaluation will be used to inform the RGN recipients and the field of genetic and genomic medicine with best practices and strategies to implement genetic and genomic advances into clinical and public health. https://www.hrsa.gov/grants/find-funding/hrsa-21-110 |
| Evaluation of Oropharyngeal responses to SARS-CoV-2 | Research Initiative | FDA | NIAID | Evaluation of Oropharyngeal responses to SARS-CoV-2 |
| Evaluation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of long-term mitapivat dosing in subjects with stable sickle cell disease | Research Initiative | FDA | NHLBI | Evaluation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of long-term mitapivat dosing in subjects with stable sickle cell disease |
| Evaluation of Visual Function in Animal Models | Research Initiative | FDA | NEI | Evaluation of Visual Function in Animal Models |
| Evidence-Based Cancer Control Programs (EBCCP) | Resource Development | CDC | NCI | The Evidence-based Cancer Control Programs website is a searchable database of cancer control interventions and program materials and is designed to provide program planners and public health practitioners easy and immediate access to research-tested materials. https://ebccp.cancercontrol.cancer.gov/index.do |
| Extracorporeal CPR (ECPR) for Out-of-hospital Cardiac Arrest | Meeting/ Workshop | OASH | NHLBI | Workshop to evaluate the gaps and barriers in clinical research needed to expedite understanding and targeting of the restoration of cardiovascular status to improve survival after OHCA with eCPR, to identify the state of the science and regulatory policy for eCPR with ECMO-facilitated OHCA, and to discuss future opportunities to facilitate the advancement of clinical research while identifying approaches to developing effective eCPR therapies. https://www.nhlbi.nih.gov/events/2021/extracorporeal-cpr-ecpr-out-hospital-cardiac-arrest |
| Factor VIII Inhibitors: Generating a National Blueprint for Future Research | Meeting/ Workshop | CDC | NHLBI, NCI, NICHD, NLM | A State of the Science meeting was planned and executed on May 15-16, 2018 in collaboration with the national and international hemophilia community. The national and international hemophilia community. The details of the planning effort, the proceedings and work of 4 working groups, and the synthesized research blueprint have been submitted to the journal Haemophilia blueprint have been submitted to the journal Haemophilia as a series of 6 papers that are currently under review. Once published they will disseminate the consensus research hemophilia community. In so doing, the strategic priorities for future National Heart, Lung, and Blood Institute (NHLBI) funding in this field were better defined. |
| FDA Antimicrobial Drugs Advisory Committee (FDA AMDAC) | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | Discuss new drug application (NDA) 215596, for maribavir oral tablets, submitted by Takeda Pharmaceuticals USA, Inc., for the treatment of adults with post-transplant cytomegalovirus infection and/or disease, including infections resistant and/or refractory to ganciclovir, valganciclovir, cidofovir, or foscarnet. |
| FDA CDER & NIH NCATS Regulatory Fitness in Rare Disease Clinical Trials Workshop | Meeting/ Workshop | FDA | NCATS | On May 16 and 17, 2022, the FDA Center for Drug Evaluation and Research (CDER) and NCATS hosted a jointly sponsored virtual workshop on regulatory fitness in rare disease clinical trials. Rare disease drug development represents an area of high unmet medical need. This workshop focused on academic investigators and those looking to learn how to bridge the gap between academic investigation and the regulatory aspects of drug development. The workshop provided lessons on the fundamentals of drug development and included discussion of rare disease case studies shared by academic investigators; shared experiences and expertise from multi-disciplinary stakeholders; discussed regulatory considerations for rare disease clinical trials; and discussed topics such as Adequate and Well-Controlled Trials, Core Principles for Clinical Trials, The Nuts and Bolts of Investigational New Drug (IND) Applications and Additional Considerations, Additional Pathways to Interact with the FDA CDER, and case studies. https://www.fda.gov/drugs/news-events-human-drugs/fda-cder-nih-ncats-regulatory-fitness-rare-disease-clinical-trials-workshop-05162022 |
| FDA Collaboration - Psilocybin Research | Research Initiative | FDA | CC | The group is working on research that might gauge the effectiveness of psilocybin for pain management and use in other facets of palliative care. |
| FDA Microbiology Devices Panel of the Medical Devices Advisory Committee | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | This Committee provides expertise in the evaluation of evidence submitted by pharmaceutical companies to the Food and Drug Administration (FDA) for drug approval. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/MicrobiologyDevicesPanel/default.htm |
| FDA-NCI Quarterly Meeting | Meeting/ Workshop | FDA | NCI | This Quarterly meeting to enhance communication between NCI DCTD/CTEP and FDA, thereby expediting the development of new anti-cancer agents. General topics discussed include patient safety, clinical efficacy, and regulatory pathways to licensure, as well as an understanding of the operations of the sister agencies. Since NCI DCTD/CTEP acts as the official regulatory sponsor of IND studies performed in the ETCTN, and selected studies in the NCTN, PBTC, and PEP-CTN, these quarterly meetings are important to ensure NCI DCTD/CTEP is performing its regulatory responsibilities in compliance with regulations and the dialogue with the FDA also helps in exploring new ways to enhance patient safety and clinical trial monitoring in a risk-based approach. The Quarterly meeting dates each year are discussed and scheduled in consultation with the FDA depending on the availability of appropriate FDA staff for the particular issue that will be discussed. NCI and FDA staff have a meeting usually 1 month prior to the next anticipated Quarterly Meeting in order to decide on topics that will be discussed. |
| FDA-NIH Joint Leadership Council | Committee, Work group, Advisory group, or Task Force | FDA | OD/OSP, NCI, NHLBI, NIAID, NIDA, NIDDK, NINDS, OD/IMOD, OD/OER | Facilitates leadership-level development of mutual priorities between both Department of Health and Human Services (HHS) operating divisions. http://www.fda.gov/ScienceResearch/SpecialTopics/RegulatoryScience/ucm201654.htm |
| FDA/NIMH Points of Contact Working Group Meeting - Drugs | Committee, Work group, Advisory group, or Task Force | FDA | NIMH | Food and Drug Administration (FDA) and National Institute of Mental Health (NIMH) representatives meet quarterly to discuss issues of mutual interest related to the development and clinical trials of pharmacologic therapeutic interventions. |
| Feasibility Study: Maternal Health Care of Pregnant Women in Custody, Expert Panel | Committee, Work group, Advisory group, or Task Force | HRSA | NICHD | Convened by Abt Associates on behalf of the U.S. Department of Justice |
| Federal Cannabis Partners | Committee, Work group, Advisory group, or Task Force | CDC, FDA, SAMHSA | NIDA, NCI | The Federal Cannabis Partners working group meets quarterly to discuss issues of interest related to cannabis and public health and to foster collaborations across HHS and other agencies. |
| Federal Cervical Cancer Collaboration | Resource Development | HRSA | NCI, OD/DPCPSI/ORWH | The FCCC is a collaboration between HRSA, NCI, CDC, and NIH Office of Women's Health to accelerate uptake of new cervical screening and management recommendations and HPV vaccination. The FCCC is hosting roundtable discussions with several groups in 2022 and will develop toolkits, particularly to support safety-net settings of care. |
| Federal Data Consortium on Pregnancy and Birth to 24 Months | Resource Development | CDC, FDA, OASH | OD/DPCPSI/ODS, NCATS, NCI, NHLBI, NIAID, NICHD, NIDDK, NIEHS, NIMHD, NINR, OD/DPCPSI/OBSSR, OD/DPCPSI/ONR, OD/DPCPSI/ORWH, OD/ECHO | The Federal Data Consortium on Pregnancy and Birth to 24 Months (P/B-24, Data Consortium) is a Federal forum for sharing information and finding solutions to resolve crucial needs for data on P/B-24 populations to inform public health initiatives. The Data Consortium facilitates the ability for Federal agencies to gather and vet input to inform projects and research plans and share information on data availability and usage. Over a dozen Federal agencies have funded projects coordinated by the Data Consortium focused on filling critical gaps in scientific knowledge to support evidence-based programs, policies, and educational initiatives across the government and non-government sectors. The collaboration spans over 200 Federal staff and leaders from around 40 agencies in six Departments (HHS, USDA, USAID, EPA, NSF, and DoD). The Data Consortium is co-led by representatives of ODPHP (within OASH), CDC, NIH, and FDA of HHS and ARS and FNS of USDA. |
| Federal Dietary Reference Intakes Steering Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, OASH, ACL | OD/DPCPSI/ONR, NHLBI, NIDDK | This Dietary Reference Intakes subcommittee reports to the Interagency Committee on Human Nutrition Research (ICHRN) to provide oversight on the process used to establish the Dietary Reference Intakes. These values serve as a basis for many federal nutrition programs and policies. https://health.gov/our-work/nutrition-physical-activity/dietary-guidelines/dietary-reference-intakes/dietary-reference-intakes-development |
| Federal Experts Security Advisory Panel (FESAP) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | Provides recommendations related to the security of biological select agents and toxins (BSAT) to the Secretaries of Health and Human Services and Agriculture and the Attorney General. https://www.phe.gov/Preparedness/legal/boards/fesap/Pages/default.aspx |
| Federal Health IT Coordinating Council | Committee, Work group, Advisory group, or Task Force | CMS, ACF, AHRQ, CDC, FDA, HRSA, IHS, OASH, ASA | NLM, NHGRI, OD/OSP | ONC promotes improved federal coordination through the Federal Health IT Coordinating Council, a voluntary group of 25 agencies that are actively involved in implementing the national health IT agenda. Among the topics addressed at coordination meetings were: 21st Century Cures Act implementation (ONC and CMS): MyHealthEData Initiative (CMS), Digital Health (FDA), and HIPAA Audits and HIPAA Access Right (OCR). Priority collaborations between ONC and CMS through the Council helped create increased attention to interoperability within the Administration and in specific CMS policies and programs. https://www.healthit.gov/topic/2020-2025-federal-health-it-strategic-plan |
| Federal HIV Implementation Science Workgroup | Committee, Work group, Advisory group, or Task Force | CDC, HRSA, SAMHSA | NIMH, NIAID, NIDA, OD/DPCPSI/OAR | Representatives from the Centers for Disease Control and Prevention (CDC, Division of HIV/AIDS Prevention), the Health Resources and Services Administration (HRSA, HIV/AIDS Bureau), and the National Institutes of Health (NIH) continued to convene a workgroup to focus on implementation science. The membership of the workgroup expanded to include the National Institutes of Health (NIH) Office of AIDS Research and the National Institute on Drug Abuse (NIDA), as well as the Substance Abuse and Mental Health Services Administration (SAMHSA). The overall goal of the workgroup is to increase collaborative efforts and decrease duplication of efforts related to implementing and studying the implementation of a broad range of interventions related to the prevention and treatment of HIV. To achieve this goal, the workgroup agrees to pursue a number of broad actions, including: 1) clearly define implementation science for the purpose of the workgroup; 2) understand current implementation science activities and interests within each agency and in the HIV prevention field; 3) identify and define current implementation science successes and challenges within each agency; 4) identify shared priorities and individual priorities for each agency and how future activities could address identified challenges; 5) within the workgroup, share lessons learned and successful strategies for program implementation and how using implementation science might advance implementation efforts; 6) advance the broader dissemination and adoption of key result and evidence-based, evidence-informed, or novel implementation strategies to programmatic and research partners; 7) align technical assistance efforts to support programs to integrate evidence-based, evidence-informed, and novel implementation strategies; and 8) support the advancement of implementation science as a field. |
| Federal HIV Web Council (HIV.gov) (FHWC) | Committee, Work group, Advisory group, or Task Force | OASH, CDC, FDA, HRSA, IHS, SAMHSA, ACF | OD/DPCPSI/OAR, NIAID, NIDA | HIV.gov expands the visibility of timely and relevant Federal HIV policies, programs, and resources to the American public. It strives to increase the use of new media tools by government, minority, and other community partners to extend the reach of HIV programs to communities at greatest risk, as well as increase knowledge about HIV and access to HIV services for people most at-risk for, or living with, HIV. https://www.hiv.gov/ |
| Federal Hypertension Control Leadership Council | Meeting/ Workshop | AHRQ, CDC, CMS, FDA, HRSA, IHS, ASPR, ONC | NHLBI, NINDS | The Federal Hypertension Control Leadership Council convenes to inspire, connect, coordinate and accelerate action to achieve and improve hypertension control. We will use our individual levers in a collective effort to achieve and improve national hypertension control. In doing so, we will save lives and dollars, eliminate disparities, and improve our nation’s health and resiliency. |
| Federal Implementation Science Workgroup | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NIAID, NIMH, NIDA, OD/DPCPSI/OAR | The Federal Implementation Science Working Group was formed to further expand existing collaborations on federal initiatives and share best practices around implementation science. |
| Federal Interagency Breastfeeding Working Group | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS | NICHD, NCI, NHLBI, NIDDK | The purpose of this working group is to discuss breastfeeding-related topics relevant to Federal agencies. |
| Federal Interagency Forum for Child and Family Statistics | Research Initiative | ACF, AHRQ, CDC, HRSA, OS, SAMHSA | NICHD, NIMH | The purpose of this Interagency Agreement is to provide funds to support the work of the Federal Interagency Forum on Child and Family Statistics (Forum). The purpose of the Forum is to foster collaboration among Federal agencies that produce or use statistical data on children and families. Specifically, the Forum seeks to improve both the quality and use of data on children and families by investigating questions of data quality, data measurement, and data integration; identifying information gaps and data inconsistencies; widening access to information on children and families through the annual publication American's Children: Key National Indicators of Well-Being and other means; coordinating the development and use of statistical data bases among Federal agencies; promoting communication among data producers, researchers, and public policymakers; and addressing concerns regarding collection, access, and dissemination of data. http://childstats.gov |
| Federal Interagency Forum on Aging Related Statistics | Resource Development | ACL, AHRQ, CDC, CMS, OS, SAMHSA | NIA | This Interagency Forum was formed with the goal of bringing together Federal agencies that share a common interest in improving aging-related data. The specific goals of the Forum are to improve both the quality and use of data on the aging population. https://agingstats.gov/about.html |
| Federal Interagency Task Force on the Arts and Human Development | Research Initiative | ACF, ACL, SAMHSA | NIA, NCCIH, NCI, NICHD, NIMH, OD/DPCPSI/OBSSR | Beginning in 2011, the National Endowment for the Arts (NEA) has convened a Federal Interagency Task Force on the Arts and Human Development to encourage more and better research on how the arts can help people reach their full potential at all stages of life. Task force members represent multiple units across the federal government, including the US Department of Health and Human Services, the National Institutes of Health, the National Science Foundation, and the US Department of Education, among others. To date, the Task Force has met quarterly to share ideas and information about research gaps and opportunities for understanding the arts' role in improving health and educational outcomes throughout the lifespan. The Task Force has conducted a series of public webinars on compelling research and practices. Additionally, the group has begun a literature review of research on the arts and human development. In November 2012, four Task Force member agencies hosted a first-ever convening at the National Academy of Sciences to review the current state of research on the arts, health, and well-being in older Americans. https://www.arts.gov/partnerships/task-force |
| Federal Interagency Traumatic Brain Injury Research Working Group (FITBIR Working Group) | Resource Development | AHRQ, CDC, HRSA, OS, SAMHSA | NINDS, CIT, NCATS, NHLBI, NIA, NIAAA, NIBIB, NICHD, NIDA, NIDCD, NIGMS, NIMH | The charge of the Interagency Committee includes promoting collaboration among federal agencies. A goal of this committee is to develop a national “Roadmap” for Traumatic Brain Injury (TBI). This strategic planning effort will represent the collective expertise of providers, educators, advocates, federal/state/national organizations, and individuals with TBI and their families and will result in a consensus document outlining the critical elements of a successful system of care for TBI service delivery. Outcomes of the planning effort include the adoption of National Institute of Neurological Disorders and Stroke (NINDS) Common Data Elements for TBI research, and creation of the FITBIR Informatics System to store data from TBI patients and controls enrolled in studies funded by the Department of Defense (DoD) and National Institutes of Health (NIH). The FITBIR Informatics System was developed to share data across the entire TBI research field and to facilitate collaboration between laboratories, as well as interconnectivity with other informatics platforms. https://fitbir.nih.gov/ |
| Federal Interagency Workgroup on Autism Spectrum Disorders (FIWA) | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, CDC, CMS, HRSA, IHS, SAMHSA, ASPE, ACF, FDA | NIMH, NINDS, NICHD | The Federal Interagency Workgroup on Autism Spectrum Disorders (FIWA) is composed of representatives from departments and agencies across the U.S. Government, who voluntarily meet to coordinate research, services, and support activities related to autism spectrum disorder (ASD). The FIWA was first convened as an interagency workgroup to address requirements of the Autism Collaboration, Accountability, Research, Education, and Support (CARES) Act of 2014 (PL 113-157), and subsequently continues to meet to address the requirements of the Autism CARES Act of 2019 (PL 116-60). The Autism CARES Act of 2014 required that the Secretary of Health and Human Services designate a National Autism Coordinator to oversee national ASD research, service, and support activities, and prevent unnecessary duplication of effort, in consultation with the Secretaries of Defense and Education. The Autism CARES Act of 2019 also required that this coordination of activities take into account the Strategic Plan developed by the Interagency Autism Coordinating Committee and requested a Report to Congress concerning the Health and Wellbeing of Individuals with ASD, published September 2021. Dr. Susan Daniels has served as the Acting National Autism Coordinator since July 2021. |
| Federal Interagency Workgroup on Child Abuse and Neglect (FEDIAWG) | Committee, Work group, Advisory group, or Task Force | ACF | NICHD, NIAAA, NIDA, NIMH, OD/DPCPSI/OBSSR | The Federal Interagency Workgroup on Child Abuse and Neglect meets to provide a forum through which staff from relevant federal agencies can communicate and exchange ideas concerning the prevention of child maltreatment and other related issues. http://www.acf.hhs.gov/cb/resource/fediawg |
| Federal Interagency Workgroup on Improving Diagnostic Safety and Quality in Health Care | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA, IHS, ONC, SAMHSA, OASH, CMS | NIBIB, NLM, NCI, NCATS | In 2015, The National Academies of Sciences, Engineering, and Medicine published a report titled Improving Diagnosis in Health Care that identified problems with diagnostic errors and their effect on the quality and safety of healthcare. The report outlined eight goals to reduce diagnostic error and improve the diagnosis of disease. AHRQ convened a cross-agency workgroup to address the lack of dedicated research into improving medical diagnosis and reducing diagnostic failures that lead to patient harm. The working group met in March, July, and November of 2022. https://www.ahrq.gov/topics/diagnostic-safety-and-quality.html |
| Federal Interagency Workgroup on Intellectual Disabilities/Developmental Disabilities (ID/DD) Administrative Data (FIW IAD) | Committee, Work group, Advisory group, or Task Force | ACL, CMS, ASPE, CDC, HRSA, AHRQ, SAMHSA | NICHD, NIMH | Launched in early 2020, the purpose of the FIW IAD is to establish greater coordination and collaboration of existing and newly developing federal activities related to ID/DD administrative data, terminology and definition concerns, data collection and related methodologies. We are committed to identifying and prioritizing opportunities to maximize the reach of federal efforts using IDD administrative data to understand and improve the lives of people with IDD. |
| Federal Interagency Workgroup on Teen Dating Violence | Committee, Work group, Advisory group, or Task Force | ACF, CDC | NICHD | The Federal Interagency Workgroup on Teen Dating Violence was established as a result of the 2006 Workshop on Teen Dating Violence, which was coordinated and led by the National Institute of Justice. Since its inception, the workgroup has coordinated teen dating violence programming, policy, and research activities to combat violence from a public health perspective. https://www.nij.gov/topics/crime/intimate-partner-violence/teen-dating-violence/Pages/research-agenda.aspx |
| Federal Interagency Working Group on Measuring Sexual Orientation and Gender Identity (FIW SOGI) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, CMS, SAMHSA | NICHD, OD/DPCPSI/SGMRO | This working group explores measurement of sexual orientation and gender identity (SOGI), considering multiple different dimensions of sex, gender, and sexuality. The Working Group examines variability in measurement by age, race, ethnicity, and cultural group. It prepares recommendations to the Office of Management and Budget (OMB) and other Federal agencies for the development, testing, and usage of SOGI measures to more accurately describe LGBT populations. |
| Federal Interagency Workshop: Nonhuman Primate Resources and Needs for Biomedical Research | Committee, Work group, Advisory group, or Task Force | CDC, FDA | OD/DPCPSI/ORIP, OD/DPCPSI/OAR, OD/OIR, OD/ORS, OD/OSP, CC, NCCIH, NEI, NHLBI, NIA, NIAAA, NICHD, NIDA, NIDCD, NIMH, NINDS | This Federal Interagency Workshop was hosted by the NIH-Wide Nonhuman Primate Resource Planning Working Group. The meeting was held March 22, 2022 in response to a recommendation of the Expert Panel forum, entitled; Challenges in Assessing Nonhuman Primate Needs and Resources for Biomedical Research, held August 23-;24, 2018. A non-public Final Report of the 2022 Federal Interagency Workshop was also developed. |
| Federal Lead Action Plan Workgroup | Committee, Work group, Advisory group, or Task Force | FDA, OS | NICHD | Developed through cross-governmental collaboration of the President’s Task Force on Environmental Health Risks and Safety Risks to Children, which includes 17 federal departments and offices, the Federal Lead Action Plan is a blueprint for reducing lead exposure and associated harms by working with a range of stakeholders, including states, tribes and local communities, along with businesses, property owners and parents. https://www.epa.gov/lead/federal-action-plan-reduce-childhood-lead-exposure |
| Federal Partners in Bullying Prevention, Intervention, and Recovery | Committee, Work group, Advisory group, or Task Force | ACF, CDC, HRSA, IHS, SAMHSA | NIMH, NIAAA, NICHD, NIDA, OD/DPCPSI/OBSSR | This workgroup meets to provide a forum through which staff from relevant federal agencies can communicate and exchange ideas concerning how to prevent or stop bullying in schools and communities. http://www.stopbullying.gov/ |
| Federal Sudden Unexpected Infant Death/Sudden Infant Death Syndrome (SUID/SIDS) Workgroup | Committee, Work group, Advisory group, or Task Force | ACF, CDC, HRSA, IHS | NICHD | The purpose of the partnership is to establish and enhance relationships among Federal agencies with responsibilities for SIDS and SUID. The partner agencies intend to work together to improve communication and coordination, and to collaborate on a range of activities designed to reduce, and, ultimately, eliminate SIDS and SUID, including the elimination of racial, ethnic and socio-economic disparities. |
| Federal Supply and Demand of Isotopes | Committee, Work group, Advisory group, or Task Force | FDA | NIBIB, NCI | A workshop on Isotope Federal Supply and Demand is held annually. The workgroup that organizes this workshop consists of representatives of federal agencies with the aim of providing a forum for interaction between agencies, departments, and medical societies to communicate about potential shortages of isotopes that are of strategic importance to the nation including the availability of medical isotopes. Also, a report of isotope supply and demand and whether needs are commercially available is compiled by the National Institutes of Health (NIH) and submitted to DOE annually. The report includes demand for NIH intramural research programs and NIH extramural projects (grantees). Not included in this report are NIH intramural research needs that are supplied by its cyclotron or isotope needs to be met by commercial suppliers. NIH collects data from ICs and submits annual reports as required. On January 12, 2021, DOE, NIH, and the members of the Isotope Needs Program held the 7th Workshop on Isotope Federal Supply and Demand. The meeting reviewed the Program’s ongoing activities and reported that the newly evolving use of electron- and alpha-emitting isotopes are seeing increased need (based on FDA’s approval for medical applications); the DOE is developing a plan to meet the current and foreseen increased use of these isotopes for cancer therapy. In support of these efforts, NIBIB conducted an August 16-17, 2021 workshop that focused on instrumentation development to directly image these new electron- and alpha-emitting isotopes for enhancing cancer therapy outcomes. https://www.imagingtherapy.nibib.nih.gov/ |
| Federal Tuberculosis (TB) Task Force | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS, OS | NICHD, NIAID | The Federal Tuberculosis (TB) Task Force is a coalition composed of the federal agencies involved in U.S. TB research and control efforts. Established in 1991, it facilitates coordination of activities among these federal agencies. |
| Federal Work Group on Suicide Prevention | Committee, Work group, Advisory group, or Task Force | SAMHSA, CDC, IHS, ACF, ACL, AHRQ, HRSA, ASPE | NIDA, NIMH, NIAAA | The Federal Work Group on Suicide Prevention, led by the Substance Abuse and Mental Health Services Administration (SAMHSA), brings together multiple agencies within HHS and across agencies (e.g., Veterans Affairs, Department of Transportation, Department of Justice) to meet and discuss suicide prevention initiatives within the federal government on a quarterly basis. Meeting topics range from SAMHSA updates on the 988 implementation and other initiatives to a round robin which provides a forum for federal agencies to share various suicide prevention initiatives they are leading or are involved in. |
| Federal Working Group on Bone Diseases | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA | NIAMS, CSR, NCATS, NCI, NIA, NIAID, NICHD, NIDCR, NIDDK, OD/DPCPSI/ORWH, NIAAA | An interagency committee focusing on osteoporosis and other bone disorders. It offers a forum for sharing information, learning from each other and invited speakers, and facilitating the development, early in the planning stages, of collaborative research activities based on each agency's mission. |
| Federal Working Group on Dietary Supplements (FWGoDS) | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, CDC, FDA, HRSA, IHS | OD/DPCPSI/ODS, CC, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDDK, NIEHS, NIGMS, NIMH, NINDS, NINR, NLM, OD/DPCPSI/OBSSR, OD/DPCPSI/ONR, OD/DPCPSI/ORWH | The National Institutes of Health's, Office of Dietary Supplement Federal Working Group on Dietary Supplements (FWGoDS) consists of representatives from federal agencies that share information and discuss issues, initiatives, and research related to dietary supplements. The FWGoDS has a mission to strengthen collaborative efforts involving dietary supplement education and communication across the government. https://ods.od.nih.gov/About/federalworkinggroupondietarysupplements.aspx |
| Filovirus Animal Non-Clinical Group (FANG) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | The Filovirus Animal Non-Clinical Group (FANG) focuses on the advanced development of Filovirus medical countermeasures (MCM), both vaccines and therapeutics. The FANG focuses on the product development tools and other interagency product development issues relevant to FDA approval of filovirus MCM. A standing interagency working group, the Portfolio Advisory Committee, oversees the FANG. The FANG will develop strategies to address broadly applicable and interagency product development issues relevant to licensure of filovirus MCM. The FANG will develop consensus recommendations to facilitate standardization of reagents, methods, and procedures across multiple agencies and laboratories. |
| Filovirus Animal Non-Clinical Group (FANG) Workshop | Meeting/ Workshop | CDC, FDA, OS | NIAID | The Filovirus Animal Non-Clinical Group (FANG) focuses on the advanced development of Filovirus medical countermeasures (MCM), both vaccines and therapeutics. The primary focus of the Workshop will be on Marburg virus, although other filoviruses will also be addressed. |
| FNIH Advanced Medicines Partnership® - Bespoke Gene Therapy Consortium (FNIH AMP BGTC) | Research Initiative | FDA | NCATS | Working with the Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER), private sector partners, and FNIH to execute AAV gene therapy research, clinical and manufacturing workstreams. https://fnih.org/bgtc |
| FNIH Biomarkers Consortium (FNIH) | Research Initiative | CMS, FDA | NIMH, NCATS, NCI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NINDS | The Biomarkers Consortium is a major public-private biomedical research partnership managed by the Foundation for the National Institutes of Health (FNIH) with broad participation from stakeholders across the health field, including government, industry, academia, patient advocacy, and other not-for-profit organizations. In addition to the FNIH, founding members include the National Institutes of Health (NIH), Food and Drug Administration (FDA), and the Pharmaceutical Research and Manufacturers of America. The Biomarkers Consortium brings together the expertise and resources of various partners to rapidly identify, develop, and qualify potential high-impact biomarkers to enable improvements in drug development, clinical care, and regulatory decision-making. https://fnih.org/our-programs/biomarkers-consortium |
| Focus on Aging: Federal Partners Webinar Series | Public Education Campaign | ACL, CDC, HRSA | NIA | The Focus on Aging: Federal Partners' Webinar Series addresses important topics for public health and health care professionals, aging services organizations, the research community, and other stakeholders in aging. The series is a joint project of four of the federal agencies that support the health and wellness of older adults in the U.S.: the Administration for Community Living, the Centers for Disease Control and Prevention, the Health Resources and Services Administration, and the National Institute on Aging. Each webinar includes information specific to individuals with Alzheimer’s disease and other types of dementia, as well as their caregivers. https://www.nia.nih.gov/alzheimers/focus-aging-federal-partners-webinar-series |
| Follow-Up Studies of a Genome-Wide Association Analysis in Pima Indians | Research Initiative | IHS | OD/OIR, NIDDK | Follow-Up Studies of a Genome-Wide Association Analysis in Pima Indians |
| Foundation for the National Institutes of Health (FNIH) PACT (Partnership for Accelerating Cancer Therapies) (FNIH PACT) | Committee, Work group, Advisory group, or Task Force | FDA | NCI | The Partnership for Accelerating Cancer Therapies (PACT) is a five-year public-private research collaboration totaling $215 million launched by the National Institutes of Health, the FNIH (Foundation for the NIH) and 11 leading pharmaceutical companies as part of the Cancer Moonshot. PACT will initially focus on efforts to identify, develop and validate robust biomarkers — standardized biological markers of disease and treatment response — to advance new immunotherapy treatments that harness the immune system to attack cancer. The partnership will be managed by the FNIH, with the Food and Drug Administration serving in an advisory role. https://fnih.org/what-we-do/current-research-programs/partnership-for-accelerating-cancer-therapies |
| Full-text health-related documents at NLM (includes HSTAT) Bookshelf/Digital Repository | Resource Development | AHRQ, ATSDR, CDC, CMS, FDA, SAMHSA | NLM | The National Library of Medicine of the National Institutes of Health provides a free, web-based resource of full-text documents that provide information on health-care decision making. The nature of the collaboration is via Bookshelf, through NLM Literature Archive agreements and additional clauses in Inter-Agency Public Access agreements, to make the full text of various federal government grey literature, such as systematic reviews, clinical guidelines, assessments, and technical reports, publicly available through the Bookshelf product. Bookshelf also manages the Health Services/Technology Assessment Texts (HSTAT) collection of health services research documents. Bookshelf is the point of contact to federal agencies in making their new and updated documents publicly accessible. https://www.ncbi.nlm.nih.gov/books/?term=intra_hhs_collaborations%5bfilter%5d |
| Functional and Structural Optical Brain Imaging | Research Initiative | FDA | NICHD | Functional and Structural Optical Brain Imaging |
| Funding Opportunity Announcement Module (FOAM) | Resource Development | ACF, ACL, AHRQ, CDC, CMS, FDA | OD/OER, CC, CIT, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/AoU, OD/DPCPSI, OD/DPCPSI/OAR, OD/DPCPSI/OBSSR, OD/DPCPSI/ODS, OD/DPCPSI/ORIP, OD/DPCPSI/ORWH, OD/DPCPSI/OSC, OD/DPCPSI/THRO, OD/DPCPSI/SGMRO, OD/ECHO, OD/IMOD, OD/OCPL, OD/OIR, OD/OIR/OTT, OD/OLPA, OD/OM/OB, OD/ORS, OD/OSP | The Funding Opportunity Announcement Module (FOAM) allows National Institutes of Health (NIH) Institutes and Centers and Department of Health and Human Services (HHS) Operating Divisions to develop content for and perform the needed approvals to publish funding opportunity announcements. The system has a flexible configuration to meet all of the needs for HHS Operating Divisions. In addition FOAM serves as a Federal Shared Service in collaboration with Grant Solutions supporting other agencies including Department of the Interior, Department of Housing and Urban Development, and Department of Homeland Security. FOAM achieves economies of scale by preventing the need for individual agencies to develop duplicate systems at a cost much greater than that of developing a unified system. |
| FY 22 Ending the HIV Epidemic in the US Funding Opportunity Announcement | Research Initiative | CDC, HRSA | NIAID, NIMH, NIDA | Three NIH EHE RFAs supports locally defined and culturally sensitive research projects that address the four key pillars of the EHE initiative (Diagnose, Treat, Prevent, and Respond). Specifically the NIH supports investigators in one of the 57 priority jurisdictions to work with implementing partners to develop and test locally defined and culturally sensitive solutions that align with jurisdictional EHE plans. CDC and HRSA provided key support in the development of the research topics. https://www.hiv.gov/blog/nih-announces-3-new-funding-opportunities-research-help-end-hiv-epidemic-ehe-jurisdictions-and |
| Gabriella Miller Kids First Common Fund Working Group | Committee, Work group, Advisory group, or Task Force | CDC | NICHD, NCI, NEI, NHGRI, NHLBI, NIAAA, NIAMS, NIDA, NIDCR, NIDDK, NIEHS, NINDS, OD/DPCPSI/ORIP | The National Institutes of Health (NIH) Gabriella Miller Kids First Common Fund Working Group supports the goals and initiatives of the NIH Gabriella Miller Kids First Common Fund Pediatric Research Program (Kids First). Kids First is developing a data resource for the pediatric research community of well-curated clinical and genetic sequence data that will allow scientists to identify genetic pathways that underlie specific pediatric conditions but that may also be shared between apparently disparate conditions. A representative from the Centers for Disease Control and Prevention (CDC) participates in the Kids First Working Group. https://commonfund.nih.gov/kidsfirst/overview |
| Gender Policy Council: HHS Women's Health & Rights Working Group | Committee, Work group, Advisory group, or Task Force | SAMHSA, HRSA, CDC, OGA, OASH | NICHD | This working group is tasked to develop a Government-Wide Strategy to Advance Gender Equity and Equality with respect to women's health and rights. |
| Genetic Epidemiology of Diabetes and Obesity | Research Initiative | IHS | NIDDK | Genetic Epidemiology of Diabetes and Obesity |
| Genetic Epidemiology of Diabetic Complications | Research Initiative | IHS | NIDDK | Genetic Epidemiology of Diabetic Complications |
| Genetic Studies in the National Birth Defects Prevention Study (NBDPS) | Research Initiative | CDC | NHGRI | This study is a collaboration between The Centers for Disease Control and Prevention (CDC) and the National Human Genome Research Institute (NHGRI) to carry out DNA sequencing and genotyping on samples collected as part of the National Birth Defects Prevention Study. https://www.cdc.gov/ncbddd/birthdefects/nbdps.html |
| Genital Herpes Workshop | Meeting/ Workshop | CDC | NIAID | This workshop was co-sponsored by NIAID and CDC to review the status of research, product development, and education on genital herpes. |
| Genome in a Bottle Consortium (GIAB) | Resource Development | CDC, FDA | NLM, NHGRI, NCI | The "Genome in a Bottle Consortium" was organized to develop the reference materials, reference data, and reference methods needed to assess performance of human genome sequencing. It is a public-private-academic consortium hosted by NIST to develop the technical infrastructure (reference standards, reference methods, and reference data) to enable translation of whole human genome sequencing to clinical practice and innovations in technologies. The priority of GIAB is authoritative characterization of human genomes for use in benchmarking, including analytical validation and technology development, optimization, and demonstration. https://www.nist.gov/programs-projects/genome-bottle |
| Genomic epidemiology of norovirus GII.4 globally | Research Initiative | FDA | FIC | Collaboration with Dr. Gabriel Parra's team at FDA. His group has compiled a global genomic dataset of thousands of norovirus GII.4 genomic sequences spanning 37 years of sampling. Dr. Nidia Trovao's team at the NIH/FIC will employ molecular epidemiology concepts and phylodynamic modeling to shed light on the viral evolutionary history and transmission dynamics. We will also gain insight into the viral diversity circulating across countries/regions, how the viral effective population size changes over time, and identify source-to-sink patterns in norovirus GII.4 spread. This will be important to inform control strategies and the development of therapeutics and vaccines. |
| Global Burden of Disease U.S. Health Disparities Working Group | Resource Development | CDC | NIMHD, NHLBI, NCI, NIA, OD/DPCPSI/OBSSR, NIAMS | Through this project, the Global Burden of Disease U.S. Health Disparities Working Group at NIH aims to generate a landmark and comprehensive report and public platform with data on the Global Burden of Disease on U.S. Health Disparities by Race/Ethnicity, Sex, Age, Socioeconomic Status and Geography. The project entails producing detailed county-level estimates of disease burden stratified by race/ethnicity, socioeconomic status (SES), age, and sex for a vast array of diseases, injuries and risk factors. The report would include a broad set of measures of the burden of disease (e.g., disability-adjusted life years and healthy life expectancy). This project would result in a platform for downloadable, publicly available data review and visualization tools for extracting information on these stratified analyses at the county-level for every U.S. county. CDC/NCVS is providing guidance on vital statistics data, algorithms and procedures used to generate life expectancy estimates, etc., by race/ethnicity. |
| Global Environmental and Occupational Health (GEOHealth) | Research Initiative | CDC | NIEHS, FIC, NCI, OD/DPCPSI/ORWH | The Global Environmental and Occupational Health (GEOHealth) program supports the development of institutions in low- or middle-income countries (LMICs) serving as regional hubs for collaborative research, data management, training, curriculum and outreach material development, and policy support around high-priority local, national and regional environmental and occupational health threats. https://www.fic.nih.gov/Programs/Pages/environmental-occupational.aspx |
| Global Health Security Agenda (GHSA) Action Package Prevent 3 (APP3), Biosafety and Biosecurity Working Group | Committee, Work group, Advisory group, or Task Force | CDC, OS | OD/OSP | Promotes awareness and implementation of comprehensive national-level biosafety and biosecurity frameworks within the Global Health Security Agenda. https://www.ghsagenda.org/ |
| Global Initiative for Cancer Registry Development (GICR) | Committee, Work group, Advisory group, or Task Force | CDC | NCI | Cancer incidence and mortality are rising rapidly worldwide, particularly in low- and middle-income countries. There is an overwhelming need for countries to adopt and implement cancer control actions. Yet only one in five low- and middle-income countries have the necessary data to drive policy and reduce the burden and suffering due to cancer. The Global Initiative for Cancer Registry Development (GICR) is a coordinated, multi-partner approach to deliver the required change. Its objective is to make cancer data count. NCI partners with the U.S. Centers for Disease Control and Prevention to provide technical and financial support to the Caribbean Hub of GICR. http://gicr.iarc.fr/ |
| Global Nutrition Coordination Plan (GNCP) | Committee, Work group, Advisory group, or Task Force | CDC, OGA, FDA | FIC, NICHD, NCI | The U.S. Government Global Nutrition Coordination Plan is an interagency effort to strengthen the impact of the many diverse nutrition investments across the U.S. Government through better communication and collaboration and by linking research to program implementation. Through coordination mechanisms, the U.S. Government is working to maximize its support to country-led programs, continue its global leadership and partnerships, and generate, share, and apply knowledge and evidence in the nutrition sector in order to accelerate progress toward shared nutrition goals. At the forefront of the Coordination Plan is the recognition that, as stewards of American investments, U.S. Government agencies must ensure that these investments are used in the most efficient and impactful way possible. https://www.usaid.gov/global-health/health-areas/nutrition/usgplan |
| Global Substance Registration System (GSRS) | Research Initiative | FDA | NCATS, OD/OIR | GSRS is a public software and web application that supports the registration and documentation of substances found in medicinal products. Importantly, the definition of substances is based on a global and consistent definition (ISO 11238 standard). The software has been heavily utilized at the FDA since 2016, and has also been adopted by other regulatory agencies around the world, such as EMA (European Medicines Agency), BfArM (Federal Institute for Drugs and Medical Devices) and WHO-UMC. NCATS provides access to a public instance of the software, and to the latest publicly available data on substance definitions and properties, as provided by the FDA, for use by the broader translational research community. https://gsrs.ncats.nih.gov/ginas/app/beta/ |
| GlycoBiology Scientific Interest Group | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NHGRI, NHLBI, NIAID, NICHD, NIDCR, NIDDK, NIGMS | A core group of laboratories representing several institutes and the FDA, form the postdoctoral training laboratories of the Glycobiology SIG. Laboratory training is augmented with a Special Topics in Glycobiology Course, a seminar series and an annual NIH FDA Glycosciences Research Day held each spring that highlights work being done locally in the glycosciences. A Steering Committee composed of both intra and extramural NIH, FDA, NIST and DOE scientists organize the SIGs activities. https://oir.nih.gov/sigs/glycobiology-scientific-interest-group |
| Government-University-Industry Research Roundtable (GUIRR) | Committee, Work group, Advisory group, or Task Force | FDA | NCATS, OD/IMOD | The National Academies of Sciences, Engineering, and Medicine Government-University-Industry Research Roundtable is charged with improving the research enterprise of the United States by successfully resolving the cross-sectoral issues that prevent the U.S. research enterprise from reaching its full potential. This mission is achieved by convening senior-most representatives from government, universities, and industry to frame the critical issues, followed – when appropriate – by the execution of activities designed to address specific cross-sectoral impediments to achieving a healthy, vibrant research enterprise. GUIRR provides a unique forum for dialogue among top government, university and industry leaders of the national science and technology enterprise. https://www.nationalacademies.org/guirr/government-university-industry-research-roundtable |
| H-CORE | Committee, Work group, Advisory group, or Task Force | ASPR/BARDA | NIAID | Conduct and coordinate preclinical activities to help facilitate the development of formerly Operation Warp Speed (OWS) vaccine candidates (etc., animal models, testing, and correlates of protection studies) |
| Harmonization of Various Common Data Models and Open Standards for Evidence Generation (CDMH II) | Resource Development | FDA | NCATS, NCI, NLM | The goal of this project is to build data infrastructure for conducting patient-centered outcomes research using data derived from the delivery of health care in routine clinical settings. These data are collectively referred to as observational data. The sources of these data may include, but are not limited to insurance billing claims, electronic health records (EHRs), and patient registries. The Common Data Model (CDM) organizes data into a standard structure, which may differ across networks. This project intends to harmonize several existing CDMs in order to support research and analyses across multiple data networks. The aim is to advance the utility of data and its interoperability across networks to facilitate patient-centered outcomes research. The enhanced data infrastructure created through this project will have the capacity to support evidence generation on patient-centered outcomes that can inform regulatory and clinical decision making within federal programs. |
| HDPulse Dissemination and Adaptation Working Group | Resource Development | OASH | NIMHD | This working group was established to promote the dissemination of the NIMHD HDPulse interventions portal and its adaptation to include the HHS Office of Minority Health's (OMH) evidence-informed practices. Building on OMH's efforts to disseminate and spread evidence-informed practices and NIMHD's development and maintenance of HDPulse, this working group is expected to achieve the following outcomes: Identification and dissemination of health equity-promoting evidence-informed practices, particularly those focused on addressing racial and ethnic health disparities, through HDPulse Increased awareness and utilization of HDPulse, including health equity-promoting interventions in the Interventions Portal, by government agencies, organizations, and practitioners serving racial and ethnic minority populations https://hdpulse.nimhd.nih.gov/ |
| Health and Retirement Study (HRS) | Research Initiative | CDC, CMS | NIA | This study follows more than 20,000 men and women over 50, offering insight into the changing lives of the older US population. Launched in 1992, this multidisciplinary, longitudinal study has become known as the Nation’s leading resource for data on the combined health and economic conditions of older Americans. http://hrsonline.isr.umich.edu/ |
| Health Information Technology Advisory Committee (HITAC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, ONC | NLM, NEI, NIAID, NIAMS, NICHD, NIEHS, NIGMS, NINDS | The Health Information Technology Advisory Committee (HITAC) was established by the 21st Century Cures Act (P.L. 114-255) and is governed by the provisions of the Federal Advisory Committee Act (FACA), P.L. 92-463, as amended, 5 U.S.C. App. 2, which sets forth standards for the formation and use of federal advisory committees. The HITAC will recommend to the National Coordinator for Health Information Technology policies, standards, implementation specifications, and certification criteria relating to the implementation of a health information technology infrastructure, nationally and locally, that advances the electronic access, exchange, and use of health information. HITAC unifies the roles of, and replaces, the Health Information Technology Policy Committee and the Health Information Technology Standards Committee that were in existence before the date of the enactment of the 21st Century Cures Act. HITAC replaced the Content Standards Workgroup of the Health Information Technology (HIT) Standards Committee, which was part of the Federal Advisory Committee that was charged with making recommendations to ONC on standards, implementation specifications, and certification criteria for the electronic exchange and use of health information. https://www.healthit.gov/hitac/committees/health-information-technology-advisory-committee-hitac |
| Health Promotion Activity to Recognize National Minority Health Month | Public Education Campaign | OASH | NIMHD | NIMHD collaborates with the Office of Minority Health, HHS to develop and promote activities for National Minority Health Month. In FY 2022, NIMHD and OMH produced a Twitter Chat to promote and engage public and community health professionals in online conversation and resource sharing responsive to the 2022 theme Give Your Community a Boost! to promote COVID-19 vaccines and trust in biomedical research. https://twitter.com/i/events/1518597941900066817?s=20 |
| Healthy People 2020/2030 Heart Disease and Stroke Federal Work Group | Committee, Work group, Advisory group, or Task Force | CDC, OS | NINDS, NHLBI | The Healthy People Initiative sets science-based, national objectives with 10-year targets to improve the health of the nation. The HP2030 HDS Federal Work Group is responsible for creation, refinement, and tracking of HP2030 goals related to heart disease and stroke related prevention and health promotion. https://www.healthypeople.gov/ |
| Healthy People 2030 - Chronic Kidney Disease Workgroup | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, HRSA, OS, OASH | NIDDK | The Office of the Secretary of Department of Health and Human Services (HHS) leads the Healthy People 2030 initiative. The lead agency for most data activities is the Centers for Disease Control and Prevention (CDC). However, for the kidney area, most of the information is provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) through the US Renal Data System. https://health.gov/healthypeople/about/workgroups/chronic-kidney-disease-workgroup |
| Healthy People 2030 - Heart Disease and Stroke Workgroup | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, OS | NHLBI, NINDS | Healthy People provides science-based, 10-year national objectives for improving the health of all Americans. https://www.healthypeople.gov/ |
| Healthy People 2030 - Nutrition and Weight Status Workgroup | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OASH, Other | OD/DPCPSI/ONR, NIDDK | The Nutrition and Weight Status group develops goals based on strong science supporting the health benefits of eating a healthful diet and maintaining a healthy body weight. The objectives also emphasize that efforts to change diet and weight should address individual behaviors, as well as the policies and environments that support these behaviors in settings such as schools, worksites, health care organizations, and communities. https://health.gov/healthypeople/about/workgroups/nutrition-and-weight-status-workgroup |
| Healthy People 2030 - Respiratory Diseases | Health Survey | CDC | NHLBI, NIA, NICHD, NIDA, NIDDK, NIMHD, NINDS, NINR, OD/DPCPSI/OBSSR, OD/DPCPSI/ODS | The purpose of the collaborative activity is to support the identification of nationally representative measures that could be used to assess progress towards achieving Healthy People respiratory disease objectives. The National Heart, Lung and Blood Institute leads this activity. https://www.healthypeople.gov/2020/About-Healthy-People/Development-Healthy-People-2030 |
| Healthy People 2030 - Sleep Health | Health Survey | CDC | NHLBI, NIA, NICHD, NIDA, NIDDK, NIMHD, NINDS, NINR, OD/DPCPSI/OBSSR, OD/DPCPSI/ODS | The purpose of the collaborative activity is to support the identification of nationally representative measures that could be used to assess progress towards achieving Healthy People sleep health objectives. The National Heart, Lung and Blood Institute leads this activity. https://health.gov/healthypeople/objectives-and-data/browse-objectives/sleep |
| Healthy People 2030 - Social Determinants Working Group | Committee, Work group, Advisory group, or Task Force | ACF, CDC, HRSA, OASH, SAMHSA, PSC, FDA | NIMHD, NIA, NCI, NIAAA | The overarching goals for Healthy People 2020 incorporate a focus on social determinants of health as well as on health outcomes and risk factors. The Working Group intends to develop objectives for the social determinants and methods to ensure their integration across all Healthy People 2020 objectives. https://www.healthypeople.gov/2020/about/history-development/Federal-Interagency-Workgroup |
| Healthy People 2030 Chronic Pain Workgroup | Committee, Work group, Advisory group, or Task Force | CDC, OASH | NINDS | The goal of the Chronic Pain Workgroup is to reduce the prevalence and impact of high-impact chronic pain and improve pain self-management. https://health.gov/healthypeople/about/workgroups/chronic-pain-workgroup |
| Healthy People 2030 Disability and Health Work Group | Committee, Work group, Advisory group, or Task Force | ACL, CDC | NICHD | Healthy People is a national effort that sets goals and objectives to improve the health and well-being of people in the United States. Every decade, the Healthy People initiative develops a new set of science-based, 10-year national objectives with the goal of improving the health of all Americans. Healthy People 2030 is the fifth edition of Healthy People. It aims at new challenges and builds on lessons learned from its first 4 decades. The development of Healthy People 2030 includes establishing a framework for the initiative, the vision, mission, foundational principles, plan of action, and overarching goals, and identifying new objectives. The development of Healthy People 2030 is a multiyear process with input from a diverse group of subject matter experts, organizations, and members of the public. The framework explains the central ideas and function of the Healthy People 2030 initiative and it will guide the selection and prioritization of 2030 objectives. https://www.healthypeople.gov/2020/About-Healthy-People/Development-Healthy-People-2030 |
| Healthy People Initiative | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, CDC, FDA, HRSA, IHS, OS, SAMHSA | OD/DPCPSI/ODP, NCI, NEI, NHLBI, NIA, NIAID, NIAMS, NICHD, NIDA, NIDCR, NIDCD, NIDDK, NIEHS, NIMH, NINDS | Healthy People provides science-based national goals and objectives with 10-year targets designed to guide national health promotion and disease prevention efforts to improve the health of all Americans. As part of its mission, Healthy People has established benchmarks and monitored progress over three decades in order to (1) engage multiple sectors to strengthen policies and improve practices that are driven by the best available evidence and (2) to increase public awareness of the determinants of health, disease, and disability and the opportunities for progress. Healthy People published a mid-course review in 2017 and can be found here: https://archive.cdc.gov/#/details?url=https://www.cdc.gov/nchs/healthy_people/hp2020/hp2020_midcourse_review.htm Office of Disease Prevention (ODP) serves as the official National Institutes of Health (NIH) liaison to the Healthy People program. ODP and NIH staff have been engaged in the HHS-wide effort to develop the objectives, targets, and evidence base for Healthy People 2030. https://www.healthypeople.gov/ |
| Healthy People Initiative - Visual Health | Health Survey | AHRQ, CDC | NEI | Healthy People Initiative is a collaboration with the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Agency for Healthcare Research and Quality (AHRQ) to survey and measure public health outcomes for a variety of common diseases over the current decade. The National Eye Institute's (NEI) goal for this program is to Improve the visual health of the Nation through prevention, early detection, timely treatment, and rehabilitation. https://www.healthypeople.gov/ |
| Healthy Vision Month | Public Education Campaign | CDC | NEI | Each May the National Eye Institute (NEI) sponsors Healthy Vision Month (HVM), which is a national observance designed to elevate eye health as a priority for Americans. The National Institutes of Health (NIH) has worked with the Centers for Disease Control and Prevention (CDC) and recently with the Office of the Surgeon General to spotlight on the connection between eye health and overall health. http://www.nei.nih.gov/hvm/ |
| Heart Failure Collaboratory | Meeting/ Workshop | CMS, FDA | NHLBI | The HFC is a public-private partnership initially convened by FDA, designed to bring together stakeholders from the Federal Government (FDA, NIH, CMS) industry, academic organizations and nonprofit organizations to collaborate to improve care for patients who suffer from any form of valvular heart disease. https://hfcollaboratory.com/ |
| Heart Valve Collaboratory | Meeting/ Workshop | CMS, FDA | NHLBI | The HVC is a group initially convened by FDA, designed to bring together stakeholders from the Federal Government (FDA, NIH, CMS) as well as industry to collaborate to improve care for patients who suffer from any form of valvular heart disease. https://www.heartvalvecollaboratory.org/ |
| Helicobacter pylori Genome Project (HpGP) | Research Initiative | CDC | NCI, NLM | Investigators in the Infections and Immunoepidemiology Branch and the Metabolic Epidemiology Branch of DCEG are undertaking a joint effort to catalog comprehensively bacterial genetic and epigenetic variation potentially related to long-term outcomes of infection. Isolates from patients with gastric cancer or advanced premalignant lesions are compared to controls with benign infection (superficial gastritis) from the same geographic area. The study goal is to sequence 1000 strains representing both high and low gastric cancer risk populations worldwide, with over 750 isolates from 50 different countries completed to date. An international team of experts is collaborating on analyses of these complex data to identify associations with the gastric carcinogenesis cascade. https://dceg.cancer.gov/research/how-we-study/genomic-studies/h-pylori-genome-project |
| Hepatitis B Research Network (HBRN) | Research Initiative | CDC | NIDDK, NCI | The Hepatitis B Research Network (HBRN), supported by NIDDK, was established in 2008 to advance understanding of disease processes and natural history of chronic hepatitis B, as well as to develop effective approaches to treatment with currently available therapies. The Network brought together clinical centers from throughout the US and Canada. This multi-center Network enrolled patients in multiple clinical trials in both adults and children with hepatitis B. The Network is currently completing and publishing analyses from these trials. http://www.hepbnet.org/ |
| HHS Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis Interagency Implementation Group (VHIG) | Research Initiative | AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA | NIDA, NIAID, NIDDK, NIMHD | The Department of Health and Human Services (HHS) agencies review the Institute of Medicine (IOM) recommendations and develop a comprehensive strategic viral hepatitis action plan that would: address IOM recommendations for viral hepatitis prevention, care, and treatment; set forth actions to improve viral hepatitis prevention and ensure that infected persons are identified and provided care and treatment; and improve coordination of all activities related to viral hepatitis across HHS and promote collaborations with other government agencies and nongovernmental organizations. https://www.hhs.gov/hepatitis/viral-hepatitis-action-plan/index.html |
| HHS Adolescent Health Working Group | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, FDA, HRSA, OS, SAMHSA | NIDA, NIAAA, NICHD, NIMH | This interagency working group, which was established in January 2010 within the Office of the Assistant Secretary for Health, provides a forum for Department of Health and Human Services (HHS) agencies and other federal agencies to learn from each other and support a full-range of evidence-based approaches to improve adolescent health, to address adolescents’ health risks, and highlight programs focused on positive youth development. This collaboration among many HHS agencies and offices serves as a forum for exchanging information relevant to improving adolescent health and well-being. https://health.gov/healthypeople/about/workgroups/adolescent-health-workgroup#about |
| HHS Adult Maltreatment Prevention Working Group | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, CDC, CMS, HRSA, IHS, OS, SAMHSA | NIA | To discuss department-wide interests and priorities. |
| HHS Agency Priority Goal on Equity Workgroup (FY 2022-2023) | Committee, Work group, Advisory group, or Task Force | AHRQ, ASPE, CDC, CMS, HRSA | NIMHD, OD/OEDI, NICHD | The goal of the Agency Priority Goal (APG) Workgroup was to investigate the feasibility of developing the Equity priority area into a viable APG. The workgroup was charged with identifying ongoing activities that align to this priority area and contain components of an APG, and if feasible, developing a draft Impact Statement for submission to HHS leadership and OMB. Agency Priority Goals (APGs) focus the attention of leadership and contributing agencies on achieving critical performance goals for the Department. APGs are required by the Government Performance and Results Act Modernization Act of 2010 (GPRAMA). |
| HHS Antiretroviral Treatment Guidelines Panel for Adults and Adolescents with HIV | Committee, Work group, Advisory group, or Task Force | HRSA, CDC, FDA | NIAID | The Panel was formed in 1996, to provide guidelines for clinicians for adult and adolescents with HIV. The Panel is a working group of the NIH Office of AIDS Research Council. One of the co-chairs of the Panel is Dr. Cliff Lane of NIAID, the executive secretary is Alice Pau of NIAID. The Panel updates the guidelines annually, and more frequently if needed. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines |
| HHS Behavioral Health Coordinating Council (BHCC) Overdose Prevention Subcommittee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA, OASH, ASPE | NIDA, OD/OSP | The National Institutes of Health (National Institute on Drug Abuse; NIDA) Serves as Co-Chair with the Food and Drug Administration (FDA) on this inter-agency subcommittee addressing drug overdose. NIDA participates on its constituent working groups whose topics include: drafting and implementation of the HHS Overdose Prevention Strategy; expanding access to contingency management; addressing pharmacy availability of buprenorphine; determining the public health impact of kratom scheduling; and improving clinician education on controlled substance prescribing. https://www.samhsa.gov/about-us/interagency |
| HHS Behavioral Health Coordinating Council, Subcommittee on Children and Youth | Committee, Work group, Advisory group, or Task Force | HRSA, SAMHSA, FDA, OASH, CMS | NICHD, NIMH, NIDA | Overall, the BHCC is intended to inform the department-wide behavioral health agenda and provide recommendations on agency priorities and strategic planning. |
| HHS Biannual Dual Use Research of Concern (DURC) Inventory | Resource Development | CDC, FDA, OS | OD/OSP, CC, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI | Develops the Department of Health and Human Services (HHS) Biannual Dual Use Research of Concern (DURC) inventory reports, as required by the United States Government (USG) Policy for Oversight of Dual Use Research of Concern. |
| HHS Biosafety and Biosecurity Coordinating Council (HHS BBCC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, OD/ORS | High-level and formal mechanism for coordinating and collaborating on biosafety and biosecurity issues across the Department of Health and Human Services. |
| HHS Border Health Intra-agency Working Group | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, FDA, HRSA, OS | NICHD, NIA, NIAID, NIDDK, NIMH, NIMHD | This intra-agency workgroup allows for the exchange of information and cooperation among the Department of Health and Human Services (HHS) agencies on issues related to border health. The purpose of this group is to convene HHS components that have a vested interest in US-Mexico border health issues to provide a platform for discussion, coordinate efforts, and potentially identify mutual areas of collaboration to improve the health and quality of life for border residents. |
| HHS Coordination Operations and Response Element (previously Operation Warp Speed) (H-CORE/OWS) | Research Initiative | CDC, FDA, ASPR | NIAID | A program designed to coordinate and respond to the public health emergency by expediting the development of vaccines, treatments, testing and other measures as needed. https://www.defense.gov/Explore/Spotlight/Coronavirus/Operation-Warp-Speed/ |
| HHS DATA Act Compliance | Committee, Work group, Advisory group, or Task Force | ASFR | OD/OER, OD/OM/NBS | The HHS Assistant Secretary for Financial Resources (ASFR) coordinates OPDIV activities including communications, implementation, and compliance with the DATA Act. |
| HHS Data Council | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ASA, ASFR, ASPA, ASPE, ASPR, ATSDR, CDC, CMS, FDA, GDM, HRSA, IHS, ONC, OMHA | OD/OER, NLM, NIGMS, OD/DPCPSI/OBSSR, OD/DPCPSI/ODSS, OD/DPCPSI/SGMRO | The HHS Data Council is the principal internal advisory body to the Secretary on health and human services data policy. The Council coordinates data collection and analysis activities in HHS, including an integrated data collection strategy as well as coordination of health data standards and privacy policy. The Council consists of senior level officials designated by their agency and staff office heads, the director of the national center for health statistics, and the HHS privacy advocate. It is co-chaired by the Assistant Secretary for Planning and Evaluation on a permanent basis and the head of an operating division on a rotating basis. A subcommittee of the HHS Data Council, the Data-Oriented Workforce Subcommittee, is composed of staff from 10 HHS agencies, including the NIH. This subcommittee is charged with developing a high-level work plan to enhance the data science capacity of HHS’ workforce by identifying training opportunities for existing staff, recruitment strategies and tools to hire new staff, and retention and succession planning strategies to sustain the data science workforce. https://aspe.hhs.gov/health-and-human-services-hhs-data-council |
| HHS Data Governance Board | Committee, Work group, Advisory group, or Task Force | OCIIO, ASPE, CDC, ACF, ACL, AHRQ, CMS, FDA, HRSA, IHS, SAMHSA, ASFR, ASPA, ASPR, OIG | OD/DPCPSI/ODSS, OD/OSP | The purpose of the DGB is to serve as the Department's principal data governance forum and decision-making body for managing HHS; data as a strategic asset to support HHS in meeting its mission and agency priorities, including implementation of the Evidence Act. In accordance with OMB M-19-23, the DGB will Support agency priorities, such as those identified in strategic plans and learning agendas, by informing strategic information resources management plans for the agency and identifying resources to implement those priorities; Coordinate and support implementation of data management responsibilities with agency data-management actors to strengthen strategic plans and learning agendas; Set agency data policy in a manner that complements, but does not supplant the statutory authority of established positions; and Coordinate implementation of the Federal Data Strategy by assessing data maturity, risks, and capabilities to recommend related data investment priorities. In accordance with the Geospatial Data Act, the DGB will: Ensure that HHS and its components fully implement the covered agency responsibilities found in GDA section 759(a). (299-908-10-1 OS) Maintain an inventory of all geospatial data assets, per section 759(b) of the GDA. (299-908-10-2 OS) https://www.hhs.gov/data/index.html |
| HHS Dietary Guidance Review Committee | Committee, Work group, Advisory group, or Task Force | ACF, CDC, FDA, HRSA, IHS, OASH | OD/DPCPSI/ONR, NIDDK | This committee reviews draft nutrition materials developed by all federal agencies and fulfills the legislative mandate (1990 NNMRRA) to ensure that Federal dietary guidance is consistent with the Dietary Guidelines for Americans and is scientifically accurate. |
| HHS Disability Collaborative | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, ASPA, ASPE, ASFR, ASA, ASPR, ACF, CDC, CMS, OASH, OCR, ONC, OIG, OGA, HRSA, SAMHSA, FDA, IHS | NIA, NICHD | The HHS Collaborative is for OpDivs and StaffDivs to work in partnership on issues that impact person with disabilities. This group will address emerging issues, funding announcements, research and evaluation, pre-clearance conversations, special events, announcements, and rollouts. Anticipated results includes enhanced communication across agencies, elevated focus on key disability issues, improved awareness and coordinated messaging, alignments of budgets and policy proposal, and enhanced knowledge transfer across HHS. This is not a governing body. The lead organizations are ACL and ASPE. |
| HHS Ebola Medical Countermeasures Scientific Working Group | Committee, Work group, Advisory group, or Task Force | ASPR, OGA, CDC, FDA | NIAID | Focuses on supporting ASPR and NSC on scientific issues related to Ebola MCMs in response and development |
| HHS Environmental Justice and Natural Disasters Working Group (EJ) | Committee, Work group, Advisory group, or Task Force | ASPR, OASH, CDC, HRSA | NIEHS | Environmental Justice is “the fair treatment and meaningful involvement of all people regardless of race, color, national origin, or income with respect to the development, implementation, and enforcement of environmental laws, regulations, and policies”. Executive Order 12898, Federal Actions to Address Environmental Justice in Minority Populations and Low-income Populations requires each Federal agency to “make achieving environmental justice part of its mission by identifying and addressing, as appropriate, disproportionately high and adverse human health or environmental effects of its programs, policies, and activities on minority populations and low-income populations.” The Executive Order also states that “each Federal agency responsibility set forth under this order shall apply equally to Native American programs.” https://www.hhs.gov/environmental-justice/index.html |
| HHS Environmental Justice Working Group (EJWG) | Committee, Work group, Advisory group, or Task Force | OASH | OD/DPCPSI/SGMRO, NIEHS | This group is designed to foster collaboration across HHS for the purposes of coordinating activities that pertain to EJ. Please note NIEHS is the lead IC on this collaboration, not SGMRO. None yet |
| HHS Health Disparities Council | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, OS, SAMHSA | NIMHD | The Department of Health and Human Services (HHS) Health Disparities Council serves as the venue to share information, leverage HHS investments, coordinate HHS activities, reduce program duplication, and track progress on the strategies and actions of the HHS Disparities Action Plan. |
| HHS HIV Bidirectional Meeting Planning Committee | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA, OS, SAMHSA | NIAID, NIMH | Committee planning meetings of the HHS global and domestic policy and program leaders to share successful strategies and lessons learned, and to discuss potential adaptations to enable the transfer/implementation of proven strategies among new environments. |
| HHS LGBT Policies Coordinating Committee (HHS LGBT CC) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, IHS, OS, Office of the Surgeon General (OSC), SAMHSA | OD/DPCPSI/SGMRO, NIMH | The Department of Health and Human Services (HHS) Lesbian, Gay, Bisexual and Transgender (LGBT) Policy Coordinating Committee is comprised of senior representatives from each division of HHS. This committee coordinates the exchange of information about LGBT-related policies across the department, and provides a mechanism for both collecting and disseminating this information across operating divisions. https://www.hhs.gov/programs/topic-sites/lgbt/reports/index.html |
| HHS Liaison to NASA | Other | FDA | NCATS, OD/IMOD | As HHS Liaison to NASA, Dr. Rutter and her team at NCATS coordinate interactions and expertise sharing among components of HHS to explore joint areas of interest. In January 2021, HHS appointed staff members to centralize the partnership and ensure continuity between administrations. NCATS remains as a leader in these efforts, working alongside NASA and HHS staff to coordinate activities, such as the Tissues Chips in Space Program. https://ncats.nih.gov/alliances/nasa/collaboration-history |
| HHS Long COVID Working Group | Committee, Work group, Advisory group, or Task Force | SAMHSA, AHRQ | NIDA, NIMH | This newly formed working group brings together HHS agencies to produce a report focused on long COVID and outlining current available programs, services, or supports and what additional support is being planned. Section 1 of the report will address the need to connect people experiencing long COVID to available services. Section 2 will tackle improving the delivery of health care services for people experiencing long COVID. Section 3 will address the needs of people dealing with bereavement and mental health and substance use challenges in the wake of the pandemic. |
| HHS Maternal Health Working Group | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ASPE, ASFR, CDC, CMS, FDA, HRSA, IHS, ONC, IOS, ATSDR, SAMHSA | NHLBI, NICHD, OD/DPCPSI/ORWH | Led by the Deputy Assistant Secretary for Women's Health and Director of the Office on Women’s Health in the Office of the Assistant Secretary for Health (OASH). This working group stimulates and coordinates within and cross-Agency efforts to mitigate the rising rate of U.S. maternal morbidity and mortality |
| HHS Minority Health Offices Directors Committee | Meeting/ Workshop | AHRQ, CDC, CMS, HRSA, IHS, FDA, SAMHSA | NIMHD | The directors of the HHS Offices of Minority Health meet monthly to discuss issues for coordination/collaboration related to minority health and health disparities in their respective agencies to leverage partnerships, foster cross-agency collaborations and share updates. |
| HHS Noise-Induced Hearing Loss Federal Partner Working Group | Committee, Work group, Advisory group, or Task Force | CDC | NIDCD | Work group to coordinate and collaborate the Department of Health and Human Services (HHS) activities and messages related to noise-induced hearing loss. Federal partners include the National Institutes of Health (NIH) National Institute on Deafness and Other Communication Disorders and the Centers for Disease Control and Prevention (CDC) National Center for Environmental Health and National Institute for Occupational Safety and Health. |
| HHS Nutrition Working Group | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, IOS, NIH, OASH, SAMHSA, OS | OD/DPCPSI/ONR, NHLBI, NCI, OD/DPCPSI/ORWH | This HHS interagency group meets frequently to discuss topics and issues that are pertinent to the implementation of the Biden-Harris National Strategy on Hunger, Nutrition, and Health. This group also helped develop the framework for the White House Conference on Hunger, Nutrition, and Health. |
| HHS Office on Womens Health, Section on Pregnancy and Newborn Care | Committee, Work group, Advisory group, or Task Force | OS, SAMHSA | NICHD, NIMH | The National Institutes of Health (NIH) scientists work together with other Department of Health and Human Services (HHS) experts to develop and review content for HHS public-facing websites, including the womenshealth.gov website. http://www.womenshealth.gov |
| HHS Panel for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children | Committee, Work group, Advisory group, or Task Force | CDC | NICHD, OD/DPCPSI/OAR | This committee has the purpose of updating the U.S. Pediatric opportunistic infection prevention and treatment guidelines for HIV-Exposed and HIV-Infected Children and serves as executive secretary. These guidelines are developed by a panel of specialists in pediatric HIV infection and infectious diseases (the Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children) from the U.S. government and academic institutions. The Panel is a working group of the Office of AIDS Research Advisory Council. For each OI, one or more pediatric specialists with subject-matter expertise reviews the literature for new information since the last guidelines were published, and then proposes revised recommendations for review by the full Panel. After these reviews and discussions, the guidelines undergo further revision, with review and approval by the Panel, and final review and endorsement by the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Disease Society (PIDS). The Panel also received input from the American Academy of Pediatrics (AAP). https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf |
| HHS Panel on Antiretroviral Guidelines for Adults and Adolescents | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA | NICHD, NIAID, OD/DPCPSI/OAR | The Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) is a working group of the Office of AIDS Research Advisory Council (OARAC). The primary goal of the Panel is to provide HIV care practitioners with recommendations based on current knowledge of antiretroviral drugs (ARVs) used to treat adults and adolescents with HIV in the United States. The Panel reviews new evidence and updates recommendations when needed. These guidelines include recommendations on baseline laboratory evaluations, treatment goals, benefits of ART and considerations when initiating therapy, choice of the initial regimen for ART-naive patients, ARV drugs or combinations to avoid, management of treatment failure, management of adverse effects and drug interactions, and special ART-related considerations in specific patient populations. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf |
| HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA | NICHD, NIAID, OD/DPCPSI/OAR | This committee has the purpose of updating the U.S. Pediatric HIV treatment guidelines and serves as executive secretary. The Department's Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children (the Panel), a working group of the Office of AIDS Research Advisory Council, reviews new data on an ongoing basis, and provides regular updates to the guidelines. The guidelines are available on the AIDSinfo website. These updated guidelines address the use of combination antiretroviral therapy for HIV-infected infants, children, and adolescents. Guidance on management of adverse events associated with use of antiretroviral drugs in children and a detailed review of information about safety, efficacy, and pharmacokinetics of antiretroviral agents in children is also included. https://aidsinfo.nih.gov/guidelines |
| HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA | NICHD, NIAID, OD/DPCPSI/OAR | Also called 'Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States'. These Guidelines update the October 2016 Perinatal Guidelines. The Department of Health and Human Services Panel on Treatment of Pregnant Women Living with HIV and Prevention of Perinatal Transmission (the Panel), a working group of the Office of AIDS Research Advisory Council, develops these guidelines. The guidelines provide health care providers with information for discussion with pregnant women living with HIV infection to enable collaborative, informed decision-making regarding the use of ARV drugs during pregnancy, use of scheduled cesarean delivery to reduce perinatal transmission of HIV, and decision-making around the use of ARV drugs for prophylaxis of infants exposed to HIV. The recommendations in these Guidelines are accompanied by a discussion of various circumstances that commonly occur in clinical practice and the factors that influence treatment considerations. The Panel recognizes that strategies to prevent perinatal transmission and concepts related to management of HIV in pregnant women are rapidly evolving and will consider new evidence and adjust recommendations accordingly. The updated guidelines are available from the AIDSinfo website http://aidsinfo.nih.gov. https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf |
| HHS Potential Pandemic Pathogens Care and Oversight Review Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | Evaluates proposed research being considered for Department of Health and Human Services (HHS) funding that is anticipated to create, transfer, or use enhanced potential pandemic pathogen (enhanced PPP)--as defined in the Department of Health and Human Services Framework for Guiding Funding Decisions about Proposed Research Involving Enhanced Potential Pandemic Pathogens (HHS P3CO Framework)--to inform agency funding decisions. |
| HHS Privacy Committee | Committee, Work group, Advisory group, or Task Force | OS | OD/OM | Coordination of Privacy related activities. HHS recognizes the importance of protecting the personally identifiable information (PII) entrusted to us by millions of members of public and employees alike, and has built a robust privacy program to safeguard this information and ensure that HHS upholds Americans' privacy rights. |
| HHS Reproductive Health Care Access Task Force (HHS RATF) | Committee, Work group, Advisory group, or Task Force | OASH, OCR, ASPE, AHRQ, CDC, HRSA, IHS | NICHD, OD | Represent NIH on this HHS task force to respond to the restrictions in access to reproductive health services. https://www.hhs.gov/about/news/2022/01/21/fact-sheet-hhs-reproductive-healthcare-access-task-force.html |
| HHS SARS-CoV-2 Assay Development Task orders | Committee, Work group, Advisory group, or Task Force | BARDA | NIAID | Assays are being developed, qualified and validated to be shared across government studies |
| HHS SARS-CoV-2 Immune Assay Testing of Ph3 clinical samples- Task Order | Resource Development | ASPR | NIAID | Coordination of testing of Phase 3 clinical samples from HHS Coordination Operations and Response Element (H-CORE) performers in H-CORE Assays (Microneutralization assay) |
| HHS Smoking Cessation Workgroup | Committee, Work group, Advisory group, or Task Force | CDC | NIMHD, NCI | Discusses tobacco cessation strategies, opportunities for collaborations among HHS agencies, and the newest evidence around tobacco cessation research. |
| HHS Social Determinants of Health Workgroup | Committee, Work group, Advisory group, or Task Force | ACL, ACF, AHRQ, CDC, HRSA, IHS, OASH, FDA, CMS, SAMHSA | NIMHD, NIA, NICHD | The HHS SDoH Workgroup has developed a strategic vision to make health outcomes more equitable by improving the delivery of, and integration between healthcare and social services with a particular focus on individuals and populations in government health and human service programs at high risk for adverse outcomes. The SDoH workgroup identifies how HHS can address SDoH and work with other federal, state, local, tribal, and private sector partners to both ascertain and achieve shared objectives. |
| HHS Strategic Plan FY 2022-2026: Subcommittee for Objective 3.4 | Committee, Work group, Advisory group, or Task Force | ASFR, CDC, ACF, SAMHSA, HRSA, ACL, ASPE | NICHD, NIMH | This subcommittee shares knowledge and expertise about HHS priorities and programs that will lead to the strategies at the heart of the HHS Strategic Plan Objective 3.4 to increase safeguards to empower families and communities to prevent and respond to neglect, abuse and violence, while supporting those who have experienced trauma or violence. https://www.hhs.gov/draft-strategic-plan |
| HHS Tick-Borne Diseases Working Group | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, OS | NIAID | The Tick-Borne Disease Working Group was established by Congress in 2016 as part of the 21st Century Cures Act to provide subject matter expertise and to review federal efforts related to all tick-borne diseases, to help ensure interagency coordination and minimize overlap, and to examine research priorities. The focus of this effort is the development of a report to the Secretary of Health and Human Services and Congress on the findings and any recommendations of the Working Group for the federal response to tick-borne disease prevention, treatment, and research, as well as how to address gaps in these areas. https://www.hhs.gov/ash/advisory-committees/tickbornedisease/index.html |
| HHS Tobacco Control Steering Committee | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA, SAMHSA, OS | NIMHD, NCI, NIDA | The committee coordinates and initiates tobacco control activities across HHS agencies. The Committee meets monthly to promote information exchange and collaboration across HHS on a wide array of tobacco prevention and control issues, and to update members on the latest relevant research findings. |
| HHS Viral Hepatitis Interagency Working Group | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA, OASH, ONC | NIDDK, NIDA, OD/DPCPSI/OAR, NIAID | The Department of Health and Human Services (HHS) Viral Hepatitis Interagency Working Group was created by the Office of the Assistant Secretary for Health to address a report sponsored by the Institute of Medicine entitled Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. The group meets to discuss collaborations and activities directed at achieving the goals for viral hepatitis research and control highlighted in the IOM report. (Although the National Institute of Allergy and Infectious Diseases (NIH Lead), the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Drug Abuse, and the NIH Office of AIDS Research represent the National Institutes of Health as Working Group members, other NIH Institutes/Centers/Offices also provide input to the VHIG through their participation in the Trans-NIH Committee on Viral Hepatitis.) The working group helped develop the 2021-2025 Viral Hepatitis National Strategic Plan. https://www.hhs.gov/hepatitis/viral-hepatitis-national-strategic-plan/national-viral-hepatitis-action-plan-overview/index.html |
| HHS-Wide Stigma Workgroup | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA, IHS, SAMHSA | NIMH | Building on the momentum of the 2019 BMC Medicine Stigma Collection and the 2019 National Institute of Mental Health (NIMH) Global Mental Health Webinar, representatives from the National Institutes of Health (NIH) formed a Stigma Planning Workgroup to coordinate and chart a course forward for research related to stigma. The overall goal was to provide leadership, vision, and support to stigma research funded by the NIH. As the NIH-focused workgroup started to meet and gain traction, other Department of Health and Human Services (HHS) partners expressed interest in joining, including the Centers for Disease Control and Prevention (CDC), Health Resources and Services and Administration (HRSA), Indian Health Services (IHS), Food and Drug Administration (FDA), and Substance Abuse and Mental Health Services Administration (SAMHSA). Moving forward, this workgroup aims to promote cross-cutting stigma research and related activities and to enhance opportunities for knowledge transfer and collaborative learning in the field of stigma and discrimination research. To achieve this goal, the workgroup agrees to pursue several broad actions, including: (1) Clearly defining stigma and discrimination for the purpose of the workgroup; (2) Organizing a speaker's series to understand current stigma research findings, and interests within each federal agency; (3) Identifying and defining current stigma and discrimination research successes and challenges within each agency; (4) Identifying shared and individual priorities for each agency and how future activities could address identified challenges; (5) See enclosed list of HHS partner interests; (6) Advancing stigma and discrimination research training to build knowledge and skills among stigma-focused researchers and among other researchers seeking to increase capacity to conduct high-quality stigma and discrimination research; (7) Advancing the broader dissemination of stigma-related research; (8) Aligning technical assistance efforts to support one another; and (9) Supporting cross-cutting stigma and discrimination research as a field. |
| HHS/Office of the Secretary, Office of the Assistant Secretary for Planning and Evaluation (OS-ASPE) - Reentry/Criminal Justice Working |Group. | Committee, Work group, Advisory group, or Task Force | CDC, CMS, HRSA, SAMHSA | NHLBI, NIDA, NIMH | Through the Federal Interagency Reentry Council, federal agencies are working together to enhance community safety and well-being, assist those returning from prison and jail in becoming productive citizens, and save taxpayer dollars by lowering the direct and collateral costs of incarceration. Because reintegration to the community after incarceration intersects with issues of health, housing, education, employment, family, faith, and community well-being, the U.S Department of Health and Human Services (HHS) and other federal agencies are focusing on the reentry population with activities that aim to improve outcomes in these areas. https://aspe.hhs.gov/incarceration-reentry |
| HIV/AIDS Cancer Match Study (HACM) | Research Initiative | CDC | NCI | A study linking HIV and cancer registries in multiple US regions to evaluate the spectrum of cancer risk in people living with HIV https://hivmatch.cancer.gov |
| Hospice to Palliative Care: Maximizing Patient Preferences and Cost Savings | Research Initiative | AHRQ | CC | The goal of the study is to provide rational, patient-defined, evidence-based recommendations to inform the redesign of the Medicare hospice benefit, transitioning policy from the current hospice benefit to a more patient-centered palliative care model. http://grantome.com/grant/NIH/R01-HS018360-01 |
| Host Immune Responses to Antigens of Malaria Parasites | Research Initiative | FDA | OD/OIR, NIAID | Host Immune Responses to Antigens of Malaria Parasites |
| HRSA Advancing Precision Medicine (HRSA APM) | Other | HRSA | OD/AoU | In 2018, HRSA awarded $456K to 40 HRSA FQHCs to work on engagement activities and EHR sharing for AoU. The period of performance ran through September 2020 with some FQHCs operating on a No Cost Extension through December 2020. NIH continues to meet with HRSA monthly to discuss the potential for future opportunities to add FQHCs to the All of Us Research Program. NIH AoURP and HRSA collaborated on a workbench presentation to HRSA and all FQHCs in winter 2021. Another presentation is planned for Spring 2022. |
| Human skin sensitization data set | Research Initiative | FDA | NIEHS | NICEATM and collaborators collected data for over 2,300 human predictive patch tests from more than 1,700 publications. |
| Human Specimen Collection to Support Basic and Clinical Research | Research Initiative | FDA | NHLBI | Human Specimen Collection to Support Basic and Clinical Research |
| I-Corps @ NIH | Training Initiative | CDC | NCI, NCATS, NCCIH, NHGRI, NHLBI, NIA, NIAAA, NIAID, NICHD, NIDA, NIDCD, NIDCR, NIEHS, NIMH, NINDS | The I-Corps™ at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. The program is designed to provide three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. Through the 8.5 week program training, companies are expected to conduct 100 interviews to gather stakeholder feedback on the product. So far, more than 100 companies have gone through the program. It is anticipated that outcomes for the I-Corps™ teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Currently NCI is reviewing the application for the second cohort of 2022. From fiscal year 2023, the management of the program will be transferred from the NCI to NIH. https://sbir.cancer.gov/programseducation/icorps |
| IAA with FDA - Using big data to compare SARS-CoV-2 infection and therapeutic efficacy between human lung on a chip and animal model testing | Other | FDA | NIAID | This collaboration will allow the development of in vitro organ on a chip technology for modeling of SARS-CoV-2 infection, identification of biomarkers and transcriptomic and tissue expression imaging by MIBI/CODEX. The data collected from the organ on a chip systems will then be compared to ongoing analysis of human clinical samples and parallel testing in animal models of COVID. |
| ICCFASD SBI Working Group for Pregnant and Postpartum People (ISBI-WG) (ISBI) | Committee, Work group, Advisory group, or Task Force | AHRQ, ASPE, CDC, CMS, IHS, HRSA, SAMHSA | NIAAA, NIDA | This is a special interest working group formed and led by the ICCFASD. The objectives of the ISBI working group are to exchange information and resources, identify gaps and opportunities for improved implementation and research, and expand collaboration and partnerships between federal agencies. The group includes representatives from the ICCFASD and other federal agencies. https://www.niaaa.nih.gov/iccfasd/iccfasd-special-focus-working-groups#topic-2 |
| ICCFASD Strategic Planning Working Group (ISP) | Committee, Work group, Advisory group, or Task Force | ASPE, CDC, CMS, HRSA, SAMHSA | NIAAA, NICHD | The ICCFASD Strategic Planning Working Group was formed to review the ICCFASD FY06-10 Strategic Plan and make recommendations to the ICCFASD on ICCFASD strategic planning to make the most impact in the next several years. The ICCFASD Strategic Planning Working Group includes representatives from a variety of ICCFASD member agencies. Continued engagement with communities is essential to the ICCFASD. Input has been sought from a range of community partners (e.g., researchers, practitioners, individuals with lived experiences) to ensure that the ICCFASD collaborative partnership and its priorities and objectives address the needs of persons affected by Fetal Alcohol Spectrum Disorders (FASD) and their families and prevention of prenatal alcohol exposure in children. https://www.niaaa.nih.gov/iccfasd/iccfasd-special-focus-working-groups#topic-1 |
| ICCVAM Ecotoxicology Workgroup (EcoWG) | Committee, Work group, Advisory group, or Task Force | FDA | NIEHS | ICCVAM workgroup that provides expertise in identifying and evaluating in vitro and in silico methods to identify ecological and environmental hazards. https://ntp.niehs.nih.gov/go/iccvam-wg |
| ICCVAM In Vitro to In Vivo Extrapolation Workgroup (IVIVE-WG) | Committee, Work group, Advisory group, or Task Force | ATSDR, FDA | NIEHS, NLM | ICCVAM workgroup established to catalog and evaluate currently available IVIVE approaches, to determine their suitability for specific research or regulatory purposes, and to assess whether additional tools or models are needed. https://ntp.niehs.nih.gov/go/iccvam-wg |
| ICCVAM Metrics Workgroup (MWG) | Committee, Work group, Advisory group, or Task Force | FDA | NIEHS, OD | ICCVAM workgroup established to develop objectives and determine how agencies can best address the recommendations in the 2019 GAO report, "Animal Use in Research" https://ntp.niehs.nih.gov/go/903258 |
| ICCVAM Nanomaterials Workgroup (NanoWG) | Committee, Work group, Advisory group, or Task Force | FDA, CDC | NIEHS | ICCVAM workgroup established to evaluate the suitability of alternative methods to assess potential toxicity of nanomaterials. https://ntp.niehs.nih.gov/go/iccvam-wg |
| ICCVAM Public Forum | Meeting/ Workshop | FDA | NIEHS, NCATS | ICCVAM holds annual public forums to promote national and international partnerships between governmental and nongovernmental groups, including academia, industry, advocacy groups, and other key stakeholders. The 2022 Public Forum was held in May. https://ntp.niehs.nih.gov/go/iccvamforum-2020 |
| ICCVAM Read Across Workgroup (RAWG) | Committee, Work group, Advisory group, or Task Force | ATSDR, FDA | NIEHS, NLM | ICCVAM workgroup established to build read-across capacity within member agencies, raise awareness of the state of the science, and work towards harmonization of read-across approaches. https://ntp.niehs.nih.gov/go/iccvam-wg |
| Identification and Validation of ctDNA Quality Control Materials | Resource Development | FDA | NCI | The ctDNA Quality Control Materials project seeks to develop a set of nationally recognized standards to enable the production of suitable quality control materials for widespread use in testing for circulating tumor DNA (ctDNA). https://fnih.org/what-we-do/biomarkers-consortium/programs/ctdna-reference-materials |
| IEEE Reporting Standards for In Vivo Neural Interface Research Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NINDS | The Institute of Electrical and Electronics Engineers (IEEE) Reporting Standards for In Vivo Neural Interface Research Working Group aims to improve the transparency, interpretability, reproducibility of in vivo research studies involving neural interface technology and establish rigorous standard experimental methodologies and outcome measures. https://sagroups.ieee.org/2794/ |
| Image-guided Interventional Therapeutics | Research Initiative | FDA | CC, NCI | This collaboration will lead to safer and more effective treatment planning and performance of image-guided interventions and therapeutic drug delivery. The results of all of these studies of image-guided interventions and related technologies and the models used to study them will have a direct impact on the effectiveness and consistency of the Food and Drug Administration (FDA) Center for Devices and Radiological Health's preclinical review of device applications while meeting the primary research goal of optimizing image-guided interventions and pre-clinical modeling of those interventions. Regulatory science and translational therapeutics have overlapping goals when it comes to drugs and devices combination therapies. |
| Imaging Core Unit | Research Initiative | FDA | NEI | Imaging Core Unit |
| Immune Responses to Influenza Vaccination | Research Initiative | FDA | NIAID | Immune Responses to Influenza Vaccination |
| ImmuneChip+ Area of Interest (AOI) | Committee, Work group, Advisory group, or Task Force | ASPR | NIAID, NCATS | This working group began with BARDA DRIVe and NCATS who developed an Microphsyiological Systems (MPS) AOI resulting in BAA contracts in 2021 for immune chip development. Continuation of these interests include refining more complex MPS that incorporate the ability to study immune responses across multiple tissues. Focus includes medical counter measures against biological, radiological and chemical threats while fostering the development of interoperable systems, biosensor incorporation (TEER etc.) and MPS standardizations. https://drive.hhs.gov/immunechip.html |
| Immunology Interest Group | Meeting/ Workshop | FDA | NCI, NIDDK, NHLBI, NIAID, NINDS, NIEHS, CC, NIAMS, NEI, NIDCR, NICHD, NIAAA, NIMH, NHGRI, NCCIH, NIA, NIDA, NIDCD, NIGMS, NIMHD, OD/OIR | The National Institute of Health (NIH) Immunology Interest Group (IIG) brings together immunologists from across all NIH institutes as well as the Food and Drug Administration (FDA). The two major activities of the IIG are a Wednesday afternoon lecture series highlighting world-class immunologists and intramural immunologists and an annual workshop where up to 350 NIH/FDA immunologists get together to present their work to the community. https://www.niaid.nih.gov/research/immunology-interest-group |
| Impact of Opioid-Related Emergencies on First Responders | Research Initiative | FDA | CC | Impact of Opioid-Related Emergencies on First Responders |
| Implementation Research in HRSA Ryan White Sites: Screening and Treatment for Mental and Substance Use Disorders to Further the National Ending the HIV Epidemic (EHE) Goals | Research Initiative | HRSA | NIMH, NIDA | The National Institute of Mental Health (NIMH) and National Institute on Drug Abuse (NIDA) collaborated with the Health Resources and Services Administration (HRSA) HIV/AIDS Bureau to develop a research funding opportunity (RFA-MH-20-520 and RFA-MH-20-521) on methods to enhance screening and treatment for mental and substance use disorders in HRSA Ryan White HIV/AIDS Program funded sites through implementation research, in order to advance the goals of the Ending the HIV Epidemic in the U.S. initiative. The research initiative seeks to strengthen the research/service delivery collaboration between NIH grantees and HRSA-funded HIV care sites, with the goal of increasing retention in HIV care and viral suppression through implementation of evidence-based mental disorder and substance use screening, prevention, and treatment. The research initiative was published in 2020. Eight grants were funded through this initiative (6 NIMH grants and 2 NIDA grants). The NIMH maintains ongoing communication with HRSA to discuss progress and outcomes. |
| Improving Genomics/Omics Technical Standards and Molecular Tools for Prebiotic Probiotic Research and Development Working Group | Research Initiative | CDC, FDA, OS | NCCIH, NCI, NHGRI, NIDA, NLM | The overarching workgroup effort is to enhance research initiatives/resource development as an Interagency Agreement (IAA) workgroup members committed to sustain and accelerate translatability of validation analytics and reference datasets using omics and other multi-omics substitutable [SMART] tools, devices, and HL-7 Fast Healthcare Interoperability Resources (FHIR) technologies to support rapid and efficient interoperability with electronic health records and clinical decision support systems. A second goal is to coordinate and plan trans-NIH and Inter-agency meetings, workshops and initiatives with greater efficiency of Institute and Center Operations (ICO) resources and expertise between agencies. Innovative technologies like HL-7 SMART on FHIR have been demonstrated to enhance health information exchange, affordably and accurately. Novel device monitoring using reference standards including, Food and Drug Administration (FDA) Precision and National Institute of Standards and Technology (NIST) nanofabrication, multi-omics and modeling strategies can be integrated to improve validation and standards biosafety, risk monitoring of adverse drug events, food safety, overuse and resistance to antibiotics, and emerging infection. The intent originated in April 2016 with an Initiative planning meeting that is now ongoing for IAA partnered with the Patient-Centered Outcomes Research Institute (PCORI); other IAA collaboratives in progress. |
| Improving Steps in the Development and Assessment of Live Microbiome-Based Products: Fecal Microbiota for Transplantation (FMT) and Live Biotherapeutic Products (LBPs) | Other | FDA | NIAID | his project seeks to support the development and assessment of live microbiome-base products for the treatment and prevention of infection. Fecal microbiota for transplantation (FMT) utilizes stool from healthy donors to reestablish the gut microbiota of individuals with recurrent C. difficile infection. Whereas live biotherapeutic products (LBPs) are drugs that consist of purified bacteria developed for the prevention, treatment or cure of bacterial vaginosis in women. In the context of this IAA, tools for FMT and LBPs are being developed to prevent disease (or reinfection) after antibiotic treatment by interacting with the human microbiome. |
| In Silico Screening for Cancer Targets | Research Initiative | FDA | NCI | In Silico Screening for Cancer Targets |
| In Vitro Assessment of Dermal Hypersensitivity: Using Alternative Methods to Predict Skin Sensitization | Research Initiative | FDA | NIEHS | The primary goal of these efforts is to assess the utility of non-animal test methods for predicting human skin sensitization hazard in an expanded chemical space |
| In Vitro Assessment of Respiratory Hypersensitivity: Using Alternative Methods to Predict Respiratory Sensitization | Research Initiative | FDA | NIEHS | The primary goal of these efforts is to assess the utility of non-animal test methods for predicting human skin sensitization hazard in an expanded chemical space |
| Industrywide exposure assessment study of workers exposed to graphene and other two-dimensional nanomaterials | Research Initiative | CDC | NIEHS | There have been relatively few studies evaluating the toxicity of 2D nanomaterials and even fewer data are available regarding workplace exposures in the United States. This project will provide real-world exposure data along with important material characteristic information for the interpretation of current and future toxicity and risk assessment studies. |
| Influenza Diagnostics Risk Management Meeting (FRMM) Strategy Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, ASPR | NIAID | Reviewing a draft strategic plan for senior leadership |
| Influenza Risk Management Meeting | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | The Influenza Risk Management Meetings provide members including the Office of the Assistant Secretary for Preparedness and Response (ASPR) Biomedical Advanced Research and Development Authority (BARDA), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the National Institutes of Health (NIH)) with a venue to discuss issues relating to the US Department of Health and Human Services (HHS) response to pandemic influenza. Subjects for discussion include but are not limited to considerations of vaccine and antiviral stockpiles and clinical trial response to influenza outbreaks such as H7N9 and H3N2v. |
| Influenza Viral Pathogenesis | Research Initiative | FDA | NIAID | Influenza Viral Pathogenesis |
| Inhibition Of Renal Injury | Research Initiative | FDA | NIDDK | Inhibition Of Renal Injury |
| Innovation Equity Forum Steering Committee (IEF SteerCo) | Research Initiative | FDA | OD/DPCPSI/ORWH, OD, NICHD, NHLBI, NINDS, NIGMS, FIC, NCATS, NIA, NCCIH | 1. Convene a global community of key stakeholders and gatekeepers of health innovation around women health R&D (e.g., funders, researchers, and community partners) 2. Mobilize and accelerate innovations to improve women health through shared understanding of critical womens health R&D priorities (where possible based on existing blueprints) 3. Foster cross-sector multinational partnerships to advance R&D efforts in womens health innovation through enhanced coordination and collaboration |
| Integrated Research Facility at Fort Detrick | Research Initiative | FDA | NIAID | Integrated Research Facility at Fort Detrick |
| Inter-Agency Working Group on the National Healthcare Quality and Disparities Report | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, HRSA, IHS, OS, ASPE, FDA | NIMHD, NCI, NHLBI, OD/DPCPSI | This working group provides expert scientific guidance for the National Healthcare Quality and Disparities Report. These annual reports measure trends in effectiveness of care, patient safety, timeliness of care, patient centeredness, and efficiency of care. The reports present, in chart form, the latest available findings on quality of and access to health care. https://www.ahrq.gov/research/findings/nhqrdr/index.html |
| Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC-PEG) | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NHGRI, CC, NCATS, NCI, NEI, NIAAA, NICHD, NLM, NIA | This education collaborative facilitates sharing interactions among professional societies, agencies, and health systems. It intends to enhance the accrual of knowledge and skill among practitioners applying genomic results to clinical care. In its start-up phase, the ISCC-PEG focused primarily on physicians and dentists. It has since expanded to engage and collaborate with allied practitioner groups such as nurse practitioners, physician assistants, pharmacists, genetic counselors, and nurses comprising integrated health care teams. It will continue to add other relevant professions and add to the reviewed and searchable educational resources on its website. https://www.genome.gov/For-Health-Professionals/Inter-Society-Coordinating-Committee-for-Practitioner-Education-in-Genomics |
| Interagency Adult Literacy Research Group | Committee, Work group, Advisory group, or Task Force | ACF | NICHD | This is an intra-government, trans-agency group shares updates on research relevant to adults with lower literacy skills (i.e., reading and writing) as well as practices and programs that are being implemented to assist these learners in various agencies. The goal is for staff and corresponding agencies to be informed of broader efforts occurring around adult literacy within the federal government and to keep abreast of research and promising programs that might inform their work. |
| Interagency Agreement NTP/NIEHS and NCTR/FDA (IAA) | Other | FDA | NIEHS | Collaborative working relationship between NTP/NIEHS and NCTR/FDA |
| Interagency Artificial Pancreas Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NIDDK, NIBIB, NICHD | The Interagency Artificial Pancreas Working Group is a group of multi-disciplined scientists and clinicians from the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) to support the Artificial Pancreas Initiative. The goals of this initiative are to provide infrastructure for narrowing the gap between basic biomedical knowledge and clinical application of novel technologies, and to cross-fertilize and partner with stakeholders in order to identify and overcome the clinical and scientific challenges to the development of an artificial pancreas. Through collaborative efforts, such as workshops, the group strives to develop innovative strategies to achieve their goals. https://www.niddk.nih.gov/news/meetings-workshops/2023/fifth-artificial-pancreas-workshop |
| Interagency Autism Coordinating Committee (IACC) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA | NIMH, NICHD, NIEHS, NINDS, NIDCD, OD | The Interagency Autism Coordinating Committee (IACC) is a federal advisory committee charged with coordinating federal activities concerning autism spectrum disorder (ASD) and providing advice to the Secretary of Health and Human Services on issues related to autism. Membership of the Committee includes a wide array of federal departments and agencies involved in ASD research and services, as well as public stakeholders, including self-advocates, family members of children and adults with ASD, advocates, service providers, and researchers, who represent a variety of perspectives from within the autism community. The Committee members myriad expertise and experience aim to equip the IACC to address the wide range of issues and challenges faced by individuals and families affected by autism. The IACC was reauthorized under the Autism Collaboration, Accountability, Research, Education, and Support (CARES) Act of 2019. In fiscal year 2022, the IACC held three full committee meetings on: October 13-14, 2021; January 19, 2022; and April 13-14, 2022. http://iacc.hhs.gov |
| InterAgency Board (IAB) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, ATSDR | NIEHS | Sanctioned by the Attorney General of the United States, the InterAgency Board for Equipment Standardization and Interoperability (IAB) was founded by the Department of Defense's Consequence Management Program Integration Office and the Department of Justice's Federal Bureau of Investigation Weapons of Mass Destruction Countermeasures on October 13, 1998. The IAB is a voluntary collaborative panel of emergency preparedness and response practitioners from a wide array of professional disciplines that represent all levels of government and the voluntary sector. The IAB provides a structured forum for the exchange of ideas among operational, technical, and support organizations to improve national preparedness and promote interoperability and compatibility among local, state, and federal response communities. Based on direct field experience, IAB members advocate for and assist the development and implementation of performance criteria, standards, test protocols, and technical, operating, and training requirements for all-hazards incident response equipment with a special emphasis on Chemical, Biological, Radiological, Nuclear, and Explosive issues. The IAB also informs broader emergency preparedness and response policy, doctrine, and practice. https://www.interagencyboard.org/ |
| Interagency Cancer Diagnostic Devises Task Force for Near-Patient Use (CD2) | Committee, Work group, Advisory group, or Task Force | CMS, FDA, HRSA | NCI | The NCI, FDA, Health Resources and Services Administration (HRSA) and CMS partnered in late 2019 to establish the Interagency Cancer Diagnostic Devices (CD2) Task Force for Near-Patient Use. Near-patient diagnostics generally refers to a system whereby a sample is analyzed, and the results are delivered in the same location and while the patient is being evaluated. Near-patient diagnostics are often offered at point-of-care settings where at-home tests may be available with a prescription or purchased over-the-counter. CD2 is a collaborative effort among four federal partners working together within and across their respective missions to bring more solutions to: detect and diagnose cancer earlier; enhance identification of patients at high risk of developing cancer and surveillance of those at risk of cancer recurrence; improve monitoring of patient response during cancer treatment; and reduce the effect of health disparities and equitably extend the benefits of health care to all populations. The primary goal of this initiative is to develop opportunities that accelerate the pace by which point of care diagnostic devices get to patients for the earlier detection and screening of cancer. The Task Force and Initiative will address cancer types for geographically isolated, medically underserved, and otherwise vulnerable communities, with emphasis to: 1) Cancer types with clear, existing need and highly prevalent, for example cervical cancer; and 2) Cancer types that have evidence of future need from emerging at-risk populations, for example liver cancers derived from nonalcoholic steatohepatitis (NASH). |
| Interagency Chemical Risk Assessment Working Group | Committee, Work group, Advisory group, or Task Force | OS | NINDS, NIAID | This working group is a Department of Homeland Security led effort to determine chemical hazards and develop Chemical Risk Threat Assessment list of priority chemicals. |
| Interagency Collaborative Animal Research Education (ICARE) Training Project | Training Initiative | CDC, FDA, ASPR | OD/OER | The Interagency Collaborative Animal Research Education (ICARE) Academies and Train the Trainer Institutes use active learning to train participants to meet their responsibilities for animal welfare oversight. The program empowers accountability for facts and conceptual understanding of Federal standards through the study of realistic problems encountered in animal care and use programs. Faculty includes subject matter experts from biomedical research institutions and federal agencies, including National Institutes of Health (NIH) and United States Department of Agriculture (USDA). Institutional Animal Care and Use Committee members, staff, institutional officials, veterinarians, animal facility personnel, administrators, consultants, as well as compliance and regulatory personnel involved in the humane use of animals in research all may participate in the ICARE program. https://olaw.nih.gov/education/icare-interagency |
| Interagency Collaborative to Advance Research in Epilepsy (ICARE) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA, OS | NINDS, FIC, NCATS, NHGRI, NHLBI, NIA, NIAAA, NIAMS, NICHD, NIDA, NIMH | The Interagency Collaborative to Advance Research in Epilepsy (ICARE) is an interagency epilepsy working group that includes broad representation across the National Institutes of Health (NIH) institutes and centers (ICs) involved in epilepsy-related research, as well as across the Department of Health and Human Services other Federal agencies multiple epilepsy research organizations, and patient advocacy groups with a primary focus on biomedical research. The purpose of this group, which is led by the National Institute of Neurological Disorders and Stroke, is to increase communication among institutes and agencies sponsoring epilepsy-related research and to explore opportunities for increased coordination. The group’s annual meetings provide a forum for sharing information about ongoing and planned epilepsy research activities, highlighting advances, discussing needs and opportunities, and promoting increased collaboration toward common research goals. https://www.ninds.nih.gov/Current-Research/Focus-Research/Focus-Epilepsy/ICARE |
| Interagency Committee on Disability Research (ICDR) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, IHS, OS, Office of the Surgeon General (OSC), SAMHSA | NICHD, NIDCD, NIMH, NINDS | The ICDR's mission is to promote coordination and cooperation among federal departments and agencies conducting disability, independent living, and rehabilitation research programs including programs relating to assistive technology research and research that incorporates the principles of universal design. https://icdr.acl.gov/ |
| Interagency Committee on Human Nutrition Research (ICHNR) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA, OASH, Other | OD/DPCPSI/ONR, NCI, OD/DPCPSI/ODS, NICHD | The Interagency Committee on Human Nutrition Research (ICHRN) is charged with improving the planning, coordination, and communication among federal agencies engaged in nutrition research and with facilitating the development and updating of plans for federal research programs to meet current and future domestic and international needs for nutrition. https://www.nal.usda.gov/fnic/interagency-committee-human-nutrition-research |
| Interagency Committee on Smoking and Health | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, HRSA, SAMHSA | NIDA, NCI | The Committee was chartered in 1985 and advises the Secretary, Department of Health and Human Services (DHHS), the Assistant Secretary for Health, and the Centers for Disease Control and Prevention on coordination of research, educational programs, and other activities within the Department that relate to the effect of smoking on human health, and on coordination of these activities with other Federal, State, local, and private agencies. The Committee established and maintains a liaison with appropriate private entities, other Federal agencies, and State and local public agencies respecting activities relating to the effect of cigarette smoking on human health. https://www.cdc.gov/tobacco/about/icsh/index.htm |
| Interagency Committee on the American Community Survey (ACS) | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, HRSA, OS | NICHD | The American Community Survey (ACS) is an ongoing survey that provides vital information on a yearly basis about our nation and its people. Information from the survey generates data that help determine how more than $400 billion in federal and state funds are distributed each year. Public officials, planners, and entrepreneurs use this information to assess the past and plan the future. https://www.census.gov/programs-surveys/acs/about.html |
| Interagency Comparative Genomics Interest Group | Meeting/ Workshop | CDC | NHGRI | Meets quarterly to discuss advances, funding opportunities, and potential points of collaboration across agencies in comparative genomics. |
| Interagency Coordinating Committee for Newborn Screening | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA | NICHD | This committee makes recommendations for screening certain disorders, developing a system to adjudicate newborn screening expansion, and assist states in implementing programs to test for the recommended conditions. |
| Interagency Coordinating Committee on Fetal Alcohol Spectrum Disorders (ICCFASD) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, ASPE, ASPR, ATSDR, CDC, CMS, HRSA, IHS, SAMHSA | NIAAA, NIMH, NIDA, NICHD | The Interagency Coordinating Committee on Fetal Alcohol Spectrum Disorders (ICCFASD) was created in October 1996 in response to recommendations of an expert committee of the Institute of Medicine that the National Institute on Alcohol Abuse and Alcoholism (NIAAA) chair an effort to coordinate Federal activities on Fetal Alcohol Syndrome (FAS) and other disorders associated with prenatal alcohol exposure. ICCFASD works to improve communication, cooperation, and collaboration among disciplines and federal agencies that address issues of health, education, developmental disability, research, justice, and social services relevant to FASD and related disorders caused by prenatal alcohol exposure. The ICCFASD meets twice a year and arranges special panels and working groups. http://www.niaaa.nih.gov/ICCFASD |
| Interagency Coordinating Committee on Human Growth Hormone and Creutzfeldt - Jakob disease | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIDDK, NICHD, NINDS | The Public Health Service Interagency Coordinating Committee on Human Growth Hormone (hGH) and Creutzfeldt-Jakob Disease (CJD) was established in 1985 by the Assistant Secretary for Health, the Department of Health and Human Services (HHS) to review information relevant to patients who received pituitary-derived hGH that was distributed through the NIH-funded National Hormone and Pituitary Program (NHPP). The Committee analyzes this information to determine the extent of the problem of transmission of CJD (a rare, incurable brain disease) through contaminated pituitary hGH, and to inform physicians and patients who received pituitary hGH about the health risks associated with pituitary hGH. Although NHPP’s distribution of hGH ceased when its potential to transmit CJD was discovered in 1985—and today, recombinant growth hormone that is not susceptible to CJD contamination is exclusively used for treatment—the Committee continues to maintain oversight of this issue because CJD may take years or decades to develop. The Committee includes representatives from the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and the Centers for Disease Control and Prevention (CDC), and is chaired by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Director. https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/interagency-coordinating-committee-human-growth-hormone-creutzfeldt-jacob |
| Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD) | Committee, Work group, Advisory group, or Task Force | ACF, CDC, IHS, OS, SAMHSA, OASH | NIDA, NIAAA | The Consolidated Appropriations Act of 2004 directed the Secretary of Health and Human Services (HHS) to establish the Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD) and to issue an annual report summarizing all Federal agency activities related to preventing underage alcohol use. HHS made ICCPUD a standing committee to provide ongoing, high-level leadership on this issue and to serve as a mechanism for coordinating Federal efforts aimed at preventing and reducing underage drinking. The Substance Abuse and Mental Health Services Administration (SAMHSA) serves as the lead ICCPUD agency. https://www.stopalcoholabuse.gov/default.aspx |
| Interagency Coordinating Committee on the Validation of Alternative Toxicological Methods (ICCVAM) | Committee, Work group, Advisory group, or Task Force | ATSDR, FDA, CDC | NIEHS, NCI, OD, NLM | Interagency committee of the federal government with representatives from 17 research and regulatory agencies that require, use, generate, or disseminate toxicological and safety testing information. https://ntp.niehs.nih.gov/go/iccvam |
| Interagency Elder Justice Working Group (EJWG) | Committee, Work group, Advisory group, or Task Force | ACL | NIA | The Elder Justice Interagency Working Group brings together federal officials responsible for carrying out elder justice activities, including elder abuse prevention, research, grant and program funding, and prosecution. Since 2001, members have met informally and on a regular basis to discuss emerging issues, promising practices, and ways to coordinate their efforts. Guest speakers have addressed a range of topics, including adult protective services, guardianship, and predatory lending. |
| Interagency Filovirus Team | Committee, Work group, Advisory group, or Task Force | ASPR | NIAID | Coordination across USG agencies of filovirus MCM activities |
| Interagency Group for Development of Lung Infection Models for P. aeruginosa and A.baumannii | Committee, Work group, Advisory group, or Task Force | BARDA, CDC, FDA | NIAID | This interagency working group meets quarterly to discuss the development of various lung infection animal models. |
| Interagency Group on Alzheimers Disease and Related Dementias for implementation of the National Alzheimers Project Act | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, AoA, ASPE, ACF, IHS, OASH, SAMHSA | NIA | This interagency group was established by Department of Health and Human Services (HHS) in response to the Congressional directive to address Alzheimer disease. The group works to carry out the National Alzheimer’s Project Act’s charges to coordinate research and services across agencies, accelerate the development of AD/ADRD treatments, improve early diagnosis and coordination of care, reduce ethnic and racial disparities in rates of AD/ADRD, and coordinate with international efforts to fight these conditions. http://aspe.hhs.gov/daltcp/napa/ |
| Interagency Group on SARS-CoV-2 Evolution and Vaccine Cadence | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, HIS, SAMHSA | NIAID | An interagency group convened to monitor SARS-CoV-2 evolution and advise on appropriate timing of vaccine and booster delivery. |
| Interagency Modeling and Analysis Group (IMAG) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, ASPR, Other | NIBIB, CSR, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NLM, OD/DPCPSI, OD/DPCPSI/OBSSR, FIC | IMAG is comprised of program directors from over 10 government agencies including the National Institutes of Health (NIH), the National Science Foundation (NSF), Department of Energy (DOE), Department of Defense (DOD), the Department of Agriculture (USDA), the National Aeronautics and Space Administration (NASA), the Department of Veterans Administration (VA), the Food and Drug Administration (FDA), and the Intelligence Advanced Research Projects Activity (IARPA). The purpose of IMAG is to bring together program staff who have a shared interest in supporting modeling and analysis methods in biomedical, biological, and behavioral systems. Since 2003, IMAG has promoted and supported a wide variety of modeling, notably multi-scale modeling (MSM) through agency-specific funding opportunity announcements. IMAG and the MSM Consortium is active through monthly IMAG meetings, MSM Steering Committee meetings and individual working group and special interest group activities (see activities on the IMAG wiki). IMAG is now co-chaired with program staff from NIBIB, NCCIH and NIAID. In 2022, IMAG and the MSM updated its Mission statement (see 2023 Mission Statement). TheMultiscale Modeling and Viral Pandemics working group celebrated its second anniversary, published several publications, including a book, and continues to hold weekly recorded webinars with participants from several IMAG agencies, including NIH, CDC, FDA, NSF and DOD and the associated extramural communities. Additionally in 2022, IMAG and the MSM began planning its return to in-person (hybrid) Consortium meeting for June 2023 on the NIH Campus. https://www.nibib.nih.gov/research-program/interagency-modeling-and-analysis-group-imag |
| Interagency Morphine Milligram Equivalent (MME) Workgroup | Committee, Work group, Advisory group, or Task Force | FDA, CDC | NIDA | The Interagency Morphine Milligram Equivalent (MME) Workgroup is a transagency workgroup that was established in 2022 to identify research priorities and set recommendations around MME calculations for research and clinical practice. |
| Interagency Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Working Group | Committee, Work group, Advisory group, or Task Force | CDC | NINDS, NIAID | The Interagency ME/CFS Working Group consists of multiple government agencies and patient ME/CFS patient advocacy organizations interested in research and care issues related to ME/CFS. The working group was established to help coordinate ME/CFS-related efforts across the federal agencies to enhance research efforts, improve treatment options and patient outcomes, promote public outreach, and strengthen workforce development. The working group, which is co-led by NINDS and CDC, met for the first time in August 2020, and will continue to meet regularly to provide updates, discuss issues relevant to ME/CFS research, and identify and foster communication and collaboration across the federal agencies and with ME/CFS stakeholders. |
| Interagency Oncology Task Force Fellowship: Track 4 | Training Initiative | FDA | NCI | This fellowship will provide training in cancer prevention (e.g., chemoprevention, vaccination, and early detection). Individuals will be trained in the drug, biologic, or device development and approval processes and their application to study populations (including healthy subjects) to facilitate the movement of novel approaches from the bench to the community. Combining training in public health, cancer prevention research, and research-related regulatory overview will allow individuals to develop expertise across these disciplines. https://www.cancer.gov/grants-training/training/at-nci/iotf |
| Interagency Pain Research Coordinating Committee (IPRCC) | Committee, Work group, Advisory group, or Task Force | CDC, AHRQ, FDA, SAMHSA | NIA, NINDS | The Interagency Pain Research Coordinating Committee (IPRCC) is a Federal advisory committee created by the Department of Health and Human Services to enhance pain research efforts and promote collaboration across the government, with the ultimate goals of advancing the fundamental understanding of pain and improving pain-related treatment strategies. https://www.iprcc.nih.gov/ |
| Interagency Pain Research Coordinating Committee (IPRCC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA | NINDS, NCCIH, NIDA, NIDCR, NINR | The Interagency Pain Research Coordinating Committee is an Affordable Care Act-mandated committee to coordinate pain research activities across the government. http://iprcc.nih.gov/ |
| Interagency Pediatric Surge Working Group | Committee, Work group, Advisory group, or Task Force | NIH, CDC, HRSA, ASPR | NICHD | The interagency working group meets weekly to discuss pressing surges and opportunities as it relates to addressing pediatric healthcare capacity, delivery and science. |
| Interagency Policy Council on Nutrition (IPC) | Committee, Work group, Advisory group, or Task Force | FDA, CMS, IOS, OASH, ACL, AHRQ, ASFR, ASPE, ASPR, CDC, HRSA, IHS, NIH, OS, SAMHSA | OD/DPCPSI/ONR, NCI, NHLBI, NICHD, NIDDK | This working group is convened by the White House Domestic Policy Council (DPC) was charged with organizing the White House Conference on Hunger, Nutrition, and Health and developed and is implementing the Biden-Harris Administration National Strategy on Hunger, Nutrition, and Health. https://health.gov/our-work/nutrition-physical-activity/white-house-conference-hunger-nutrition-and-health |
| Interagency Rehabilitation and Disability Research Portfolio (IRAD) | Resource Development | ACL, CDC | NICHD | IRAD is a searchable database of government funded research projects in the areas of disability, independent living and rehabilitation research. The purpose of IRAD is to provide a publicly available resource that enables analysis of the federal research portfolio in disability, independent living, and rehabilitation research. This will aid in collaboration and coordination of research activities across federal agencies, as well as increase transparency and visibility for the public and legislative stakeholders. https://irad.nih.gov/ |
| Interagency Select Agent Review Group (ISARG) | Committee, Work group, Advisory group, or Task Force | CDC, OS | NIAID, OD/OM/OB, OD/OSP | The Interagency Select Agent Review Group (ISARG), composed of members from the Centers for Disease Control and Prevention (CDC), the Department of Justice, the Department of State, the National Institutes of Health Office of the Director (NIH-OD) and the Biomedical Advanced Research and Development Authority (BARDA), advises the National Institute of Allergy and Infectious Diseases (NIAID) on whether facilities and procedures at NIAID-funded foreign research sites are comparable to those required by the Select Agent Regulations for domestic institutions before Select Agent work at the foreign site may proceed. |
| Interagency Task Force on the Arts and Human Development | Committee, Work group, Advisory group, or Task Force | ACF, CDC, SAMHSA | NICHD, NCCIH, NCI, NIA, NIMH, OD/DPCPSI/OBSSR | Beginning in 2011, the National Endowment for the Arts (NEA) has convened a Federal Interagency Task Force on the Arts and Human Development to encourage more and better research on how the arts can help people reach their full potential at all stages of life. https://www.arts.gov/national-initiatives/task-force/members |
| Interagency Task Force on Trauma-Informed Care | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, FDA, HRSA, IHS, OS, SAMHSA | NIMH, NICHD | The Interagency Task Force on Trauma-Informed Care (TIC Task Force) was established on October 13th, 2018, with the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act of 2018 (Public Law 115-271). The TIC Task Force is charged with identifying, evaluating, and making recommendations regarding: (1) best practices with respect to children and youth, and their families as appropriate, who have experienced or are at risk of experiencing trauma; and (2) ways in which federal agencies can better coordinate to improve the federal response to families impacted by substance use disorders and other forms of trauma. https://www.samhsa.gov/sites/default/files/programs_campaigns/trauma_informed_care/support-act-section-n.pdf |
| Interagency Workgroup on Technology to Facilitate Aging in Place | Research Initiative | ACL, CMS, FDA | NIA, NCI, NHLBI, NIBIB, NINDS, NINR | The purpose of this Trans-National Institutes of Health (NIH) Inter-Agency group is to develop new platforms for everyday life technology that will enhance the common goals of multiple NIH institutes and other federal government agencies by improving the capability to rapidly conduct peer-reviewed technology research to facilitate aging in place, with a special emphasis on people from underrepresented groups. A platform is a group of technologies that are used as a base upon which other applications, processes or technologies are developed. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-16-021.html |
| Interagency Working Group (IWG) on Communicating Hazard Information and Other Types of Uncertainty, White House Office of Science and Technology Policy (OSTP) Subcommittee on Social and Behavioral Sciences (SBS) | Committee, Work group, Advisory group, or Task Force | FDA | NIMHD, OD/DPCPSI/OBSSR, NCI, NINR, NCATS | The primary goal of the SBS is to focus on the ways in which social and behavioral research can be created and mobilized to support the U.S. government in making evidence-based decisions. This subgroup of the SBS aims to increase USG;s effective and equitable communication of hazard information and various types of uncertainty in a variety of domains to the American public. It may explore topics including health communication (e.g., regarding COVID-19 and other public health crises), environmental hazard communication, and climate crisis communication, among others. It will emphasize how approaches informed by social and behavioral sciences can increase the likelihood that diverse subpopulations of the U.S. public will receive the information they need in ways that enable responses consistent with individuals; overall health and well-being, no matter where they live or how they identify. https://www.whitehouse.gov/wp-content/uploads/2022/09/09-2022-Policy-Development-in-the-Social-and-Behavioral-Sciences-Subcommittee.pdf |
| Interagency Working Group in the Glycosciences | Committee, Work group, Advisory group, or Task Force | FDA | NIGMS, NCI, NICHD, NIDCR, NIDDK | This group meets annually to identify synergies, discuss progress on the development of national standards for carbohydrates, and exchange information on the glycosciences being pursued at each agency. https://crs.od.nih.gov/CRSPublic/View.aspx?Id=4703 |
| Interagency working group on Biological Data Sharing (IWGBDS) | Committee, Work group, Advisory group, or Task Force | FDA | NIGMS, NCI | The working group will identify the diverse types of biological and clinical data, define specific needs and best practices for storing, managing, curating, archiving, and maintaining the confidentiality and integrity of these data, and define agency roles and responsibilities for addressing research and policy (exclusive of regulatory) priority gaps to enable data sharing. The working group will develop a road map to enable robust sharing and maximize reuse of data, identifying opportunities for interagency coordination, and academic, industrial, and international partnerships. |
| Interagency Working Group on Harmful Algal Bloom and Hypoxia Research and Control Act (IWG-HABHRCA) | Committee, Work group, Advisory group, or Task Force | FDA, CDC | NIEHS | Harmful algal bloom (HAB) and hypoxia (severe oxygen depletion) events are scientifically complex and economically damaging. They challenge our ability to safeguard the health of our nation’s coastal, Great Lakes, and freshwater ecosystems. Nearly every state experiences some type of hypoxia or HAB event. Federal agencies are working together to advance the understanding of HAB and hypoxia events, and respond to, detect, predict, control, and mitigate these events to the greatest extent possible, as mandated by the Harmful Algal Bloom and Hypoxia Research and Control Amendments Act of 2014 (HABHRCA). |
| Interagency Working Group on Scientific Collections of the National Science and Technology Council (IWGSC) | Committee, Work group, Advisory group, or Task Force | CDC | NLM, NCI, OD | The Interagency Working Group on Scientific Collections (IWGSC) was established by the White House National Science and Technology Council (NSTC) in June 2006. IWGSC currently operates as a subcommittee under the Committee on Science and Technology Enterprise. IWGSC is co-chaired by U.S. Department of Agriculture and the Smithsonian and originally reported to the NSTC Committee on Science. IWGSC's mission was to assess the status and needs of the scientific collections owned, managed, and/or supported by the U.S. Federal Government, and to recommend ways to improve their management, effectiveness and impact. The IWGSC is currently implementing the three recommendations which: Formalize each Department's and Agency's policies toward scientific collections; Establish appropriate budgeting guidelines and procedures that ensure proper stewardship for scientific collections, which are considered government assets; and Create a public clearinghouse for information on the scientific collections that are owned, managed and supported by the Federal Government. https://iwgsc.nal.usda.gov/about-iwgsc |
| Interdepartmental Health Equity Collaborative (formerly FIHET) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | NIMHD, NCATS, NCI, NHLBI, NIA, NIAAA, NIAID, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIMH, NINR | Federal leadership for the National Partnership for Action to End Health Disparities (NPA) is provided by the Interdepartmental Health Equity Collaborative (IHEC). The IHEC was established to foster communications and activities of the NPA within federal agencies and their partners; and to increase the efficiencies and effectiveness of related policies and programs at the national, state, tribal, and local levels. http://www.minorityhealth.hhs.gov/npa/ |
| Interdepartmental Serious Mental Illness Coordinating Committee (ISMICC) | Committee, Work group, Advisory group, or Task Force | CMS, SAMHSA | NIMH | In December 2016, the 21st Century Cures Act was signed into law (Public Law 114-255). Through this Act, the Interdepartmental Serious Mental Illness Coordinating Committee (ISMICC) was established to address the needs of adults with serious mental illness (SMI) and children and youth with serious emotional disturbance (SED) and their families so that Americans with SMI and SED are able to improve their lives and receive the highest possible standard of care-care that is deeply informed by knowledge of science and medicine. The ISMICC includes representatives from eight federal departments that support programs that address the needs of people with SMI and SED and is informed and strengthened by the participation of non-federal members, including national experts on health care research, mental health providers, advocates, people with living with mental health conditions, and their families and caregivers. This cross-sector, public-private partnership provides a unique opportunity to share and generate solutions to the problems facing the mental health system. The ISMICC seeks to support a system where individuals with SMI or SED are able to engage effectively with a range of treatment and recovery support services that promote opportunities for people to live well in their communities. A central charge of this committee is to submit two reports to Congress, the first no later than one year after the enactment of the Act, and the second five years following enactment. The ISMICC has five priority areas and corresponding workgroups for these priority areas. Representatives from the National Institute of Mental Health (NIMH) sit on each of these workgroups. https://www.samhsa.gov/ismicc |
| Interdepartmental Substance Use Disorders Coordinating Committee (ISUDCC) | Committee, Work group, Advisory group, or Task Force | SAMHSA | NIDA | The Secretary of Health and Human Services, in coordination with the Director of the Office of National Drug Control Policy, is required by the SUPPORT for Patients and Communities Act Public Law 115-271 to establish an Interdepartmental Substance Use Disorders Coordinating Committee composed of federal and non-federal members to accomplish the following duties: 1. Identify areas for improved coordination of activities, if any, related to substance use disorders, including research, services, supports, and prevention activities across all relevant federal agencies; 2. Identify and provide to the Secretary recommendations for improving federal programs for the prevention and treatment of, and recovery from, substance use disorders, including by expanding access to prevention, treatment, and recovery services; 3. Analyze substance use disorder prevention and treatment strategies in different regions of and populations in the United States and evaluate the extent to which federal substance use disorder prevention and treatment strategies are aligned with State and local substance use disorder prevention and treatment strategies; 4. Make recommendations to the Secretary regarding any appropriate changes with respect to the activities and strategies described in items (1) through (3) above; 5. Make recommendations to the Secretary regarding public participation in decisions relating to substance use disorders and the process by which public feedback can be better integrated into such decisions; and 6. Make recommendations to ensure that substance use disorder research, services, supports, and prevention activities of the Department of Health and Human Services and other federal agencies are not unnecessarily duplicative. https://www.samhsa.gov/about-us/advisory-councils/isudcc |
| International Cancer Control Partnership (ICCP) | Other | CDC | NCI | The National Cancer Institute and the Union for International Cancer Control convened global partners including the Centers for Disease Control and Prevention (CDC) to cooperate in assisting countries to develop and implement quality cancer plans linked to Non-communicable Disease (NCD) control. This International Cancer Control Partnership, ICCP, believes that prioritizing cancer is critical to reaching the “25x25” goal. ICCP partners assist countries by: (1) Creating and maintaining a searchable database of current cancer control plans from around the globe; (2) Performing analysis of gaps and highlighting priority areas for inclusion in plans; (3) Providing technical assistance to countries working to develop plans with targets and evaluation strategies; (4) Providing planners with relevant existing materials and tools; and (5) Coordinating an online community of practice (through partnership with the University of New Mexico's Project ECHO) for dissemination and utilization of scientific knowledge for National Cancer Control Plan implementation. ICCP partners will use their collective state, country, and regional-level planning experience to guide plan development and implementation and will ensure planners utilize effective, evidence-based strategies to help meet the global NCD targets. http://www.iccp-portal.org/ |
| International Cancer Screening Network (ICSN) | Committee, Work group, Advisory group, or Task Force | CDC | NCI | The International Cancer Screening Network (ICSN) is a voluntary consortium of screening practitioners who work in countries that are planning for or implemented population-based cancer screening programs with the mission of reducing the burden of cancer by promoting dialogue and collaborative cancer screening research, evaluation and dialogue regarding the effectiveness of context-specific evidence-based cancer screening programs, including promotion, recruitment and follow-up among other relevant topics. ICSN goals include: 1. To provide global leadership in cancer screening research and evaluation by organizing scientific studies, biennial conferences, consultations, mentorship, training, and by publishing collaborative papers. 2. To create a community of screening practitioners (researchers, evaluators, implementers and screening program staff) to exchange data, evidence, ideas and experiences that advance the field of cancer screening. 3. To assist in the design of studies to evaluate the process and effectiveness of cancer screening programs; to evaluate and promote innovation in cancer screening through new technologies; to enhance the screening process for treatment of screen-detected lesions, among other topics. 4. To be a source of education and dialogue about basic aspects of cancer screening as well as advanced and emerging concepts and technology. 5. To include membership who conducts cancer screening research, develop infrastructure for cancer screening, and establish programs whose goal is to deliver the highest quality health care while producing the maximum benefit to the population and minimizing its harms. https://www.cancer.gov/about-nci/organization/cgh/partnerships-dissemination/icsn-international-cancer-screening-network |
| International Neonatal Consortium | Meeting/ Workshop | FDA | NICHD | Launched on May 19, 2015, INC is C-Path’s ninth consortium – a global collaboration formed to forge a predictable regulatory path for evaluating the safety and effectiveness of therapies for neonates. “By uniting stakeholders from research institutions, drug developers, regulatory agencies, patient advocacy and other organizations,” said Janet Woodcock, Director of the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research (FDA/CDER), “INC can develop practical tools that can be incorporated into clinical trials for neonates, which will then lead to more successful, efficient trials and provide this population with better treatments.” https://c-path.org/programs/inc/ |
| International Rare Diseases Research Consortium (IRDiRC) Funders Committee | Committee, Work group, Advisory group, or Task Force | FDA | NICHD, NCATS, NCI, NEI, NHGRI, NIAMS, NINDS | The International Rare Diseases Research Consortium (IRDiRC) teams up researchers and organizations investing in rare diseases research in order to achieve two main objectives by the year 2020, namely to deliver 200 new therapies for rare diseases and means to diagnose most rare diseases. A number of grand challenges are being addressed through collaborative actions to reach these 2020 goals such as establishing and providing access to harmonized data and samples, performing the molecular and clinical characterization of rare diseases, boosting translational, preclinical and clinical research, and streamlining ethical and regulatory procedures. http://www.irdirc.org/about-us/ |
| International TB Working Group | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | This is a working group of the Federal Tuberculosis (TB) Task Force. The International TB Working Group is chaired and organized by the US Agency for International Development (USAID). It meets monthly to coordinate international TB support. |
| Interoperability Standards Priorities Task Force of the Health Information Technology (HIT) Standards Committee | Committee, Work group, Advisory group, or Task Force | ONC | NLM | The Interoperability Standards Advisory Task Force of the Health Information Technology (HIT) Standards Committee is part of the Federal Advisory Committee that is charged with making recommendations to the Office of the National Coordinator for Health Information Technology (ONC) on standards and implementation specifications to promote interoperability of computer systems and health information (The Health Information Technology Advisory Committee, or HITAC). https://www.healthit.gov/facas/calendar/2017/01/17/standards-2017-interoperability-standards-advisory-task-force |
| Intragovernmental Select Agents and Toxins Technical Advisory Committee (ISATTAC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID, NCI, OD/ORS, OD/OSP | The ISATTAC is a working group of subject matter experts from the Federal Government formed by the Centers for Disease Control and Prevention (CDC) Director to provide recommendations to the CDC's Division of Select Agents and Toxins in three technical areas: 1) review requests for exclusion of attenuated strains, 2) review requests to conduct restricted experiments, and 3) review select agents and toxins. The Committee conducts a biannual review, required by the Select Agent Rule, of the Select Agents and Toxins list for HHS. https://report.nih.gov/crs/View.aspx?Id=2117 |
| Iodine Initiative | Resource Development | FDA, CDC | OD/DPCPSI/ODS, NICHD, OD/DPCPSI/ORWH | The National Institutes of Health's, Office of Dietary Supplement's Iodine Initiative was originally developed in response to concerns that some pregnant women in the U.S. might have inadequate iodine intake at a time of high physiological demand. Past and current activities include convening state of the science workshops and symposia, development of databases that characterize the iodine content of foods and dietary supplements, supporting the improvement of existing analytical methods, new methods and development of standard reference materials for assessing iodine status, assessments of U.S. population-level iodine intake and iodine status via funding iodized salt collection and markers of iodine status in the National Health and Nutrition Examination Survey, and funding opportunities for investigator-initiated iodine research. Finally, summaries of the scientific literature on iodine are made available on the Office of Dietary Supplement's website. https://ods.od.nih.gov/Research/Iodine.aspx |
| Its a Noisy Planet. Protect Their Hearing® Public Education campaign | Public Education Campaign | CDC | NIDCD | The National Institute on Deafness and Other Communication Disorders (NIDCD) sponsors It’s a Noisy Planet Protect Their Hearing®, a national public education campaign to increase awareness among parents of children ages 8 to 12 about noise-induced hearing loss (NIHL) and how to prevent it. The campaign disseminates messages through print and digital materials, social media, community events, school presentations, and other methods. The CDC’s National Center for Environmental Health and National Institute for Occupational Safety and Health (NIOSH) have actively collaborated with the NIDCD for this campaign. https://www.noisyplanet.nidcd.nih.gov |
| JDRF/NIH Beta Cell Replacement Workshop | Committee, Work group, Advisory group, or Task Force | FDA | NIAID, NIDDK | JDRF and NIH have partnered to plan the workshop “How Do We Get to the Clinic with Beta Cell Therapies for Type 1 Diabetes (T1D)” for May 18-19, 2022 on the NIH campus. This meeting will focus on developing the paradigm in research and development for T1D shifts toward clinical translation and testing of cell based therapies. We would like to bring the community of T1D researchers, industry, regulators and patients together to discuss the ways we can accelerate the translation of beta cell replacement therapies to the clinic and identifying ways to address gaps that remain. |
| Joint Agency Microbiome Working Group (JAM) | Committee, Work group, Advisory group, or Task Force | FDA | OD/DPCPSI/ONR, NCI | The Joint Agency Microbiome (JAM) Working Group's mission is to communicate, across Federal Agencies, ongoing microbiome-focused research. The JAM was founded in 2017 by researchers from FDA and NIH. In 2019, NIST joined the JAM. And in 2021, USDA joined the JAM. The JAM has quarterly virtual meetings. https://jam-2021.virtualpostersession.org/ |
| Joint Agency Nutrition Working Group (JAN) | Committee, Work group, Advisory group, or Task Force | FDA | OD/DPCPSI/ONR, NICHD, NCI, OD/OSP | The Joint Agency Nutrition (JAN) was established to address gaps and opportunities in the areas of dietary supplements and nutrition research related to pregnant women and children and chronic diseases. The Working Group reports to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) Joint Leadership Council. |
| Joint External Evaluation Working Group (JEEWG) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NCI, NIEHS, NINDS, OD/ORS | Supports the Global Health Security Agenda activities related to International Health Regulations implementation to include internal and external joint evaluations, draft a National Action Plan (NAP) to address recommendations, and periodically review and report the status of the NAP. https://www.ghsagenda.org/ |
| Joint Fellowship Program | Training Initiative | FDA | NCI | The objective of the NCI-FDA Joint Fellowship Training Program is to train a cadre of scientists in research and research-related regulatory review, policies, and regulations so that they develop a skill set bridging the two disparate processes. Fellows learn to build awareness of regulatory requirements into the early stages of the medical product development process and develop strategies to improve planning throughout research and regulatory review. http://iotftraining.nci.nih.gov/ |
| Justice40/Environmental Justice Stakeholder Engagement Meeting | Meeting/ Workshop | ASPR, OASH, CDC, HRSA | NIEHS | The NIEHS Environmental Career Worker Training Program (ECWTP) has been named a pilot program for the White House’s Justice40 Initiative. This meeting was held to engage stakeholders to learn about ECWTP and hear feedback for future directions. https://www.niehs.nih.gov/news/events/pastmtg/hazmat/2021/Fall_Meeting/index.cfm |
| Kaposi Sarcoma and HHV8 in Sickle Cell and Other Ugandan Populations | Research Initiative | CDC | NCI | Epidemiological studies are being conducted to assess small-area variation of Kaposi's sarcoma-associated herpesvirus (HHV8) and to learn about socio-demographical and environmental risk factors for HHV8 and Kaposi sarcoma in Uganda. |
| Kidney Innovation Accelerator (KidneyX) | Research Initiative | FDA, OASH, ASPR | NIDDK, NCATS, NIBIB | KidneyX, also called the Kidney Innovation Accelerator, is a public-private partnership between the U.S. Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN). Established in April 2018, KidneyX aims to use prize competitions to accelerate the development of innovative solutions that can prevent, diagnose, and/or treat kidney diseases. KidneyX aims to promote collaboration between patients, health professionals, innovators, industry, and government with the ultimate goal of improving quality of life for people living with kidney diseases. http://www.kidneyx.org |
| Kidney, Urologic, and Hematologic Diseases Interagency Coordinating Committee (KUHICC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS | NIDDK, NCCIH, NCI, NHLBI, NIA, NICHD, NINDS, OD/DPCPSI/OBSSR | The Kidney, Urologic, and Hematologic Diseases Interagency Coordinating Committee (KUHICC), chaired by NIDDK, encourages cooperation, communication, and collaboration among all Federal agencies involved in kidney, urology, and hematology research and other activities. Section 429 of Public Law 99-158 created the KUHICC in 1987. The committee met for the first time in 1988, and has the following subcommittees: Kidney Interagency Coordinating Committee, Urology Subcommittee, and Hematology Subcommittee. Meetings focus on interagency collaboration to elicit ideas from meeting participants to enhance current research directions within the National Institutes of Health and to form partnerships among agencies. https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/kuh-icc |
| Know Stroke | Public Education Campaign | CDC | NINDS | The goal of the Know Stroke campaign is to help educate the public about the symptoms of stroke and the importance of timely access to medical care. The campaign includes outreach to consumers and health care professionals using mass media, partnerships, and community education. https://www.stroke.nih.gov/about/index.htm |
| Laboratory Services Section, Department of Transfusion Medicine Core Report | Research Initiative | FDA | CC | Laboratory Services Section, Department of Transfusion Medicine Core Report |
| Leprosy Research Support in Armadillos (Dasypus Novemcinctus) | Other | HRSA | NIAID | The Leprosy Research Support and Maintenance of an Armadillo Colony – Post Genome Era interagency agreement provides standardized research reagents to investigators worldwide to assist in the development of skin test antigens used to detect leprosy. This agreement supports collaborative research to continuously improve biochemical, microbiological, and immunological models for leprosy research in an effort to provide the most up-to-date resource and expertise for mycobacterial researchers. |
| Leveraging Novel Technologies for Chronic Disease Management for Aging Underserved Populations | Research Initiative | OASH | NHLBI | HHS Office of the Assistant Secretary for Health (OASH), in partnership with other federal agencies, has issued a Request for Information (RFI) to gain a more comprehensive understanding from our stakeholders regarding innovative solutions to chronic disease management. The RFI is focused on how to leverage novel technologies to optimize compliance with evidence-based standards of care in disease states that cause significant morbidity and mortality in aging populations in underserved areas. The RFI also seeks to identify opportunities to strengthen the U.S. healthcare system through public-private partnerships in data sharing, comprehensive analytics including AI, and other potential mechanisms. https://www.federalregister.gov/documents/2020/11/17/2020-25328/request-for-information-landscape-analysis-to-leverage-novel-technologies-for-chronic-disease |
| LGBT Healthy People 2030 Working Group (LGBT HP 2030) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ATSDR, BARDA, CDC, CMS, FDA, HRSA, IHS, OS, Office of the Surgeon General (OSC), SAMHSA | OD/DPCPSI/SGMRO, NCI, NEI, NHLBI, NIA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIMH, NINDS | Healthy People provides science-based national goals and objectives with 10-year targets designed to guide national health promotion and disease prevention efforts to improve the health of all Americans. As part of its mission, Healthy People has established benchmarks and monitored progress over three decades in order to (1) engage multiple sectors to strengthen policies and improve practices that are driven by the best available evidence and (2) to increase public awareness of the determinants of health, disease, and disability and the opportunities for progress. https://www.healthypeople.gov/2020/topics-objectives/topic/lesbian-gay-bisexual-and-transgender-health |
| Linkage of Surveillance, Epidemiology, End Results data to Centers for Medicare and Medicaid data (SEER-CMS) | Resource Development | CMS | NCI | SEER registry data (e.g., cancer diagnosis date, site, histology) are individually linked to CMS data (e.g., enrollment, claims, assessments and surveys) using personally identifiable information. The data on the matching cancer cases are pulled together with CMS data on non-cancer controls (e.g., individuals not known to have a cancer diagnosis who reside in a SEER area) to create four research data resources: SEER-Medicare, SEER-Medicare Health Outcomes Survey (SEER-MHOS), SEER-Consumer Assessment of Healthcare Providers and Systems (SEER-CAHPS) and SEER-Medicaid. The SEER-CAHPS data set is a resource for quality of cancer care research based on a linkage between the NCI's Surveillance, Epidemiology and End Results (SEER) cancer registry data and the Centers for Medicare Medicaid Services' (CMS) Medicare Consumer Assessment of Healthcare Providers and Systems (CAHPS®) patient surveys. The SEER-MHOS is a data resource for cancer health outcomes research. It is based on a linkage between the NCI's Surveillance, Epidemiology and End Results (SEER)External Web Site Policy cancer registry data and the Centers for Medicare Medicaid Services' (CMS) Health Outcomes Survey (HOS). https://healthcaredelivery.cancer.gov/seermedicare |
| Liquid Biopsy Working Group (LBWG) | Committee, Work group, Advisory group, or Task Force | CMS, FDA | NCI | This transagency work group meets monthly to review progress in liquid biopsy toward early detection of cancer. Members from several NCI Divisions and Offices, CMS and FDA participate in the meeting. As part of this committee, experts from the extramural community are invited to speak about latest progress in liquid biopsy. |
| Logical Observation Identifiers Names and Codes (LOINC) | Resource Development | AHRQ, CDC, CMS, HRSA, IHS, IOS | NLM | This activity supports the maintenance, distribution, and continued development of LOINC®, a set of universal codes and names to identify laboratory and other clinical observations which facilitates the exchange and pooling of clinical results for clinical care, outcomes management, public health, and research. NLM has a contract with Regenstrief to distribute the LOINC vocabulary through the UMLS and to cover some special projects to enhance parts of the LOINC vocabulary. Regenstrief creates and maintains the LOINC database and supporting documentation, and the RELMA mapping program. AHRQ, CDC, CMS, HRSA, HIS and IOS use LOINC. The past and current contract allows for tasks to be assigned to Regienstrief to review and enhance portions of the LOINC vocabulary based on special or new topic areas. In the past the collaborators have asked NLM to designate a special task/ work to be done through an MOU or IAA; the collaborators provide funding for the special task. http://www.nlm.nih.gov/research/umls/loinc_main.html |
| Long-Term Impact of Military-Relevant Brain Injury (LIMBIC) Consortium/Chronic Effects of Neurotrauma Consortium (GENC) Government Steering Committee | Committee, Work group, Advisory group, or Task Force | ACL | NINDS | The goals of LIMBIC-CENC are to examine the immediate effects of concussion on the brain as well as those later in life (e.g. risk for dementia), to identify the best treatments for concussion. and to disseminate this information to service members and relevant stakeholders. https://www.limbic-cenc.org/index.php/about/government-steering-committee/ |
| Lower Limb Prosthetics Research Standards Working Group | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, CMS, FDA | NICHD, NIDDK, OD | This working group helps to determine research standards for lower limb prosthetics. |
| Lupus Clinical Trials | Research Initiative | FDA | OD/OIR, NIAMS | Lupus Clinical Trials |
| Lupus Federal Working Group | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA, OS | NIAMS, NCCIH, NEI, NHLBI, NIAID, NICHD, NIDCR, NIDDK, NIEHS, NIMHD, NINDS, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH | The Lupus Federal Working Group, established on behalf of the Department of Health and Human Services (HHS) Secretary by the National Institutes of Health (NIH), facilitates collaboration among NIH components, other Federal agencies, voluntary and professional organizations, and industry groups with an interest in lupus. https://www.niams.nih.gov/about/working-groups/lupus-federal |
| Lyme and Tick-borne Diseases Work Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS, CMS | NIAID | This workgroup involves members from agencies including the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and the National Institutes of Health (NIH) with the purpose of continued coordination and communication of activities, policy updates, events, agency highlights, and other shared interests relating to Lyme disease and other tick-borne diseases. https://www.hhs.gov/ash/advisory-committees/tickbornedisease/index.html |
| Macaque models for preclinical development of iPSCs | Research Initiative | FDA | NHLBI | Macaque models for preclinical development of iPSCs |
| Machine learning methods for literature data extraction | Research Initiative | FDA | NIEHS | This project is applying natural language processing and machine learning methods to identify specific data elements in the full text of scientific publications |
| Magnetic Resonance Spectroscopy Core Facility | Research Initiative | FDA | NIMH | Magnetic Resonance Spectroscopy Core Facility |
| Making Medicaid Data More Accessible Through Common Data Models and FHIR APIs | Resource Development | ASPE, FDA | NLM | This project aims to develop and publish open-source code to format Transformed Medicaid Statistical Information System (T-MSIS) Research Identifiable File (RIFs) to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) in conjunction with the U.S. Food and Drug Administration's (FDA) formatting to the Sentinel Common Data Model (CDM). Data quality will be characterized using a harmonized Data Quality Assessment Framework for electronic healthcare data that was developed in a previously funded Office of the Secretary Patient-Centered Outcomes Research (OS-PCORTF) project. Lastly, the project will assess the feasibility of using Fast Healthcare Interoperability Resources (FHIR) to link Electronic Health Records (EHR) to Transformed Medicaid Statistical Information System (T-MSIS) claims data. |
| Mapping of the Systematized Nomenclature of Medicine-Clinical Terms (SNOMED CT) and International Classification of Disease (ICD) Clinical Terminology | Resource Development | CDC, IOS | NLM | The US Department of Health and Human Services (HHS) has set a goal for the nationwide implementation of an interoperable health information technology infrastructure to improve the quality and efficiency of healthcare. Achieving this goal will require that key clinical data elements are captured or recorded in detailed, standardized form (using standard vocabularies, codes, and formats) as close to their original sources (patients, healthcare providers, laboratories, diagnostic devices, etc.) as possible. If these standardized clinical data can also be used to generate HIPAA- compliant billing transactions automatically, this will provide another incentive for adoption of clinical data standards. For the automated generation of bills from clinical data to become a reality, robust mappings from standard clinical terminologies to the HIPAA code sets must be created. To support the transition to ICD-10-CM in 2015, a map from SNOMED CT to ICD-10-CM is being created. https://www.nlm.nih.gov/research/umls/mapping_projects/snomedct_to_icd10cm.html |
| Maternal Health Working Group | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | NICHD, NHLBI, NIMHD, OD/DPCPSI/ORWH | This internal Department of Health and Human Services (HHS) group was formed in June 2019, with the goal of developing a trans-HHS Action Plan aimed at making the U.S. the safest place in the world to give birth. |
| Measuring Efficacy in Neonatal Clinical Trials | Meeting/ Workshop | FDA | NICHD | Public Workshop funded by the FDA to improve clinical trials in Neonates. Contracted with the Duke Margolis Center for Health Policy. |
| Mechanobiology | Research Initiative | FDA | NIBIB | Mechanobiology |
| Medical Expenditure Panel Survey (MEPS): Experiences with Cancer Survivorship Supplement (MEPS CSAQ) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC | NCI, OD/DPCPSI/OBSSR | The National Cancer Institute (NCI) has collaborated with CDC, AHRQ, and other organizations to provide supplemental funding for the Medical Expenditure Panel Survey (MEPS) to improve the quality of data for estimating the cancer survivorship burden in the United States. Using responses to the National Health Interview Survey (NHIS) question about ever receiving a cancer diagnoses, households with cancer survivors were oversampled for selection in this MEPS Supplement. The increased sample of cancer survivors will improve national estimates of the burden of cancer. Additionally, this collaborative group developed a targeted questionnaire and associated database to further understand the burden of cancer, its treatment and impact on access to health care, the ability to work and participate in usual activities, health insurance, and quality of care. The collaborative group is developing an updated version of this questionnaire, with additional questions on employment impacts of cancer and social determinants of health, for future administration. https://healthcaredelivery.cancer.gov/meps/ |
| Medical Imaging & Data Resource Center (MIDRC) | Resource Development | FDA | NIBIB, NCI, CC, NCATS, NHLBI, NLM | MIDRC curates medical images and develops AI-ready data and AI/ML algorithms for helping with the clinical management of COVID-19 patients and the pandemic in general. As of this date, over 105,000 highly curated AI-ready COVID image-sets are already available for public access and investigation, about 200,000 more image-sets are in the pipeline, and 24 algorithms are under development. MIDRC-sponsored challenges have enhanced algorithm development. The contract was extended to a third year (ongoing) to include study patients who have suffered from longer-term symptoms of COVID. MIDRC has expanded interoperability with other NIH ICs (e.g., NCATS, NHBLI) and Argonne National Lab (DOE). An internal NIH advisory board monitors MIDRC progress along with NIBIB. MIDRC is now a national resource of curated medical images of COVID patients, ready to be used to develop clinically useful AI applications. Medical facilities in 24 US states contribute information and interact with MIDRC through the American Association of Medical Physicists, the American College of Radiology, and the Radiological Association of America. https://www.midrc.org/ |
| Memorandum of Understanding (MoU) between FDA/Center for Drug Evaluation and Research (CDER) and NIH/NINDS | Other | FDA | NINDS | This MoU provides a mechanism for addressing cross-cutting issues related to drug evaluation and research for neurological disorders, from bench science to clinical studies and the Food and Drug Administration (FDA) approval. https://www.fda.gov/about-fda/domestic-mous/mou-225-19-027 |
| Memorandum of Understanding (MOU) between the FDA Center for Devices and Radiological Health and NIH/NINDS | Other | FDA | NINDS | This MOU provides a mechanism for addressing cross-cutting issues related to the development of devices for neurological disorders, from bench science to clinical studies and the Food and Drug Administration (FDA) approval. https://www.fda.gov/about-fda/domestic-mous/mou-225-13-023 |
| Memorandum of Understanding (MOU) between the FDA/Center for Biologics Evaluation and Research (FDA/CBER) and NIH/NINDS | Other | FDA | NINDS | This Memorandum of Understanding (MOU) provides a mechanism for addressing cross-cutting issues related to therapy development for neurological disorders, from bench science to clinical trials and the Food and Drug Administration (FDA) approval and licensure. https://www.fda.gov/about-fda/domestic-mous/mou-225-18-017 |
| Microphysiological Systems for Drug Efficacy and Toxicity Testing (Tissue Chip for Drug Screening) | Research Initiative | FDA, ASPR | NCATS, NCI, NEI, NHLBI, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIGMS, NINDS, NINR, OD/DPCPSI/ORWH, OD/DPCPSI/OSC | The Microphysiological systems (MPS) initiative aims to develop 3-D human tissue chips that accurately model the structure and function of human organs, such as the lung, liver, and heart. Researchers are currently using these models to predict whether a candidate drug, vaccine, or biologic agent is safe or toxic in humans in a faster and more cost-effective way than current methods. More than 30 percent of promising medications have failed in human clinical trials because they are determined to be toxic despite promising pre-clinical studies in animal models. These organs-on-chips will also enable scientists to predict more accurately how effective a therapeutic candidate would be in clinical studies. To help streamline the therapeutic development pipeline, NIH, in collaboration with the US Food and Drug Administration (FDA) and the Innovation and Quality (IQ) Consortium of pharmaceutical companies, is leading this initiative to improve the process for predicting whether drugs will be safe and effective in humans. In an effort to overcome some clinical trial challenges, Clinical Trials on a Chip is supporting the development of tissue chips to inform clinical trial design for both common and rare diseases; support the planning and execution of clinical trials; assist in patient stratification; help identify reliable clinical trial endpoints; and ultimately develop tools for more informative and efficient clinical trials for both common and rare diseases. Another program, the Tissue Chips in Space initiative, is creating tissue- and organ-on-chip platforms that can be sent to the ISS National Lab so that scientists can better understand the role of microgravity on human health and diseases and translate those findings to improve human health on Earth. Current efforts aim to bring tissue chips towards FDA regulatory qualification as drug development tools by establishing Translational Centers for MPS. https://ncats.nih.gov/tissuechip |
| Mind Your Risks | Public Education Campaign | CDC, CMS | NINDS | The Mind Your Risks campaign is designed to create awareness and action about the fact that risk factors for stroke, particularly hypertension, may be linked to cognitive impairment and dementia. http://www.mindyourrisks.nih.gov/ |
| Molecular Approaches To Antiviral Development For Viral Hepatitis and Other Viral Diseases | Research Initiative | IHS | NIDDK | Molecular Approaches To Antiviral Development For Viral Hepatitis and Other Viral Diseases |
| Molecular approaches to understand vector-host and vector-pathogen interactions | Research Initiative | FDA | NIAID | Molecular approaches to understand vector-host and vector-pathogen interactions |
| Molecular Immunohematology in Ethiopian Sub-populations | Research Initiative | FDA | CC | Molecular Immunohematology in Ethiopian Sub-populations |
| Molecular Mechanisms of Pathogenesis of Acute and Chronic Liver Diseases | Research Initiative | FDA | NIAID | Molecular Mechanisms of Pathogenesis of Acute and Chronic Liver Diseases |
| Molecular Profiling of Diabetes and its Complications | Research Initiative | IHS | NIDDK | Molecular Profiling of Diabetes and its Complications |
| Monthly Zika Vaccine Development Meeting | Resource Development | BARDA, FDA | NIAID | This working group is collaborating on development of assays and animal models for zika vaccines. Collaboration includes exchange of study data, study reports, and regulatory strategy for assay and model development and development of a regulatory package to support licensure of products through alternative pathways. |
| Mortality Disparities in American Communities (MDAC) Study | Research Initiative | CDC, FDA | NHLBI, NCI, NIA | The Mortality Disparities in American Communities study leverages the very large, nationally representative, American Community Survey to examine mortality disparities according to a range of social and demographic factors including: age, race, ethnicity, geography, neighborhood characteristics, education, income, and household factors. The study can further examine disparities in Medicare and Medicaid utilization. https://www.census.gov/topics/research/mdac.html |
| MOU with FDA in Clinical Proteomics | Resource Development | FDA | NCI | CPTAC renewed its coordination with the FDA via a memorandum of understanding. This partnership provides regulatory science continuance on proteomic/proteogenomic analytical technologies, such 510(k) presubmissions. Partners include the Center for Devices and Radiological Health and Oncology Center of Excellence. https://proteomics.cancer.gov/news_and_announcements/fda-and-nih-sign-memorandum-understanding-interagency-collaboration-advance |
| Multiagency Data Initiatives to Build Data Capacity for Patient-Centered Outcomes Research for COVID-19 | Resource Development | AHRQ, ASPE | NIDDK, NCATS | NIH is working with the HHS Office of the Assistant Secretary for Preparedness and Evaluation on several initiatives related to building data capacity for patient-centered outcomes research for COVID-19. The “Understanding COVID-19 Trajectory and Outcomes in the Context of MCC Through e-Care Plan Development” project (a collaboration between AHRQ, NIDDK, and ASPE) works to expand standards-based e-Care plan tools to facilitate aggregation and sharing of person-centered-planning data, including health concerns, social determinants of health, complex constellations of COVID 19 sequelae, and behavioral health concerns, across disparate systems for people living with multiple chronic conditions, their caregivers, and their care teams. The “National COVID-19 Longitudinal Research Database Linked to CMS Data” project (a collaboration between ASPE, NIDDK, and NCATS) works to evaluate disparities by looking at community characteristics using geocoding approaches and information on air quality and housing. It also seeks to capture care and outcomes of vulnerable populations such as patients on dialysis, nursing home residents, and low-income individuals. https://aspe.hhs.gov/sites/default/files/2021-07/covid-pcor-report.pdf |
| Multiple Chronic Conditions eCare Plan Project | Resource Development | AHRQ, ASPE | NIDDK | The goal of this initiative is to build data capacity for conducting pragmatic, patient-centered outcomes research (PCOR) by developing an interoperable electronic care (eCare) plan to facilitate aggregation and sharing of critical patient-centered data across home, community, clinic and research-based settings by extracting data from point-of-care health systems and allowing transfer of that data cross settings. This is a joint initiative between the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the Agency for Healthcare Research and Quality (AHRQ), and the Assistant Secretary for Planning and Evaluation (ASPE). https://ecareplan.ahrq.gov/ |
| Muscular Dystrophy Coordinating Committee (MDCC) | Committee, Work group, Advisory group, or Task Force | ACL, CDC, FDA, HRSA | NINDS, NHLBI, NIAMS, NICHD | This Federal Advisory Committee coordinates activities relevant to the various forms of muscular dystrophy across the National Institutes of Health (NIH) and other federal agencies. The committee also includes members from patient organizations. Strategic planning efforts by the coordinating committee led to the development of an Action Plan for the Muscular Dystrophies, which contains specific research objectives appropriate to the missions of all committee member agencies and organizations, and thus serves as a central focus for research coordination. The plan is available at the MDCC web site. https://mdcc.nih.gov/ |
| My Family Health Portrait (MFHP) | Resource Development | CDC | NHGRI, NCI | My Family Health Portrait (MFHP) is a web-based tool from the National Human Genome Research Institute (NHGRI) and the US Surgeon General’s Family History Initiative that helps individuals track their family health history. Using any computer, an Internet connection, and an up-to-date Web browser, individuals add health information to build a drawing of their family tree and a chart of their family health history while exploring disease calculators. The tool is designed to keep all data on the client side to maximize privacy using HTML, CSS, and client-side JavaScript as its principal platforms. Users interact with the tool in a browser to build family health history generating an XML data file (HL7v3 standard) that users store locally or in the cloud. Both the family tree and the chart can be printed and shared with family members and an individual’s doctor. https://cbiit.github.io/FHH/html/index.html |
| Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | Research Initiative | FDA | OD/OIR, NINDS | Myalgic Encephalomyelitis/Chronic Fatigue Syndrome |
| MyHealthfinder Steering Committee | Committee, Work group, Advisory group, or Task Force | ODPHP, OASH, AHRQ, CDC, HRSA, FDA, CMS, SAMHSA | NLM, NCI, NIA | The MyHealthfinder Steering Committee comprises federal partners to help provide insight into the ways MyHealthfinder (an online health resource from HHS/ODPHP) more useful for public health professionals and the clients they serve. This group was formed in December 2020 and meets quarterly. |
| Nanotechnology Characterization Laboratory (NCL) | Research Initiative | FDA | NCI | The Nanotechnology Characterization Laboratory (NCL) performs and standardizes the preclinical characterization of nanomaterials intended for cancer therapeutics and diagnostics developed by researchers from academia, government, and industry. The NCL serves as a national resource and knowledge base for cancer researchers and facilitates the development and translation of nanoscale particles and devices for clinical applications. http://ncl.cancer.gov/ |
| NAPA Federal Subgroup | Committee, Work group, Advisory group, or Task Force | AHRQ, ASPE, ACL, CDC, CMS, FDA, HRSA, IHS | NIA, NINDS | This informal group of federal staff meets quarterly, in advance of the meetings of the Alzheimer’s Council for Alzheimer’s Research, Care, and Services, to exchange information on federal activities in the Alzheimer’s disease space and foster collaborations across agencies. From 2014-2021, NIA facilitated these meetings and set the focus on research opportunities; starting in 2022, HHS/ASPE will coordinate these meetings and promote discussion across all NAPA goals, including those related to research, care, supports, and risk reduction. |
| NASEM Aging Disability and Independence Forum | Committee, Work group, Advisory group, or Task Force | ACL | NIA | The National Academies of Sciences, Engineering, and Medicine have formed the Forum on Aging, Disability, and Independence to foster dialogue and address issues of mutual interest and concern related to aging and disability. https://www.nationalacademies.org/our-work/forum-on-aging-disability-and-independence |
| NASEM Forum on Drug Discovery, Development, and Translation | Committee, Work group, Advisory group, or Task Force | FDA, ASPR | NCATS, NINDS, NIAID, NCI, NIMH, OD/OSP | The Forum on Drug Discovery, Development, and Translation provides a neutral venue for stakeholders in government, academia, industry – including pharmaceutical, biotechnology, and digital health companies, foundations, and disease and patient advocacy to highlight critical issues, spur cross-sector collaboration, and inspire action towards improving the system of drug discovery, development, and translation. Forum-hosted public workshops, action collaboratives, and meetings focus on critical issues and practical approaches for advancing a clinical trials enterprise that is more efficient, effective, patient-centered, and integrated into the health delivery system. https://www.nationalacademies.org/our-work/forum-on-drug-discovery-development-and-translation |
| NASEM Forum on Neuroscience and Nervous System Disorders | Committee, Work group, Advisory group, or Task Force | FDA | NINDS, NCCIH, NIMH, NIAAA, NIA, NIEHS, NIDA | The National Academies of Sciences, Engineering, and Medicine's Forum on Neuroscience and Nervous System Disorders was established to bring together leaders from government, industry, academia, and disease advocacy organizations to examine issues concerning scientific needs and policies related to neuroscience and nervous system disorders research and the development and use of interventions for the nervous system. The Forum also sponsors workshops for its members and the public on key challenges and issues in the field. https://www.nationalacademies.org/our-work/forum-on-neuroscience-and-nervous-system-disorders |
| NASEM Forum on Traumatic Brain Injury | Committee, Work group, Advisory group, or Task Force | ACL, CDC | NINDS, NICHD, NIA | The National Academies of Sciences, Engineering, and Medicine Forum on Traumatic Brain Injury provides a setting for experts to discuss how to advance the prevention, treatment, and care for people with brain injuries. The TBI Forum addresses topics relating to critical research gaps, TBI treatment and rehabilitation, and other related needs and challenges. https://www.nationalacademies.org/our-work/traumatic-brain-injury-forum |
| National Academy of Medicine Committee on Emerging Science, Technology, and Innovation in Health and Medicine | Committee, Work group, Advisory group, or Task Force | FDA | NIMH | The National Academy of Medicine has recently launched a new Committee on Emerging Science, Technology, and Innovation in health and medicine. The Committee will bring together experts in diverse fields to assess the landscape of emerging scientific advances and technologies in health and medicine and address the potential societal, ethical, legal, and workforce implications of such technologies. The goal of the Committee is to develop a multi-sectoral governance policy framework. The Committee plans to examine examples of emerging technologies and their implications for society, through a multi-sectoral lens. The first point of focus will be on neurotechnology, specifically transcranial direct current stimulation. https://nam.edu/programs/committee-on-emerging-science-technology-and-innovation-in-health-and-medicine/ |
| National Action Alliance for Suicide Prevention (NAASP) | Committee, Work group, Advisory group, or Task Force | ACL, CDC, HRSA, IHS, OS, Office of the Surgeon General (OSC), SAMHSA | NIMH, NIAAA, NIDA, OD/DPCPSI/OBSSR | Founded in September 2010, the National Action Alliance for Suicide Prevention (NAASP) is a public-private partnership designed to advance the National Strategy for Suicide Prevention in the United States. The NAASP's Research Prioritization Task Force (RPTF) was charged with developing a process to prioritize suicide prevention research efforts and consider ways to integrate science and service to ensure that suicide deaths decrease significantly within the next decade. The RPTF released the Nation's first suicide research agenda, A Prioritized Research Agenda for Suicide Prevention: An Action Plan to Save Lives. The research agenda includes an overarching goal to advance suicide prevention research more rapidly, seeking ways to reduce suicide deaths and attempts by 20 percent in five years and by 40 percent or greater in ten years. In 2015, the RPTF produced the "U.S. National Suicide Prevention Research Efforts: 2008-2013 Portfolio Analyses." The analyses revealed that investments in suicide research are severely lagging, but there is a growing knowledge base of intervention research. The National Institute of Mental Health (NIMH) Director serves as an ex-officio member of the Executive Committee of the NAASP. NIMH participates in a number of NAASP activities related to identifying research needs for improving risk identification and suicide preventive care within healthcare systems, justice, and school settings. http://actionallianceforsuicideprevention.org/ |
| National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB) 2020-2025 | Committee, Work group, Advisory group, or Task Force | AHRQ, BARDA, CDC, CMS, FDA, HRSA, OS | NIAID | The National Action Plan for Combating Antibiotic-resistant Bacteria, 2020-2025, was developed through the CARB Task Force, now reporting coordinated, strategic actions that the U.S. government takes to reduce the impact of antibiotic and antimicrobial resistance on the nation. |
| National Action Plan for the Elimination of multi-drug resistant Tuberculosis (MDR TB) | Other | CDC | NIAID, CC, FIC, NCATS, NCI, NHLBI, NIA, NIAAA, NICHD, NIDA | Federal agencies involved in the National Action Plan for the Elimination of Multidrug-Resistant Tuberculosis (MDR-TB) coordinate reporting across agencies. Annual reporting and regular updates on opportunities for cross-agency collaboration and information sharing are provided. https://www.usaid.gov/what-we-do/global-health/tuberculosis/resources/news-and-updates/national-action-plan-combating-mdr |
| National Advisory Board for Medical Rehabilitation Research | Committee, Work group, Advisory group, or Task Force | ACL, CDC | NICHD, NHLBI, NIA, NIAMS, NIDCD, NINDS, OD/DPCPSI | The Director of the National Institutes of Health (NIH) was mandated in P.L. 101-613 to establish the National Advisory Board on Medical Rehabilitation Research. The Board advises the directors of the NIH, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and NICHD's National Center for Medical Rehabilitation Research (NCMRR) on matters and policies relating to the NCMRR's programs. The Board is comprised of 12 members representing health and scientific disciplines related to medical rehabilitation and six members representing persons with disabilities. http://www.nichd.nih.gov/about/advisory/nabmrr/pages/index.aspx |
| National Advisory Committee on Children and Disasters (NAACD) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA, ASPR | NICHD, NIEHS | The Secretary of the U.S. Department of Health and Human Service (HHS) is responsible for a wide range of activities that include monitoring for emerging issues and concerns as they relate to medical and public health preparedness and response; developing, overseeing, and providing guidance for implementation of national preparedness goals for disasters of all types at the federal, state and local levels; identifying, conducting responses to, and recovery from public health and medical emergencies; assisting other federal agencies responsible for aspects of planning for, responding to, and recovering from public health emergencies; and taking into account the special physical, psychological, emotional, and behavioral needs of children. On behalf of HHS, the Assistant Secretary for Preparedness and Response (ASPR) leads public health and medical planning for, response to, and recovery from disasters and public health emergencies in accordance with the National Response Framework Emergency Support Function (ESF) #8 (Public Health and Medical Services). Additionally, the federal responsibilities and partnerships described in ESF #6 (Mass Care, Emergency Assistance, Housing, and Human Services) and the Health and Social Services Recovery Support Function are critical to comprehensive consideration of issues related to children and disasters. The NACCD shall provide advice and consultation to the Secretary of HHS to assist him in carrying out these and related activities as they pertain to the unique needs of children in preparation for, responses to, and recovery from disasters. The NACCD shall evaluate issues and programs and provide findings, advice, and recommendations to the Secretary of HHS in accordance with FACA to support and enhance all-hazards public health and medical preparedness, response activities, and recovery aimed at meeting the unique needs of children, in a developmentally and socially appropriate manner, across the entire spectrum of their physical, mental, emotional, and behavioral wellbeing. https://www.phe.gov/Preparedness/legal/boards/naccd/Pages/default.aspx |
| National Amyotrophic Lateral Sclerosis Registry (National ALS Registry) | Committee, Work group, Advisory group, or Task Force | ATSDR, CDC | NINDS | The National ALS Registry is a congressionally mandated registry for persons in the US with ALS. It is the only population-based registry in the US that collects information to help scientists learn more about who gets ALS and its causes. http://wwwn.cdc.gov/als/ |
| National Asthma Education and Prevention Program | Committee, Work group, Advisory group, or Task Force | CDC | NHLBI, NIAID | Oversees development of the clinical practice guidelines for asthma https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines |
| National Biodefense Strategy - Vaccines Joint Capabilities Plan writing group | Other | ASPR, CDC, FDA | NIAID | The Vaccines Joint Capabilities Plan (JCP) writing group, developed in support of the National Biodefense Strategy and Implementation Plan for Countering Biological Threats, Enhancing Pandemic Preparedness, and Achieving Global Health Security, focuses on: Vaccine design, testing, and authorization; Vaccine production; Vaccine distribution; and Vaccine administration and allocation to work towards the bold goal of having a vaccine poised to deploy within 100 days following the identification of an emergent viral pandemic. |
| National Cancer Control Strategy | Committee, Work group, Advisory group, or Task Force | CDC | NCI | The National Cancer Control Strategy is an NCI-funded study through the National Academies of Sciences, Engineering, and Medicine, which examines cancer control efforts in the United States. This study is expected to produce a report in 2018, which will recommend a national strategy to reduce the incidence, morbidity, and mortality from cancer and to improve quality of life for cancer survivors. https://www.nationalacademies.org/our-work/a-national-strategy-for-cancer-control-in-the-united-states |
| National Center for Advancing Translational Sciences (NCATS) Toolkit for Patient-focused Therapy Development | Resource Development | FDA | NCATS | NCATS is dedicated to engaging the patient community throughout the translational science process. The NCATS Toolkit for Patient-Focused Therapy Development (Toolkit) was created to provide a collection of online resources that can help patient groups advance through the process of therapy development and provide them with the tools they need to advance medical research. Launched in September 2017, the Toolkit includes resources that have been developed primarily for the rare diseases community to facilitate therapeutics research and development. https://ncats.nih.gov/toolkit |
| National Clinical Trials Network (NCTN) Scientific Steering Committees (SSCs) | Committee, Work group, Advisory group, or Task Force | FDA | NCI | Scientific Steering Committees (SSCs) are composed of leading cancer experts and advocates from outside the Institute as well as NCI senior investigators who meet regularly to: (1) increase the transparency and openness of the trial design and prioritization process; (2) enhance patient advocate and community oncologist involvement in clinical trial design and prioritization; (3) convene Clinical Trial Planning Meetings to identify critical questions, unmet needs, and prioritize key strategies. https://www.cancer.gov/about-nci/organization/ccct/steering-committees |
| National Coalition for Oversight of Assisted Reproductive Technologies (NCOART) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NICHD | The National Coalition for Oversight of Assisted Reproductive Technologies (NCOART) has become a successful forum for discussion of issues by organizations involved in the assisted reproductive technologies (ART) in the United States. |
| National Collaborative on Childhood Obesity Research (NCCOR) | Research Initiative | CDC | NICHD, NCI, NHLBI, NIDDK, FIC, NIAMS, NIMHD, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP, OD/DPCPSI/ODS, OD/DPCPSI/ONR, OD/ECHO | The mission of the National Collaborative on Childhood Obesity Research is to improve the efficiency, effectiveness, and application of childhood obesity research, and to halt -- and reverse -- childhood obesity through enhanced coordination, communication, and collaboration. https://www.nccor.org/ |
| National Counterintelligence Task Force (NCITF) | Committee, Work group, Advisory group, or Task Force | OS | OD/OM | As the lead U.S. counterintelligence agency, the FBI is responsible for detecting and lawfully countering the actions of foreign intelligence services and organizations as they seek to adversely affect U.S. national interests. The FBI recognized the need to coordinate similar efforts across all agencies, and therefore established the National Counterintelligence Task Force (NCITF) to create a whole-of-government approach to counterintelligence. |
| National COVID Cohort Collaborative (N3C) | Research Initiative | FDA, ASPR, CMS | NCATS, NIGMS | The N3C is a partnership among the NCATS-supported Clinical and Translational Science Awards (CTSA) Program hubs, the National Center for Data to Health (CD2H), and NIGMS-supported Institutional Development Award Networks for Clinical and Translational Research (IDeA-CTR), to provide clinical data in close to real time to improve our knowledge of COVID-19 and potential treatment strategies. Collaborators will contribute and use COVID-19 clinical data to answer critical research questions to address the pandemic. As the largest limited dataset in US history with more than 11 Million participants (https://covid.cd2h.org/), the N3C initiative has demonstrated that it is possible to conduct science/learning healthcare across a large network, share and harmonize sensitive clinical data across modalities at a national scale and to realize the promise of precision medicine. The N3C effort is centered on the following: Establishing a secure data repository (the N3C Data Enclave) for studying COVID-19-related data. Receiving existing patient data derived from electronic health records (EHRs) provided by participating U.S. health care sites. Providing operational support for researchers using the N3C Data Enclave to navigate in the N3C platform and collaborate on COVID-19 research. Ensuring research using the N3C Data Enclave follows the rules and expectations of NCATS and its partners to keep the data secure and protect patient privacy. https://ncats.nih.gov/n3c |
| National Database for Antibiotic Resistant Organisms (NDARO) | Resource Development | CDC, FDA | NIAID, CC, FIC, NCATS, NCI, NHLBI, NIA, NIAAA, NIDA | The objective of this collaboration is to produce a collection of high-quality genome sequences from antibiotic-resistant strains and to create and maintain a publicly accessible database -- National Database for antibiotic resistance (AR), developed and housed at the National Center for Biotechnology Information of the National Library of Medicine (NLM). |
| National Death Index Linkage Collaboration (NIH-NDI Agreement) | Resource Development | CDC | OD/DPCPSI/OBSSR, OD/IMOD | Beginning January 1, 2020, through an agreement between the National Institutes of Health (NIH) and the Centers for Disease Control (CDC) National Center for Health Statistics, (NCHS), NIH began reimbursing the NCHS National Death Index (NDI) for the costs of NIH-supported investigators to link their research databases with the NDI for the research aims supported by the NIH. "NIH-supported investigators" refers to extramural investigators actively funded by the NIH, contract investigators working under an active contract with the NIH, and intramural researchers employed by the NIH. These NIH-supported investigators can link their research data to the National Death Index (NDI) at no cost to the NIH supported investigator. NIH-supported investigators will continue to submit applications for NDI linkage as per current NDI procedures, including NDI review and approval. This agreement applies only to NIH-supported investigators who are actively funded by the NIH to conduct research that requires NDI linkage. To be covered under this agreement, the NIH-supported investigator must be the owner or steward of the research data to be linked to the NDI datafile, and subject to limitations in linkages as identified in the agreement. As a part of the NIH/NCHS agreement, NCHS will be implementing an enhanced online application and will increase the frequency of NDI releases to quarterly. NDI allows fully deidentified (public access) research datasets with NDI-linked data to be shared without further NDI approval. Potentially re-identifiable datasets also may be shared without further NDI approval provided the research dataset is not transferred from one investigator to another but instead shared via a data enclave provided that the investigator obtained approval in the original NDI application to share the data via an enclave. An investigator also may share potentially re-identifiable NDI-linked research datasets with a data repository without further NDI approval provided the data repository shares the dataset on behalf of the investigator bound to the same constraints as the investigator (i.e., shared only if the dataset is fully-deidentified or shared only via a data enclave if potentially re-identifiable). During the period of this agreement, NDI will attempt to negotiate with the 57 vital registration jurisdictions to allow further data sharing flexibility without NDI approval. The MOU was reissued in FY2022 between CDC/NCHS and NIH/IMOD and OBSSR. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-057.html |
| National Death Index Working Group | Committee, Work group, Advisory group, or Task Force | CDC | NICHD, CC, NCATS, NCI, NHLBI, NIA, NIAID, NIDA, NIMH, OD/DPCPSI/OBSSR | The National Death Index (NDI) is a centralized database of death record information on file in state vital statistics offices. Working with these state offices, the National Center for Health Statistics (NCHS) established the NDI as a resource to aid epidemiologists and other health and medical investigators with their mortality ascertainment activities. The National Death Index Working Group brings together federal and non-federal demographic experts to improve the quality, comprehensiveness, and utility of the National Death Index. |
| National Emerging Contaminant Research Initiative | Research Initiative | CDC, ATSDR, FDA | NIEHS | Congressional Mandate |
| National Family Health History Group | Public Education Campaign | CDC | NHGRI, CC, OD/OSP | Federal, state, and other stakeholders focus on increasing awareness of the value of family health history in managing health risks. National Family History Day is designated by the Surgeon General for increasing awareness of the above. Members of this group coordinate public communications and resource development. https://www.genome.gov/Health/Family-Health-History/Health-Professionals/Family-Health-History-Group |
| National Food and Nutrient Analysis Program (NFNAP) | Committee, Work group, Advisory group, or Task Force | CDC, IHS, FDA | NCI, NHLBI, NEI, NIA, NICHD, NIDCR, NIDDK, CSR, NIEHS, OD | The generation of original analytical data for foods at the US Department of Agriculture (USDA) is conducted through the National Food and Nutrient Analysis Program (NFNAP) in collaboration with multiple groups including the Department of Health and Human Services (HHS) and other federal agencies. NFNAP includes statistically based sampling plans for Key Foods and analysis of foods by qualified laboratories. The five Specific Aims of the NFNAP are to: (1) establish a monitoring program for Key Foods and critical nutrients. Key Foods are frequently consumed foods and ingredients, which collectively contributed more than 75 percent of the intake of any specific nutrient for the US population; (2) conduct comprehensive analyses of selected Key Foods; (3) develop databases for high priority foods consumed by US ethnic subpopulations; (4) develop databases for new bioactive components; and (5) develop a validated database for ingredients in dietary supplements. Analytical data generated through the NFNAP are compiled and released in annual updates of the USDA National Nutrient Database for Standard Reference (SR). They are also used to calculate estimates for related foods not analyzed, to assess nutrient variability, and to evaluate methods for estimating the nutrient content of multi-ingredient foods. These values will be used by the Food Surveys Research Group (FSRG), Agricultural Research Service (ARS) to develop the Food and Nutrient Dataset for Dietary Surveys used in the “What We Eat in America” (WWEIA) component of the National Health and Nutrition Examination Survey (NHANES). https://www.ars.usda.gov/ARSUserFiles/80400525/FactSheets/NDL_FactSheet_NFNAP.pdf |
| National Health Interview Survey (NHIS) Cancer Control Supplement | Health Survey | CDC | NCI | The National Health Interview Survey (NHIS) - started in 1957 - is a continuous, nationwide in-person survey of approximately 27,000 sample adult and 9,000 sample child interviews annually, in the civilian non-institutionalized population. The NHIS oversamples African-American and Hispanic respondents. The National Cancer Institute (NCI) periodically sponsors a Cancer Control Supplement (CCS) which is administered to a randomly selected sample of 39,000 adults. The CCS focuses on issues pertaining to knowledge, attitudes, and practices of cancer-related health behaviors, screening, and risk assessment. http://www.cdc.gov/nchs/nhis.htm |
| National Hispanic Science Network (NHSN) | Meeting/ Workshop | AHRQ, CDC, SAMHSA | NIDA, NIAAA, NIMH | The National Hispanic Science Network is dedicated to improving the health equity of Hispanics. It has broad representation from academic and government agencies, including several National Institutes of Health Institutes and Centers, the Centers for Disease Control and Prevention, the Substance Abuse and Mental Health Services Administration, and the Agency for Healthcare Research and Quality. https://www.the-nhsn.org/ |
| National HIV/AIDS Strategy Steering Committee (NHAS) | Committee, Work group, Advisory group, or Task Force | OASH, CDC, HRSA, IHS, SAMHSA, CMS, FDA, ACL, AHRQ | NIAID, NIDDK, OD/DPCPSI/OAR | This multi-agency steering committee led by the White House's Office of National AIDS Policy. The Committee provided input to update the NHAS with the current administration's priorities which includes strategies to address social determinants of health. The committee was expanded to engage other departments and programs (Labor, Education, Housing, Agriculture, Transportation) to create a whole-of-government approach. The revised NHAS was released in December 2021. |
| National Hospital Care Survey (NHCS) Patient-Centered Outcomes Research Trust Fund (PCORTF) Project | Other | CDC, SAMHSA, ASPE, FDA | NIDA, NIMH | This technical expert panel meets on a quarterly basis with agencies across HHS to discuss the enhancement of identifying opioid-related health outcomes using hospital and linked National Death Index (NDI) mortality data. |
| National Institute on Deafness and Other Communication Disorders (NIDCD) Directory of Organizations | Resource Development | AHRQ, CDC, CMS | NIDCD | The National Institute on Deafness and Other Communication Disorders (NIDCD) Directory of Organizations is designed to help patients, health consumers, providers, and others find agencies and organizations with an interest in the diseases and disorders of human communication. The directory is maintained as an online database accessible to the public from the NIDCD website. Several US Department of Health and Human Services agencies are included. https://www.nidcd.nih.gov/directory/ |
| National Institutes of Health (NIH) Flow Cytometry Interest Group | Committee, Work group, Advisory group, or Task Force | FDA | NCI, CC, NEI, NHLBI, NIAID, NIAMS, NIDCR | The NIH Flow Cytometry Interest Group, an NIH-affiliated scientific interest group supported by the NIH Office of the Director, provides central information for basic and clinical investigators doing flow and image cytometry at NIH. The group sponsors two meetings a year on the science and technology of cytometry, and is a central clearinghouse for cytometry resources at NIH. https://oir.nih.gov/sigs/flow-cytometry-interest-group |
| National Interagency Confederation for Biological Research | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, NIAID | The National Interagency Confederation for Biological Research (NICBR) is a consortium of eight agencies with a common vision of Federal research partners working in synergy to achieve a healthier and more secure nation. It serves as a framework for facilitating and encouraging interaction among the NICBR member organizations where there are areas of mutual interest. Members collaborate and share technical expertise and scientific services. This multiagency confederation operates by consensus to ensure a balanced direction and focus. The eight members include elements of the Department of Defense, Health and Human Services, Agriculture, and Homeland Security. The mission of NICBR is to develop unique knowledge, tools, and products by leveraging advanced technologies and innovative discoveries to secure and defend the health of the American people. https://www.nicbr.mil/ |
| National Nanotechnology Initiative (NNI) Nanotechnology Signature Initiative on Nanotechnology Knowledge Infrastructure: Enabling National Leadership in Sustainable Design | Committee, Work group, Advisory group, or Task Force | FDA, CDC | NCI, NIBIB | This is an interagency effort to provide a community-based, solutions-oriented knowledge infrastructure to accelerate nanotechnology discovery and innovation. http://www.nano.gov/NKIPortal |
| National Neurological Conditions Surveillance System (NNCSS) | Research Initiative | CDC | NINDS | The NNCSS is a congressionally mandated program of the Centers for Disease Control and Prevention (CDC). The authorizing legislation requires CDC to "enhance and expand infrastructure and activities to track the epidemiology of neurological diseases and incorporate information obtained through such activities into an integrated surveillance system, which may consist of or include a registry, to be known as the National Neurological Conditions Surveillance System." https://www.cdc.gov/surveillance/neurology/index.html |
| National PAD Action Plan | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA | NHLBI, NIA, NIDDK | Public-private collaboration led by the American Heart Association (AHA) to develop and implement a national action plan to raise peripheral artery disease (PAD) awareness through public and professional education; improve outcomes for individuals with PAD; increase PAD research; and coordinate advocacy. https://www.heart.org/en/health-topics/peripheral-artery-disease/pad-resources/pad-summit |
| National Response Team (NRT) | Committee, Work group, Advisory group, or Task Force | ASPR, ATSDR, CDC | NIEHS | The U.S. National Response Team (NRT) provides technical assistance, resources and coordination on preparedness, planning, response and recovery activities for emergencies involving hazardous substances, pollutants and contaminants, oil, and weapons of mass destruction in natural and technological disasters and other environmental incidents of national significance. https://www.nrt.org/ |
| National Robotics Initiative (NRI) | Research Initiative | CDC | NIBIB, NCATS, NEI, NIA, NINR, NICHD | The National Robotics Initiative 3.0: Innovations in Integration of Robotics (NRI-3.0) program was launched by NSF in February of 2021. It builds upon the preceding National Robotics Initiative (NRI) programs to support fundamental research in the United States that will advance the science of robot integration. The program supports research that promotes integration of robots to the benefit of humans including human safety and human independence. The National Institute of Health (NIH) has joined NRI 3.0 to promote robotics to address health needs. The first round of funding occurred if FY 2022. http://www.nsf.gov/funding/pgm_summ.jsp?pims_id=503641org=CISE |
| National Science Advisory Board for Biosecurity | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | The NSABB is a federal advisory committee that addresses issues related to biosecurity and dual use research at the request of the United States Government. http://osp.od.nih.gov/office-biotechnology-activities/biosecurity/nsabb |
| National Sexually Transmitted Infections (STI) Strategic Plan | Committee, Work group, Advisory group, or Task Force | OASH, ACF, ACL, CDC, CMS, FDA, HRSA, IHS, SAMHSA | NIAID | Plan sets national goals, objectives, and strategies to respond to the STI epidemic. The plan will serve as a roadmap to help federal and non-federal stakeholders at all levels and in all sectors reverse the sharp upward trends in STI rates https://www.hhs.gov/programs/topic-sites/sexually-transmitted-infections/plan-overview/index.html |
| National Survey of Family Growth | Health Survey | ACF, CDC | NICHD | The National Survey of Family Growth (NSFG) gathers information on family life, marriage and divorce, pregnancy, infertility, use of contraception, and men's and women's health. The survey results are used by the US Department of Health and Human Services and others to plan health services and health education programs and to do statistical studies of families, fertility, and health. The NSFG is used by: scholars in the behavioral sciences (e.g., sociology, demography, and economics) to study marriage, divorce, fertility, and family life; scholars in public health to study reproductive, maternal and infant health topics; agencies of the US Department of Health and Human Services to brief senior officials and to inform program decision-making; in research programs and in health and social service programs; state and local governments to plan health and social service programs; and the press, to prepare articles on a number of topics related to health and family life. https://www.cdc.gov/nchs/nsfg/index.htm |
| National Toxicology Board of Scientific Counselors (NTP BSC) | Meeting/ Workshop | CDC, FDA | NIEHS | A federally chartered external advisory committee whose members are appointed by the Secretary of Health and Human Services https://ntp.niehs.nih.gov/events/bsc/index.cfm |
| National Toxicology Program Executive Committee (NTP EC) | Meeting/ Workshop | ATSDR, CDC, FDA, OASH | NIEHS | An internal government group comprised of heads (or designees) of HHS (NCEH/ATSDR, FDA, NCI, NIEHS, NIOSH) and non-HHS (CPSC, DoD, EPA, OSHA) agencies https://ntp.niehs.nih.gov/go/advisory |
| National Toxicology Program Steering Committee (NTP SC) | Meeting/ Workshop | CDC, FDA | NIEHS | An internal government group comprised of the principal agencies of the National Toxicology Program |
| Native American Research Center for Health (NARCH) | Research Initiative | IHS | NIGMS, CSR, NCI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIMH, NIMHD, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH, NCCIH, NHGRI, NHLBI | The Native American Research for Health (NARCH) program is a trans-NIH collaboration with the Indian Health Service (IHS) that supports collaborations between federally-recognized American Indian/Alaska Native (AI/AN) Tribes or Tribal organizations and research-intensive academic institutions that support health research projects prioritized by the Tribal communities. NARCH supports competitive research linked to the health priorities of AI/AN organizations and health disparities; increasing the capacity of both AI/AN organizations and research-intensive institutions to reduce distrust by AI/AN communities and people toward research; and developing a cadre of AI/AN scientists and health professionals engaged in biomedical, clinical, behavioral, and health services research who will be competitive in securing the National Institutes of Health (NIH) funding. https://www.nigms.nih.gov/Research/CRCB/NARCH/Pages/default.aspx |
| Natural Experiments and Effectiveness Studies in the Prevention and Control of Diabetes (NEXT-D/NEXT-D 2.0/NEXT-D3) | Research Initiative | CDC | NIDDK | This project will focus on population-targeted interventions that health systems, communities, and governments can undertake to reduce the incidence of diabetes and its complications. This project will also strengthen the capacity of the Centers for Disease Control and Prevention (CDC) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to conduct vital health services and health policy research related to diabetes prevention and care. NEXT-D3 is funded through FY25 |
| NBS Implementation Plans Joint Capabilities Plans-Clinical Research Capacity, Therapeutics | Committee, Work group, Advisory group, or Task Force | FDA, ASPR | NIAID | Several JCP WG to inform implementation |
| NCATS N3C Collaboration | Resource Development | FDA | NCI, NCATS | During the COVID pandemic, NCATS established N3C project to create an NIH infrastructure to query national real world databases using an OMOP 5.3.1 central model/database to store query results. This required manual/hard coding of mappings between OMOP 5.3.1 and other national CDM that are being used by the community, specifically PCORNET 5.1, OMOP 5.2, TriNetX, and I2B2/ACT 2.0. New metadata needs to be created in caDSR and new APIs which are very similar/potentially reusable by NCI Cancer Research Data Commons |
| NCCOR- National collaborative for childhood obesity research | Committee, Work group, Advisory group, or Task Force | CDC | NHLBI, NCI, NICHD, NIDDK, OD/DPCPSI/OBSSR | To accelerate progress in reducing childhood obesity in America. https://www.nccor.org/about/ |
| NCHS-CDC NHANES, Dietary Supplements and Selected Nutritional Biomarkers | Research Initiative | CDC | OD/DPCPSI/ODS | The National Institutes of Health's, Office of Dietary Supplement has funded the collection of the usage of dietary supplements and selected nutritional biomarkers in the National Health and Nutrition Examination Survey (NHANES) study since 1999. NHANES is a major program of the National Center for Health Statistics (NCHS) - part of the Centers for Disease Control and Prevention (CDC) and is a program of studies designed to assess the health and nutritional status of adults and children in the United States. The prevalence of dietary supplement use in the US is high and increases with age. Data from the NHANES 2017-March 2020 survey indicate that 58.5% of adults aged 20 years and older and 34.8% children aged 0-19 years take at least one dietary supplement. Dietary supplements can and many do contain 100% or more of the daily recommended amounts for nutrients, vitamins and or minerals and therefore, and with such a high percentage of the US population taking them, it's critical that they be collected when assessing dietary intake. If they are not included, dietary intake of nutrients can be underestimated for individuals and on the national level, this can lead to overestimating nutrient deficiencies in the U.S. or underestimating nutrient excesses. NHANES also collects biospecimens which allows for the measurement of biomarkers. The Office of Dietary Supplements has provided funding for several biomarkers over the years and most recently biomarkers for folate status, iodine status and magnesium. Most data from the NHANES survey is released publicly on their website. https://www.cdc.gov/nchs/nhanes/index.htm |
| NCHS-CDC NHIS Hearing Supplement | Health Survey | CDC | NIDCD | "Hearing loss and balance impairment, including inner ear vestibular disorders (vertigo, other dizziness problems) can profoundly affect a persons life and health; impacting the ability to work, interact socially and engage during health care encounters. Adults with hearing and balance disabilities are at risk for decreased quality of life, poorer health status, and diminished health care services received. Targeted interventions delivered in a community or medical setting, provided by audiologists, Ear, Nose, and Throat (ENT) doctors [aka, otolaryngologists-head and neck surgeons], neuro-otologists, occupational and physical therapists, pediatricians, gerontologists and other trained health care workers can potentially mitigate risks for long-term disability. The ability of individuals to hear, like the ability to see, contributes immeasurably to quality of life. The hearing health of individuals affects their educational success, employment opportunities, workplace productivity (and safety), and social and mental health. Hearing loss is the third most common chronic physical condition in the US; it is twice as prevalent as diabetes or cancer. About 12 million (6 percent) American adults report they have serious difficulty hearing or are deaf. Approximately 50 million Americans have hearing loss of mild, moderate, severe, or greater degree in one or both ears. Hearing loss is one of the top three most prevalent chronic conditions in older Americans, together with hypertension and arthritis. As age increases, hearing loss can be so gradual that a person often is unaware of it until the loss becomes difficult to manage. Yet the prevalence of hearing loss doubles with each decade of advancing age. The number is expected to increase as the baby-boomer population ages; by 2030, nearly one in five U.S. residents is expected to be 65 and older. This age group is projected to increase to 88.5 million in 2050, which is more than double the number of adults over age 65 in 2008 (38.7 million). The proposed questions on hearing and balance disorders were asked about children and adults (with some minor changes) in the 2014 National Health Interview Survey (NHIS) Hearing Supplement and the 2016 NHIS Balance and Dizziness Supplement. To maintain validity for cross-survey comparisons, wording has been standardized for hearing and balance questions asked during home interviews, prior to physical exams in mobile exam centers, in NHANES 2015-16, 2017-18, and 2019-23. Advantages to obtaining the information from the NHIS include the large sample size (~13,000 children, ~35,000 adults) in a single year of data collection and the relatively quick availability of the data collected as Public Use files approximately 6 months after data collection ends for NHIS each year. For timely analysis and release of information to the public and, also, to inform scientific research, NHIS is an appropriate nationally representative health survey of the civilian, non-institutionalized US population. These advantages are important as well for tracking and monitoring US Healthy People objectives. https://www.cdc.gov/nchs/nhis/index.htm |
| NCHS-CDC NHIS Taste & Smell and NHIS Voice, Speech, and Language Questionnaire Supplements | Health Survey | CDC | NIDCD | To provide support to the National Center for Health Statistics (NCHS), CDC for implementation of a nationally representative health interview survey questions inquiring about taste smell and communication disorders and disabilities of voice, swallowing, speech, and language in both childhood and adults. Communication disabilities, including voice, swallowing, speech, and language disabilities, can profoundly affect a person’s life and health; impacting the ability to work, interact socially and engage during health care encounters. Adults with communication disabilities are at risk for decreased quality of life, health status, and health care services received. Targeted interventions delivered in a community or medical setting, including speech-language pathology services, and occupational support can potentially mitigate these risks. Few current epidemiological studies have explored the prevalence of communication disorders and their associated etiologies in the United States. While voice, swallowing, speech, and language disorders are distinct disabilities with different biological mechanisms, they can all cause a person to have difficulty communicating and thus are collectively referred to as communication disorders. Multiple national surveys, including the American Community Survey (ACS), the Current Population Survey – Annual Social and Economic Supplement (CPS-ASEC), and the Decennial Census of Population and Housing, collect information on the prevalence of disability in the United States, but these surveys do not specifically identify or distinguish between voice, swallowing, speech, and language disorders. https://www.cdc.gov/nchs/nhis/index.htm |
| NCHS-CDC-NHANES, Audiometry, Balance, and Words in Noise Component | Health Survey | CDC | NIDCD | To provide support to the National Center for Health Statistics (NCHS), CDC for balance/vestibular testing and related questions on balance and dizziness problems in the U.S. population aged 40+ years.in the National Health and Nutrition Examination Survey (NHANES Epidemiology Survey), 2018 (pilot testing) and 2019-2020 (implementation). In addition the Audiometry Component of NHANES 2019-2020 will be augmented with a Word in Noise test administered to older adults, 70+ years of age. The prevalence of balance disorders in the US is high and increases with age. Data from NHANES 2000-2004 epidemiological survey indicate that 35.4% (69 million) US adults aged 40 or older have some balance dysfunction; prevalence jumps to 69% among those aged 70-79 years and 85% among those aged 80+ years. The higher risk of balance impairments among the elderly is due to functional changes associated with aging. The control of balance becomes increasingly dependent on visual and proprioceptive cues as we age, making the elderly more vulnerable to falls when those orientation cues are degraded. Individuals with balance trouble have a six-fold increase in the risk of falling; fall risk increases even further among individuals who report symptoms of dizziness. Falls are the leading cause of both fatal and nonfatal injuries among older adults (aged 65 years and older). In 2014, approximately 3 million older adults sought treatment in emergency rooms for fall-related injuries; 800,000 of these patients required hospitalization and 27,000 patients died. Direct medical costs of falls in the US in 2000 were more than $19 billion. Many people who fall develop a fear of falling, even if they are not injured. This fear may cause them to limit their activities leading to reduced mobility and loss of physical fitness, which in turn increases their actual risk of falling. In addition to the elderly, several other groups are at increased risk for balance disorders. Race other than white, lower educational status, diabetes, and hearing loss is associated with poorer balance function. In addition, individuals who have sustained head injuries are likely to suffer from problems with balance and dizziness. http://www.cdc.gov/nchs/nhanes.htm |
| NCI Cancer Data Standards Repository and Registry (caDSR) | Committee, Work group, Advisory group, or Task Force | FDA, ASPE | NCI, CIT, NEI, NHLBI, NIAMS, NIBIB, NICHD, NIMH, NINDS, NLM, NIDA, NIDCD, NCATS | The National Cancer Institute (NCI) is collaborating with other NIH institutes to develop and harmonize data standards across NCI and others NIH institutes for basic, translational and clinical research, clinical care, epidemiology, public health, administration, and public information. NCI caDSR provides services to meet NCI needs, and works with other NIH institutes to reuse/share existing content. https://cadsr.cancer.gov |
| NCI Cervical Cancer "Last Mile" Initiative (LMI) | Research Initiative | FDA, CDC | NCI | The NCI Cervical Cancer ‘Last Mile’ Initiative (LMI) is a public private partnership between several stakeholders (including federal agencies, industry partners, and professional societies/clinical practice guidelines organizations) to validate self-sampling-based HPV testing approaches as comparable (non-inferior) alternatives to provider-collected cervical specimen for HPV testing in cervical cancer screening, and accelerate progress towards regulatory approvals. https://prevention.cancer.gov/major-programs/nci-cervical-cancer-last-mile-initiative |
| NCI Clinical Trials and Translational Research Advisory Committee (CTAC) | Committee, Work group, Advisory group, or Task Force | CMS, FDA | NCI | The Clinical Trials and Translational Research Advisory Committee makes recommendations on the National Cancer Institute-supported national clinical trials enterprise to build a strong scientific infrastructure by bringing together a broadly developed and engaged coalition of stakeholders involved in the clinical trial process. The Committee will provide advice on matters related to the conduct, oversight, and implementation of clinical trials and translational research across the Institute. http://deainfo.nci.nih.gov/advisory/ctac/ctac.htm |
| NCI Enterprise Vocabulary Services (EVS) controlled terminology and standards development in collaboration with FDA and international regulatory agencies including NCI/FDA Memorandum of Understanding for Drug Related Information | Resource Development | FDA | NCI | The National Cancer Institute (NCI) Enterprise Vocabulary Services is working with the US Food and Drug Administration (FDA) to develop and support controlled terminology in several areas. More than 25,800+ FDA terms and codes are stored in the NCI Thesaurus. http://www.cancer.gov/cancertopics/cancerlibrary/terminologyresources/fda |
| NCI Fecal Microbiota Transplants and Defined Microbiota Cancer Therapeutics Clinical Research Working Group/NCI Convenes Workshop on Reproducibility of Fecal Microbiota Transplants in Cancer Therapeutics | Committee, Work group, Advisory group, or Task Force | FDA | NCI | To explore the potential role that fecal microbiota transplants (FMT) and pre/probiotics may play in cancer therapeutics and to address reproducibility and safety to inform translational human studies and clinical trials, NCI convened a “Strategic Workshop on Rigor and Reproducibility: Precision Fecal Microbiota Transplant and Microbiome Cancer Therapeutics” on September 5, 2019. This timely meeting brought together scientists and FDA regulatory staff in the fields of FMT, pre/probiotics, nutrition, microbiome, synthetic biology, biomarkers, computation, immunology, gastroenterology, oncology, and infection. Workshop Goals Assess the current state of clinical research and clinical trials involving FMT and microbiome-based cancer therapeutics; Discuss the knowledge gaps and future opportunities in the field; Provide feedback to National Cancer Institute (NCI) and National Institutes of Health (NIH) regarding future priority areas to enhance precision- and mechanism-based rigor and reproducibility of defined microbiome-based therapeutic clinical research for cancer and other diseases Workshop Focus Areas Standardization (material manufacture and quality control), FMT donor selection, microbiome measurement, clinical protocols, procedures, and trial design; Microbiome composition and function as biomarkers associated with cancer therapy, such as reproducibility, safety, and efficacy; Confounding variables — host genetic and disease state, environment, antibiotics, diet and other lifestyle factors; Clinical efficacy and safety of FMT and microbiome-based cancer therapy; Clinically relevant models and human translational studies; Data sharing; FDA regulatory issuesNCI Fecal Microbiota Transplants and Defined Microbiota Cancer Therapeutics Clinical Research Working GroupSince 2019 NCI FMT workshop, the Working Group continues hosting seminar series, yearly to highlight the research discovery and assess the research needs. The most recent webinar is on Nov 6, 2022 in which Drs. Hassane Zarour and Giorgio Trinchieri, the world experts on FMT and cancer immunotherapy, discussed NCI funded study published in Science this year “Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients”. The next coming FMT talk will be on April 8th, 2022, at 2pmIn addition to the webinar, in FY 2022,Working Groupis working on developing FOA: RFA:Fecal Microbiota Transplants and Defined Microbiota Cancer Therapeutics Clinical Research Network. Plan to present in DCTD meeting in April, May or July. Plan future meeting in 2024.*******************************************************************A2016 NCI workshop on the “State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research” and the recent upsurge in the field of gut microbiota research suggest that the microbiome plays a role in cancer therapeutic outcomes. This may be especially important for patients receiving anti-PD-1 immunotherapy. To explore the potential role that fecal microbiota transplants (FMT) and pre/probiotics may play in cancer therapeutics and to address reproducibility and safety to inform translational human studies and clinical trials, NCI convened a “Strategic Workshop on Rigor and Reproducibility: Precision Fecal Microbiota Transplant and Microbiome Cancer Therapeutics” on September 5, 2019 (agenda). This timely meeting brought together scientists and FDA regulatory staff in the fields of FMT, pre/probiotics, nutrition, microbiome, synthetic biology, biomarkers, computation, immunology, gastroenterology, oncology, and infection. Workshop Goals Assess the current state of clinical research and clinical trials involving FMT and microbiome-based cancer therapeutics Discuss the knowledge gaps and future opportunities in the field Provide feedback to NCI and NIH regarding future priority areas to enhance precision- and mechanism-based rigor and reproducibility of defined microbiome-based therapeutic clinical research for cancer and other diseases Workshop Focus Areas Standardization (material manufacture and quality control), FMT donor selection, microbiome measurement, clinical protocols, procedures, and trial design Microbiome composition and function as biomarkers associated with cancer therapy, such as reproducibility, safety, and efficacy Confounding variables — host genetic and disease state, environment, antibiotics, diet and other lifestyle factors Clinical efficacy and safety of FMT and microbiome-based cancer therapy Clinically relevant models and human translational studies Data sharing FDA regulatory issues https://dctd.cancer.gov/NewsEvents/20191031_reproducibility_of_fecal_microbiota_transplants.htm |
| NCI Multi-Cancer Detection (MCD) Trial Team | Research Initiative | CMS, FDA | NCI, OD/DPCPSI/ORWH | Scientific development for the evaluation of Multi-Cancer Detection (MCD) assays for the purpose of cancer screening. This group is also known internally as the Tiger Team https://prevention.cancer.gov/major-programs/mcd |
| NCI/CCR-FDA Clinical Investigator Program | Research Initiative | FDA | NCI | Multilateral Benefit in a Joint Program to Recruit Combined Food and Drug Administration (FDA) and the National Cancer Institute's (NCI) Center for Cancer Research (CCR) Clinical Investigators: the FDA gains an academic oncologist with disease-specific expertise who is actively involved and understands critical nuances of the field; NCI gains a clinical investigator and leader who understands regulatory considerations in drug development; and the oncologic community gains a regulator/academic who will provide a leadership voice to help design trials with regulatory endpoints in mind. https://deainfo.nci.nih.gov/advisory/joint/0615/03%20Pazdur.pdf |
| NCI/FDA Memorandum of Understanding for Proteomics | Research Initiative | FDA | NCI | This Memorandum of Understanding (MOU), signed in 2007, renewed in 2012, 2017, and 2022 establishes an official relationship in clinical proteomic regulatory science between NCI's Office of Cancer Clinical Proteomics Research and the FDA. Active areas of research collaboration include sample collection, preparation, storage and processing; bioinformatics and data analysis; discovery and validation of biomarkers; and surrogate biomarkers of cancer development and drug response, including standardization among technology platforms and assay standards development. https://proteomics.cancer.gov/news_and_announcements/fda-and-nih-sign-memorandum-understanding-interagency-collaboration-advance |
| NEHEP Partnership Summit | Meeting/ Workshop | OASH | NEI | The National Eye Institute's National Eye Health Education Program (NEHEP) will be joined by the Office of Disease Prevention and Health Promotion in a partnership summit in 2023 to connect NEI and NEHEPs work to the Healthy People 2030 vision objectives. |
| NEI-FDA-ONC Joint Workshop on Promoting Adoption of Ocular Imaging Standards | Meeting/ Workshop | ONC, FDA | NEI | This virtual NEI, FDA, and ONC hosted workshop will focus on delineating the state of the science and improving interoperability among ocular imaging modalities and devices to improve biomedical research and patient care. This meeting will consist of a day of discussion that will identify the gaps in knowledge, barriers to progress, and potential strategies for overcoming them in the context of addressing the goal of Promoting the Adoption of Ocular Imaging Standards. This will be an open workshop to the general public, and it is anticipated that researchers from academia, industry, non-profits, other government agencies, patients and care partners will attend. The discussion will be disseminated to the vision community in the form of a published white paper. |
| Networking and Information Technology Research and Development (NITRD) Program | Committee, Work group, Advisory group, or Task Force | AHRQ, ONC, CDC | OD/DPCPSI/ODSS, NLM, NHGRI, NIBIB, NCI, NCATS, NIGMS | NITRD coordinates Federal RD to identify, develop, and transition into use the secure, advanced IT, high-performance computing, networking, and software capabilities needed by the Nation, and to foster public-private partnerships that provide world-leading IT capabilities. As a NSTC subcommittee, the President’s Council of Advisors for Science and Technology (PCAST) provides regular reviews of the NITRD programs. https://www.nitrd.gov/ |
| Newborn Screening Coding and Terminology Guide | Resource Development | CDC, FDA, HRSA, IOS, AHRQ | NLM, NHGRI, NHLBI, NICHD | This ongoing collaboration develops, supplements, and publicizes a free online resource with guidance to help promote the efficient electronic exchange of standardized newborn screening data. Related efforts include studying the screening process for diseases including severe combined immunodeficiency (SCID), lysosomal storage disorders (LSDs), and critical congenital heart disease (CCHD), and developing standard codes for ordering and reporting the results of newborn screening for SCID, CCHD, and other conditions added to the Uniform Recommended Screening Panel by the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children. https://newbornscreeningcodes.nlm.nih.gov/ |
| Newborn Screening Federal Partners Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA | NICHD, NHGRI, NLM | The federal members of the Advisory Committee on Heritable Disorders in Newborns and Children meet monthly to share information about newborn screening activities. |
| Next Generation Microfluidics Workshop | Meeting/ Workshop | FDA | NHLBI | This workshop focused on discussion of the state of the microfluidics (MF) field in biomedical applications, limitations in the field of MF, and how to move the field forward to extract the maximum utility to help patients. This meeting was a call to educate colleagues at the National Institutes of Health (NIH) about what can be done collectively to enable better research and move closer to translational applications, and bring more products to researchers in the MF space and to clinicians and patients. |
| NF-kappaB in pathogenesis and therapy of head and neck cancer | Research Initiative | FDA | NICHD | NF-kappaB in pathogenesis and therapy of head and neck cancer |
| NGSP (formerly the National Glycohemoglobin Standardization Program) (NGSP) | Resource Development | CDC | NIDDK, CC | The purpose of the NGSP (formerly the National Glycohemoglobin Standardization Program) is to standardize Hemoglobin A1c test results to those of the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS), which established the direct relationships between HbA1c levels and outcome risks in patients with diabetes. NIDDK has provided funding for NGSP research initiatives, and NIDDK Extramural Program staff have served on committees. http://www.ngsp.org/ |
| NHAS Quality of Life Working Group | Committee, Work group, Advisory group, or Task Force | CDC, HRSA, SAMHSA, ACL | OD/DPCPSI/OAR, NIMH, NIAID | A working group of representatives from six federal agencies involved in developing and implementing the NHAS was tasked with carefully listening to community input and evaluating options for possible quality of life measures, data sources, and targets that could be adopted and implemented. As a result of their work and community input, the Office of National AIDS Policy ultimately adopted five indicators that reflect the multi-dimensional nature of quality of life among people with HIV. Indicators address self-rated health status, mental health, food insecurity, employment status, and unstable housing or homelessness. https://www.hiv.gov/blog/white-house-publishes-federal-implementation-plan-national-hivaids-strategy/ |
| NIA Confocal Imaging Facility | Research Initiative | FDA | NIA | NIA Confocal Imaging Facility |
| NIA IMPACT Collaboratory Transforming Dementia Care (IMPACT Collaboratory) | Research Initiative | CDC | NIA | The mission of the IMbedded Pragmatic Alzheimers disease (AD) and AD Related Dementias (AD/ADRD) Clinical Trials (IMPACT) Collaboratory is to build the nation’s capacity to conduct pragmatic clinical trials of interventions embedded within health care systems for people living with dementia and their care partners. The IMPACT Collaboratory accomplishes this mission by: developing and disseminating best practice research methods; supporting the design and conduct of pragmatic trials, including pilot studies; building investigator capacity through training and knowledge generation; catalyzing collaboration among stakeholders, healthcare providers, and investigators; and ensuring the research includes culturally-tailored interventions and people from diverse and under-represented backgrounds. https://impactcollaboratory.org/overview/ |
| NIAID/Armed Forces Radiobiology Research Institute (AFRRI) Research Coordination Team (RCT) | Committee, Work group, Advisory group, or Task Force | ASPR | NIAID | The Research Coordinating Team (RCT) has been successfully reestablished and will continue to meet quarterly in 2021. The purpose of the RCT is to discuss progress, resolve any concerns and to explore new areas of research to be conducted under the IAA. |
| NIAID/CDC Dual Use Research of Concern (DURC) Risk Mitigation Reviews | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | The Centers for Disease Control and Prevention (CDC) Division of Select Agents and Toxins Division will provide technical assistance in evaluating the sufficiency of the biosecurity and/or biosafety measures incorporated into risk mitigation plans received from institutions, and cross-check risk mitigation plans and research conducted using select agents and toxins against information in the Federal Select Agent Program (FSAP) database. |
| NIAID/FDA/BARDA Meeting on Gastrointestinal Acute Radiation Syndrome (GI-ARS) | Meeting/ Workshop | FDA, ASPR | NIAID | The purpose of this meeting is to bring together medical countermeasures stakeholders such as academicians, industry, and funding and regulatory agencies to consider animal models and endpoints for radiation injuries to the gastrointestinal tract. |
| NIAID/NASA Medical Countermeasures Working Group | Committee, Work group, Advisory group, or Task Force | BARDA, FDA | NIAID, NCI, NHLBI | The purpose of this Working Group (WG) is to bring together experts in radiation countermeasures to look for complementary areas of research across agencies in the following areas: medical countermeasure selection, repurposing, research strategies, and animal models for select endpoints. |
| Nicotine Research Cigarettes (SPECTRUM) | Committee, Work group, Advisory group, or Task Force | FDA | NIDA | This partnership with the Food and Drug Administration (FDA) is for the production of research cigarettes. |
| NIDA-FDA Interagency Clinical Outcomes Assessment Working Group (ICOAWG) | Committee, Work group, Advisory group, or Task Force | FDA | NIDA, NCI, OD/DPCPSI/OBSSR | The Interagency Clinical Outcomes Assessment Working Group (ICOAWG) facilitates scientific exchange between the National Institutes of Health (NIH) and Federal Drug Administration (FDA) and helps to guide research and stay abreast of new and ongoing clinical trials and measurement approaches being used. There is a focus on standards and use of Clinical Outcome Assessments. |
| NIEHS SBIR PHASE IIB Awards for Validation and Commercialization of Approaches to Reduce Animal Use in Toxicology Testing (U44) | Committee, Work group, Advisory group, or Task Force | FDA | NIEHS | This SBIR program uses a cooperative agreement mechanism, including regular consultation with a Steering Committee (SC), to conduct formal validation of alternative test methods. The SCs consist of ICCVAM NICEATM members. https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-15-016.html |
| NIH Autoimmune Diseases Coordinating Committee (ADCC) | Committee, Work group, Advisory group, or Task Force | FDA, HRSA | NIEHS, NIAID, OD, NCI, NCATS, NCCIH, NEI, NHLBI, NHGRI, NIAMS, NIBIB | The purpose of the ADCC is to facilitate coordination of research across the National Institutes of Health (NIH), federal agencies, professional societies, and patient and advocacy organizations with an interest in autoimmune diseases. The ADCC meets once or twice yearly. https://www.niaid.nih.gov/about/autoimmune-diseases-committee |
| NIH Common Data Elements Task Force (CDETF) | Committee, Work group, Advisory group, or Task Force | AHRQ, FDA, CMS, ASPE, CDC | NLM, CC, CIT, CSR, FIC, NCATS, NCCIH, NCI, NCMHD, NCRR, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NINDS, NINR, OD/DPCPSI/OBSSR, OD/DPCPSI/ODSS, OD/OER, OD/AoU, OD/DPCPSI/ORWH, OD/DPCPSI/SGMRO, OD/ECHO, NIGMS, NIMH, NIMHD | The NIH CDE Task Force as a whole provides a trans-NIH communications forum – including COVID-related activities. Through its subgroups, such as the COVID CDE Coordinating Committee and the NIH CDE Governance Committee, the Task Force addresses specific trans-NIH issues like coordination across COVID efforts, NIH CDE governance, etc. |
| NIH COVID-19 Treatment Guidelines Panel | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID | The Panel was formed in March 2020, at the beginning of the COVID-19 pandemic in the US. The Panel includes members from academia and professional societies. Five USG ex-officio members are on the Panel, including representatives from BARDA, CDC, DoD, FDA, and VA. The Panel is responsible for writing and updating guidelines for the treatment of COVID-19 https://www.covid19treatmentguidelines.nih.gov |
| NIH Guide for Grants and Contracts | Resource Development | AHRQ, CDC, FDA | OD/OER, CC, CIT, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI | The National Institutes of Health (NIH) Guide for Grants and Contracts is the official publication for NIH medical and behavioral grant policies, guidelines, and funding opportunities. Other US Department of Health and Human Services agencies also use the Guide to disseminate Funding Opportunity Announcements to its 60,000 subscribers. http://grants.nih.gov/grants/guide/index.html |
| NIH Medical Rehabilitation Coordinating Committee (MRCC) | Committee, Work group, Advisory group, or Task Force | CDC, HRSA, SAMHSA | NICHD, CC, CSR, NCCIH, NCI, NEI, NHLBI, NIA, NIAMS, NIBIB, NIDCD, NIDDK, NIMH, NINDS, NINR | Pursuant to Public Law 101-613, the National Institutes of Health (NIH) Director established the Medical Rehabilitation Coordinating Committee. The Coordinating Committee makes recommendations to the National Institute of Child Health and Human Development (NICHD) Director and the Director of the National Center for Medical Rehabilitation Research with respect to the content of the research plan and activities that are carried out in conjunction with other components of NIH and with other Federal Government agencies. https://www.nichd.nih.gov/sites/default/files/publications/pubs/Documents/NIH_ResearchPlan_Rehabilitation.pdf#search=NIH_ResearchPlan_Rehabilitation |
| NIH World AIDS Day | Other | OASH | OD/DPCPSI/OAR, NIAID, NIDA, NINDS, NIMH, NCI, NIAAA, NHLBI, NICHD, OD/DPCPSI/ODP, NLM, CC | OAR led coordination and planning for the 2023 NIH World AIDS Day event, which involved a panel discussion followed by a public Q&A session. Representatives from OASH and the White House Office of National AIDS Policy participated in the event by providing opening remarks. https://oar.nih.gov/news-and-updates/meetings-events/world-aids-day-2022 |
| NIH, HUD, CDC Housing and Health Group | Committee, Work group, Advisory group, or Task Force | CDC | OD/DPCPSI/ODP, NCI, NICHD, NIDDK, NHLBI, NIEHS, NIMHD, NINR, OD/DPCPSI/OBSSR | The collaboration between National Institutes Health (NIH), Centers for Disease Control and Prevention (CDC) and Department of Housing and Urban Development (HUD) is focused on identifying housing and health-related research resources, current activities and investments on this topic by each agency, and opportunities for collaboration to advance housing and health research. In 2020, a portfolio analysis was conducted of NIH and CDC applications and funded research pertaining to housing and health. https://prevention.nih.gov/about-odp/partnerships-collaborations |
| NIH-FDA Interagency Clinical Outcome Assessments Working Group (ICOAWG) | Committee, Work group, Advisory group, or Task Force | FDA | NCI, CC, NHLBI, NIA, NIAMS, NICHD, NIDA, NIDDK, NIMH, NINDS, OD/DPCPSI/OBSSR, OD/DPCPSI/SGMRO | The Interagency Clinical Outcome Assessments Working Group (ICOA WG) works to foster the development, evaluation and qualification of Clinical Outcomes Assessments (COAs) for use in both medical product development and clinical research. https://report.nih.gov/CRS/View.aspx?Id=2732 |
| NIH-FDA Medical Device Research Interest Group (MDRIG) | Committee, Work group, Advisory group, or Task Force | CMS, FDA | NIBIB, NCATS, NCI, NEI, NHLBI, NIA, NIAID, NICHD, NIDDK, NINR, OD/DPCPSI/ORIP, FIC, NIAMS, NIDA, NCCIH, NHGRI, NIAAA, NIDCD, NIGMS, NIEHS, NLM, OD | MDRIG meets quarterly to share information and ideas on supporting research throughout the device development pipeline. Recent topics of interest included clinical innovation and translation efforts, artificial intelligence and machine learning in imaging, digital twins, and early feasibility supplements for the Small Business Innovation Research (SBIR) grantees that would facilitate grantee Food and Drug Administration (FDA) meetings and communication in the formative years to increase appropriate planning during the development of their technologies toward eventual FDA approval. Recently, a successful pilot program was launched through collaboration between the NCI and FDA. Scalability to other institutes was discussed. Supported by NIBIB, MDRIG continues to meet four times per year. In 2018, NIBIB hosted a trans-NIH workshop on gadolinium retention in patients after magnetic resonance imaging. Collaborators included the extramural medical imaging community. A subsequent widely referenced white paper identified gaps in knowledge and future areas for research. This workshop included FDA participation. |
| NIH/BARDA Antimicrobial Resistance (AMR) Diagnostic Challenge Working Group | Committee, Work group, Advisory group, or Task Force | ASPR, FDA, CDC | NIAID | The Working Group designed, launched, and managed the largest USG Challenge competition of $20M through each of the three stages during the 5 years of the competition. The goal was to support the development of novel, innovative, rapid, point-of-need diagnostic in vitro assays to improve antibiotic stewardship and decrease the rapidly expanding AMR pandemic. |
| NIMH-SAMHSA collaboration to support the delivery of evidence based practices in Certified Community Behavioral Health Clinic-Expansion (CCBHC-E) awardees | Research Initiative | SAMHSA | NIMH, NIDA | The goal of this collaboration is to identify mutual National Institute of Mental Health (NIHMH) and Substance Abuse and Mental Health Services Administration (SAMHSA) priority areas of interest and to develop relevant funding initiatives that will invest in mental health services and implementation science research to support the adoption and sustained fidelity of evidence-based practices in Certified Community Behavioral Health Clinic-Expansion awardees. https://grants.nih.gov/grants/guide/notice-files/NOT-MH-22-170.html |
| NINDS Common Data Elements Program | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NINDS, CIT, NICHD, NEI, NHGRI, NCATS, NIA, NIMH, NIEHS, NIGMS, NIBIB, NIDDK, NIDCR, NINR, NHLBI | NINDS works closely with the research community (academia and industry), patient advocates, and other federal agencies to develop and maintain data standards called common data elements (CDEs). Data standards facilitate data collection and data sharing in clinical research. Through the efforts of several working groups, CDEs have been developed for use in adult and pediatric research studies of many neurological disorders, including ALS, cerebral palsy, Chiari I malformation, epilepsy, Friedreich’s ataxia, headache, Huntington’s disease, mitochondrial disease, multiple sclerosis, ME/CFS, several neuromuscular diseases, Parkinson’s, spinal cord injury, stroke, and TBI. https://www.commondataelements.ninds.nih.gov/ |
| NIOSH SGM Equity Work Group | Committee, Work group, Advisory group, or Task Force | CDC | OD/DPCPSI/SGMRO | The National Institute for Occupational Health and Safety, part of CDC, organized a SGM work group in 2021 to advance inclusion of SGM populations in data collection and work related to occupational health and safety. There are not good demographic data available about experiences and differences in LGBTQI+ folks experienced at work or ways to look for systematic barriers or disparities for these populations in workforce settings. |
| Nipah viral replicon particle vaccine safety & efficacy evaluation in NHP model | Research Initiative | CDC | NIAID | Testing in nonhuman primates of a newly developed vaccine for protection against Nipah virus infection |
| NITRD Digital Health R&D Interagency Working Group | Committee, Work group, Advisory group, or Task Force | AHRQ, FDA, ONC | NCI, NCATS, NHLBI, NIA, NIMH, NIBIB, NICHD, OD/DPCPSI/OBSSR, OD/OSP | The Digital Health R&D (DHRD) Interagency Working Group was formed in 2010 as the Health Information Technology R&D IWG to coordinate Federal R&D for improving medical, functional, and public health outcomes across 15 participating agencies. Guided by the four fundamental challenges described in the Federal Health Information Technology Research Development Strategic Framework, the IWG advances R&D by coordinating agency plans and activities, promoting collaborations, and providing a forum for exchanging information and articulating R&D needs to policy-makers and decision-makers https://www.nitrd.gov/coordination-areas/dhrd/ |
| Non-animal approaches to assess cardiotoxicity hazard | Research Initiative | FDA | NIEHS | This project aims to identify and develop human cell- and protein-based assays, as well as in silico QSAR models, to more efficiently screen drugs and chemicals for their potential to be toxic to the heart or circulatory system https://ntp.niehs.nih.gov/go/cardio |
| Noroviruses and Epidemic Gastroenteritis | Research Initiative | FDA | OD/OIR, NIAID | Noroviruses and Epidemic Gastroenteritis |
| Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis Response Services | Research Initiative | SAMHSA | NIMH | The National Institute of Mental Health (NIMH) collaborated with the Substance Abuse and Mental Health Services Administration (SAMHSA) to develop a Notice of Special Interest (NOT-MH-23-140) that communicates priority research opportunities in crisis response services. This includes research on 1) treatment and services interventions; 2) triage, dispatch, and other forms of decision support; and 3) strategies to promote service engagement/continuity and quality of care. https://grants.nih.gov/grants/guide/notice-files/NOT-MH-23-140.html |
| Novel Tools and Approaches Research Program | Research Initiative | ATSDR | NIEHS | Novel Tools and Approaches Research Program |
| NSTC Subcommittee on Biological Defense Research and Development - Interagency Bioconvergence Working Group | Committee, Work group, Advisory group, or Task Force | OS | OD/OSP | The National Science and Technology Council (NSTC) Health Security Threats Bioconvergence Strategic Objective is focused on gaining insight about areas of opportunity and areas of risk for biodefense arising from the convergence of the most recent advances in biosciences with leading edge discoveries in other areas of physical, computational, and life sciences research. The co-leads of the group are Cindy Bruckner-Lea and Ashley Predith at the Department of Energy. |
| NSTC Subcommittee on Biological Sciences | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP | Advises and assists the Committee on Science and the National Science and Technology Council (NSTC) on Federal policies, procedures and plans in the biological sciences; also explore ways in which the Federal government can increase the overall effectiveness and productivity of its investment in biological sciences research, especially regarding issues that cut across agency boundaries. |
| NSTC Subcommittee on Biological Sciences -Interagency Synthetic Biology Working Group (BSSC-SBWG) | Committee, Work group, Advisory group, or Task Force | CDC | OD/OSP, NIBIB | Provides coordination and strategic planning to help ensure responsible innovation and significant advances in research in synthetic biology. |
| NSTC Subcommittee on Open Science (NSTC SOS) | Committee, Work group, Advisory group, or Task Force | AHRQ, ASPR, CDC, FDA | OD/DPCPSI/ODSS | The NSTC Subcommittee on Open Science advances cross-agency efforts in open science. The newly established NSTC SOS Open Science Infrastructure Subgroup will develop a coordinated, cross-agency approach to implementing digital infrastructure that supports and enables open science. The original group was formed under Obama Administration, but it became a sub committee under the Trump Administration. |
| Nutrition Research Coordinating Committee (NRCC) | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, CDC, FDA, HRSA, OASH | OD/DPCPSI/ONR, NCATS, NCCIH, FIC, CSR, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI, OD/DPCPSI/OAR, OD/DPCPSI/OBSSR, OD/DPCPSI/ODS, OD/DPCPSI/ORWH, OD/DPCPSI/OSC, OD/ECHO | The Nutrition Research Coordinating Committee (NRCC) was established by the National Institutes of Health (NIH) Office of the Director in 1975 to improve communication and research coordination of nutrition activities within the NIH and across the federal government. Today it provides an open forum for members to discuss current and future nutrition research challenges and opportunities. The NRCC has broad representation from the NIH institutes and centers. In addition, liaisons from other federal offices and agencies also participate. The NRCC meets monthly, alternating between intra-NIH and interagency meetings. NRCC membership is open to any federal staff member interested in carrying out any trans-NIH or trans-agency nutrition research efforts. https://dpcpsi.nih.gov/onr/nrcc |
| Obesity Prevention and Control: Combined School-Based Interventions to Increase Healthier Food and Beverage Consumption and Physical Activity | Meeting/ Workshop | CDC | NHLBI | Ongoing participation on monthly calls by the Community Guide Coordinating Team. https://www.thecommunityguide.org/ |
| Observational Cohort to Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance following Initiation of Tenofovir-Lamivudine-Dolutegravir (TLD) | Research Initiative | CDC | NIAID | This is a study of the safety, adherence, and efficacy of a fixed-dose combination of drug tenofovir/lamivudine/dolutegravir (TLD) among HIV patients, including those co-infected with tuberculosis, receiving care at PEPFAR (President’s Emergency Plan for AIDS Relief) funded sites in resource limited countries. https://actgnetwork.org/ |
| Occupational Exposure Assessment of a-Pinene and related Monoterpenes | Research Initiative | CDC, FDA | NIEHS | This research will define the range of exposures present across several industries that routinely handle monoterpene compounds, to determine which working populations are most at risk of elevated exposures to monoterpenes. |
| Occupational Exposure Assessment of Emerging Per- and Polyfluoroalkyl Substances (PFAS) | Research Initiative | CDC | NIEHS | The primary objectives of this study are to identify PFAS compounds currently in use in commerce or industry and the companies, industries, and worker populations who are manufacturing, processing, or using PFAS products and to conduct targeted occupational exposure assessments in high- and moderate-PFAS volume industries. Based on the results of the exposure assessment, secondary objectives of this study are to assess health effects associated with PFAS exposure. To meet the objectives of this study, we propose four specific aims. |
| ODP Prevention Scientific Interest Groups (SIGs) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, OASH, FDA | OD/DPCPSI/ODP, NCCIH, NCI, NHGRI, NHLBI, NIA, NIAAA, NIAMS, NICHD, NIDA, NIDCR, NIDDK, NIMHD, NINDS | The Office of Disease Prevention (ODP) Prevention Scientific Interest Groups (SIGs) develop collaborative research initiatives to address unmet prevention research needs. To avoid overlap with other collaborative research planning groups, they focus on areas where there are no existing collaborative NIH-wide or federal groups. https://prevention.nih.gov/about-odp/partnerships-collaborations/prevention-scientific-interest-groups |
| Office for Human Research Protections/Division of Human Subjects Research | Meeting/ Workshop | OS | OD/OER | The Office for Human Research Protections (OHRP) collaborated with the NIH OER Division of Human Subjects Research to provide comprehensive human subjects protection training at the NIH Virtual Meeting PreCon event for the extramural community. https://grants.nih.gov/news/contact-in-person/seminars.htm |
| Office of AIDS Research Advisory Council (OARAC) | Committee, Work group, Advisory group, or Task Force | CDC | OD/DPCPSI/OAR, OD, NIAID, OD/DPCPSI | The Office of AIDS Research Advisory Council (OARAC) provides advice to the Office of AIDS Research (OAR) Director on the planning, coordination, and evaluation of research and other HIV/AIDS activities conducted or supported by the National Institutes of Health (NIH). The OARAC advises the Secretary of Health and Human Services, the Assistant Secretary for Health, the Director of NIH, and the Director of OAR on HIV/AIDS research programs and the development and annual review of the comprehensive NIH Strategic Plan for HIV and HIV-Related Research. https://www.oar.nih.gov/about/oarac |
| Office of Emergency Care (OECR)-FDA Update Meetings | Meeting/ Workshop | FDA | NINDS | The NINDS Office for Emergency Care Research (OECR) and the FDA meet quarterly to learn of each other's ongoing activities and streamline any areas of overlap. |
| Office of National Drug Control Policy (ONDCP) Data Interagency Working Group (DIWG) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ASA, ASPE, CDC, CMS, FDA, IHS, NIH, ONC, SAMHSA | NIDA, NIAAA | The Office of National Drug Control Policy (ONDCP) Data Interagency Working Group (DIWG) is led by ONDCP to review and recommend drug data and research to address the policy priorities articulated by the current Administration. Agency contributions will help inform and be incorporated into the National Drug Control Strategy. |
| Office of Secretary, Patient-Centered Outcomes Research Trust Fund (OS-PCORTF) PCORTF Projects titled, Data Capacity for PCOR through eCare Planning for People with Multiple Chronic Conditions Disability. | Other | ACL, AHRQ, IHS | NHLBI, NCI, NIA, NIDDK, NLM | This project aims to improve the accessibility of patient-centered data for research and care by developing an accessible, interoperable, person-centered electronic (e)care plan. |
| Office of the Clinical Director Clinical Services Research | Research Initiative | IHS | NIMH | Office of the Clinical Director Clinical Services Research |
| Older Individuals Collaborative Nutrition Group (OICN) | Meeting/ Workshop | AHRQ, CDC, CMS, FDA, HRSA, IHS, NIH, OASH, OS, ACL | OD/DPCPSI/ODP, NIA, OD/DPCPSI/ODSS, OD/DPCPSI/ODS, OD/DPCPSI/ONR | The purpose of this group is to connect and inform federal nutrition and public health researchers, educators, communicators, and policy makers across federal agencies who touch the lives of older adults. |
| ONDCP Harm Reduction Interagency Workgroup | Committee, Work group, Advisory group, or Task Force | SAMHSA, ASPE, CMS, HRSA, CDC | NIDA | This interagency working group (IWG) will help drive action in support of the Biden-Harris Administration goal of increasing access to evidence-based harm reduction services through expanded Medicaid reimbursement, comprehensive federal grant funding, research, and workforce training. Specifically, the IWG will focus on integrating harm reduction services with traditional health care infrastructure by developing sustainable funding streams needed to expand the availability of syringe services programs, naloxone, fentanyl test strips, and low-threshold medication treatment for opioid use disorder at harm reduction programs, as outlined in the 2022 National Drug Control Strategy. |
| ONDCP Methadone Modernization Interagency Workgroup | Committee, Work group, Advisory group, or Task Force | SAMHSA, HRSA, CMS | NIDA | This interagency workgroup (IWG) will help drive action in support of the Biden-Harris Administration goal of reducing barriers and increasing access to evidence-based treatment, specifically methadone for opioid use disorder (OUD). In line with the goals set forth in the 2022 National Drug Control Strategy, this IWG will work to review and update regulations governing opioid treatment programs (OTP) - currently the only location where patients can access methadone - to make it easier for patients to initiate and stay in treatment. This work to remove barriers to methadone access will also support the Strategy goal of increasing the availability of methadone in jails and prisons. |
| One Health Coordination Unit (OHCU) | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | A multisectoral coordination mechanism to strengthen One Health collaboration related to prevention, detection, control, and response for zoonotic diseases and related One Health work across the federal government |
| Open Science Infrastructure Working Group of the Subcommittee on Open Science of the National Science and Technology Council (OSI) | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, ASPR, CDC, FDA | NLM, OD/DPCPSI/ODSS, OD/OSP, OD/OER | To advance a trans-federal government understanding and best practices of infrastructure that facilitates open science. |
| Operation of the COVID-19 Treatment Guidelines Website | Research Initiative | FDA | NIAID | Operation of the COVID-19 Treatment Guidelines Website |
| Opioids & Substance Use: Workplace Prevention & Response | Training Initiative | CDC | NIEHS, OD/DPCPSI/ODP | Development of training curricula for the training and education of workers, supervisors, and organizations on the hazards of opioids. Collaboration with NIOSH’s Total Worker Health program to address the use and misuse of opioids. https://tools.niehs.nih.gov/wetp/index.cfm?id=2587 |
| Oral Health Aging: Information for Caregivers | Public Education Campaign | ACL, HRSA, OASH | NIDCR, NIA | Fact sheets designed to provide caregivers with information they need to assist older adults with oral hygiene. There are four fact sheets in the series: Brushing, Flossing, Dry Mouth, and Finding Low-Cost Dental Care. https://catalog.nidcr.nih.gov/OrderPublications/#101 |
| Oral Health in America: Advances and Challenges | Resource Development | OASH, FDA, CMS, CDC, HRSA, IHS, SAMHSA | NIDCR, NIAID, NIAAA, NIDA, NCATS | This report was a federally supported, multi-agency public-private-partner effort to examine the nation's oral health, highlighting advances and challenges, over the 20 years since the publication of the first U.S. Surgeon General's Report on oral health, published in 2000. The report continues to be disseminated and serves as a call to action for coordinated efforts among engaged communities including clinicians, scientists, professional and patient organizations, and local, state, and federal government agencies. https://www.nidcr.nih.gov/research/oralhealthinamerica |
| OS-Patient-Centered Outcomes Research Trust Fund (PCORTF) CMS Pilot Data Linkage Projects Discussion | Committee, Work group, Advisory group, or Task Force | ASPE, CDC, CMS | NICHD, NCATS, NIA, NCCIH, NIDDK | Convened by ASPE to develop a series of pilot projects to build out a thoughtful record linkage framework for CMS and other HHS administrative datasets, under the PCORTF. https://aspe.hhs.gov/collaborations-committees-advisory-groups/os-pcortf |
| P2P on Postpartum Health | Meeting/ Workshop | AHRQ | NICHD, OD/DPCPSI/ORWH, NHLBI, NIMHD | ODP/ORWH-led Pathways to Prevention meeting on maternal health. |
| P63, P13K and RAS oncogenes in tumorigenesis, immune deregulation and therapy of squamous cell carcinoma | Research Initiative | FDA | NIDCD | At the Food and Drug Administration (FDA), Dr. Weinberg is transducing murine keratinocytes with combinations of oncogenes found in human squamous cell carcinomas to determine if they generate transformation and tumors in laboratory conditions. Dr. Van Waes’ laboratory at the National Institute on Deafness and Other Communication Disorders (NIDCD) will study how these oncogene-driven tumors in mice deregulate keratinocytes and host immune responses, as well as response to various standard, molecular, and immune therapies. |
| Pain Assessments Web-Based Tool | Resource Development | CMS | NINDS, CC, NCCIH, NINR, NIDCR, NIDA, NCI, NIA, NICHD, NIAMS, NIMH, NEI, NIGMS, NIDDK, NIAAA, NIMHD, NIBIB, NIDCD, NCATS, NHLBI, FIC | The NIH Pain Consortium and CMS pain assessments tool provides health care practitioners with relevant and validated pain assessment tools that are appropriate to their patient population and easily embedded into their practices. The goal is to provide access to measures across biopsychosocial pain domains to facilitate discussions between clinicians and patients to develop a treatment plan and monitor progress. The website lists and describes validated, commonly used measures across pain domains and collections of additional measures. https://www.painconsortium.nih.gov/resource-library/pain-assessment-resources-professionals |
| PALM007 | Research Initiative | CDC | NIAID | Clinical trial of safety and efficacy of tecovirimat to treat Mpox in adults and children in DRC |
| Pandemic Influenza Translational Research and novel universal countermeasure development | Research Initiative | FDA | OD/OIR, NIAID | Pandemic Influenza Translational Research and novel universal countermeasure development |
| Pandemic Response Team | Other | ASPR, CDC | NIAID | Ongoing work and collaboration since the COVID-19 pandemic for COVID-19 vaccines allocation approvals for the use in NIH clinical trials and preclinical studies |
| PAR 22-049 'Integrating Biospecimen Science Approaches into Clinical Assay Development' Steering Committee Collaboration | Committee, Work group, Advisory group, or Task Force | FDA | NCI | As part of a U01 grants program/network, the Steering Committee provides an opportunity to improve the quality of funded research and potentially amplify the impact of the grants program through collaborative activities. The Steering Committee collaboratively reviews research progress and develops collaborative activities that may include, among other activities, joint research projects, and advocates for the sharing of data and biospecimens within the network. |
| Pathogen Detection Project and Interagency Collaboration on Genomics for Food and Feed Safety (Gen-FS) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NLM | The Pathogen Detection Project is a multi-agency collaboration that combines data from pathogen outbreaks with other information to determine the major source of contamination. Collaborating agencies include NLM, the Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), USDA-Food Safety and Inspection Service, and Public Health England. The US agencies formalized their collaboration in a charter document (Interagency Collaboration on Genomics for Food and Feed Safety (Gen-FS)) that includes coordinating activities on antimicrobial resistance. http://www.ncbi.nlm.nih.gov/pathogens/ |
| Pathophysiological Actions of Anthrax Virulence Determinants | Research Initiative | FDA | NIAID | Pathophysiological Actions of Anthrax Virulence Determinants |
| Pathways to Prevention (P2P) Workshop Program | Meeting/ Workshop | AHRQ, CDC, ONC, OASH, ASPE, SAMHSA, HRSA, IHS | OD/DPCPSI/ODP, NCATS, NHLBI, NCI, NIMH, NIMHD, NICHD, NINDS, NIA, OD/DPCPSI/ORWH | The Pathways to Prevention (P2P) program is a workshop series hosted by the Office of Disease Prevention (ODP) to identify research gaps in a selected scientific area, identify methodological and scientific weaknesses in that scientific area, suggest research needs, and move the field forward through an unbiased, evidence-based assessment of a complex public health issue. P2P workshops are designed for topics that have incomplete or underdeveloped research and for which there is a need for a systematic evidence review that synthesizes the published literature. After each workshop, ODP also organizes a meeting of all Federal Partners who have an interest in or activities related to the workshop topic to discuss ways that the Federal Partners might collaborate to implement workshop recommendations. https://prevention.nih.gov/programs-events/pathways-to-prevention/ |
| PCC Technical Working Group on PFAS | Committee, Work group, Advisory group, or Task Force | CDC, FDA, ATSDR | NIEHS | Technical coordination on toxicology, exposure, analysis, mitigation of PFAS https://www.who.int/ipcs/network/en/ |
| PCORTF Frailty Functional Disabilities Project Working Group | Research Initiative | ASPE, AHRQ, CDC, CMS | NIA | Validate and Expand Claims-Based Algorithms, Identifying Patients with Frailty and Functional Disabilities across Payer and Patient Populations https://aspe.hhs.gov/validating-and-expanding-claims-based-algorithms-frailty-and-functional-disability-value-based-care-and-payment |
| Pediatric COVID-19/MIS-C Interagency Team | Committee, Work group, Advisory group, or Task Force | FDA, CDC, ASPR | NICHD, NHLBI, NIAID | This group was initially focused on MIS-C and coordinating MIS-C efforts across CDC, FDA and NIH. The case definition was finalized by CDC colleagues; the mission of this group remains the same, which is to coordinate surveillance and research in human services programmatic development across HHS; group shifted to focusing on both pediatric COVID more broadly as well as MIS-C. |
| Pediatric Radiation Medical Countermeasures Working Group | Committee, Work group, Advisory group, or Task Force | ASPR, FDA | NIAID, NICHD | This group was established in an effort to harmonize efforts in the pediatric space and to push ahead pediatric radiation and multi-utility (Chem/Rad) products. The plan is to critically evaluate the status of pediatric drug development against radiation injury. Identify resources and cross-cutting efforts in this area to ensure a clear pathway is established to advance radiation products with a pediatric indication |
| Persistent Identifiers subgroup of the Subcommittee on Open Science of the National Science and Technology Council | Committee, Work group, Advisory group, or Task Force | ACL | NLM, OD, OD/DPCPSI/ODSS | The August 2022 OSTP Public Access Memo directed agencies to develop, among other things, an implementation plan for providing digital persistent identifiers for researchers, authors, affiliations, funding awards, research protocols, and research outputs. The PIDs working group shares information about existing services, issues, and needs toward supporting agency responses to provisions outlined in Section 4 of the Public Access Memo. |
| Physiological Effects of Natural or Contaminating Compounds in a Rodent's Microenvironment | Research Initiative | FDA | OD/OIR, NIEHS | Physiological Effects of Natural or Contaminating Compounds in a Rodent's Microenvironment |
| Pilot Biosurveillance Working Group - National Biodefense Strategy | Committee, Work group, Advisory group, or Task Force | CDC, FDA, ASPR | NIAID | This pilot working group was convened to develop objectives and work packages for biosurveillance topics in order to plan/implement these topics as indicated by the National Biodefense Strategy. A follow-on working group was to be convened. |
| Population Assessment of Tobacco and Health (PATH) Study | Health Survey | FDA | NIDA | The Population Assessment of Tobacco and Health (PATH) Study is the first large-scale National Institutes of Health (NIH)/ and the US Food and Drug Administration (FDA) collaboration since Congress granted FDA the authority to regulate tobacco products in the Family Smoking Prevention and Tobacco Control Act (FSPTCA) in 2009. The PATH Study is a national longitudinal cohort study that will follow an estimated 59,000 US household residents ages 12 years and older for at least three years. Objectives are to assess initiation and use patterns; to study trends in tobacco-product use cessation and relapse; to monitor behavioral and health impacts, including in risk perceptions and other tobacco-related attitudes; and to assess differences in tobacco-related attitudes, behaviors, and health outcomes among racial/ethnic, gender, and age subgroups. The PATH Study will also collect biospecimens from adults to analyze biomarkers of tobacco use and related health outcomes. By measuring and accurately reporting on the social, behavioral, and health effects associated with tobacco-product use in the United States, the PATH Study will provide an empirical evidence base to help inform FDA’s decisions about changes in tobacco products in meeting the objectives of the 2009 FSPTCA. http://www.PATHStudyInfo.nih.gov |
| Post-Traumatic Stress Disorder (PTSD)/Trauma Brain Injury (TBI), Suicide Prevention National Research Action Plan (NRAP) Workgroup | Committee, Work group, Advisory group, or Task Force | OS | NIMH, NIAAA, NIDA, NINDS | A 2012 White House Executive Order, emphasizing support of Service Members, Veterans, and their families as a top priority, called for an urgent increase in the Departments of Health and Human Services (HHS), Defense (DoD), and Veterans Affairs (VA) research coordination to address the problems of Post-Traumatic Stress Disorders (PTSD), Trauma Brain Injury (TBI), and suicide. Section 5 of this Executive Order requested a National Research Action Plan (NRAP) to develop biomarkers, define the pathophysiology, and develop new treatments for PTSD. HHS charged the National Institute of Mental Health (NIMH) to lead this effort along with a parallel effort for TBI led by National Institute of Neurological Disorders and Stroke (NINDS), with both Institutes working closely with VA and DoD. The NRAP was published in 2013. Prior investments integrating the molecular, genomic, and brain circuitry changes that give rise to PTSD in the context of environmental factors provide the requisite foundation to respond to this White House request for biomarkers for risk prediction, as well as new targets for medications, and other therapies to treat PTSD. This investment has the potential to revolutionize care for individuals at high risk for PTSD and prevent the development of chronic, complex treatment-resistant PTSD. The agencies meet weekly and produce quarterly progress reports. http://www.whitehouse.gov/the-press-office/2012/08/31/executive-order-improving-access-mental-health-services-veterans-service |
| Postdoctoral Fellowship in Genomic Science and Health Equity | Training Initiative | FDA | NHGRI | The FDA, Office of Minority Health and Health Equity and the NHGRI jointly sponsor a postdoctoral fellowship program to provide training in genetic, genomic, and pharmacogenomic approaches to advance minority health and health equity. Working closely with mentors at both the FDA and NIH, this program helps fellows learn to bridge research, development and review processes, advance their knowledge of health disparities, and build awareness of regulatory sciences. https://www.genome.gov/careers-training/research-training/postdoctoral-fellowship-in-genomic-science-and-health-equity |
| PRAMS Interagency Workgroup | Committee, Work group, Advisory group, or Task Force | CDC, NIH, CMS, HRSA | NICHD | Support team of PRAMS users as they build their internal capacity to link MCH data sets and inform their future programming. |
| Precision Oncology Interest Group (POIG) | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NIAID, NHLBI, NIDDK, NIAMS, NCATS, NINDS, NIBIB, NICHD, NIDCR, OD | The POIG, and its attendant listserv will aim to foster effective communication across the basic and clinical research oncology communities, to harness the translational powers of the NIH to advance precision therapy across cancers. The goals of the POIG are to discuss, plan, implement and execute the current CCR initiative to perform standardized genomic analyses (RNA-SEQ, exome-SEQ, methylation analysis) on a large cohort of NCI patients, with the goal of using these data to drive collaborative predictive and prognostic biomarker discovery and precision therapy strategies for improving patient outcomes, to discuss and implement best sample acquisition and management practices to learn the most from any precious patient material, to discuss and implement the best technologies and informatics to help us discover candidates for targeted therapies with the goal of maximizing favorable outcomes for oncology patients, and to rationally design clinical trials in oncology with a focus on precise therapies that have the potential to maximize benefit and minimize side effects. https://oir.nih.gov/sigs/precision-oncology-interest-group |
| Preclinical and Clinical Investigations of Severe Infection and Critical Illness - CDC Covid Response Team | Research Initiative | CDC | CC | Preclinical and Clinical Investigations of Severe Infection and Critical Illness - CDC Covid Response Team |
| Preclinical and Clinical Investigations of Severe Infection and Critical Illness - CDC Covid Task Force | Research Initiative | CDC | CC | Preclinical and Clinical Investigations of Severe Infection and Critical Illness - CDC Covid Task Force |
| Preclinical and Clinical Investigations of Severe Infection and Critical Illness - CDC Foundation | Research Initiative | CDC | CC | Preclinical and Clinical Investigations of Severe Infection and Critical Illness - CDC Foundation |
| Preclinical Assessment of Phage Therapy for Pathogen Decolonization | Research Initiative | FDA | NIAID | This project addresses key regulatory considerations relevant to using bacteriophages for decolonization of the drug-resistant nosocomial pathogens, vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). These include characterizing pathogen resistance to phage, defining phage mixtures ("cocktails") to circumvent resistance, optimizing mouse models to evaluate pathogen decolonization, and identifying endpoints that support claims for clinical benefit (e.g., reduced risk of disease transmission). |
| Predicting Drug Resistance with Machine Learning | Resource Development | ASPE | NLM, NIAID | This project has its origin in an ASPE-funded PCOR project: Training Data for Machine Learning to Enhance Patient-Centered Outcomes Research Data Infrastructure. The project acquires, curates, and uses high-quality training data sets to predict tuberculosis (TB) drug resistance, in collaboration with NIAID and its TB Portals program. TB drug resistance has been concerning because it is difficult to diagnose in a patient during the early stages and it complicates and prolongs treatment considerably. The idea of the project is to develop new ways of detecting drug-resistance in chest radiographs by using deep learning in combination with large image repositories, clinical data, and genomic information of the bacteria for drug-sensitive and drug-resistant tuberculosis. Researchers use this data to train machine learning models that can detect signs of TB drug resistance. |
| Pregnancy and Birth to 24 Months Project (P/B-24) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA, OS | NICHD, NCI, NHLBI, NIDDK | In 2012, the US Department of Agriculture (USDA) and Department of Health and Human Services (HHS) initiated a project informally called the B-24 project. This multi-phase project was originally intended to conclude in 2018 with information that could help the Departments develop dietary recommendations for infants and toddlers for release separate from the Dietary Guidelines. The first phase was completed in 2012-2013. In February 2014, Congress passed the Agricultural Act of 2014, also known as the Farm Bill, mandating that the Dietary Guidelines expand to include dietary guidance for infants and toddlers (from birth to age 24 months), as well as women who are pregnant, beginning with the 2020-2025 edition. Thus, USDA and HHS adjusted the purpose, timeline, and scope of the project. Now called the Pregnancy and Birth to 24 Months project or P/B-24 project to reflect the addition of pregnant women, this project is a joint initiative led by USDA and HHS in collaboration with programmatic and scientific experts. Rather than concluding in 2018 with dietary recommendations, the goal of the current project is to begin examining topics of public health importance for women who are pregnant and infants and toddlers from birth to 24 months of age. The findings from this work will be made publicly available at the completion of the project. https://www.fns.usda.gov/resource/pregnancy-and-birth-24-months |
| Pregnant People, Substance Use Disorder and Child Welfare, Sub Interagency Policy Committee (IPC) of the Maternal Health IPC | Committee, Work group, Advisory group, or Task Force | ACF, ASPE, CDC, HRSA, IHS, SAMHSA, OS, IOS | NIDA, NICHD | Originating in 2022, the Pregnant People, Substance Use Disorder and Child Welfare Sub Interagency Policy Committee (IPC) of the Maternal Health IPC will address the Biden-Harris Administration's First Year Drug Policy Priority, “Explore, identify barriers, and establish policy to help pregnant people with substance use disorder obtain prenatal care and addiction treatment without fear of child removal.” This Sub-IPC will provide short- and long-term federal actions to improve equitable outcomes for families affected by substance use disorder involved in, or at risk of being involved in, the child welfare system. The sub-IPC will prioritize actions that improve equity and are informed by those with lived experience. |
| PregSource® Management Team | Public Education Campaign | CDC, HRSA | NICHD, NCCIH, NHLBI, NIEHS, NIMHD, NINR, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH | PregSource is a crowdsourcing research project that aims to learn about the pregnancy experience. Getting information directly from pregnant women about what they feel, think, do, and experience during pregnancy and after giving birth can teach us more about pregnancy and how to improve care. https://pregsource.nih.gov/ |
| President's Advisory Council for HIV/AIDS (PACHA) | Committee, Work group, Advisory group, or Task Force | CDC, CMS, HRSA, IHS, OASH | OD/DPCPSI/OAR | The Presidential Advisory Council on HIV/AIDS (PACHA) provides advice, information, and recommendations to the Secretary of Health Human Services regarding programs, policies, and research to promote effective treatment, prevention and cure of HIV disease and AIDS, including considering common co-morbidities of those infected with HIV as needed to promote effective HIV prevention and treatment and quality services to persons living with HIV disease and AIDS. https://www.hiv.gov/federal-response/pacha/about-pacha |
| President's Emergency Plan for AIDS Relief (PEPFAR) Cervical Cancer Prevention Expert Task Force | Committee, Work group, Advisory group, or Task Force | CDC | NCI, NIAID | NCI participates with other US government agencies (Department of State, CDC, USAID, and others) on an expert task force to inform the development and oversight of cervical cancer prevention programs within the US President's Emergency Plan for AIDS Relief (PEPFAR) initiative. The Department of State convenes an Expert Task Force from experts from the CDC, NIH (NCI), and other US government agencies including Department of State, US Agency for International Development (USAID), Department of Defense, and Peace Corps to inform the development and oversight of cervical cancer prevention programs within the US President's Emergency Plan for AIDS Relief (PEPFAR) initiative. The task force meets periodically to review progress and updates from focus countries in the PEPFAR cervical cancer prevention efforts, refines and updates guidance for screening and precancer treatment for implementing partners in target countries, and provides recommendations for procedures for quality assurance and adverse event monitoring and reporting. https://www.pepfar.gov/press/releases/281984.htm |
| President's Emergency Plan for AIDS Relief (PEPFAR) Implementation Science/Combination Prevention | Research Initiative | CDC | NIAID, FIC, NCI, NIAAA, NIDA, NIMH, OD/DPCPSI/OAR | This President's Emergency Plan for AIDS Relief (PEPFAR) activity focuses on testing treatment as prevention on the population level in South Africa and Zambia. This activity was initiated through the HIV Prevention Trials Network (HPTN), with support of multiple National Institutes of Health (NIH) Institutes and Centers, PEFPAR, and the Bill Melinda Gates Foundation. The Requests for Application (RFA) was issued concurrently with a Centers for Disease Control and Prevention (CDC) RFA for combination prevention, and the agencies have worked together to ensure that the studies are complementary and do not overlap. http://www.pepfar.gov/ |
| President's Task Force on Environmental Health Risks and Safety Risks to Children (PTFCEH) | Committee, Work group, Advisory group, or Task Force | ACF, ASPR, CDC, ATSDR, FDA, OASH, SAMHSA | NIEHS, NICHD, NHLBI, NIMH, NIMHD | The PTFCEH is the focal point for coordinating federal government efforts to explore, understand, and act together to improve children's environmental health. The Task Force mission includes a goal of prioritizing issues of environmental justice and health disparities among children. ptfceh.niehs.nih.gov |
| President's Task Force on Environmental Health Risks and Safety Risks to Children: Lead Exposures Subcommittee | Committee, Work group, Advisory group, or Task Force | ACF, CDC, FDA, HRSA, OS | NICHD, NHLBI, NIEHS | The President's Task Force on Environmental Health and Safety Risks to Children is the focal point for coordinating the federal government's effort to explore, understand, and improve children's environmental health. The task force's objectives are to: 1) develop federal interagency strategies to protect children’s environmental health and safety; 2) identify priority children's environmental health and safety issues best addressed through federal interagency efforts; and 3) communicate information to federal, state, and local decision-makers to protect children from environmental health risks. The Lead Subcommittee seeks to reduce lead exposure and associated harms through collaboration among federal agencies and with a range of stakeholders, including states, tribes and local communities, along with businesses, property owners and parents. This Subcommittee will help federal agencies work strategically and collaboratively to reduce exposure to lead with the aim of ultimately improving children’s health. https://ptfceh.niehs.nih.gov/activities/lead-exposures/index.htm |
| Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) | Committee, Work group, Advisory group, or Task Force | ASPR | NIAID | In March 2015, the Department of Health and Human Services (HHS) announced the establishment of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB). This Federal Advisory Committee (FACA) includes public voting members, non-voting liaison representatives from organizations and/or interest groups, and non-voting federal ex-officio members. PACCARB provides advice, information, and recommendations to the Secretary regarding programs and policies intended to support and evaluate the implementation of Executive Order 13676, including the National Strategy for CARB and the National Action Plan for CARB. PACCARB has been reauthorized until January 18, 2019 (based on its charter), through Executive Order 13811 on September 29, 2017. https://www.hhs.gov/ash/advisory-committees/paccarb/index.html |
| President’s Task Force (PTF) on Environmental Health Risks and Safety Risks to Children: Chemical Exposures (ChEx) Subcommittee | Committee, Work group, Advisory group, or Task Force | FDA, OASH | NINDS, NIEHS | The goal of the PTF ChEx subcommittee is to coordinate federal research and action to address early-life exposures to chemicals that impact children's health, such as the development of methods and models to enhance exposure assessment relevant to public health. https://ptfcehs.niehs.nih.gov/activities/chemical-exposures |
| Prevention Research Coordinating Committee (PRCC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, OS, FDA, OASH | OD/DPCPSI/ODP, CC, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/OAR, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH, OD/DPCPSI/ODS, OD/OLPA | The NIH Prevention Research Coordinating Committee (PRCC) serves as a venue for exchanging information on recent scientific advances in disease prevention; examining the impact of new policies on research; planning new or discussing ongoing initiatives; and highlighting program accomplishments. As a trans-NIH, trans-agency committee, the PRCC provides a broad perspective on the current state-of-the-science and actively disseminates information about prevention-related activities sponsored by federal and non-federal organizations to the NIH Institutes and Centers. https://prevention.nih.gov/prevention-research/prcc |
| Probiotic and Prebiotic Working Group [PPWG] (PPWG) | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NCCIH, NIAMS, NIDA, NIDCR, OD/DPCPSI/ODS, CC, CIT, CSR, FIC, NCATS, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIBIB, NICHD, NIDCD, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/OEDI | The Probiotic and Prebiotic Working Group (PPWG) is a trans-NIH effort formed in 2006 to identify gaps and challenges in prebiotic and probiotic research. Their goals include (1) facilitating interactions and collaborations among research scientists in the field of probiotics and prebiotics, (2) advancing prebiotic and probiotic research, and (3) understanding the role of gut microbiota and use of prebiotics and probiotics in health and disease. The working group strives to promote constructive interactions across NIH Institutes, Centers, and Offices, by disseminating real-time information and keeping PPWG members abreast of current and future activities occurring in the fields of probiotics and prebiotics. The group meets quarterly to form allied partnerships and collaborate on various pre- and probiotic activities. 2022 updates - Trans-NIH workshop held: Precision Probiotic Therapies Challenges and Opportunities, April 26-27th, 2022. The workshop was led by NCCIH. Two trans-NIH Program Announcements were released in 2015 and were renewed in 2018:PA-18-902 Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional) https://grants.nih.gov/grants/guide/pa-files/pa-18-902.html |
| Production and purification of biological compounds | Research Initiative | FDA | NIDDK | Production and purification of biological compounds |
| Public Health and Emergency Medical Countermeasures Enterprise (PHEMCE) | Committee, Work group, Advisory group, or Task Force | ACF, CDC, FDA, OS, SAMHSA | NIAID, NIAMS, NICHD, NINDS, NLM | The Public Health and Emergency Medical Countermeasures Enterprise (PHEMCE) advances national preparedness for natural, accidental, and intentional threats by coordinating medical countermeasure-related efforts within HHS and in cooperation with PHEMCE interagency partners. NIAID has representatives on many groups within PHEMCE. http://www.phe.gov/Preparedness/mcm/phemce/Pages/mission.aspx |
| Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Preparedness Against Chemical Threats (PACT) Working Group (PHEMCE PACT Working Group) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NINDS, NIAID | The US Department of Health and Human Services (HHS) Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) leads the mission to develop and acquire medical countermeasures that will improve public health emergency preparedness as well as prevent and mitigate the adverse health consequences associated with chemical, biological, radiological and nuclear (CBRN), and naturally occurring threats. https://www.medicalcountermeasures.gov/ |
| Public Health Service Technology Transfer Policy Board (TTPB) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | OD/OIR, OD/OIR/OTT, OD/OSP, OD/OER | The purpose of the Public Health Service (PHS) Technology Transfer Policy Board (TTPB) is to serve as the principal advisory board for establishing PHS technology transfer policies and modifying existing policies, as applicable. Membership is drawn from the National Institutes of Health (NIH) as lead agency in the PHS technology transfer program, the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA). |
| Quantitative Biophotonics for Tissue Characterization and Function | Research Initiative | FDA | OD/OIR, NICHD | Quantitative Biophotonics for Tissue Characterization and Function |
| Quantum Barcoding for analysis of Ebola infection | Other | FDA | NIAID | Viral MIBI and Quantum barcoding: These projects are part of a Food and Drug Administration (FDA) contract with Dr. Gary Nolan's group at Stanford. The first project will develop and validate an assay for nucleic acid-based method for viral detection on the MIBI, compatible with Formalin-Fixed Paraffin-Embedded tissue, and then apply to Ebola samples. The second will use quantum barcoding to develop anti-human and anti-macaque antibody reagents, to hep develop a system that will replace multiplexing technologies such as high parameter FACS and CyTOF with a platform based on sequence tags (rather than fluorophores or mass tags) that uses decontaminated and ambient temperature-stable samples. This will be applied to BSL-3/4 samples. |
| Racial and Ethnic Disparities in Excess Deaths During the COVID-19 Pandemic | Research Initiative | CDC | NCI, NIMHD | Although racial/ethnic disparities in U.S. COVID-19 death rates are striking, focusing on COVID-19 deaths alone may underestimate the true effect of the pandemic on disparities. Excess death estimates capture deaths both directly and indirectly caused by COVID-19 excess deaths and excess deaths per 100,000 persons from March to December 2020 were estimated by race/ethnicity, sex, age group, and cause of death, using provisional death certificate data from the Centers for Disease Control and Prevention (CDC) and U.S. Census Bureau population estimates. |
| Racial/Ethnic Variation of HPV Type Distribution in High-Grade Cervical Precancers and Invasive Cancers in the United States | Research Initiative | CDC | NCI | The National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating in pooled analysis of seven U.S. studies conducted between 1997-2015 to examine HPV genotype attribution for cervical precancer and cancer by race/ethnicity. |
| Radiation and Chemical Defense Working Group | Committee, Work group, Advisory group, or Task Force | ASPR, FDA | NIAID, NIEHS, NIAMS | This group is responsible for ensuring that any scientific or budgetary overlap between the chemical defense and radiation defense missions are identified and leveraged to advance the missions of both research areas. Goals are to understand areas of synergy in chemical and radiological insults, identify key pathways, foci of intervention, MCM development. The group includes staff from across the NIH, FDA and ASPR. Special Journal Issue and Government staff positional paper are planned. |
| Radiation Biodosimetry Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | This working group is focused on regulatory and scientific issues regarding technologies and devices for radiation biodosimetry. The working group assisted in drafting the new Food and Drug Administration (FDA) Center for Device and Radiological Health (CDRH) guidance for industry. |
| Radiation-Induced Immune Dysfunction Meeting | Meeting/ Workshop | ASPR | NIAID | The purpose of the workshop held in 2021 was to bring investigators together from the radiation biology and basic immunology fields to examine effects of radiation-induced hematopoietic injury, including natural history, early effects, recovery and residual damage. An RFA was issued on this topic, with eight awards made in 2022, and a meeting report has been accepted for publication in Radiation Research (anticipated early 2023). |
| Radiation-Induced Multi Organ Dysfunction Meeting Planning Group | Meeting/ Workshop | ASPR | NIAID, NCI | The objectives of the workshop are to 1) explore radiation-induced multi-organ injury, in particular, the connections and underlying mechanisms driving injury to affected organs; 2) assess how various treatments can ameliorate these injuries; and 3) publish a meeting report in a peer-review journal. Meeting will be held November 2-3, 2021. |
| Radiobiology Bioterrorism Research and Training Group (RABRAT) | Committee, Work group, Advisory group, or Task Force | FDA, ASPR | NCI, NIAID | This activity involves monthly meetings to discuss research initiatives, funding opportunities, training, conferences, publications, and other events and information related to preparing the US Government to respond to nuclear terrorism. Radiation review and conversation of subject matter experts across the USG. https://rrp.cancer.gov/programsResources/program_collaborations.htm |
| Rapid Acceleration of Diagnostics Tech Program (RADx Tech) | Research Initiative | CMS, FDA, CDC, ASPR | NIBIB | To help address the COVID-19 pandemic, National Institute of Biomedical Imaging and Bioengineering (NIBIB) received $651 million (in FY2021) to support the development of new SARS-CoV-2 virus testing technologies. The Rapid Acceleration of Diagnostics (RADx®) Tech program is leveraging NIBIB's existing Point-of-Care Technologies Research Network (POCTRN) to accelerate the development, validation, and commercialization of innovative POC and home-based tests, as well as improvements to existing clinical laboratory methods. RADx Tech is supporting the full range of product development including technology validation, clinical translation, commercialization, and product distribution. RADx Tech also established the Independent Test Assessment Program (ITAP) in order to accelerate regulatory review and availability of high-quality, accurate, and reliable over-the-counter COVID-19 tests to the public. https://www.poctrn.org/radx |
| Rare Disease Day at NIH | Meeting/ Workshop | FDA | NCATS, NHLBI, NCI, CC, NIAAA, NINDS | Rare Disease Day; takes place worldwide, typically on or near the last day of February each year, to raise awareness among policymakers and the public about rare diseases and their impact on patients; lives. Each year, the National Center for Advancing Translational Sciences (NCATS) and the National Institutes of Health (NIH) Clinical Center sponsor Rare Disease Day at NIH as part of this global observance. Rare Disease Day at NIH aims to raise awareness about rare diseases, the people they affect, and NIH collaborations that address scientific challenges and advance research for new treatments. The goals of Rare Disease Day at NIH are to: demonstrate the NIH commitment to helping people with rare diseases through research; highlight NIH-supported rare diseases research and the development of diagnostics and treatments; initiate a mutually beneficial dialogue among the rare disease community; exchange the latest rare diseases information with stakeholders to advance research and therapeutic efforts; shine a spotlight on stories told by people living with a rare disease, their families, and their communities. https://ncats.nih.gov/rdd |
| Rare Diseases Registry Program (RaDaR) | Research Initiative | FDA | NCATS | NCATS launched the Rare Diseases Registry Program (RaDaR) website to provide the rare diseases community with easily accessible guidance on how to set up and maintain high-quality registries that are based on best practices and data standards. The goal is to enable rare diseases patient organizations to better promote and support patient-focused research and the collection of patient data that can be used in developing treatments for rare diseases. https://ncats.nih.gov/radar |
| Reciprocal Educational and Training Partnerships between FDA/CDER and the NIH Clinical Center | Training Initiative | FDA | CC, NCI, NIAID, NIDCR, NIDDK, NIMH, NINDS | This activity is sponsored by the Clinical Pharmacology Program, Office of Clinical Research Training and Medical Education (OCRTME) at The National Institutes of Health (NIH) Clinical Center (CC). It consists of elective rotations at the Office of Clinical Pharmacology (OCP) and the Office of New Drugs (OND) of the US Food and Drug Administration's (FDA) Center for Drug Evaluation and Research. It is for NIH staff, with a primary focus on clinical fellows and research fellows, who expressed an interest in learning more about FDA regulatory sciences applicable to drug development research. Rotating fellows are mentored by FDA staff on the required elements of an Investigational New Drug (IND) application and the key elements of the FDA review process from a regulatory perspective. This program also established a mechanism for FDA scientific reviewers at the OCP to rotate at the NIH CC and to interact with members of a clinical research team, thus acquiring a better perspective on clinical research protocol implementation and the requirements of an Institutional Review Board (IRB) at the NIH. |
| Recognize, Assist, Include, Support and Engage (RAISE) Family Caregiving Advisory Council | Committee, Work group, Advisory group, or Task Force | ACF, ACL, CDC, CMS, FDA, HRSA, IHS, SAMHSA | NIA | Federal and non-federal advisory council is charged with providing recommendations to the Secretary of Health and Human Services on effective models of both family caregiving and support to family caregivers, as well as improving coordination across federal government programs, as mandated by the Recognize, Assist, Include, Support, and Engage (RAISE) Family Caregivers Act of 2017. https://acl.gov/programs/support-caregivers/raise-family-caregiving-advisory-council |
| Reentry Research Network | Committee, Work group, Advisory group, or Task Force | ACF, SAMHSA | NIDA, OD/DPCPSI/OBSSR | This is a subgroup that reports to the Federal Interagency Reentry Council. The purpose of this group is to bring together numerous federal agencies to make communities safer, assist those returning from prison and jail to becoming productive, tax-paying citizens, and save taxpayer dollars by lowering the direct and collateral costs of incarceration. The National Institute on Drug Abuse (NIDA) serves on the HHS Re-entry/CJ working group. Staff meets by phone monthly. https://nationalreentryresourcecenter.org/reentry-council |
| Regenerative Medicine Innovation Project Senior Oversight Committee | Committee, Work group, Advisory group, or Task Force | FDA | NIAID, NCATS, NEI, NHLBI, NIA, NIAMS, NIDCD, NIDCR, NIDDK, NINDS | The Regenerative Medicine Innovation Project was established by the 21st Century Cures Act to accelerate progress in the field by supporting clinical research on adult stem cells, while promoting scientific rigor and protecting patient safety. This initiative is a trans-NIH effort, in coordination with the Food and Drug Administration (FDA). |
| Regenerative Medicine Project | Research Initiative | FDA | NIA | The Regenerative Medicine Innovation Project (RMIP) was established by the 21st Century Cures Act to accelerate progress in the field by supporting clinical research on adult stem cells, while promoting scientific rigor and protecting patient safety. This initiative is a trans-NIH effort, in coordination with the Food and Drug Administration (FDA). https://www.nih.gov/rmi |
| Registry-based studies of hematologic malignancy incidence and survivorship | Research Initiative | FDA | NCI | NCI and FDA investigators are collaborating to utilize registry-based data to describe incidence trends of hematologic malignancies as well as second cancer risk and mortality patterns among hematologic malignancy survivors. |
| Regulation of Virulence Genes in Bordetella pertussis | Research Initiative | FDA | OD/OIR, NIDDK | Regulation of Virulence Genes in Bordetella pertussis |
| RePORT South Africa | Research Initiative | CDC, OS | NIAID | RePORT South Africa is a jointly funded project between the National Institutes of Health (NIH), the US President's Emergency Plan for AIDS Relief (PEPFAR), and the South African Medical Research Council and Department of Science and Technology to establish a consortium of Tuberculosis (TB) researchers in South Africa. |
| Research in Diabetes Mellitus, Its Complications, and Obesity | Research Initiative | IHS | NIDDK | The objectives are to identify the determinants and understand the progression of type 2 diabetes, obesity, and other chronic diseases in Native American and related populations. |
| Research Operations Supporting the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods | Research Initiative | ATSDR | NIEHS | Research Operations Supporting the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods |
| Retina Network | Research Initiative | OS | NEI, NIDDK | The Retina Network (formerly known as the Diabetic Retinopathy Clinical Research Network (DRCR.net)) is a collaborative network dedicated to facilitating multicenter clinical research of diabetic retinopathy, diabetic macular edema, and associated conditions. The DRCR.net supports the identification, design, and implementation of multicenter clinical research initiatives focused on diabetes-induced retinal disorders. Principal emphasis is placed on clinical trials, but epidemiologic outcomes and other research may be supported as well. The network is funded by the National Eye Institute (NEI), and co-funded by the Office of the Secretary (OS), through National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with the Special Funding Program for Type 1 Diabetes Research. https://public.jaeb.org/drcrnet |
| Review Policy Committee (RPC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC | OD/OER, CSR, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, NIDCD, OD | The Review Policy Committee (RPC) is the principal forum for the development, implementation, and evaluation of review policies and procedures for all types of research, training, and development awards submitted to the NIH. RPC membership includes one senior extramural review official from each NIH Institute and Center that has extramural review functions. The RPC has designated liaisons from other HHS agencies including Agency for Healthcare Research and Quality (AHRQ) and Centers for Disease Control and Prevention (CDC). |
| Revision of Centers for Disease Control and Prevention (CDC) Guidelines on Hepatitis B | Committee, Work group, Advisory group, or Task Force | CDC | CC | The collaboration serves to revise guidelines for managing occupational exposures to the human immunodeficiency virus (HIV) and managing healthcare workers infected with hepatitis B. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6103a1.htm?s_cid=rr6103a1_e |
| Rheumatic and Autoimmune Diseases in Minority Communities | Research Initiative | FDA | NIAMS | Rheumatic and Autoimmune Diseases in Minority Communities |
| Role of Class B Scavenger Receptors in Lipid Metabolism and Inflammation | Research Initiative | FDA | CC | Role of Class B Scavenger Receptors in Lipid Metabolism and Inflammation |
| Role of Gs-alpha in pancreatic islet cell growth and function | Research Initiative | FDA | NIDDK | Role of Gs-alpha in pancreatic islet cell growth and function |
| Rural Opioid Initiative (ROI) | Research Initiative | CDC, SAMHSA | NIDA | The National Institute on Drug Abuse (NIDA), in partnership with the Appalachian Regional Commission (ARC), the Centers for Disease Control and Prevention (CDC) and the Substance Abuse and Mental Health Services Administration (SAMHSA) funded the Rural Opioid Initiative (ROI) Research Consortium to help communities develop comprehensive approaches to prevent and treat outcomes related to substance use. This biphasic, multi-site research initiative will address the rural opioid epidemic and its consequences by bringing together expert physicians, epidemiologists, and behavioral health professionals to build collaborations between state and local communities and conduct research, use findings from the rapid assessment phase to propose locally relevant intervention projects, and implement interventions over a period of three years. https://ruralopioidinitiative.org/ |
| Ruth L. Kirschstein National Research Service Award Program | Training Initiative | AHRQ, HRSA | OD/OER | The National Institutes of Health (NIH) Ruth L. Kirschstein National Research Service Award program provides predoctoral and postdoctoral training to meet the nation’s need for investigators in biomedical, behavioral, and clinical research. In accordance with the Public Health Service Act and annual appropriations acts, NIH annually transfers a portion of these funds to the Agency for Healthcare Research and Quality and Health Resources and Services Administration to foster the training of health services and primary care researchers. NIH: https://researchtraining.nih.gov |
| RxNorm | Resource Development | FDA | NLM | RxNorm provides normalized names for clinical drugs and links its names to many of the drug vocabularies commonly used in pharmacy management and drug interaction software. By providing links between these vocabularies, RxNorm can mediate messages between systems not using the same software and vocabulary. http://www.nlm.nih.gov/research/umls/rxnorm/ |
| Sabbatical in Clinical Research Management Program | Training Initiative | FDA, OS | CC, FIC, NCATS, NEI, NHLBI, NIAID, NIDCR, NIDDK | Experienced investigators come to the National Institutes of Health (NIH) to learn about management of a clinical research enterprise, including topics such as planning and budget development, protocol writing and tracking, and scientific review. Sabbaticals are self-directed, meaning that the participant chooses from a list of electives and helps determine how much time to spend studying each topic. The electives are offered by leaders at the NIH and other US Department of Health and Human Services agencies with the NIH Clinical Center being the most heavily involved. http://www.cc.nih.gov/training/sabbatical/index.html |
| Safe to Sleep | Public Education Campaign | CDC, HRSA | NICHD | The Safe to Sleep; campaign seeks to educate parents and caregivers about ways to reduce the risk of Sudden Infant Death Syndrome (SIDS) and other sleep-related causes of infant death, such as accidental suffocation. The National Institute of Child Health and Human Development (NICHD) offers print and electronic materials, media resources, toolkits, and a continuing education program for nurses to help spread the word about safe infant sleep. The Safe to Sleep; campaign partners with organizations to help reach various audiences, including African American, and American Indian/Alaska Native communities, which have the highest SIDS rates of any racial/ethnic group in the United States. https://safetosleep.nichd.nih.gov/ |
| SAMHSA Recovery Month | Public Education Campaign | SAMHSA | NIDA | The Substance Abuse and Mental Health Services Administration (SAMHSA) holds an annual public health observance for people in recovery from substance abuse. The National Institute on Drug Abuse (NIDA) is part of SAMHSA's inter-agency planning committee and a promotional partner. http://www.recoverymonth.gov/ |
| SARS-CoV-2 Assay Development, Training, and Standardization | Resource Development | FDA | NIAID | SARS-CoV-2 Assay Development, Training, and Standardization in BSL4 lab at Integrated Research Facility, Fort Dietrick |
| SARS-CoV-2 Assessment of Viral Evolution Program (SAVE) | Committee, Work group, Advisory group, or Task Force | FDA, CDC, ASPR | NIAID | SAVE provides a comprehensive real-time risk assessment of emerging mutations in SARS-CoV-2 that could impact transmissibility, virulence, and susceptibility to infection- or vaccine-induced immunity. The goals of the SAVE program are to understand emerging changes in the virus that could impact transmissibility, virulence, susceptibility to convalescent and vaccine-induced immunity and diagnostic testing. https://www.niaid.nih.gov/research/sars-cov-2-assessment-viral-evolution-program |
| SARS-CoV-2 evolution in immunocompromised people | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | Working Group that performs a systematic literature review in the area of immunocompromised patients with prolonged SARS-CoV-2 infections. The aim is to assess potential risk factors that may lead to intra-host evolution of the virus. |
| SARS-CoV-2 Interagency Group on Resistance to Medical Countermeasures (MCMs) | Committee, Work group, Advisory group, or Task Force | ASPR, CDC, FDA | NIAID | SARS-CoV-2 interagency Working Group with vaccine, therapeutics, and diagnostics subgroups |
| SARS-CoV-2 Pathogenesis | Research Initiative | FDA | OD/OIR, NIAID | SARS-CoV-2 Pathogenesis |
| SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology and Surveillance (SPHERES) | Other | CDC | NLM, NIAID | To help accelerate the use of near-realtime pathogen genomic data throughout the pandemic response, CDC established an open genomics consortium to spearhead and organize public health sequencing and response efforts across the United States. This consortium, SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology and Surveillance (SPHERES), helps coordinate and support sequencing at state and local public health laboratories across the country, and to better engage clinical, academic and commercial laboratories that are sequencing, or planning to sequence -- SARS-CoV-2 at any scale. The coalition aims to improve communication and knowledge-sharing between US laboratories, to develop consensus guidance on data and metadata standards, to reduce barriers to bioinformatic analysis and data sharing, and to better align sequencing requirements and resource needs with different sources of funding, technology, expertise and Other means of support. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/spheres.html |
| SARS-CoV-2 Virology Core | Research Initiative | FDA | NIAID | SARS-CoV-2 Virology Core |
| SARS-CoV-2Interagency Working Group: Therapeutics, Diagnostics, Vaccines. DCR involved in Thx and DX (SIG) | Committee, Work group, Advisory group, or Task Force | NIH, FDA, ASPR | NIAID | Developed to monitor the impact of variants on efficacy of MCMs |
| SEARCH for Diabetes in Youth (SEARCH) | Research Initiative | CDC | NIDDK | SEARCH is a multi-center study designed to characterize the epidemiology of both type 1 diabetes and type 2 diabetes in the population aged 20 years, along with the associated complications, quality of diabetes care, and quality of life of children and youth with diabetes. SEARCH aims also include 1) the development and validation of simple and low-cost case definitions and classifications of diabetes types in youth, 2) the establishment of a repository of biological specimens, and 3) systems to maintain contact with study participants to facilitate studies of childhood diabetes. SEARCH is funded by NIDDK and CDC. http://www.searchfordiabetes.org |
| Secretary's Advisory Committee on Infant Mortality | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NICHD | The Secretary's Advisory Committee on Infant Mortality (SACIM) was formed in 1991 to advise the Secretary on Department of Health and Human Services programs that are directed at reducing infant mortality and improving the health status of pregnant women and infants. https://www.hrsa.gov/advisory-committees/infant-mortality/index.html |
| Senior Medical Advisor to Assistant Secretary for Preparedness and Response (ASPR) | Committee, Work group, Advisory group, or Task Force | OS, IOS | NCI | A NCI staff member serves as Senior Medical Advisor to ASPR. This is as a global leader and subject matter expert in nuclear and radiological incidents and disasters as well as disaster preparedness in general. As such, NCI helps to develop plans for emergency and disaster responses and plays a role in responses operations as needed. A good number of the Operations plans and models that apply to all hazards have been developed from NCI science and knowledge. https://www.phe.gov/about/aspr/Pages/default.aspx |
| Sepsis Interagency Meeting | Meeting/ Workshop | AHRQ, CDC, CMS | NIGMS, CC, NHLBI, NIAID, NICHD | Discuss Sepsis Priority Areas identified in Biomedical Advanced Research and Development (BARDA) market research: Unifying definitions of Sepsis across the patient continuum, Harmonizing Data for Access and Interoperability, Optimizing Health Outcomes and Reducing Economic Burden, Improving Evaluation and Catalyzing Adoption of Critical Technologies. https://crs.od.nih.gov/CRSPublic/View.aspx?Id=7166amp;FY=2020 |
| Sequencing Quality Control Phase 2 (SEQC2) | Resource Development | FDA | NLM, CIT, NCI, NHLBI, NIEHS | The Sequencing Quality Control (SEQC) consortium is an FDA-led community-wide effort. SEQC2 is a project within the consortium. SEQC2 goals: (1) to develop quality metrics for reproducible NGS results from both whole genome sequencing (WGS) and targeted gene sequencing (TGS), (2) to benchmark bioinformatics methods for WGS and TGS towards the development of standard data analysis protocols, and (3) to assess the joint effects of key parameters affecting NGS results and interpretation for clinical application. NLM/NCBI provides an NCBI data portal for and contributes data analysis to this effort. https://www.fda.gov/science-research/bioinformatics-tools/microarraysequencing-quality-control-maqcseqc |
| Serum organochlorine/PCB concentrations and risk of prostate cancer in men from Ghana | Research Initiative | CDC | NCI | National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating to measure serum levels of persistent organic pollutants for a case-control study of prostate cancer in the Ghana Prostate Study. |
| Serum PFAS concentrations and risk of renal cell carcinoma in the Multiethnic Cohort | Research Initiative | CDC | NCI | National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating to measure serum levels of per- and polyfluoroalkyl substances (PFAS) for a nested case-control study of renal cell carcinoma (RCC) in the Multiethnic Cohort. |
| Severe Maternal Morbidity and Mortality (SMM&M) EHR Data Infrastructure Project | Other | ONC, CDC, ASPE | NICHD, NLM | The purpose of the SMM&M EHR Data Infrastructure Project is to develop a standardized approach to link electronic data on maternal and infant health for use in studying the effect of medical conditions and/or interventions on pregnant, postpartum or lactating women and their infants. The SMM&M EHR Data Infrastructure is a project of the Maternal Health Consortium, funded by the Assistant Secretary for Planning and Evaluation (ASPE). https://aspe.hhs.gov/severe-maternal-morbidity-mortality-electronic-health-record-ehr-data-infrastructure |
| Sex Differences Meeting Planning Committee | Meeting/ Workshop | BARDA | NIAID, OD/DPCPSI/ORWH | Understanding sex differences within animal models is needed to develop effective biodosimeters and MCMs. Therefore, a meeting is planned to 1) explore sex differences in metabolomics and/or other biomarkers that may track with assessing acute radiation syndrome (ARS), delayed effects of acute radiation exposure (DEARE), and/or predicting the efficacy of MCMs; 2) look at effects of synchronizing estrocycle in pre-clinical studies, and pheromones when co-housing male and female animals; 3) explore regulatory challenges in clinical studies involving representation from both sexes and policies that influence inclusion of women in research, and the gaps that exist in these practices. Meeting to be held Oct 25-26, 2021. |
| SHIELD Standardization of Lab Data to Enhance Outcomes Research and Value Based Care (SHIELD) | Committee, Work group, Advisory group, or Task Force | FDA, CDC | NLM | This project will expand the collaborative efforts of FDA and other stakeholders involved in the SHIELD initiative to ensure laboratory information interoperability, such that the same type of device is described the same way in electronic health records (EHR) systems. To realize this goal, this project will develop code mapping manuals to consistently map the same LOINC (Logical Observations Identifiers Names and Codes) to the same type of IVD. This is important because without the specific guidance, manufacturers of IVD devices and laboratories often assign different (and frequently incorrect) LOINC codes for the same type of device. This project will also pilot implementation of SHIELD standard digital formats to update infrastructure in active healthcare provider laboratories, which will include the seamless distribution of LOINC and SNOMED-CT (Systematized Nomenclature of Medicine--Clinical Terms) coding to those provider institutions and registries. https://aspe.hhs.gov/shield-standardization-lab-data-enhance-patient-centered-outcomes-research-and-value-based-care |
| Sickle Cell Disease Federal Interagency Work Group (SCD FIWG) | Committee, Work group, Advisory group, or Task Force | FDA, CDC, HRSA, OASH | NHGRI, NHLBI | The Sickle Cell Disease Federal Interagency Work Group (FIWG) fosters a community of partners engaged in achieving the vision of long, healthy, productive lives for those living with Sickle Cell Disease (SCD) and those with Sickle Cell Trait (SCT)." This involves building the capacity to address the recommendations shared in the NASEM Sickle Cell Disease Strategic Plan and Blueprint for action. |
| Smokefree.gov Initiative | Resource Development | CDC, FDA, IHS | NCI, NIMHD | TheSmokefree.govInitiative (SFGI)provides tobacco users who want to quit with free, evidence-based cessation information and on-demand support. SFGI includes 6 mobile-optimized websites, 9 SMS text programs, 2 smartphone apps, and 6 social media platforms. Tailored content is provided for special populations including women, teens, Spanish speakers, veterans, and older adults. https://smokefree.gov/ |
| Social Determinants of Health Interagency Policy Committee (SDOH-IPC) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, CDC, CMS, HRSA, SAMHSA, Other, ASPR | NINR | Convened by the White House Domestic Policy Council and the Office of Science and Technology Policy - the SDOH-IPC purpose is to support a Federal framework for a Coordinated Care Delivery Model to Address SDOH Develop a White House Action Plan sharing guidance and potential policy levers to address Social Determinants of Health through data accessibility, integration and blending and braiding of funds. |
| Social Determinants of Health Research Coordinating Committee (NIH SDOH RCC) | Committee, Work group, Advisory group, or Task Force | SAMHSA | NCI, NIMHD, NIA, NINR, NIEHS, NCATS, FIC, NIAMS, NCCIH, OD/DPCPSI/ORWH, OD/DPCPSI/ODP, OD/DPCPSI/OBSSR | The overall goal of the Research Coordinating Committee (RCC) is to accelerate NIH-wide SDOH research across diseases and conditions, populations, stages of the life course, and SDOH domains, domestically and globally. |
| Society for Prevention Research Annual Conference (SPR) | Meeting/ Workshop | CDC, ACF | NIAAA, NCCIH, NCI, NIDA | This annual conference is funded by an R13 award and is co-funded by several other NIH Institutes as well as the ACF and the CDC. |
| Somatic Cell Genome Editing | Research Initiative | FDA | OD/DPCPSI/OSC, NCATS, NCI, NHGRI, NHLBI, NIAID, NIAMS, NIDDK, NIMH, NINDS, OD/DPCPSI/ORIP, NIBIB, NEI, NICHD, NIDA, NIEHS | The Somatic Cell Genome Editing (SCGE) program aims to develop quality tools to perform effective and safe genome editing in human patients. These research tools will be made widely available to the research community to reduce the time and cost required to develop new therapies. A representative from Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) plays an advisory role for the program regarding regulatory issues. The SCGE program is a member of the National Institute of Standards and Technology (NIST) Gene Editing Consortium. The SCGE program also coordinates with the DARPA Safe Genes program when appropriate. https://commonfund.nih.gov/editing |
| Special Populations Research Forum, Clinical Research Recommendations Subcommittee (SPRF-CRRC) | Committee, Work group, Advisory group, or Task Force | SAMHSA | NCI, NINDS, NHLBI, OD/DPCPSI/SGMRO, OD/AoU | The Special Populations Research Forum (SPRF) provides a resource for NIH and HHS staff to share best practices and lessons learned in promoting diversity, equity, and inclusion (DEI) in intramural and extramural training and research. https://oir.nih.gov/sigs/special-populations-research-forum |
| State Cancer Profiles | Resource Development | CDC | NCI | State Cancer Profiles is an interactive mapping engine produced in collaboration between the National Cancer Institute and Centers for Disease Control and Prevention. It was developed with the idea to provide a geographic profile of cancer burden in the United States and reveal geographic disparities in cancer incidence, mortality, risk factors for cancer, and cancer screening across different population subgroups. The target audiences are health planners, policy makers, and cancer information providers who need quick and easy access to cancer related data and maps to inform and prioritize investments in cancer control. https://statecancerprofiles.cancer.gov/ |
| State of Illinois - Governor Challenge | Committee, Work group, Advisory group, or Task Force | SAMHSA | CC | Outcome Measurements for Interventions to Decrease Veteran Suicide. This collaboration works to measure various outcomes for interventions to decrease suicide among US Veterans. Following this evaluation, the group will make recommendations based of their assessments. |
| Steering Committee of the Scientific Interest Group in Glycobiology | Committee, Work group, Advisory group, or Task Force | FDA | NIGMS, NCI, NHGRI, NHLBI, NIAID, NICHD, NIDCR, NIDDK | The Steering Committee of the Scientific Interest Group in Glycobiology (GlycoSIG) is comprised of National Institutes of Health (NIH) intramural scientists and program staff as well researchers from the Food and Drug Administration (FDA) and the National Institute of Standards and Technology (NIST). The committee organizes a seminar series; an annual NIH/FDA Glycosciences Research Day Meeting (averaging 250 people in attendance); and a Mentoring Networking Luncheon for graduate students and postdoctoral fellows to meet with staff from federal agencies and learn about NIH extramural programs. The Committee also offers a Special Topics in the Glycosciences Course every other year. In addition, the GlycoSIG maintains an email list serve to distribute information on meetings, jobs, funding opportunities, and seminars. The SIG cross posts with other NIH SIG’s that share interests. https://oir.nih.gov/sigs/glycobiology-scientific-interest-group |
| Structural Analysis Of Candidate Genes For Type 2 Diabetes and Obesity | Research Initiative | IHS | OD/OIR, NIDDK | Structural Analysis Of Candidate Genes For Type 2 Diabetes and Obesity |
| STS/ACC TVT Registry | Meeting/ Workshop | CMS, FDA | NHLBI | The STS/ACC TVT Registry, created through a collaboration between STS and the American College of Cardiology (ACC), monitors patient safety and real-world outcomes related to transcatheter valve replacement and repair procedures – emerging treatments for valve disease patients. https://www.sts.org/registries/stsacc-tvt-registry |
| Studies of the Natural History of Sickle Cell Disease | Research Initiative | FDA | NHLBI | Studies of the Natural History of Sickle Cell Disease |
| Subcommittee on Open Science (Formerly Interagency Working Group on Open Science) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ASPR, CDC, CMS, FDA | OD/OSP, NLM, OD/OER | The Subcommittee on Open Science (SOS) advances Federal efforts to support open science by increasing access to, and use of, the results of federally funded research and development, including, but not limited to, scholarly publications and digital data. Among its responsibilities, the SOS aims to improve implementation of policies to increase access to the results of federally funded scientific research and to identify additional steps that Federal Departments and Agencies can take to enhance the preservation, discoverability, accessibility, quality, and utility of research outputs. Meets monthly to advance government-wide efforts to advance open science by coordinating agency efforts to improve access to publications, data, and Other outputs of Federally funded research. http://www.hhs.gov/open/publicaccess/index.html |
| Sudden Death in the Young (SDY) Registry | Resource Development | CDC, HRSA | NHLBI, NINDS | The Sudden Death in the Young (SDY) Registry is a surveillance system to track sudden deaths in youths less than or equal to 19 years of age in up to 10 states and to gather clinical data and a DNA sample to be used for research to explore the causes and risk factors for sudden death in the young. The SDY Registry is a collaboration between the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Neurological Disorders and Stroke (NINDS), and Centers for Disease Control and Prevention (CDC). https://www.sdyregistry.org/research/ |
| SUDV Medical Countermeasures Acceleration Meeting | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, HIS, SAMHSA | NIAID | An interagency meeting designed to coordinate and respond to SUDV by expediting the development and distribution of vaccines, treatments, testing and other measures as needed. |
| Support for Implementation of Agency Public Access Policies | Resource Development | AHRQ, CDC, FDA, IOS, ASPR | NLM, OD/OSP | NLM collaborates with other Federal agencies to provide free public access through NLM;s PubMed Central digital archive to peer reviewed publications resulting from agency-funded research. These agencies include five divisions and offices in HHS and four agencies outside HHS. Interagency agreements have been signed with AHRQ, ASPR, CDC, FDA and ACL within HHS, as well as with NIST, VA, EPA, and DHS. IAAs with VA and AHRQ have also been extended to support inclusion of non-journal literature in NCBI;s Bookshelf resource. NLM has also agreed to manuscript redistribution terms with NOAA and DOD to streamline public access compliance across the federal government. https://www.ncbi.nlm.nih.gov/pmc/about/public-access-info/ |
| Supporting Early Psychosis Research and Implementation | Research Initiative | OS, ASPE | NIMH | The National Institute of Mental Health (NIMH) supports research on the delivery of evidence-based early psychosis care, including facilitating the implementation of evidence-based coordinated specialty care (CSC) for early psychosis. Collaborators from NIMH and the Department of Health and Human Services (HHS) Office of the Secretary (OS) and the Office of the Assistant Secretary for Planning and Evaluation (ASPE) meet on a regular basis to inform each other's research agenda on early psychosis care generally and CSC specifically, identify synergies in research initiatives and formulate new research initiatives, and share related draft reports and funding opportunity announcements for comment. |
| Surveillance, Epidemiology, and End Results (SEER) Program | Resource Development | CDC | NCI | The Surveillance, Epidemiology, and End Results (SEER) program is the premier source for cancer statistics in the US. It collects information on incidence, prevalence, and survival from specific geographic areas representing 48 percent of the US population. Through SEER, NCI develops reports on all of these information areas plus cancer mortality for the entire country. The site is intended for anyone interested in US cancer statistics or cancer surveillance methods. https://seer.cancer.gov/ |
| Synthetic DNA Working Group | Committee, Work group, Advisory group, or Task Force | CDC, OS | OD/OSP | Re-examining and updating (if necessary) the Screening Framework Guidance for Providers of Synthetic Double-Stranded DNA, which was released in 2010. |
| Systematic Evidence Review of Trauma Informed Care (TIC) | Research Initiative | AHRQ | NIMH | This project, a collaboration between the National Institute of Mental Health (NIMH) and the Agency for Healthcare Research and Quality (AHRQ) will aim to review the effectiveness of trauma-informed care in improving patient care and outcomes. |
| Systematized Nomenclature of Medicine-Clinical Terms (SNOMED CT) | Resource Development | AHRQ, CDC, CMS, FDA, HRSA, IHS, IOS, SAMHSA | NLM | SNOMED CT (formerly Systematized Nomenclature of Medicine Clinical Terms) is a comprehensive and precise, multilingual health terminology. It assists with the electronic exchange of clinical health information, can be mapped to other coding systems, and is a resource with extensive, scientifically validated clinical content. NLM serves as the US National Release Center (NRC) and member of SNOMED International and is responsible for creating and distributing the US Edition of SNOMED CT, as well as accepting content requests for inclusion in the US Edition of SNOMED CT. Collaborators such as VA, NCI, AHRQ, CDC, CMS, and FDA have integrated SNOMED CT into their resources and provided requests for content in the US Edition of SNOMED CT. http://www.nlm.nih.gov/research/umls/Snomed/snomed_main.html |
| Systems Immunology of COVID-19 | Research Initiative | FDA | NIAID | Systems Immunology of COVID-19 |
| Systems immunology of influenza vaccination responses in healthy COVID-19 recovered individual versus those with no history of COVID-19 | Research Initiative | FDA | NIAID | Systems immunology of influenza vaccination responses in healthy COVID-19 recovered individual versus those with no history of COVID-19 |
| Task Force for Combating Antibiotic-Resistant Bacteria (CARB) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, ASPR | NIAID | Established by Executive Order 13676, the Task Force facilitates implementation of the CARB Action Plan and provides progress reports and quarterly updates describing key achievements. The Task Force is an internal government committee comprised of federal representatives and co-chaired by the Secretaries of Defense, Agriculture, and HHS. https://aspe.hhs.gov/pdf-report/national-action-plan-combating-antibiotic-resistant-bacteria-progress-report-year-3 |
| Taxonomics Methods Using DNA | Research Initiative | FDA | NLM | Taxonomics Methods Using DNA |
| Technical Expert Panel on the development of Evidence-Based Practice Guide on the treatment of serious mental illness (SMI) in older adults. | Meeting/ Workshop | SAMHSA | NIMH | Substance Abuse and Mental Health Services Administration (SAMHSA) convened a technical expert panel to provide guidance on the development of an evidence-based practice guide on the treatment of serious mental illness in older adults. The guide is an important part of the 21st Century Cures Act's charge at SAMHSA to disseminate information on evidence-based practices and will address best practices for older adults. |
| The Administration for Strategic Preparedness and Response (ASPR)'s chemical, biological, radiological and nuclear defense subject matter expert team | Committee, Work group, Advisory group, or Task Force | OS, ASPR | NCI, NIAID | The National Cancer Institute (NCI) and the National Institute of Allergy and Infectious Diseases (NIAID) participate in Assistant Secretary for Preparedness and Response (ASPR)'s chemical, biological, radiological and nuclear defense team. Both NCI and NIAID provide expertise on radiation topics and for the Biomedical Advanced Research and Development Authority (BARDA), within the Office of ASPR in the U.S. https://www.phe.gov/about/aspr/Pages/default.aspx |
| The APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Steering Committee Meetings | Committee, Work group, Advisory group, or Task Force | HRSA | NIAID, NIDDK, NIMH | The APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) aims to prospectively assess the effects of renal-risk variants (RRVs) in the apolipoprotein L1 gene (APOL1) on outcomes for kidneys from donors with recent African ancestry and the recipients of their kidneys, after deceased- and living-donor renal transplantation. For the purposes of APOLLO, recent African ancestry is defined as individuals with similar genetic make-up to those currently residing in Africa. APOLLO will also study the impact of APOL1 RRVs on the health of living kidney donors with recent African ancestry. |
| The Biology of HIV Infections | Research Initiative | FDA | NIAID | The Biology of HIV Infections |
| The contribution folate and vitamin B12 genes to disease. | Research Initiative | CDC | NHGRI | The contribution folate and vitamin B12 genes to disease. |
| The Environmental Determinants of Diabetes in the Young (TEDDY) | Research Initiative | CDC | NIDDK, NIAID, NICHD, NIEHS | This consortium, established and funded by NIDDK, is organizing international efforts to identify infectious agents, dietary factors, or other environmental factors that trigger type 1 diabetes in genetically susceptible people. The study enrolled over 8,000 newborns and is following them for 15 years to identify environmental triggers of type 1 diabetes. http://www.teddystudy.org |
| The Epidemiology of Burkitt Lymphoma in East-African Children and Minors (EMBLEM) | Research Initiative | CDC, FDA | NCI, NHGRI, NHLBI | The Epidemiology of Burkitt Lymphoma in East-African Children and Minors (EMBLEM) initiative provides a unique infrastructure to obtain valuable data and samples to study Burkitt’s lymphoma (BL) epidemiology. Study data will help characterize or investigate: (1) The association of malaria-resistance genes with endemic BL. (2) Host genetic polymorphisms associated with BL using genome-wide association methods. (3) The role of the Epstein-Barr virus (EBV) genetic variants in endemic BL. (4) The role of malaria immunology and phenotype of inflammation in BL. (5) The complexity of coinfection with different P. falciparum malaria genotypes in BL. (6) The interaction between helminthic parasites, HIV, malaria, and EBV in BL. (7) The immunohistochemistry and molecular pathology of BL. (8) The impact of malaria, helminthic parasites, and HIV on childhood BL. https://emblem.cancer.gov/ |
| The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) | Research Initiative | CDC | NIDDK, NHLBI | GRADE is an NIDDK-supported randomized clinical trial of participants diagnosed with type 2 diabetes within the past 10 years who are already on metformin. Participants will be randomly assigned to 1 of 4 commonly-used glucose-lowering drugs (glimepiride, sitagliptin, liraglutide, and basal insulin glargine), plus metformin, and will be followed for up to 7 years. The goal of the GRADE Study is to determine which combination of two diabetes medications is best for achieving good glycemic control, has the fewest side effects, and is the most beneficial for overall health in long-term treatment for people with type 2 diabetes. https://portal.bsc.gwu.edu/web/grade |
| The Golestan Cohort Study of Esophageal Cancer | Research Initiative | CDC | NCI | The National Cancer Institute (NCI) and the Centers for Disease Control and Prevention (CDC) are collaborating on a pilot study to measure nitrate in urine. The aim of the pilot is to determine if drinking water sources in high and low nitrate regions of Golestan province are associated with higher urinary nitrate concentrations (a biomarker of ingestion) after accounting for dietary intake. |
| The Impact of Tobacco Use on Oral Health and the Oral Microbiome | Research Initiative | CDC, FDA | NCI | The US Food and Drug Administration Intramural Center of Tobacco Regulatory Science Award Program funded a project examining how tobacco affects oral health and the oral microbiome in the National Health and Nutrition Examination Survey (NHANES) study. https://www.fda.gov/TobaccoProducts/PublicHealthScienceResearch/Research/ucm404564.htm |
| The Incidence of Breast and Other Cancers Among Female Flight Attendants | Research Initiative | CDC | NCI | A cohort study of approximately 10,000 Pan Am flight attendants to determine cancer incidence (primarily breast cancer) associated with cosmic radiation and circadian disruption from their work. |
| The Medical Devices Epidemiology Network (MDEpiNet) TMJ RoundTable (MDEpiNet TMJ RoundTable) | Meeting/ Workshop | AHRQ, FDA | NIDCR | This workshop facilitated collaboration of stakeholders to address data on implant performance, surgical outcomes, and adverse events in an effort to: develop outcome and assessment and reporting tools based on patient input, the intersection of patient biology, anatomy, genetics, physiology with TMJ medical devices, and clinical patient-centered outcomes to better target therapies. https://www.mdepinet.net/ |
| The Nanoscale Science, Engineering, and Technology (NSET) Subcommittee | Committee, Work group, Advisory group, or Task Force | CDC, FDA, ATSDR | NCI, OD/OSP | This subcommittee of the National Science and Technology Council's Committee on Technology is responsible for coordinating the National Nanotechnology Initiative (NNI). The NNI was established in 2001 to coordinate federal research and development in nanotechnology by providing a vision of the long-term benefits and opportunities offered by nanotechnology and acting as a locus for communication, cooperation, and collaboration between federal agencies involved in nanotechnology research and development. In 2016, the NSET updated its strategic plan to reflect the fact that nanotechnology is now a broadly enabling technology, not simply an area of research at the nanoscale. The new strategic plan outlines four goals: (1) advance a world-class nanotechnology research and development program, (2) foster the transfer of new technologies into products for commercial and public benefit, (3) develop and sustain educational resources, a skilled workforce, and a dynamic infrastructure and toolset to advance nanotechnology, and (4) support responsible development of nanotechnology. http://www.nano.gov/nset |
| The National Ending the HIV Epidemic (EHE) Meeting | Meeting/ Workshop | CDC, HRSA, OASH | NIAID, NICHD, NIDA, NIMH, OD/DPCPSI/OAR | On September 15, 2022, 350 researchers, government leaders, public health partners, and community members from throughout the U.S. participated in the hybrid "2nd National Meeting for Research and Community Collaboration towards Ending the HIV Epidemic (EHE) in the U.S. Meeting" hosted by the NIH and the UAB CFAR. The meeting featured presentations by academic investigators and their implementation and community partners funded through NIH EHE awards and promoted the sharing of best practices and generalizable findings. |
| The NIH Helping to End Addiction Long Term (HEAL) Initiative | Research Initiative | AHRQ, CDC, CMS, FDA, HRSA, OS, SAMHSA | NIDA, NCATS, NCCIH, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDDK, NIMH, NINDS, OD/OSP, OD/DPCPSI/OBSSR | In April 2018, the National Institutes of Health (NIH) launched the HEAL (Helping to End Addiction Long-term) Initiative, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. This Initiative will build on extensive, well-established NIH research, including basic science of the complex neurological pathways involved in pain and addiction, implementation science to develop and test treatment models, and research to integrate behavioral interventions with medications for opioid use disorder (OUD) The NIH HEAL Initiative will bolster research across NIH to improve treatments for opioid misuse and addiction and enhance pain management. The NIH HEAL Initiative forges collaborations among research programs across NIH, the U.S. Department of Health and Human Services, and the private sector. https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative |
| The Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) | Research Initiative | CDC | NIAID | The PREVAIL partnership was established between the governments of Liberia and the United States. The Government of Liberia is represented through the Ministry of Health (MOH) and three autonomous agencies, the United States government is represented through NIAID and the Centers for Disease Control (CDC). The purpose of this partnership is to conduct collaborative biomedical and public health research to advance science, strengthen health policy and practice, and improve the health of Liberians and people worldwide while enhancing Liberian preparedness and agility to rapidly respond during any future infectious disease outbreaks. |
| The President's Task Force on Environmental Health risks and Safety risks to children; Asthma Disparities working group | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, IHS | NHLBI, NIAID, NICHD, NIMHD, NINR | Group of federal partners (HHS and non-HHS) working to eliminate disparities in children with asthma https://ptfceh.niehs.nih.gov/activities/asthma/index.htm |
| The Role of the Scavenger Receptor B Family Proteins (SR-BI, SR-BII and CD36) in Infection and Sepsis | Research Initiative | FDA | CC | The Role of the Scavenger Receptor B Family Proteins (SR-BI, SR-BII and CD36) in Infection and Sepsis |
| The Scientific Registry of Transplant Recipients (SRTR) Visiting Committee | Committee, Work group, Advisory group, or Task Force | HRSA | NIAID | The SRTR Visiting Committee advises the SRTR on:(1) analytic methodologies to support the Organ Procurement and Transplantation Network policy development and evaluation; (2) objectives, study designs, and statistical methods for research projects performed by SRTR, including risk-adjusted analyses of organ procurement organization and transplant program performance; (3) methods used in simulated allocation models; (4) new areas of research and innovative advances in analytical methodologies that might improve the effectiveness of SRTR. https://www.srtr.org/about-srtr/visiting-committee/ |
| The United States Renal Data System (USRDS) | Resource Development | CMS, HRSA | NIDDK | The United States Renal Data System (USRDS), supported and hosted by NIDDK, is a national data system that collects, analyzes, and distributes information about chronic kidney disease and end-stage renal disease (ESRD) in the United States. The missions of USRDS are: (1) To characterize the total renal patient population and describe the distribution of patients by socio-demographic variables across treatment modalities; (2) To report on the incidence, prevalence, mortality rates, and trends over time of renal disease by primary diagnosis, treatment modality and other variables; (3) To develop and analyze data on the effect of various modalities of treatment by disease and patient group categories; (4) To identify problems and opportunities for more focused special studies of renal research issues; (5) To conduct cost effectiveness studies and other economic studies of ESRD; and (6) To make the data available to investigators, and by supporting investigator-initiated projects, to conduct biomedical and economic analyses of ESRD patients. http://www.usrds.org |
| Therapies for patients with rare tumors and genetic tumor predisposition | Research Initiative | FDA | NCI | Therapies for patients with rare tumors and genetic tumor predisposition |
| Tobacco and Nicotine Research Interest Group (TANRIG) | Committee, Work group, Advisory group, or Task Force | CDC, SAMHSA, FDA, CMS | OD/DPCPSI/ODP, FIC, NCI, NEI, NHGRI, CSR, NCCIH, NIAMS, NIMH | The Tobacco and Nicotine Research Interest Group (TANRIG) was formed in January 2003 with the goal of increasing collaboration, coordination, and communication of tobacco- and nicotine-related research among National Institutes of Health Institutes and Centers, as well as with other relevant US Department of Health and Human Services agencies. https://oir.nih.gov/sigs/tobacco-nicotine-research-interest-group |
| Tobacco Product Disease Risks | Research Initiative | FDA | NCI | NCI and the FDA-Center for Tobacco Products, in collaboration with the US Census Bureau, co-lead this study, which harmonizes data on cigarette, cigar, and pipe use from various Tobacco Use Supplements that have been administered over the years as part of the Current Population Survey. The participants in these surveys have been followed for mortality by linkage to the National Death Index. These data are used to provide contemporary estimates of the mortality risks of daily and non-daily use of cigarettes, pipes, and cigars. |
| Tobacco Regulatory Science Program (TRSP) | Research Initiative | FDA | OD/DPCPSI/ODP, CSR, NCI, NHLBI, NIAAA, NICHD, NIDA, NIEHS, OD/OER | Located in the National Institutes of Health (NIH) Office of Disease Prevention, the Tobacco Regulatory Science Program (TRSP) coordinates the trans-NIH collaborative effort with the US Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP) to conduct research to support its regulatory activities over tobacco products. Within the framework of the Tobacco Control Act, the NIH and FDA formed an interagency partnership to foster tobacco regulatory research. The NIH has the infrastructure for the solicitation, review, and management of research. The FDA has expertise in tobacco regulatory science and the authority and resources to support research responsive to FDA’s regulatory authority. Support from FDA was used to fund grants and to provide administrative support and oversight to manage Funding Opportunity Announcements (FOA), application review, policy implementation and oversight, and communicating and reporting to a variety of sources. https://prevention.nih.gov/tobacco-regulatory-science-program |
| Tobacco Use Supplement to Current Population Survey (TUS-CPS) | Health Survey | CDC, FDA | NCI, NIMHD | The Tobacco Use Supplement to the Current Population Survey (TUS-CPS) is an NCI-sponsored survey of tobacco use that has been administered as part of the US Census Bureau'sCurrent Population Survey approximately every 3-4 years since 1992-93. http://cancercontrol.cancer.gov/tus-cps |
| Toxicology in the 21st Century (Tox 21) | Resource Development | FDA | NCATS, NIEHS | The Toxicology in the 21st Century (Tox21) program is a federal collaboration among National Institutes of Health(NIH) National Center for Advancing Translational Science (NCATS) and the National Toxicology Program at the National Institute of Environmental Health Sciences; the Environmental Protection Agency; and the Food and Drug Administration. Tox21 researchers aim to develop better toxicity assessment methods to quickly and efficiently test whether certain chemical compounds have the potential to disrupt processes in the human body that may lead to negative health effects. https://ncats.nih.gov/tox21/about |
| Toxicology in the 21st Century Federal Consortium: NCATS Interagency Agreement, ES-7020-01, Year 11 (Tox21) | Research Initiative | FDA | NIEHS, NCATS | Tox21 is a US federal research collaboration focused on driving the evolution of Toxicology in the 21st Century by developing methods to rapidly and efficiently evaluate the safety of commercial chemicals, pesticides, food additives/contaminants, and medical products. This IAA is designed to explore new, effective, primarily non-animal methods and technologies to elucidate critically important questions pertaining to impacts of environmental exposures on cellular toxicity pathways that may lead to human disease. A major focus is the development of innovative approaches in toxicology assessment. https://tox21.gov/overview/ |
| Toxicology in the 21st Century Program (Tox21) - Computational Toxicology | Research Initiative | FDA | NCATS | Toxicology in the 21st Century Program (Tox21) - Computational Toxicology |
| Toxicology in the 21st Century Program (Tox21) - Systems Toxicology | Research Initiative | FDA | NCATS | Toxicology in the 21st Century Program (Tox21) - Systems Toxicology |
| Toxin Working Group of the Intragovernmental Select Agents and Toxins Technical Advisory Committee (ISATTAC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID | The workgroup holds biweekly meetings to discuss the following: point of regulation of select toxins (Botulinum neurotoxins, Staphylococcal enterotoxins, Abrin, Ricin, Conotoxins, Saxitoxin, Tetrodotoxin, Diacetoxyscirpenol, T-2 toxin), natural environment, toxin exclusion limits, space decontamination, and potential updates to the Centers for Disease Control and Prevention (CDC) manual “Biosafety in Microbiological and Biomedical Laboratories.” http://www.cdc.gov/phpr/dsat.htm |
| Toxins Assessment Working Group | Committee, Work group, Advisory group, or Task Force | ASPR, CDC, FDA | NIAID | Biological (not engineered) toxins with specific effects on the nervous system, focusing on neurotoxins, applications in medical research and historical consideration as bioweapons |
| Tracking Resistance and Coronavirus Evolution (TRACE) | Research Initiative | ASPR, CDC, FDA | NCATS, NIAID | The ACTIV Tracking Resistance and Coronavirus Evolution (TRACE) initiative is focused on identifying emerging variants of SARS-CoV-2, the coronavirus that causes COVID-19 disease. The initiative is surveying new viral variants, assessing vaccine and therapeutic resistance, and evaluating the impact of genetic variation on viral biology and on the clinical approaches for preventing and treating illness. TRACE aims to prioritize which viral variants should be studied to determine the effectiveness of vaccines and therapeutics currently in late stages of development against these variants; coordinate data sharing; and confirm testing and periodic (e.g. weekly) public reporting of results to allow confident decision making by the U.S. Government (USG), health professionals, and pharmaceutical organizations. The initiative, which is being led by NIH and facilitated by the Foundation for the National Institutes of Health, with participation by the ACTIV public-private partners, is developing the infrastructure and processes for monitoring and testing emerging SARS-CoV-2 variants and standardizing, gathering, and sharing variant sequencing data. https://www.nih.gov/research-training/medical-research-initiatives/activ/tracking-resistance-coronavirus-evolution-trace |
| Training Advisory Committee (TAC) | Committee, Work group, Advisory group, or Task Force | AHRQ | OD/OER, CSR, FIC, NCATS, NCCIH, NCI, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/ORIP | The Training Advisory Committee (TAC) advises on programmatic, review, and management issues related to extramural research training, research education, career development and diversity programs and the Loan Repayment Programs (LRP), and evaluation of these programs. TAC provides a trans-NIH forum to identify and discuss issues related to these programs and recommend solutions. |
| Trans-Agency (Medical) Imaging Phantom (TAIP) Workgroup | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NIBIB | A common set of scientifically validated medical phantoms that have long term curation, convenient dissemination, associated measurement protocols and analysis software, will be of great benefit to the FDA, NIH, NIST and to the scientific community they serve. This working group is created to enhance collaboration between FDA, NIST, and NIH to cooperate, where possible, on the development, validation, and dissemination of these medical calibration objects and to maintain at library of these medical phantoms for use by the larger medical community. |
| Trans-Agency Meeting on Adult Obesity Treatment and Prevention: State of the Science, Research Gaps, and Opportunities for Future Research | Meeting/ Workshop | AHRQ, CDC, HRSA, OASH | NHLBI, NCI, NIDDK, NIAMS, NCCIH, NIMHD, OD/DPCPSI/OBSSR, OD/DPCPSI/OPA | The Trans-Agency Meeting on Adult Obesity Treatment and Prevention: State of the Science, Research Gaps and Opportunities for Future Research was held virtually on September 16 and 24, 2021. The purpose of this meeting was to bring together key staff from NIH and other federal and non-governmental organizations to discuss the current state of adult obesity prevention and treatment research, knowledge gaps, and opportunities for future research and directions. The meeting was attended by 58 participants across 20 NIH Institutes, Centers or Offices (ICOs), five (5) other federal agencies, and two (2) non-governmental organizations (NGOs). The meeting laid the groundwork for a future workshop on this topic and other trans-agency activities in FY 2022 and beyond. The federal agencies represented at this meeting included NIH, HHS Health Resources and Services Administration (HRSA), HHS Office of the Assistant Secretary for Health (OASH), Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control (CDC), and the Veterans Health Administration (VA). |
| Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, ASPR | NIAID | The presidential declaration issued at the 2009 EU-US summit called for the creation of “a transatlantic task force on urgent antimicrobial resistance issues focused on appropriate therapeutic use of antimicrobial drugs in the medical and veterinary communities, prevention of both healthcare- and community-associated drug-resistant infections, and strategies for improving the pipeline of new antimicrobial drugs, which could be better addressed by intensified cooperation between us.” The objectives of the Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) are to increase the mutual understanding of US and EU activities and programs relevant to the antimicrobial resistance issues identified in the declaration in order to deepen the transatlantic dialogue, provide opportunities to learn from each other, and promote information exchange, coordination, and cooperation. http://www.cdc.gov/drugresistance/tatfar/ |
| Trans-HHS program for Multi-System Inflammatory Syndrome in Children (MIS-C) and pediatric SARS-CoV-2 (CARING) | Research Initiative | CDC, FDA, OASH | NHLBI | Staff from NHLBI and NICHD, the NIH co-leads, as well as NIAID collaborate with the Office of the Assistant Secretary of Health, CDC, and the FDA to guide a federal research program for MIS-C and pediatric SARS-CoV-2. |
| Trans-NIH Liver Cancer Working Group | Committee, Work group, Advisory group, or Task Force | CDC | NCI, NIDDK, NIAAA, NIAID | The charge of this working group is to develop an integrated NIH-wide plan for research in liver cancer that addresses basic, behavioral, translational, and clinical aspects of liver cancer aimed at understanding the basic mechanisms, the prevention, and cure of the disease. Additionally, the working group is interested in global health and health disparities research on liver disease. |
| Trans-NIH Mitochondrial Disorders Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NINDS, NIMH, NIA, NIGMS, NICHD, NIEHS, NEI, NIDDK, NCATS, NCI, NHLBI, NIAMS | The Trans-NIH Mitochondrial Disorders Working Group meets every 2-3 years to discuss and share information about ongoing funded research related to mitochondrial disorders including mechanisms and therapies. |
| Trans-NIH Working Group for Objective Measures in Cancer | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NIBIB, NIDDK | An National Institutes of Health (NIH) working group was formed to develop and consolidate wearable, passive and continuous out-of-clinic monitoring strategies for clinical assessment and understanding of disease progression in cancer. The goal of this group and its activities is to examine how these devices and techniques can be used to assess and understand cancer progression from multi-parameter data (context, vitals, and/or chemistry). Currently, several non-HHS agencies (National Institute of Standards and Technology (NIST), Department of Defense (DoD), Department of Energy (DOE), the National Aeronautics and Space Administration (NASA) and HHS agencies (NIH and the Food and Drug Administration) are also involved in these discussions and will integrate their expertise/mission to propagate for medical purposes. |
| Translational Science Interagency Fellowship (TSIF) | Training Initiative | FDA | NCATS | The Translational Science Interagency Fellowship (TSIF) program is a three-year postdoctoral fellowship opportunity jointly sponsored by the National Center for Advancing Translational Science (NCATS) and the U.S. Food and Drug Administration (FDA). The program aims to provide training in both translational science and regulatory science. The common goal of NCATS and the FDA is to bring safe and effective drugs, regimens, and devices from bench-to-bedside as quickly and efficiently as possible. To that end, fellows are trained in preclinical translational science, technology development, and regulatory research and review. By combining training in translational science and research-related regulatory review, the program enables fellows to build awareness of regulatory requirements into the early stages of medical product development thereby improving efficiencies in both the development and review processes. Fellows in this program will develop valuable skills for future careers in academia, the pharmaceutical industry, and government. https://ncats.nih.gov/training-education/training/TSIF |
| Transplant Cancer Match Study | Research Initiative | HRSA | NCI | A study linking databases of US transplant recipients, donors, and waitlist candidates to multiple US cancer registries to evaluate the spectrum of cancer risk and outcomes in the transplant population. https://transplantmatch.cancer.gov/ |
| Trial to Assess Chelation Therapy 2 (TACT2) | Research Initiative | CDC | NIDDK, NCCIH, NHLBI, NIEHS | TACT2 is a clinical trial to determine whether intravenous 2EDTA chelation therapy in combinations with oral multivitamins or alone will reduce the risk of major cardiovascular events (such as stroke and heart attack) in patients who have already had a heart attack and who also have type 2 diabetes. NIDDK has funded trials within this research initiative. http://tact2.org/ |
| Trial Transparency via Registration and Results Reporting at NIH ClinicalTrials.gov | Resource Development | FDA | NLM, CC, NCATS, NCCIH, NCI, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, OD/DPCPSI/OBSSR, OD/OER, OD/OLPA, OD/OSP | The purpose of this trans-NIH, inter-agency collaboration is to implement legal and policy requirements related to disseminating clinical trial information and promote understanding of these requirements through engagement with and the development of resources for stakeholders. NLM collaborates with FDA, OD/OSP, OGC, and other parts of NIH to improve transparency of clinical trials via registration and results reporting at NLM's ClinicalTrials.gov through implementing regulatory requirements and NIH trial transparency policies, including the 2016 NIH Policy on the Dissemination of NIH-funded Clinical Trial Information. NLM has also collaborated with OD/OBSSR to develop resources for the behavioral and social science community to support submitting study information to ClinicalTrials.gov and with OD/OBSSR, OD/OSP, OER, OLPA, and OCPL to engage the basic science community and understand their concerns about reporting NIH-funded basic experimental studies with humans to ClinicalTrials.gov. https://www.clinicaltrials.gov/ |
| Tribal Epidemiology Centers Program | Research Initiative | IHS, CDC | NIMHD, OD/DPCPSI/THRO | The Tribal Epidemiology Centers Program develops Epidemiology Centers for ongoing disease surveillance and public health infrastructure for American Indian and Alaska Native communities. NIMHD issued a funding opportunity announcement, the Collaborative Minority Health, and Health Disparities Research with Tribal Epidemiology Centers (R01 and R21 Clinical Trials Not Allowed).PAR-17-484andPAR-17-48. In addition, in 2022 NIMHD with support from the NIH Office of Data Science Strategy (ODSS) established a Resource Center for Tribal Epidemiology Centers (RC-TEC). http://www.ihs.gov/epi/index.cfm?module=epi_tec_tecs |
| Tumor Mutational Burden (TMB) Harmonization Project | Resource Development | FDA | NCI | The project conducts analytical and clinical validation studies to support a standardized method of (tumor mutational burden) TMB measurement to enable consistent TMB reporting in a clinical setting despite differences in the testing panel used. https://www.focr.org/tmb |
| U.S. and Canada Human Milk Composition Initiative (HMCI) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NICHD, OD/DPCPSI/ODS, NIDDK, NCI | Coordinate and support the development of human milk composition data in the U.S. and Canada for use by federal policy, program and other stakeholders to provide nutrition and dietary guidelines, education and programs for infants. |
| U.S. Breastfeeding Coalition (USBC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, HRSA, IHS, OASH | NICHD | The United States Breastfeeding Committee (USBC) is an independent nonprofit coalition of more than 100 influential professional, educational, and governmental organizations that share a common mission to drive collaborative efforts for policy and practices that create a landscape of breastfeeding support across the United States. http://www.usbreastfeeding.org/ |
| U.S. FDA Medical Imaging Drugs Advisory Committee | Committee, Work group, Advisory group, or Task Force | FDA | CC | The Committee reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in diagnostic and therapeutic procedures using radioactive pharmaceuticals and contrast media used in diagnostic radiology and makes appropriate recommendations to the Commissioner of Food and Drugs. https://www.fda.gov/advisory-committees/human-drug-advisory-committees/medical-imaging-drugs-advisory-committee |
| U.S. Preventative Services Task Force (USPSTF), NIH IC Liaison Group | Committee, Work group, Advisory group, or Task Force | AHRQ | NICHD, NIA, NIAID, NIMHD, NINR, OD/DPCPSI/OAR, OD/DPCPSI/ODS, OD/DPCPSI/ORWH | Created in 1984, the U.S. Preventive Services Task Force (USPSTF or Task Force) is an independent group of national experts in prevention and evidence-based medicine that works to improve the health of all Americans by making evidence-based recommendations about clinical preventive services such as screenings, counseling services, or preventive medications. The USPSTF NIH Institutes and Centers (IC) Liaison Workgroup is made up of IC representatives who work with AHRQ to identify research needs related to the fields of preventive medicine and primary care, including internal medicine, family medicine, pediatrics, behavioral health, obstetrics/gynecology, and nursing. https://www.uspreventiveservicestaskforce.org/ |
| Unified Medical Language System Metathesaurus (UMLS) | Resource Development | AHRQ, CDC, CMS, FDA | NLM | The National Library of Medicine (NLM) Unified Medical Language System (UMLS) integrates and distributes key terminology, classification and coding standards, and associated resources to promote creation of more effective and interoperable biomedical information systems and services, including electronic health records. NLM ingests over 200 different medical vocabulary sources, mapping these vocabularies into a unified terminology set, and providing access to the native versions of these terminologies to enable interoperability between researchers, health professionals and health data systems. Collaborators such as NCI, AHRQ, CDC, CMS, and FDA have provided vocabularies for inclusion in the UMLS and have provided input for UMLS development and enhancements. |
| Union for International Cancer Control (UICC) | Other | OGA | NCI | The Union for International Cancer Control (UICC) is the largest and oldest international cancer-fighting organisation. Founded in Geneva in 1933, UICC has over 1,200 members in 173 countries, enjoys consultative status with the United Nations (ECOSOC) and has official relations with the following institutions: WHO, IARC, IAEA, UNODC. UICC has over 60 partners, including associations working to fight cancer, as well as companies and foundations. UICC is a founding member of the NCD Alliance, McCabe Centre and ICCP. UICC’s mission is to unite and support the cancer community to reduce the global cancer burden, to promote greater equality and to ensure that the cancer control continues to be a priority in the world health and development agenda. Its main areas of activity focus on convening the world's leaders for innovative, wide-reaching, cancer-control events and initiatives; building capacity to meet regional needs; and developing awareness campaigns. The purpose of the Memorandum of Understanding (MOU) with NCI/CGH is to serve as a framework for collaboration between NCI/CGH and UICC to develop and implement joint activities to support global cancer control, leveraging each other’s expertise and experience for greater impact. The focus areas of the Collaboration:• Convening meetings and other events, such as the World Cancer Congress;• Capacity building, such as the UICC Technical Fellowships, and the UICC-led replication of the Project ECHO for Knowledge Summaries for Comprehensive Breast Cancer Control;• Knowledge, advocacy and policy, such as scientific collaboration on the TNM cancer staging system and tobacco control, and the International Cancer Control Partnership (ICCP); and• Additional areas mutually identified by the Participants. https://www.uicc.org/ |
| United States Government Children in Adversity Working Group (APCCA WG) | Committee, Work group, Advisory group, or Task Force | CDC, ACF | NICHD, FIC, NIEHS, NIMH | The United States Government (USG) Children in Adversity Working Group (WG) is a United States Agency for International Development (USAID)-led, USG-wide working group aimed at coordinating USG activities focused on at-risk children globally in accordance with Public Law 109-95. https://www.childreninadversity.gov/home |
| United States Government Global Nutrition Coordination Plan | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NICHD | The purpose of the US Government Global Nutrition Coordination Plan is to strengthen the impact of the many diverse nutrition investments across the US Government through better communication and collaboration and through linking research to program implementation. Through coordination mechanisms, the US Government will maximize its support to country-led programs, continue its global leadership and partnerships, and generate, share, and apply knowledge and evidence in the nutrition sector in order to accelerate progress toward shared nutrition goals. The US Government is committed to improving nutrition throughout the world in order to enhance health, productivity, and human potential. https://www.usaid.gov/what-we-do/global-health/nutrition/usgplan |
| United States Government SARS-CoV-2 Interagency Group (SIG), Genomic Surveillance and Bioinformatics Working Group | Committee, Work group, Advisory group, or Task Force | CDC | NLM, NIAID | Interagency working group tasked with reviewing current SARS-CoV-2 genetic surveillance data and applicability of data to public health decisions. |
| Urine biomarkers and risk of lung cancer in the Sisters Study | Research Initiative | CDC, FDA | NCI | The National Cancer Institute (NCI) is using urine samples from the Sisters study cohort National Institute of Environmental Health Sciences (NIEHS) and the laboratory resources of the Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) funding to examine urine biomarkers of tobacco exposure and risk of lung cancer in a prospective study. |
| Urine biomarkers of tobacco and opium and risk of cancers and heart disease | Research Initiative | CDC, FDA | NCI | The National Cancer Institute (NCI) is using urine samples from the Golestan Cohort Study and the laboratory resources of the Centers for Disease Control and Prevention (CDC) and partial Food and Drug Administration (FDA) funding to examine urine biomarkers of tobacco and opium exposure and risk of several cancers, heart disease, and lung disease. |
| US Government Health Agencies' Efforts to Address HIV-Related Intersectional Stigma | Other | CDC, HRSA, IHS, OASH, SAMHSA | OD/DPCPSI/OAR, NIMH | Editorial published in American Journal of Public Health in June 2022 on HIV-related intersectional stigma. Authors included staff from CDC, NIH, HRSA, IHS, and OASH, and SAMHSA. https://pubmed.ncbi.nlm.nih.gov/35763747/ |
| US Preventive Services Task Force (USPSTF) | Resource Development | AHRQ, CDC, CMS, HRSA, IHS, OASH, FDA, SAMHSA | OD/DPCPSI/ODP, NCI | The US Preventive Services Task Force (USPSTF) is an independent panel of non-Federal experts in prevention and evidence-based medicine. The USPSTF uses information from systematic evidence reviews to make recommendations for a broad range of clinical preventive health care services (such as screening, counseling, and preventive medications) that are delivered in or referred from primary care practice. USPSTF recommendations are developed for primary care clinicians, health systems, and policy-makers, and published in the form of "Recommendation Statements." The Agency for Healthcare Research and Quality (AHRQ) has been authorized by the US Congress to convene the Task Force and to provide ongoing scientific, administrative, and dissemination support to the Task Force. The NIH Office of Disease Prevention (ODP) works closely with AHRQ and the USPSTF to provide scientific input from NIH Institutes and Centers on draft research plans, draft evidence reviews, and draft recommendation statements. The ODP also disseminates information to NIH Institutes and Centers about high-priority evidence gaps for clinical preventive services that have been identified by the USPSTF. http://www.uspreventiveservicestaskforce.org/ |
| US Public Health Service (USPHS) Physicians Professional Advisory Committee (PPAC) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ATSDR, BARDA, CDC, CMS, FDA, HRSA, IHS, OS, Office of the Surgeon General (OSC), SAMHSA | NIAID | The purpose of this committee is to provide advice and consultation to the Surgeon General on issues relating to the professional practice and personnel activities, civil service, and Commissioned Corps of the Medical Category. The committee provides advisory assistance to the Chief Professional Officer and to the Agency and/or Program Heads of the USPHS and to non-PHS programs that routinely use USPHS personnel. |
| USDA-HHS Birth to 24 Months Pregnant Women Project Federal Expert Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NHLBI, NCI, NICHD, NIDDK, OD/DPCPSI/OBSSR | The current work includes identifying topics of public health importance and conducting a small number of systematic reviews on diet and health for infants, toddlers, and women who are pregnant; it will not include specific dietary recommendations or advice. The scientific basis for dietary guidance for these population groups will be informed by the advisory report of the next (2020) Dietary Guidelines Advisory Committee. https://www.cnpp.usda.gov/birthto24months |
| Using Real-time Prescription and Insurance Claims Data to Support the HIV Care Continuum | Research Initiative | CDC | NIMH | The Centers for Disease Control and Prevention (CDC) and the National Institute of Mental Health (NIMH) have established a cooperative agreement titled Using Real-time Prescription and Insurance Claims Data to Support the HIV Care Continuum (CDC RFA-PS-19-003). The purpose of the cooperative agreement is to develop, implement, and evaluate an "insurance-based data-to-care (D2C)" model. The insurance-based D2C model will start with Medicaid claims (diagnosis and procedure) to identify persons with diagnosed HIV, and then use real-time Medicaid claims data to determine whether these individuals have current antiretroviral (ARV) prescriptions. Persons with HIV who show lapsed ARV medications will receive a set of escalating adherence, retention, and re-linkage interventions. The research study will test the effectiveness of the approach (on viral suppression) as well as the cost-effectiveness of the approach. |
| Vaccines and Related Biological Products Advisory Committee (VRBPAC) | Committee, Work group, Advisory group, or Task Force | FDA | NCATS | The Committee reviews and evaluates data concerning the safety, effectiveness, and appropriate use of vaccines and related biological products which are intended for use in the prevention, treatment, or diagnosis of human diseases, and, as required, any other products for which the Food and Drug Administration has regulatory responsibility. The Committee also considers the quality and relevance of FDA's research program which provides scientific support for the regulation of these products and makes appropriate recommendations to the Commissioner of Food and Drugs. The Committee shall consist of a core of 15 voting members including the Chair. Members and the Chair are selected by the Commissioner or designee from among authorities knowledgeable in the fields of immunology, molecular biology, rDNA, virology; bacteriology, epidemiology or biostatistics, vaccine policy, vaccine safety science, federal immunization activities, vaccine development including translational and clinical evaluation programs, allergy, preventive medicine, infectious diseases, pediatrics, microbiology, and biochemistry. https://www.fda.gov/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee |
| Vaccines and Therapeutics for Anthrax | Research Initiative | FDA | NIAID | Vaccines and Therapeutics for Anthrax |
| Validation study of the electrophilic allergen screening assay | Research Initiative | FDA | NIEHS | The study is evaluating the assay's usefulness for identifying potential skin sensitizers. https://ntp.niehs.nih.gov/go/903348 |
| Value Set Authority Center (VSAC) | Resource Development | AHRQ, CDC, CMS, IOS | NLM | The National Library of Medicine (NLM) provides an online repository of value sets (code sets from standardized medical vocabularies) that are used for clinical quality measurement in the CMS EHR Incentive Program (meaningful use). The Value Set Authority Center (VSAC) provides downloadable access to all official versions of vocabulary value sets contained in the electronic Clinical Quality Measures (eCQMs) from CMS and C-CDA (Consolidated Clinical Document Architecture) data from ONC. NLM works with CMS and ONC to publish the eCQM and C-CDA value sets in VSAC for public use in the U.S. Each value set consists of the numerical values (codes) and human-readable names (terms), drawn from standard vocabularies such as SNOMED CT ;, RxNorm, LOINC, and ICD-10-CM, which are used to define clinical concepts used in clinical quality measures (e.g., patients with diabetes, clinical visit). NLM, CMS and ONC work together to provide technical features in VSAC that support both the use of eCQM and C-CDA data. http://vsac.nlm.nih.gov |
| Vector-borne pathogen transmission | Research Initiative | FDA | NIAID | Vector-borne pathogen transmission |
| Veterans Affairs Science and Health Initiative to Combat Infectious and Emerging Life-threatening Diseases (VA SHIELD) | Other | CDC | NIAID | Advancing rapid detection, therapy and prevention of emerging diseases aimed at improving the quality and safety of health care for Veterans. |
| Virology Interest Group | Committee, Work group, Advisory group, or Task Force | FDA | NCI, NHLBI, NIAID, NIAMS, NICHD, NIDCR, NIDDK, NIMH, NINDS | The Virology Interest Group comprises researchers at National Institutes of Health (NIH) and in the local area who are interested in virology. The group organizes activities designed to promote interactions and exchange information. https://ccr.cancer.gov/sig/nih-virology-scientific-interest-group-nih-vig |
| Virus Ecology Unit | Research Initiative | CDC | NIAID | Virus Ecology Unit |
| Vision Research Collaborative | Research Initiative | FDA | NEI | The Vision Research Collaborative (VRC) is a joint initiative between the National Eye Institute (NEI) and the Congressionally Directed Medical Research Programs (CDMRP) Vision Research Program (VRP) of the Department of Defense (DOD). The goal of this partnership is to provide additional funding opportunities for VRP proposals, enhance current NEI Program portfolios, expand the scope of research supported by the NEI, and provide support for high quality projects addressing critical gaps in civilian and military vision research. https://grants.nih.gov/grants/guide/pa-files/PAR-20-152.html |
| Weighting methods for healthy worker survivor bias | Research Initiative | CDC | NCI | In collaboration with the National Institute of Occupational Safety and Health, we are developing new methods to address healthy worker survivor bias, a bias in occupational studies that can result in underestimates about the effects of occupational exposures on cancer outcomes. |
| White House Gender Policy Council: Science & Technology Interagency Working Group | Committee, Work group, Advisory group, or Task Force | OASH, FDA | NICHD, NCI | White House led interagency group on gender policy in science technology https://www.whitehouse.gov/gpc/ |
| WHO Risk Assessment Netword | Public Education Campaign | CDC | NIEHS | International communication, education, collaboration. Several workgroups, work products, and international meetings. |
| Whole Genome and Whole Exome Sequencing to Identify Genes for Type 2 Diabetes and Obesity | Research Initiative | IHS | OD/OIR, NIDDK | Whole Genome and Whole Exome Sequencing to Identify Genes for Type 2 Diabetes and Obesity |
| Why has progress in hypertension control plateaued in the United States, and how can progress be restarted? Establishing a Research Agenda for the 2020s | Meeting/ Workshop | CDC | NHLBI | Workshop to develop a research agenda for Centers for Disease Control and Prevention (CDC) and National Heart, Lung, and Blood Institute (NHLBI). |
| Working Groups to Develop HIV/AIDS Treatment and Prevention Guidelines | Committee, Work group, Advisory group, or Task Force | OASH | OD/DPCPSI/OAR, CC, NIAID, NICHD, NLM, OD/DPCPSI | There are five Office of AIDS Research Advisory Council (OARAC) Working Groups to maintain updated federally approved medical practice guidelines for HIV/AIDS Treatment and the Prevention of HIV Transmission from Mother to Infant. The five working groups are the 1) Panel on Antiretroviral Guidelines for Adults and Adolescents, 2) Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents, 3) Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV, 4) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children, and 5) Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission. The HIV/AIDS Treatment and Prevention Guideline Panels update guidelines for HIV/AIDS care providers with the most current information on combination antiretroviral therapy, treatment and prevention of opportunistic infections for people with HIV; the prevention of HIV transmission from an infected mother to her infant; and the safety and efficacy of HIV/AIDS therapies. https://clinicalinfo.hiv.gov/en/guidelines |
| Workshop on Housing and Obesity: Gaps, Opportunities, and Future Directions for Advancing Health Equity | Meeting/ Workshop | CDC | NIDDK, NHLBI, NCI, OD/DPCPSI/ODP, NICHD, NINR, NIMHD | The overall goal of this workshop is to accelerate research on the role of housing insecurity- including housing affordability, quality, stability, and its neighborhood context on behaviors and pathways underlying risk for obesity-related health disparities across the lifespan. The workshop will emphasize existing research that connects housing policies and programs with obesity and also address methods for housing and obesity research, including study design, measures, data linkages and analytic approaches. The event will highlight interventions focused on addressing housing as a social need and that also move upstream to address housing as a core social determinant of health. The workshop will include engaging and interactive discussions to identify key research questions for advancing health equity research priorities relevant to diverse sectors and identify opportunities to create research partnerships and collaborations across Federal, regional and local housing programs. https://www.niddk.nih.gov/news/meetings-workshops/2022/workshop-housing-obesity |
| World Cancer Research Day, HPVAware, and World No Tobacco Day, World Cancer Day observances | Committee, Work group, Advisory group, or Task Force | OGA | NCI, FIC | The National Cancer Institute (NCI) Office of Communications and Public Liaison and Center for Global Health collaborate with the Department of Health and Human Services (DHHS) Assistant Secretary for Public Affairs Digital Media Office to coordinate public education campaigns featuring digital materials that highlight prevention promotion and wellness programs. These materials are shared across all HHS Operating Divisions (OPDIVs). https://www.cancer.gov/about-nci/organization/cgh |
| World Health Organization (WHO) Programme on Prevention of Deafness and Hearing Loss | Committee, Work group, Advisory group, or Task Force | CDC | NIDCD | NIDCD is a founding member of WHO;s World Hearing Forum, a global network of stakeholders promoting ear and hearing care worldwide. Members work, in part, to raise awareness about and promote key interventions from the World Report on Hearing, published in 2021. NIDCD supported the development of this report, the first of its kind,; via a contract mechanism and subject matter expertise via stakeholders' meetings. https://www.who.int/activities/promoting-world-hearing-forum |
| World Health Organization Pediatric Antiretroviral Drug Optimization (PADO) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NICHD | WHO-led drug optimization activities are designed to promote broad access to more efficacious, safer and more tolerable antiretroviral (ARV) regimens in optimal formulations for adults, adolescents, children, and pregnant and lactating women. https://www.who.int/groups/antiretroviral-drug-optimization |
| WTP 2022 Spring Workshop: Preparing Workers for the Impacts of Climate Change through Training | Meeting/ Workshop | OASH | NIEHS | The purpose of the NIEHS Spring 2022 Worker Training Program (WTP) workshop was to share strategies regarding mitigating occupational hazards related to climate change; share case studies and approaches grantees have used; and provide an overview on how to conduct occupational climate vulnerability assessments. Attendees left the workshop with an increased familiarity of the many ways climate change impacts workers and an understanding of the content and approaches to best train workers, employers, and communities to prepare for and mitigate the hazards associated with climate change. https://www.niehs.nih.gov/news/events/pastmtg/hazmat/2022/Spring_Meeting/index.cfm |
| Year of Open Science subgroup of the Subcommittee on Open Science of the National Science and Technology Council | Committee, Work group, Advisory group, or Task Force | CDC | NLM | The White House has declared 2023 the Year of Open Science. Participating agencies have formed a subcommittee of OSTP's Subcommittee on Open Science and will host events celebrating open science, communicate the value of making research outputs open, and collaborate with other participating agencies on activities to advance open science. A central site has been created at open.science.gov where agencies will post highlights of their open science activities throughout the year. https://open.science.gov |
| ZIA CARCI Carcinogenicity Health Effects innovation Research Program | Research Initiative | ATSDR | NIEHS | ZIA CARCI Carcinogenicity Health Effects innovation Research Program |
An official website of the United States government
Here's how you know
Official websites use .gov
A .gov website belongs to an official government
organization in the United States.
A .gov website belongs to an official government
organization in the United States.
Secure .gov websites use HTTPS
A lock (🔒) or https:// means you've safely connected to the .gov website.
Share sensitive information only on official, secure websites.
A lock (🔒) or https:// means you've safely connected to the .gov website.
Share sensitive information only on official, secure websites.